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Abstract 
The research presented in this thesis focuses on the synthesis of functional glycosides 
and the investigation of their properties. This included the study of their ability to 
form metal complexes and the study of the antiparasitic activity of both the free 
glycosides and metal complexes, the use of glycosides to serve as precursors to 
conformationally constrained macrocyclic molecules and a preliminary investigation 
of the photophysical properties of a collection of glycosidic compounds. 
Two novel classes of glycosylated chelators were synthesized and characterized; one 
containing a dinitrogen aminopyridyl chelating motif and another containing a 
dinitrogen/oxygen phenoxy-iminopyridyl metal binding unit. The ability of these 
compounds to form stable metal complexes with several metals (Cu(II), Zn(II) and 
Fe(II)) was investigated and the coordination complexes obtained were 
characterized. 
The anti-chagasic and anti-leishmanial activity of a selection of these compounds 
were evaluated in collaboration with the group of Prof André Luis Souza dos Santos 
at the Microbiology Institute Paulo de Góes in Universidade Federal do Rio de Janeiro 
(UFRJ), in addition to their toxicity towards mammalian macrophage cells. Several 
compounds with antiparasitic activity with excellent selectivity indexes were 
identified. From the analysis of these preliminary investigations, structural features 
were identified that appear to be necessary for their antiparasitic activity. 
Preliminary investigations into the probably mode of action involving the study of the 
susceptibility of the glycosylated compounds to enzymatic hydrolysis by β-
glycosidase were carried out. The toxicity of the most potent compounds was also 
investigated using the Galleria Mellonella model. 
The use of carbohydrates as scaffolds to synthesize conformationally constrained 
macrocycles was also explored. To this end, several galactosyl donors were 
synthesized and their reactivity towards glycosylation with a serine derivative and 2- 
chloroethanol was investigated. Two different synthetic strategies were compared 
to highlight the intramolecular glycosylation as the most suitable route for 
macrocyclization.  
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Finally, the photophysical properties of a collection of glycosides and structural 
analogues was examined. This involved the synthesis of a family of substituted 
iminopyridyl compounds and the preliminary analysis of their fluorescent properties. 
Based on these studies, a plausible explanation for the fluorescent behaviour of 
glycoside functionalised iminopyridyl compounds is proposed.
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1.1   Biological Role of Carbohydrates 
Carbohydrates are a class of biological molecules consisting of carbon, hydrogen and 
oxygen and generally conform to the formula CnH2nOn. They are found ubiquitously 
in nature and perform many roles in biology. Some of these primary functions are as 
sources of energy, information transfer and as structural molecules. 
1.1.1   Carbohydrates as a Source of Energy 
Carbohydrates are the primary source of energy in nature. Every year, 10 billion 
metric tons of CO2 and H2O are converted by photosynthesis into cellulose and other 
carbohydrate derived plant products.1 In plants, energy is primarily stored as starch, 
a polymer formed primarily of α(14) linked glucose monomers. Animals utilize the 
structurally related carbohydrate polymer glycogen as the primary polysaccharide 
used to store energy. Like starch, this is comprised of α(14) linked glucose 
monomers. However, unlike starch, glycogen is highly branched with α(1→6) bonds 
occurring every 24 to 30 glucose units. These polymers are degraded enzymatically 
and release energy upon cellular respiration which oxidizes the carbohydrates to CO2 
and H2O.2 
1.1.2   Carbohydrates as Information Carrying Molecules 
Carbohydrates serve as information carrying molecules in nature and are involved in 
the majority of cell-cell interactions. They are well suited to this task due to the 
multitude of complex structures that carbohydrates can exist as; a pyranose sugar 
with 5 stereocenters has 25 isomers possible, without considering other forms that 
sugar can exist in. This array of distinct structures originating from such a small 
molecule makes them unique biomolecules in terms of information storage. 
Carbohydrates, often conjugated to a protein or other biomolecule, serve as 
mediators for a range of signalling processes such as immune signalling, blood 
clotting and microbial adhesion.1,3 These interactions occur primarily by the 
recognition of the carbohydrate motif by protein based receptors, known as lectins.4 
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1.1.3   Structural Functions of Carbohydrates 
Carbohydrates play an essential role in providing rigid structures in plants. Cellulose, 
the most abundant polymer on earth, is produced at a rate of approximately 1.5 x 
1012 tons per year.5 It is a tough, fibrous material that is found in wood and the plant 
cell wall. Like glycogen and starch, it is comprised of glucose monomers however it is 
linked in a β(14) fashion unlike the α(14) linkage found in the above polymers.  
Most animals cannot utilize cellulose as a fuel source as they lack the enzymes 
necessary to digest it. Some animals such as cows and sheep have a symbiotic 
relationship with bacteria that live in their rumen which possess enzymes to break 
down cellulose which is then digested by the animal.1 
1.2   Chemical Attributes of Carbohydrates 
1.2.1   Carbohydrates as Scaffolds in Synthesis 
Carbohydrates are extremely useful as scaffolds upon which to build highly specific 
structures with control over the final stereochemistry and conformation of the 
molecule.  A typical hexose can exist as an open chain structure with 4 chiral centres, 
a 6-membered heterocyclic ring (pyranose) with 5 chiral centres, or as a 5-membered 
heterocyclic ring (furanose), also with 5 chiral centres. This extra chiral centre present 
in the cyclic form of saccharides occurs at the anomeric carbon, termed the C-1 
position. This chiral centre has a significant effect on the reactivity and behaviour in 
biological systems and are denoted as α or β, depending on their relationship to the 
configuration of a reference group. This reference group is the stereocenter furthest 
from the C-1 position (typically C-5). An α-anomer is one which the C-1 OH group is 
on the same side as the reference group when the sugar is drawn as a Fischer 
projection, while a β anomer has the anomeric OH group on the opposite side. As 
described above, there is an enormous variety of possible structures available, 
depending on the sugar and the form it adopts. This feature, together with the 
abundance of synthetic methodologies available for the selective manipulation of the 
sugars functional groups, make carbohydrates ideal synthetic building blocks. 
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1.2.2   Carbohydrate Conjugation 
Carbohydrates are extremely attractive as pendant groups to conjugate to a 
molecule with the intention of modifying its physicochemical properties.  Quite 
often, this attribute is solubility, as the hydroxyl groups present in the carbohydrate 
greatly improve the solubility of the compound in water and other hydrophilic 
solvents.6  
Carbohydrates are also utilized to modulate the biological properties of molecules of 
interest. As described above, carbohydrates are involved in a multitude of highly 
specific biological recognition processes. This can be taken advantage of to target 
specific receptors by conjugating the sugar motif of interest to a molecule and 
thereby utilize naturally occurring biological processes such as active transport or 
recognition by the immune system in conjunction with the activity of the conjugated 
molecule.7,  The highly specific nature of carbohydrate recognition in vivo makes 
them uniquely effective as activity modifying conjugates in the design of biologically 
active molecules. 
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2.1   Introduction 
2.1.1   Leishmaniasis 
 
Leishmaniasis is a group of tropical diseases resulting from infection of protozoan 
parasites of the genus Leishmania. It occurs in several forms, of which the three most 
important are cutaneous, mucocutaneous and visceral leishmaniasis. The cutaneous 
form presents with skin ulcers, while the mucocutaneous form presents with ulcers 
of the skin, mouth, and nose. Visceral Leishmaniasis, the most severe form, begins 
with skin ulcers and then later presents with fever, low count of red blood cells and 
enlarged spleen and liver.8 This disease is fatal if left untreated. 
Leishmaniasis affects more than 12 million people worldwide in 88 countries, 
primarily in South America, Africa and Asia.9  It is transmitted by the bite of infected 
female sandflies which can transmit the infective stage of the parasite, metacyclic 
promastigotes, during the blood meal. The promastigotes then develop into 
amastigotes inside host macrophages where they multiply and spread to different 
tissues in the host. The cycle of infection continues when they are ingested by 
another sandfly during a blood meal and they go on to develop into metacyclic 
promastigotes inside the midgut of the sandfly. (Figure 2. 1)  
 
Figure 2. 1. Life cycle of leishmania parasite.3 
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2.1.1.1   Current Therapies 
Pentavalent Antimonials: 
First line treatment of leishmaniasis typically employs pentavalent antimonial based 
therapeutics. These were first introduced in 1945 building upon the work of Prof. 
Upendranath Brahmachari. He discovered urea stibamine in 1912, the first effective 
drug against L. donovani, for which he was nominated for the Nobel Prize in 
Physiology and Medicine in 1929 and again in 1949. The most common drugs 
prescribed are sodium stibogluconate and meglumine antimoniate (Figure 2.2) 
although these present with several problems. The first of which is the route of 
administration; these drugs are not orally active and require intramuscular or 
intralymphatic injection every day for up to 3 days.10 In addition to this, there are 
several unwanted side effects which include pancreatitis, peripheral neuropathy, 
gastrointestinal problems, hepatotoxicity, renal toxicity and cardiotoxicity leading to 
sudden death.11 Due to their widespread use over the last 60 years there has been 
widespread resistance to these drugs with more than 60% of patients in the Indian 
state of Bihar presenting with cases that are unresponsive to antimony based drugs.12   
 
 
Figure 2. 2. Chemical structures of sodium stibogluconate and meglumine 
antimoniate.13  
Amphotericin B: 
In the areas where resistance to antimonial antileishmanial treatment is common, 
amphotericin B (Figure. 2.3), a macrolide polyene antibiotic, is the preferred drug of 
choice.14 Its mode of action involves the complexation with ergosterol, a major 
component of the cell wall of leishmania parasites. Pores in the cell membrane are 
formed following this complexation which causes increased membrane permeability 
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to monovalent cations, anions and small metabolites and ultimately leads to cell 
death.15  
 
 
Figure 2. 3. Chemical structure  of amphotericin B.11 
Amphotericin B is administered as an injection with several formulations available 
including amphotericin B deoxycholate and various liposomal formulations. Lipid 
formulations of amphotericin B exhibit improved pharmacokinetic profiles and 
efficacy by facilitating its preferential uptake by reticuloendothelial cells, which 
reduces undesired side effects and increase its bioavailability.16 While it is more 
efficacious than pentavalent antimonial therapies, amphotericin B is not without its 
drawbacks. It is quite costly and requires prolonged hospitalization which is a 
significant issue considering that Leishmaniasis is a disease of poverty and primarily 
affects people in developing countries with limited access to medical care. Liposomal 
formulations of amphotericin B are only stable at temperatures below 25 °C, which 
limits its usefulness and the lack of an orally active dosage form further reduces its 
use. While its affinity for cholesterol is significantly lower than for ergosterol, 
amphotericin B does exhibit binding to cholesterol present in human cell walls and 
this can cause toxic side effects. These include nephrotoxicity, bone pain, 
hypotension, anorexia, dyspnoea, thrombophlebitis and myocarditis.17 Although no 
cases of resistance have been clinically presented, resistance of laboratory strains of 
Leishmania has been observed.10 
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Miltefosine: 
Miltefosine (Figure 2.4) is the first orally administered drug available for the 
treatment of leishmaniasis. It was originally developed as a treatment for skin 
metastasis of breast cancer and its use as an antileishmanial therapy began in the 
mid 1980’s in India. Several clinical trials were conducted throughout the 1990’s and 
it achieved FDA approval in 2014 for treatments of all forms of leishmaniasis making 
it the first approved drug for cutaneous and mucosal leishmaniasis.18  
 
Figure 2. 4. Chemical structure of Miltefosine.19 
Miltefosine shows high activity in several strains of Leishmaniasis with a cure rate of 
above 90% in India and Colombia. However, against L. braziliensis and L. mexicana  it 
only showed activity in approximately 50% of cases.20  The mechanism of action is 
unknown but several mechanisms have been proposed including inhibition of 
phosphatidylcholine biosynthesis, alteration of phospholipid and sterol composition 
of the parasite membrane and inhibition of calcium homeostasis.19 As with other 
treatments for leishmaniasis, miltefosine is not without its drawbacks. It is known to 
be teratogenic in addition to causing hepatotoxicity, gastrointestinal problems and 
nephrotoxicity.  
Paromomycin: 
Paromomycin (Figure 2.5) is a broad spectrum aminoglycoside antibiotic which is 
used for the treatment of visceral and cutaneous leishmaniasis although it does 
display reduced activity against visceral leishmaniasis. It can be administered both as 
a parenteral injection for visceral leishmaniasis and as a topical ointment for the 
treatment of cutaneous leishmaniasis. It is now off patent and is recognised as an 
orphan drug by both the FDA and EMEA and was approved in India in 2006 as a 
treatment for visceral leishmaniasis on the recommendation of the WHO.11 The 
precise mode of action of paromomycin against leishmania is not fully elucidated, it 
has been observed that it inhibits protein synthesis of the parasites by promoting 
10 
 
ribosomal subunit association following a low Mg2+ concentration induced 
dissociation. This association of the ribosomal subunits prevents subunit recycling 
and ultimately leads to the death of the parasite.21 Other proposed mechanisms 
include the alteration of membrane fluidity and the induction of respiratory 
dysfunction.22,23 Paromomycin has exhibited adverse reactions in patients such as 
ototoxicity, diarrhoea, abdominal cramps and nausea. Resistance has not been 
observed in the clinic but has been shown in a laboratory strain of L. donovani.24 
 
 
Figure 2. 5. Chemical structure of paromomycin.11 
2.1.1.2   Metallodrugs as Novel Antileishmanial Therapeutics 
 
Metallodrugs have been drawing increasing interest in recent years for the 
development of new antiparasitic drugs. Three main strategies have emerged to best 
utilise metals in this regard;  
1) The complexation of a metal to a known antiparasitic agent to modify and 
improve its pharmacodynamics properties e.g. Incorporating a redox active 
metal centre to generate reactive oxygen species (ROS) to induce parasite 
death.25 
2) The complexation of a metal to known antiparasitic agent to modulate its 
pharmacokinetic profile e.g. The complexation of ruthenium to benznidazole 
to improve solubility and cellular uptake.26 
3) The use of novel metal complexes as antiparasitic therapeutics. 
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A wide variety of metal containing compounds have been investigated as novel 
antileishmanial agents.  
2.1.1.2.1   Cu(II) Complexes 
Cu(II) complexes are attractive candidates for the development of novel 
antimicrobial drugs as Cu(II) is an endogenously occurring metal in mammalian 
biology. Humans therefore possess pathways for the regulation of copper levels in 
vivo which reduces the likelihood of metal induced toxicity.27 There have been many 
Cu(II) compounds reported in the literature with the ability to inhibit the growth of 
Leishmania parasites, several of which show good potency and selectivity.   
Moreno et al. have synthesized Cu(II) complexes of 5,7-dimethyl-s-triazolo[1,5-
a]pyrimidine (dtmp), a ligand known to form metal complexes with antiparasitic 
effects.28 These were assayed against L. braziliensis and L. infantum and the complex 
[Cu(dtmp)4(H2O)2](ClO4)2.2H2O (Figure 2.6) displayed IC50 values of 39.6 and 10.3 μM 
respectively with selectivity indexes of 15 and 54 when compared to their toxicity 
towards mammalian Vero cells. The IC50 value is a measure of how much of a 
substance is required to inhibit the growth of an organism by 50% and is used to 
describe the toxicity of a compound towards an organism. 
 
Figure 2. 6. Complex prepared by Cabellero et al.28 
A Cu(II) complex of a limonene-thiosemicarbazone ligand has been prepared by Britta 
et al, termed BenzCo, and its effect on L. amazonensis was studied.29 It was 
discovered that this complex (Figure 2.7) has potent antileishmanial properties and 
is effective against several stages of the parasite, namely leishmania promastigotes, 
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axenic amastigotes and intracellular amastigotes with IC50 values of 3.8, 9.5 and 10.7 
μM respectively. The effect that this compound has on the parasites has been studied 
in detail and it was found that it primarily effects the mitochondria of the 
promastigotes. Depolarization of mitochondrial membrane potential in the cells was 
observed which suggests interference with the proton potential of the mitochondrial 
membrane. Transmission electron spectroscopy was used to inspect the parasites 
following administration of BenzCo at its IC50 value. This revealed protrusion in the 
flagellar pocket of the promastigotes, which would further support this hypothesis. 
 
 
Figure 2. 7. Chemical structure of BenzCo.29 
 
Espósito et al. have prepared a series of α-hydroxycarboxylate Cu(II) complexes 
(Figure 2.8) and examined their antileishmanial effects.30 These complexes produced 
dose dependent leishmania inhibition with the highest activity observed when R = 
CH3 with an IC50 value of 242 μM. This figure is similar to that of CuSO4 (IC50: 218 μM) 
which indicates that the complexes retain the biocidal activity of the ‘free’ Cu(II) ion. 
While the ligands do not enhance the antiparasitic activity of the metal, it is proposed 
that chelating the copper with the ligands will prevent off target binding of the 
copper if administered to a mammal, considering the high binding affinity site on the 
abundant plasma protein albumin for Cu(II) in vivo.31 
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Figure 2.8. Complexes prepared by Esposito et al.30 
Metal complexes of polyaromatic ligands have been widely studied in bioinorganic 
chemistry due to their ability to act as DNA intercalators. Navarro et al. have 
investigated Cu(II) complexes of dipyrido[3,2-a:2’,3’-c]phenazine (dppz) and 
dipyrido[3,2-a:2’,3’-h]quinoxaline (dpq) (Figure 2.9) as agents against 
leishmaniasis.32 They found these complexes to be highly effective DNA intercalators 
and as agents for killing L. braziliensis. With the exception of [Cu(dpq)(NO3)](NO3), all 
of the compounds studied were successful at killing 100% of the parasites after 64 h 
at 10 μM. [Cu(dppz)2(NO3)]NO3 showed the highest activity with all of the parasites 
dead after 1.5 h at a concentration of 10 μM.  
 
 
Figure 2. 9. Ligands used by Navarro.32 
2.1.1.2.2   Zn(II) Complexes 
Zn(II) has been shown to be highly effective in combatting Leishmania infections. The 
most simple Zn(II) compound investigated and found to be effective is the simple salt 
zinc sulfate which has been shown to be an effective therapy for visceral 
leishmaniasis when administered orally for 45 days.33  
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Work has been carried out by Peniche et al. on the co-administration of zinc sulfate 
and zinc chloride with disulfiram (Figure 2.10), a drug used to treat alcoholism with 
known antiprotazoal activity,34 as a strategy to enhance its leishmaniacidal effects.35 
This was found to be very successful, with an IC50 value of 0.003 μM against L. major 
with an in vitro therapeutic index of 8337 when co-administered with ZnCl2 to 
infected RAW murine macrophage cells. The metal salts alone did not produce any 
significant antiparasitic effects nor did they prove to be toxic to the mammalian cells 
used.  
 
Figure 2.10. Chemical structure of disulfiram.35 
2-picolylamine Zn(II) complexes (Figure 2.11) have been recently reported and their 
effects on L. major have been studied in depth.36 These compounds showed potent 
antileishmanial properties with IC50 values as low as 0.3 μM. The researchers 
fluorescently labelled these compounds in order to establish their localisation when 
administered to parasitized mice. This revealed that the compounds rapidly 
accumulate in the promastigote cytosol. The fluorescent label, when administered 
without conjugation to the Zn(II) complex, did not show any uptake into the 
parasites. This would suggest that the Zn(II) is required for the complex to cross the 
parasite membrane. It is suggested that the selectivity of the compounds is due to 
their cationic nature, which allows them to distinguish the negatively charged 
parasite cell surface from the near neutral surface of mammalian cells.  The 
compounds did not exhibit appreciable toxic affects towards mammalian cells and 
were successful at eradicating the parasitic infection after 12 days of treatment in a 
mouse model. The mode of action for these compounds has not yet been deduced 
but it is suggested that it involves the disruption of the parasites membrane. 
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Figure 2.11. Structure of fluorescently labelled Zn(II) complex studied by Rice et al.36 
Carbonic anhydrase has recently been shown by Pal et al. to be the target of metal 
dithiocarbamate complexes.37 They examined the effect of several Mn(II) and Zn(II) 
dithiocarbonate complexes and found them to be effective inhibitors of β-carbonic 
anhydrase from several different microbial species including M. tuberculosis, 
Legionella pneumophila, and C. neoformans. Following this discovery, they 
investigated the use of the complexes as antileishmanial compounds. All of the 
compounds studied were effective at inhibiting the growth of L. major. The complex 
utilizing Propineb as a ligand (Figure 2.12) exhibited the highest activity with an IC50 
value of 0.27 μM with a selectivity index of 50.  
 
Figure 2. 12.  Zn(II) complex of Propineb.37 
Tosylsulfonamide ligands have been shown to possess potent antileishmanial activity 
which is further enhanced by complexation to Zn(II) (Figure 2.13).38 IC50 values as low 
as 0.32 μM were reported which are comparable to the activity of amphotericin B 
(0.29 μM). In addition, these compounds showed low toxicity in mammalian Vero 
cells. Their interaction with carbonic anhydrase, a Zn(II) containing metalloenzyme, 
was studied in depth in vitro and in silico. Inhibition studies show that both the 
16 
 
ligands and corresponding Zn(II) complexes are efficient inhibitors of bovine carbonic 
anhydrase with the Zn(II) complexes exhibiting enhanced activity when compared to 
the ligands alone. Docking studies revealed that the tosylsulfonamide ligands bind 
quite well to the active site of the enzyme with a strong interaction between the 
carboxylic acid OH and Zn(II) present in the enzyme. While the Zn(II) complex did 
show higher activity than the ligands alone, no docking studies were performed on 
these metal complexes to elucidate the cause of this increase of activity.  
 
Figure 2.13. Zinc tosylsulfonamide complexes used as carbonic anhydrase 
inhibitors.38 
2.1.2   Chagas’ Disease 
 
Chagas’ disease (CD) is a chronic, debilitating parasitic disease caused by 
Trypanosoma Cruzi and is primarily transmitted by blood-sucking insects of the 
subfamily Triatominae, most commonly the kissing bug,  although transmission from 
blood donations, consumption of contaminated food and vertical transmission have 
also been reported.39  
Following the bite of a kissing bug, metacyclic trypomastigotes are transferred into 
the host and find their way into cells near the bite where they develop into 
amastigotes. These amastigotes then multiply by binary fission and continue to infect 
surrounding tissue. Following this, they grow into trypomastigotes and enter into the 
blood stream where they can infect other sites in the host or be consumed by a 
kissing bug during a blood meal. Once consumed by a kissing bug, they transform into 
epimastigotes in the midgut of the insect where they multiply. The epimastigotes 
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move into the triatomine hindgut where they can then infect a new host when the 
fly takes a blood meal of another human (Figure 2.14). 
 
 
Figure 2.14. Life cycle of the T. cruzi parasite.40 
CD is a significant healthcare problem and is estimated to infect more than 10 million 
people worldwide. It presents a substantial socioeconomic burden in addition to a 
high mortality rate.41  The disease does not always initially present with symptoms; 
however, when it does they are typically mild symptoms such as fever, swollen lymph 
nodes, headaches, or swelling at the site of the bite. After several weeks, individuals 
enter the chronic phase of disease in which 60–70% of patients do not present 
further symptoms. The other 30 to 40% of people develop further symptoms 10 to 
30 years after the initial infection. These include enlargement of the ventricles of the 
heart which can lead to heart failure in addition to the enlargement of the 
oesophagus or colon which may also occur. 
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2.1.2.1   Current Therapies 
 
Nifurtimox: 
Nifurtimox (Figure 2.15) is an orally available medication used for the treatment of 
CD and is typically administered over the course of 30-60 days. It was first introduced 
in 1967 and its use is currently discouraged due to the numerous and severe side 
effects. It is known to cause gastrointestinal side effects, central nervous system 
issues, birth defects and increase the risk of heart failure.42 
Nifurtimox is only effective during the initial stages of infection.  In the chronic stages 
of the diseases it is ineffective due to its poor pharmacokinetic profile which does 
not allow for a sufficiently high concentration in all tissues where the infection is 
present.43 
 
Figure 2.15.  Chemical structure of Nifurtimox.42 
Nifurtimox is thought to exert its effects in vivo by undergoing enzymatic reduction 
and generating oxidative stress, which the trypanosome parasites are extremely 
sensitive to. This is due to their lack of the catalase enzyme which protects 
mammalian cells in addition to the absence of a glutathione-dependent hydrogen 
peroxide metabolism.44 This reduction can be effected by two nitroreductases found 
in the parasite which leads to either the generation of hydroxyl radicals or the 
oxidation of trypanosomal thiol species (Scheme 2.1).45 It is proposed that the 
primary mode of antitrypanosomal activity is the oxygen cycling pathway to generate 
hydroxyl radicals. 
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Scheme 2.1. Bioreduction of nitroaromatic drugs (ArNO2). (A) One-electron reduction 
by type II nitroreductases (NTR) promoting redox-cycling with superoxide/H2O2 
formation and drug regeneration. ROS production oxidizes parasite thiols. (b) Two-
electron reduction by type I NTR yielding the nitroso-compound (ArNO), a good 
scavenger of thiols. SOD = superoxide dismutase; T(SH)2= reduced trypanothione, 
TS2= oxidized trypanothione; TR = trypanothione reductase.45 
Benznidazole: 
Benznidazole is a 2-nitroimidazole derivative first introduced in 1972 and is used as 
the first line treatment of CD (Figure 2.16). It is orally available and it is typically 
administered daily for a period of 60 days and cures up to 80% of patients in the 
acute phase of infection and 5-20% of chronic cases.46 While it is currently the 
preferred treatment for CD, benznidazole is known to cause side effects such as 
gastrointestinal problems, rashes, anorexia, insomnia, immunosuppression and 
peripheral neuropathy.47 The efficacy and tolerance of benznidazole is inversely 
related to the age of the patient, with adverse effects seen more frequently and 
severely among elderly patients.48 
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Figure 2.16. Chemical structure of Benznidazole.  
Similar to nifurtimox, benznidazole is a prodrug which exerts its trypanocidal effects 
following the reduction of the nitro group by nitroreductases in vivo. However, the 
antikinetoplastic effects of benznidazole do not depend on the generation of oxygen 
radicals as nifurtimox does. The generation of H2O2 or O2- have not been observed in 
amastigotes when benznidazole is administered at concentrations significant enough 
to inhibit the growth of the parasite. Homogenates of T. Cruzi administered with 
benznidazole exhibit EPR signals corresponding to the nitrate anion which further 
supports the hypothesis of a different reduction pathway than nifurtimox.49 It is likely 
that the pathway involves the covalent binding of the electrophilic metabolites with 
trypanosome macromolecules, but there is no single accepted pathway for the drugs 
mode of action and it is likely that several are involved.50, 51                               
2.1.2.2   Metallodrugs as Novel Antichagasic Therapeutics 
 
As with leishmaniasis, many researchers have been exploring metal based drugs in 
the quest to find new treatments for CD. The use of DNA intercalating ligands such 
as phenanthroline or the conjugation of a known antiparasitic compound with a 
metal have been exhaustively studied. To this end a wide variety of metal-based 
compounds have been explored as novel antichagasic agents.   
2.1.2.2.1   Cu(II) Complexes 
Heteroleptic Cu(II) complexes of norfloxacin (NOR), an antimicrobial quinolone, have 
been prepared by Martins et al. using either bipyridine (bipy) or phenanthroline 
(phen).52 It was found that the [CuCl2(phen)] and [CuCl2(phen)(NOR)].3H2O (Figure 
2.17) had significant activity against T. Cruzi trypomastigotes. Further studies indicate 
that the norfloxacin ligand is quite labile; in vitro experiments with bovine serum 
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albumin (BSA) and human serum albumin indicate that it binds in competition with 
these endogenous ligands to form mixed ligand complexes. Only the Cu(II)-phen 
bond remains intact and it is this moiety that irreversibly binds to DNA, suggesting 
that it is this interaction which gives rise to the trypanocidal activity. This is supported 
by the relative lack of activity of the bipy complexes which show a lower ability to 
intercalate DNA. 
 
Figure 2.17. Chemical structure of [CuCl2(phen)(NOR)] .3H2O.52   
Moreno et al. assayed his previously described Cu(II)-dmtp complex (Figure 2.6) 
against T. cruzi and established its selectivity index with respect to mammalian 
macrophage cells.28 While the Cu(II) complex displayed higher activity than the other 
first row transition metal complexes assayed, its IC50 value was a moderate 19.2 μM 
and displayed a selectivity index of 3.4. This value is less than 50 which has been 
suggested as the minimum selectivity value acceptable for a compound to be a 
successful ‘hit’ compound for a trypanocidal drug.53 
Several dimethylphenanthroline and dimethylbipyridine complexes have been 
prepared by Becco et al. featuring either acetylacetonate or glycinate ligands. Their 
antitrypanosomal activity and mode of action have been studied extensively.54 They 
have found that [Cu(dimethylphen)glycinate]NO3 (Figure 2.18) showed the highest 
activity with an IC50 value of 3.9 μM. However, they did not examine the toxicity 
towards mammalian cells. 
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Figure 2.18. Cu(II) complex prepared by Becco et al.54 
Extensive studies were performed to examine the interactions of the compounds 
with DNA and proteins in order to establish the mechanism of their trypanocidal 
activity. These studies revealed that the primary inhibitory effects arise from the 
intercalation of the complex with the target DNA, followed by radical mediated 
cleavage of the DNA. Interactions with tubulin, integrin and fibronectin, which cause 
protein misfolding, are also observed. This would suggest that these interactions may 
also play a role in the activity of the compounds. 
Risedronate, a bisphosphonate compound currently being used as a drug for several 
bone diseases, has been investigated as a ligand for the synthesis of antiparasitic 
metal complexes (Figure 2.19) by Demoro et al.55 This work found that the copper 
complex was effective at reducing the growth of both T. cruzi promastigotes and 
epimastigotes. The antiproliferative effects of the metal complexes of risedronate 
exceeded that of the free risedronate ligand, which indicates that the coordination 
of metal ions significantly contributes to its effectiveness against the parasites.  
The target of bisphosphonate compounds in kinetoplasts has been identified as 
farnesyl diphosphate synthase enzyme.56  The authors studied the interaction of the 
compounds with this enzyme and found that they were effective inhibitors of its 
activity. Furthermore, they found that their enzyme inhibition effects correlated with 
their ability to inhibit the growth of T. cruzi, which indicates that this is the likely 
mode of action of the drugs. 
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Figure 2.19. Cu(II) risedronate complex.55 
2.1.2.2.2   Zinc(II) Complexes 
Gouvea et al. has investigated Zn(II) complexes of the antibacterial compound 
norfloxacin as antichagasic agents (Figure 2.20).57 It was found that while norfloxacin 
and its Zn(II) complex exhibited little activity against T. cruzi, the corresponding 
[ZnCl2(NOR)(phen)].2H2O complex showed good activity with an IC50 value of 12 μM. 
The analogous [ZnCl2(phen)] complex showed a similar activity of 14 μM, which 
would suggest that incorporation of the norfloxacin has little effect on the mode of 
action of the complex. Studies into the interaction of the complexes with DNA and 
BSA show that the [Zn(phen)]2+ moiety is able to intercalate with DNA, which is likely 
the cause of growth inhibition observed. 
 
Figure 2.20. Zn(II) complex synthesized by Gouvea et al. 57 
Work by Cabellero’s group into the antiparasitic activity of previously mentioned 
dtmp metal complexes revealed that the Zn(II) complex showed the highest activity 
of the compounds screened against T. cruzi (Figure 2.21).28 However, the IC50 value 
and selectivity index were inferior to the therapies currently used to treat the 
disease.  
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Figure 2.21. Zn(II) complex synthesized by Cabellero et al.28 
2.1.3   Carbohydrate Conjugation in Drug Design: 
 
Glycoconjugation is an attractive strategy in drug design as carbohydrates can confer 
superior biological activities to a potential drug through a variety of mechanisms. 
They can act as targeting groups and increase the uptake of the compound into cells 
by taking advantages of specific glucose transporters such as GLUT or SLC2A which 
actively transport the glycosylated compound into the cell. This approach avoids 
absorption problems caused by unsatisfactory lipophilicity profiles.58  A further 
advantage to using glycosylated compounds is the marked increase in water 
solubility, which can be up to 700 times more soluble when compared to the aglycon 
compound.59 Glycosylation also allows for the use of a prodrug strategy which uses 
the sugar moiety to mask a pharmacologically significant group within the molecule 
which is only revealed after the sugar is cleaved enzymatically in vivo by 
glycosidases.60  
Interestingly, a pro-prodrug scheme is emerging as a more favourable alternative to 
the traditional prodrug method. This uses an ester-protected sugar as the pendant 
group on the compound of interest which must first undergo hydrolysis by esterases 
in vivo to reveal the deprotected per-hydroxylated sugar. This can then undergo 
active transport into the cell before glycolysis to reveal the active compound. This 
offers the advantage of increasing the lipophilicity of the compound, assisting with 
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absorption via passive diffusion and can improve oral bioavailability which can be 
compromised by the use of deprotected sugars.7 
2.1.3.1   Carbohydrate Conjugated Metal Chelators 
 
The investigation of metal complexes bearing pendant sugar groups has been an area 
of intense research over the past number of years. Glycosylated coordination 
compounds have generated significant interest in the area of targeted diagnostic 
agents for positron emission topography (PET) and computed topography (CT) 
applications. The sugar moiety can serve as both a solubilizing agent and as a 
targeting unit in complexes containing radioactive nuclides such as 99mTc(I), 186Re(I) 
and 55Co(II) (Figure 2.22).61,62,63,64  
 
Figure 2.22. Examples of carbohydrate conjugated radiotracers investigated by 
Schibli, Ferreira and Banerjee.61,62,63 
This strategy has also been extended to the design of novel contrast agents for 
magnetic resonance imaging (MRI). This technique utilises lanthanide ions, typically 
Gd(III), to modulate local water-proton T1 and T2 relaxation times which improves 
the image obtained. These typically feature a macrocyclic core with additional 
coordinating pendant groups to ensure the stability of the compound given the 
toxicity associated with free lanthanide cations. A range of targeting moieties have 
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been investigated and some are widely used in the clinic such as Gadofosveset 
(Figure 2.23), trade name Vasovist, which targets the blood. This uses a 
biphenylcyclohexyl unit that has a high affinity for human serum albumin and 
therefore gives a higher concentration of the agent in the blood than the surrounding 
tissue, thereby improving its appearance in the MRI image.65  
 
Figure 2.23. Chemical structure of Vasovist.66 
 
Glycosylation has been widely explored in this area.67,68,69,70,71 In particular, galactose 
conjugates have attracted attention due to their ability to target liver cells by 
selective uptake by the hepatic asyaloglycoprotein receptor (ASGP-R) which is found 
on hepatic cells, liver cancers and in some cases, metastases of hepatic tumours. 
Geraldes et al. have studied complexes of Gd(III) and the γ-emitting 153Sm(III) nuclide 
coordinated to ligands bearing galactose moieties conjugated via a thioglycosidic 
bond to prevent enzymatic cleavage. They found that increasing the number of 
galactose residues on the molecule increase the affinity for ASGP-R in vitro while 
substituting galactose for glucose or lactose inhibits this targeting behaviour.67 This 
has lead other researchers to explore polyglycosylated ligands and dendritic 
glycoclusters as targeting agents (Figure 2.24).68,72 
27 
 
 
Figure 2.24. Complex used by Parker et al.68 
The use of carbohydrate conjugated metal complexes as therapeutics, however, is an 
underdeveloped yet emerging area of medicinal chemistry. The most well-known 
example is Auranofin, an organogold complex derived from 2,3,4,6-O-tetraacetyl-β-
D-glucopyranosyl-1-thiol (Figure 2.25). It was originally used as an antirheumatic 
agent, however, it is currently undergoing investigation as a potential antibacterial 
agent.73,74 The exact mechanism of action of this compound is still being studied;  
current hypothesis is that Au(I) is released from the drug and can bind to the redox-
active dithiol group of thioredoxin reductase (TrxR). Au(I) binding in the active site is 
thought to prevent electron transfer to the downstream substrate thioredoxin (Trx), 
thus interfering with redox homeostasis in the parasite.75 
 
Figure 2.25. Chemical structure of Auranofin.73 
Carbohydrates have been used to modulate the activity of anticancer Pt(II) 
compounds. Research by Wang’s group involved the investigation of a glucose 
derived cisplatin analogue (Figure 2.26).76 While this work did not show significant 
improvement over the parent Pt(II) compound, it was the first example of a 
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carbohydrate conjugated metal complex that did not feature the sugar as a 
coordinating ligand. 
 
Figure 2.26. Cisplatin analogue prepared by Wang et al.76 
Work by Ma et al. has investigated glycoconjugates of anticancer terpyridine Pt(II) 
complexes using a wide variety of peractylated sugars (Figure 2.27).77 They 
discovered that these compounds can be up to 100 times more cytotoxic against 
human cancer cell lines that cisplatin. Their studies indicate that the compounds 
exert their effect by interaction with ctDNA by a non-intercalating binding mode, 
which may explain why the activity is much higher than other derivatives which 
typically follow a DNA intercalation mechanism of activity. 
 
Figure. 2.27.  Example of Pt(II) complex synthesised by Ma et al.77 
Goa et al. have made significant advances in the field of carbohydrate conjugated 
Pt(II) anticancer compounds.59,78,6,79 This work has shown substantial improvements 
in both the efficacy of the compounds and the in vivo tolerance of the compounds 
when compared to the currently used drug Oxaliplatin. The improved anticancer 
activity can be attributed to the targeting action of the sugar moiety which exploits 
the Warburg effect (Figure 2.28). The Warburg effect is the significantly increased 
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uptake of glucose by tumours compared to healthy tissue. Exploiting this effect by 
use of a targeting sugar moiety provides a higher local concentration of the drug in 
the tumour than the rest of the body. The side effects caused by Pt(II) compounds 
can in part be attributed to their insolubility which impedes excretion by the kidney 
and often leads to nephrotoxicity. The solubilizing nature of the carbohydrate moiety 
is thought to be a key factor in the reduced toxicity observed in these compounds.6 
 
Figure 2.28. Chemical structure of Pt(II) complex prepared by Gao et al.79 
Ru(II) complexes bearing ligands based on galactose and fructose have been 
synthesized by Fernandes et al. (Figure 2.29).80 These were assayed against HeLa cells 
and showed dose dependent activity with IC50 values lower than cisplatin. Further 
studies of these complexes and their Fe(II) analogues revealed that these compounds 
act by increasing activity of caspase-3 and caspase-7 which trigger apoptosis.81 Their 
work revealed that the Fe(II) complexes were significantly less active than their Ru(II) 
analogues. The nature of the carbohydrate ligand also proved to be significant to the 
activity of the compounds; the cyclic glucose and galactose ligands were significantly 
more active than the open chained ligands which were also studied.   
 
Figure 2.29. Compounds studied by Fernandes et al.81 
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Fructose derived cobalt carbonyl complexes have been investigated as novel 
therapeutics against a breast cancer cell line.82 These proved only moderately 
effective and the potency of the compound was correlated to the number of 
isopropylidene protecting groups present on the sugar. The highest activity was 
observed when the fructose contained two protecting groups (Figure 2.30) which 
suggests that the lipophilicity of the compound is important for cellular uptake. This 
was investigated by means of atomic absorption spectroscopy to quantify the levels 
of Co present 24 h after administration of the compound. This showed that only low 
amounts of the deprotected compound was able to cross into the cell while the 
mono- and diprotected compounds presented a much higher uptake, clearly 
demonstrating the advantage of using protected carbohydrates as drug conjugates 
than their perhydroxylated analogues. 
 
Figure 2.30. Cobalt complex prepared by Ott et al.82 
Ag(I) complexes of thiosugar derived tripodal ligands have been synthesized and 
evaluated as antibacterial agents by Gottschaldt et al. (Figure 2.31).83 These 
complexes proved to be active against a broad range of bacteria and significantly less 
toxic to human cells than the simple salts used as a control. However, the activity 
was independent of the type of sugar used which suggests that they cross the cell 
wall by non-specific diffusion and the activity arises solely from the Ag(I) cation. 
 
Figure 2.31. Silver complex prepared by Gottschaldt et al.83 
31 
 
The above compounds represent almost the entirety of the carbohydrate conjugated 
metallotherapeutics reported in the literature. As can be seen, a wide variety of 
metals and coordination environments have been studied using these ligands, 
primarily for cancer, but also for antibacterial uses. While this area is still in its 
infancy, the potential for carbohydrate conjugation as a strategy for designing novel 
metallodrugs is clearly demonstrated.  
2.2   Aim 
The aim of this work was to: 
i. Design and synthesize a library of novel amino- and iminopyridyl ligands and 
their corresponding glycosylated derivatives. 
ii. Investigate the coordination chemistry of these novel ligands to form Cu(II), 
Zn(II) and Fe(II) complexes. 
As demonstrated vide supra, both Cu(II) and Zn(II) have been shown to be highly 
efficacious at increasing both the potency and selectivity of antikinetoplastic 
compounds.  The incorporation of a dinitrogen chelating ligand has proven successful 
in the design of metal-based therapeutics with the widespread use of bipyridine and 
phenanthroline based compounds reported in the literature. However, the ability of 
these compounds to intercalate DNA can also cause cytotoxic effects due to the non-
specific nature of the interactions. We therefore sought to investigate novel 
dinitrogen chelating ligands which do not have these structural features associated 
with their cytotoxicity, ie. a rigid, extended aromatic surface, to act as efficient DNA 
intercalators as a means to avoid this.  
We decided to explore the use of aryl-picolylamine based chelating motif as the core 
of the ligands described in this work. The aryl moiety features a para-phenolic group; 
this serves a dual purpose: (i) to act as a redox active site and (ii) to provide a point 
of functionalisation to append pharmacokinetic modulating groups (Figure 2.32).  
As previously outlined, carbohydrate conjugation is an extremely attractive strategy 
to modulate bioactivity. In order to investigate the importance of the phenolic OH 
group, several compounds featuring both metabolically labile and stable ether 
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linkages were prepared. Glucosidases are known to effect hydrolysis at the anomeric 
position and yield a hydroxylated sugar and the aglycon unit as an alcohol.84 
Therefore, two types of glucosylated ligand were studied: 
i) Aryl glucosides whereby the phenolic oxygen is directly linked to the 
anomeric centre. Enzymatic hydrolysis would liberate this redox active 
ligand. 
ii) Glucoconjugates with an ethylene linker incorporated between the sugar 
and the aryl ring. Enzymatic hydrolysis of these species would liberate a 
primary alcohol with the linker still attached to the phenolic oxygen and 
thus inhibit its potential redox activity. 
The aryl ring can also incorporate an additional phenolic hydroxyl group to provide a 
third coordination point with the aim of increasing the metal binding ability of the 
ligand. Thus, two distinct series of compounds with different coordination sites were 
investigated; namely, a dinitrogen N2 series and the N2O series which features an 
additional OH phenolic group.  
The coordination chemistry of the ligands with divalent cations Cu(II), Zn(II) and Fe(II) 
salts was then explored. 
 
Figure 2.32. Chemical structure of the ligand scaffold under investigation. 
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2.3   Results and Discussion 
2.3.1   Synthesis of the N2 Ligand Series 
2.3.1.1 Imine ligands 
 
 
Scheme 2.2. Reagents and conditions: i) MgSO4, EtOH 
The initial investigations focused on ligands featuring a dinitrogen iminopyridine 
chelating unit with a para-phenoxy group.  The synthesis of ligand 2.3 was attempted 
by the direct reaction of 2-picolylamine (2.2) with 4-hydroxybenzaldehyde (2.1) 
(Scheme 2.2). These proved to be unsatisfactory as the desired compounds could not 
be isolated in sufficient purity. Efforts were made in a wide variety of solvents using 
anhydrous conditions and different techniques to remove the water generated, such 
as Dean-Stark distillation and the addition of desiccating agents such as MgSO4 in 
order to drive the reaction to completion. Formation of the imine could be observed 
by TLC and NMR but they proved to be unstable and immediately begin to 
decompose to the corresponding amine and aldehyde starting materials upon 
isolation.  
 
 
Scheme 2.3. Reagents and conditions: i) 2-chloroethanol, DBU, NaI, 4 h, isopropanol, 
120 °C (microwave), 59%; ii) 2-picolylamine (2.2), MgSO4, EtOH, 6 hr. 
The synthesis of ligand 2.5 was attempted by the reaction of 4-(2-
hydroxyethoxy)benzaldehyde (2.4) with 2.2 (Scheme 2.3). 2.4 was prepared by a 
microwave promoted Williamson ether synthesis between 2-chloroethanol and 4-
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hydroxybenzaldehyde, utilizing DBU as the base and NaI as a nucleophilic catalyst in 
isopropanol. This route offered higher yields and easier purification than the 
analogous reaction using conventional heating, which necessitates the use of DMF 
or DMSO as the solvent due to the high temperature required to obtain sufficient 
conversion. As was observed with ligand 2.3, the imine proved to be highly unstable 
under ambient conditions and could not be satisfactorily isolated. 
 
Scheme 2.4. Reagents and conditions: i) HBr/AcOH, rt, 4 h, 87%; ii) 4-
hydroxybenzaldehyde (2.1), Ag2O, rt, 18h, 63%; iii) 2-picolylamine (2.2), MgSO4, 80°C, 
6 h.  
The synthesis for glycosylated ligand 2.9 utilizes the reaction of a glucosylated 
phenoxyaldehyde 2.8 with 2.2, as can be seen in Scheme 2.4. It follows a Koenigs-
Knorr glycosylation of 2.1 with glucosyl bromide 2.7 for the functionalization of the 
phenolic hydroxyl group of 2.1. Attempts were made to directly glycosylate 2.1 using 
an acetate glucosyl donor 2.6. However, this did not produce the target intermediate 
in sufficiently high yield. A glycosyl bromide donor 2.7 was therefore used to obtain 
the target glycosylated aldehyde 2.8. 2.7 was prepared by the stereospecific 
bromination of glucose pentaacetate with 33% HBr in AcOH to furnish the alpha 
anomer in high yield. The glycosylation was carried out in the dark under inert 
conditions using Ag2O as the halophilic promoter to activate the glucosyl donor. This 
generated the target aldehyde stereospecifically as the beta anomer in good yield. 
Both Ag(OTf) and Ag2CO3 were screened as reaction promotors, however, these did 
not produce appreciable conversion of the starting material.  
35 
 
The stereoselectivity of this glycosylation is governed by the acetyl group in the two 
position which participates in anchimeric assistance (Scheme 2.5). Following the 
abstraction of bromide by Ag(I), the carbonyl oxygen of the acetate group acts as a 
nucleophile to attack the resulting oxocarbenium intermediate to form a five 
membered acetoxonium ring. This ring blocks nucleophilic attack of 4-
hydroxybenzaldehyde from the bottom face which results in the formation of the 
beta anomer exclusively. 
 
Scheme 2.5. Mechanism for the formation of 2.6. 
As with the previously studied N2 imine compounds, the desired imine could not be 
obtained due to its instability under ambient conditions.  
Scheme 2.6. Reagents and conditions: i) 2-chloroethanol, BF3.OEt2, 0°C – rt, 17 h, 
55%; ii) 4-hydroxybenzaldehyde, K2CO3 (2.1), TBAI, 110 °C, 17 h, 87%; iii) 2-
picolylamine (2.2), MgSO4, 80 °C, 6 h. 
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Ligand 2.12 was envisaged to be obtained from the route shown above (Scheme 2.6). 
The glycosyl donor 2.6 was the commercially available β-D-glucose pentaacetate 
which was glycosylated with 2-chloroethanol in good yield using BF3.OEt2 to give the 
β-anomer exclusively. In this reaction, the oxocarbenium ion is generated by the 
Lewis acid activation of the anomeric acetyl group and subsequent abstraction by 
BF3. The acetyl group at the 2-position participates in anchimeric assistance in the 
same manner as described in Scheme 2.5. This anchimeric assistance controls the 
stereochemical outcome of the reaction and explains the stereospecificity observed 
in the reaction (Scheme 2.7). This stereochemistry is confirmed by both the chemical 
shift of the H-1 signal at 4.68 ppm which occurs significantly lower than the alpha-
anomer and also by the coupling constant of 3J1,2= 8 Hz, which is larger than would 
be expected for an alpha-glucoside. 
 
 
Scheme 2.7. Mechanism of BF3 promoted glycosylation of peractylated glucose. 
The ether linkage in 2.10 was formed in high yield using a Williamson ether synthesis 
in DMF using tetrabutylammonium iodide(TBAI) as a nucleophilic catalyst. The yield 
for this reaction is higher than the analogous reaction using 2-chloroethanol in place 
of the glucoside. This may be explained by the competing self-reaction of 2-
37 
 
chloroethanol during the etherification, which is not possible with the glucosylated 
2.10. Once aldehyde 2.11 was prepared, it was then reacted with 2.2 with the aid of 
desiccating agents. As with the other members of the N2 imine series, the product 
was found to be unstable under ambient conditions and hydrolyses back to the 
corresponding aldehyde and amine starting materials. 
Efforts were made to form coordination complexes in situ under inert conditions with 
the hope that coordination to a metal might provide some stability to the ligand. 
Unfortunately, these experiments yielded only hydrolysis products as were 
determined by NMR and IR spectroscopy. 
2.3.1.2 Amine Ligands 
 
Due to the instability of the N2 imine ligands, we decided to focus our efforts on the 
investigation of the analogous secondary amines which would not present the same 
challenges with regards to the stability of the ligands (Scheme 2.8). To synthesize the 
target amines, we used a reductive amination approach by the in situ reduction of 
the imine using sodium borohydride and acetic acid.  
 
 
Scheme 2.8. Intended synthetic route to the N2 ligand series.  
The ligand 2.13 and its corresponding platinum complex have been previously 
synthesized by Brunner et al. using diethyl ether as a solvent and a portion-wise 
addition of NaBH4 as a solid.85 While his method for the synthesis of compound 2.13 
proved to be quite facile, it is not directly applicable to the other members of the 
series due to the lack of solubility of several of our aldehydes in diethyl ether, which 
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prevents the formation of the imine. Instead, the compounds were synthesized by 
the formation of the imine in refluxing anhydrous ethanol under N2 with MgSO4. The 
imine is then directly reduced by the addition of a solution of NaBH4 in anhydrous 
ethanol to generate the corresponding amine following an aqueous quench and 
extractive work up.  
It is worth noting that extensive optimization of the reaction conditions was required. 
It is necessary to stir the NaBH4 solution for at least 15 min before addition to the 
reaction as several undesirable byproducts are formed if NaBH4 is added directly to 
the reaction. This suggests that partial ethanolysis of the reducing agent is necessary 
to attenuate the reducing ability of the reagent. The diminished reducing ability may 
grant it selectivity to preferentially reduce imines which mirrors the selectivity 
observed with the triacetoxyborohydride reducing agent.86 The reaction requires 
rigorously dry conditions in order to cleanly reduce the imine to yield only a single 
product. This necessitates the drying of all glassware and MgSO4 at 150 °C for 24 h 
and carrying out the reaction and filtration of desiccating agent under a stream of N2.  
Scheme 2.9. Reagents and conditions: i) MgSO4, ethanol, 3 h; ii) AcOH, NaBH4, 16 h, 
68% over two steps. 
 
As discussed above, ligand 2.13 was synthesized via the direct reaction of 4-
hydroxybenzaldehyde 2.1 and 2-picolylamine 2.2 and subsequent reduction using 
NaBH4 (Scheme 2.9).  This produces the target amine as a single product in high purity 
as indicated by the elemental analysis. During the optimization of this synthetic 
procedure, a tertiary amine byproduct 2.18 was isolated and characterized by X-ray 
crystallography (Figure 2.33). This compound is obtained by the reaction of the 
desired product 2.13 with a second molecule of 4-hydroxybenzaldehyde to form a 
second iminium species. This is subsequently reduced to yield the observed tertiary 
amine 2.18. This takes place when the imine formation step has not gone to 
completion or if there is water present in the reaction mixture to shift the equilibrium 
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from the imine towards the more thermodynamically favored amine and aldehyde. 
This demonstrates the need for rigorously anhydrous conditions in order to achieve 
full conversion of the starting materials and ensure the synthesis of only a single 
product.  
             
Figure 2.33. X-ray crystal structure of 2.18  
 
 
Scheme 2.10. Reagents and conditions: i) 2-chloroethanol, DBU, NaI, 4 h, isopropanol, 
120 °C (microwave), 59%; ii) 2-picolylamine, MgSO4, EtOH, 3 h; iii) AcOH, NaBH4, 68% 
over two steps.  
Compound 2.14 was prepared in a similar manner to 2.13 following an identical 
reductive amination protocol (Scheme 2.10).  This utilized the previously described 
aldehyde 2.4 to generate the imine intermediate 2.5 which was then reduced in situ. 
Following protocol optimized for 2.13, the reaction yielded the target compound as 
a single product in good yield and high purity.  
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Scheme 2.11. Reagents and conditions: i) HBr/AcOH, rt, 4 h, 87%; ii) 4-
hydroxybenzaldehyde, Ag2O, rt, 18h, 63%; iii) 2-picolylamine, MgSO4, 80°C, 4h; iv) 
AcOH, NaBH4, 16 h, rt, 76% over two steps. 
 
The glycosylated analogue N2 ligand 2.15 was obtained by the in situ reduction of 2.9 
(Scheme 2.11). The reductive amination followed a similar procedure to the other 
compounds in this series. The reaction quench did prove problematic however. 
Earlier iterations of the reductive amination procedure utilized HCl to quench the 
reaction. However, for this compound it promoted the formation of unwanted by 
products. After further optimization, the best conditions to quench the reaction were 
identified as the addition of water to the reaction and heating the mixture to 
deactivate unreacted NaBH4 prior to the work up. The protocol was used for all 
subsequent syntheses of the N2 ligands. 
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Scheme 2.12. Reagents and conditions: i) 2-chloroethanol, BF3.OEt2, 0°C – rt, 17 h, 
55%; ii) 4-hydroxybenzaldehyde, K2CO3, TBAI, 110 °C, 17 h, 87%; iii) 2-picolylamine, 
MgSO4, 80 °C, 4 h; iv) NaBH4, AcOH, rt, 16 h, 42% over two steps. 
Compound 2.16 was prepared by the formation of the glucosylated linker followed 
by etherification with 4-hydroxybenzaldehyde and subsequent reductive amination 
(Scheme 2.12). Using the same method as described for 2.15 with the water 
quenched reductive amination, the compound was obtained in a reasonable yield 
with a sufficiently high purity.  
 
Scheme 2.13. Reagents and conditions: i) NaOMe, MeOH/H2O, rt, 1 h, 98% 
Deprotected ligand 2.17 was prepared in a quantitive yield using a Zemplén 
deprotection to hydrolyze the acetyl protecting groups (Scheme 2.13). This initally 
yielded the target compound as a hygroscopic, tar-like substance but upon 
lyophilization for 48 h the product was obtained as an air stable solid. 
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Figure 2.34. N2 ligands synthesized 
2.3.2   Coordination complexes of the N2 Series 
 
 
Scheme 2.14. Reagents and conditions: i) CuCl2.2H2O, EtOH, 18 h, 69% 
The 1:1 Cu(II) complex 2.19 was generated from the reaction of ligand 2.13 with one 
equivalent of CuCl2.2H2O in ethanol at room temperature (Scheme 2.14). This 
produced a green precipitate which was collected by vacuum filtration and dried in 
vacuo to yield the product as a green powder. Elemental analysis indicates that the 
Cu(II) is bound in a 1:1 ratio with the ligand in addition to one molecule of water. The 
IR spectrum of the free ligand shows a broad, poorly defined band at 3430 cm-1 
representing the νN-H  and νO-H  stretches, whereas the Cu(II) complex shows distinct 
bands at 3495, 3378 and 3198 cm-1 representing the νN-H, νO-H and νO-H  bands. This 
indicates the coordination of the ligand to the Cu(II) ion. The coordination of the 
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pyridine ring to the metal is also suggested by the shift in the νpyr band from 1475 cm-
1 in the ligand to 1484 cm-1.  
The structure was unambiguously confirmed by X-ray crystallography. Crystals 
suitable for X-ray crystal analysis were grown by dissolving the sample in warm 
(approx. 40 ˚C) acetonitrile. The solution was allowed to cool slowly to room 
temperature and stand for several days in the dark to yield small green crystals. The 
crystals were found to contain two different Cu(II) species which together form a 
triclinic unit cell (Figure 2.35). 
 
Figure 2.35. Unit cell of 2.19 
At the vertices of the cell there are dimers of a five-coordinate Cu(II)  centre bound 
in a bidentate fashion by the ligand, a terminal chloride and two bridging chloride 
ligands (Figure 2.36). The geometry of 5-coordinate compounds can be described by 
the geometry parameter τ, which describes the degree of distortion from the square 
pyramidal to trigonal bipyramidal geometry.87 The value is calculated by Addison’s 
equation 𝜏5 =  
𝛽−𝛼
60°
, where β and α are the two largest coordination angles with a 
value of 0 signifying an ideal square pyramidal geometry and 1 representative of a 
trigonal bipyramidal structure. The Cu(II)  centre in this structure has a τ5 value of 
0.15, indicating a square pyramidal coordination geometry. 
44 
 
 The CuCl2 dimer is planar with Cl-Cu-Cl bond lengths of 2.302 and 2.695 Å and a bond 
angle of 84.54˚ for the Cu-Cl-Cu bond. The terminal chloride occupies one of the 
corners of the square planar arrangement with a bond length of 2.257 Å and an angle 
of 176.89˚ with respect to the trans nitrogen. These molecules interact with the 
dimers of neighbouring unit cells via π-π stacking, with the aryl rings displaying a 
parallel displaced arrangement and a length of 3.395 Å. 2.19 is coordinated in a 
bidentate fashion with a bite angle of 82.25 ° with bond lengths of 2.010 and 2.036 
Å for the Cu-Npyr and Cu-Namine interactions respectively, significantly shorter than the 
Cu-Cl bonds and reflects the greater binding affinity of the ligand.  
 
Figure 2.36. Crystal structure of the chloride bridged dimer of 2.19 
Encapsulated in the unit cell are two molecules of a mononuclear pentacoordinate 
Cu(II) complex. This adopts a square pyramidal geometry with two terminal chloride 
ligands and an acetonitrile molecule occupying the axial position (Figure 2.37). This 
species has a τ5 value of 0.07 which indicates a less distorted square pyramidal 
structure than the previously describe bridged dimer. The Cu-Cl bonds display equal 
lengths of 2.313 Å and a Cl-Cu-Cl angle of 93.53˚, similar to the coordination of the 
terminal chlorides in the bridged species. The bidentate ligand exhibits a bite angle 
of 82.6˚, similar to the angle observed in the dimeric complex. The Cu-N bond lengths 
are slightly longer in this species than the previously described dimer with a Cu-Npyr 
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length of 2.025 Å and a Cu-Namine length of 2.046 Å.  The acetonitrile ligand in the axial 
position shows a bond length of 2.302 Å, significantly shorter than the 2.692 Å bond 
length of the axial chloride of the dimeric species. The Cu(II) centre shows a weak 
interaction with a chloride ligand of another molecule with a distance of 2.997 Å.  As 
the elemental analysis suggests the presence of one water molecule, it can be 
proposed that this occupies the axial position in place of the acetonitrile molecule 
which is observed in the crystal structure of the compound. 
 
Figure 2.37. Mononuclear complex observed in the crystal structure of 2.19 
 
 
Scheme 2.15. Reagents and conditions: i)  CuCl2.2H2O, EtOH, 93% 
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The 2:1 Cu(II)  complex 2.20 of ligand 2.13 was prepared by reacting CuCl2.2H2O with 
a threefold excess of ligand 2.13 in ethanol at room temperature to yield the product 
as a blue green powder (Scheme 2.15).  Elemental analysis indicates the formation 
of the 2:1 complex. The IR spectra exhibits characteristic shifts in bands from 3430 
cm-1 and 1475 cm-1 in the free ligand to 3340cm-1 and 1489 cm-1 in the complex, which 
confirms that the metal binding occurs through the two chelating nitrogen atoms. As 
the Cu-Cl IR bands occur below 400 cm-1 and a crystal structure could not be 
obtained, the coordination of the chloride cannot be confirmed. It is possible that 
the complex could exist as an octahedral 6-coordinate complex or the 4-coordinate 
complex with two chloride counter ions as depicted in Scheme 2.15. Given that the 
reaction was done with three equivalents of a chelating ligand and only a 2:1 complex 
with two chlorides present was obtained, it is likely that this system favours a 4-
coordinate geometry. This can be deduced as the conditions used could allow for a 
6-coordinate structure with 3 strongly coordinating chelating ligands yet only two for 
found to coordinate with the metal centre.  
 
 
Scheme 2.16. Reagents and conditions: i) ZnCl2, EtOH, 50% 
The reaction of equimolar amounts of 2.13 with ZnCl2 in ethanol at room 
temperature produces the 1:1 complex 2.21 which precipitated as a light brown 
powder (Scheme 2.16). The 1:1 coordination of the ligand to the metal was 
confirmed by elemental analysis and it is supported by the IR spectrum of the 
compound. This shows characteristic signals of the νN-H  and νO-H  stretches at 3415 
and 3233 cm-1 and a  shift in the νpyr band from 1475 cm-1 to 1480 cm-1 when 
compared to 2.13. The 1H NMR reveals slight downfield shifts in the spectrum 
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following complexation with the electron withdrawing Zn(II) cation.  The largest shift 
observed occurs in the Pyr-H signal which resonates at 7.77 ppm in the free ligand 
and following complexation is observed at 7.91 ppm. 
The precise structure of the compound was confirmed by X-ray crystallography. 
Crystals suitable for X-ray analysis were grown by slow evaporation of the filtrate 
over several weeks to yield pale brown rhombic crystals. (Figure 2.38). 
 
 
Figure 2.38. Crystal structure of 2.21 
As is typical for Zn(II) complexes, the compound adopts a 4-coordinate structure. 
(Figure 2.38). Each zinc atom is bound in a bidentate fashion by the ligand through 
the two nitrogen atoms with almost identical bond lengths of 2.059 and 2.056 Å, 
unlike 2.20 where there was a noted difference in the Cu-N bond lengths. The two 
chloride ligands present display bond lengths of 2.232 and 2.209 Å which are shorter 
than those of the analogous Cu(II) complex. The elongation of one of these chloride 
bond lengths may be explained by its hydrogen bonding with both the phenolic H 
atom of a neighboring molecule and an amine H as seen in the crystal packing 
diagram (Figure 2.39). The primary intermolecular interactions observed in the 
crystal structure are π-stacking interactions between phenolic aromatic rings. These 
participate in two separate parallel displaced interactions; one with a displacement 
angle of 21.59° and a distance of 3.369 Å and the other with a distance of 3.845 Å 
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and a displacement angle of 55.39°. The pyridine ring is also involved with π-stacking 
with the phenolic ring, in this case in a T-shaped manner with a distance of 2.741 Å.  
The ligand binds the metal with a bite angle of 83.21° and two chloride ligands bind 
with a Cl-Zn-Cl angle of 116.28°. These angles are significantly different from the ideal 
angle of 109.5° for tetrahedral structures and more close resemble those of a trigonal 
pyramidal geometry (90 and 120° respectively). The geometry parameter for 4-
coordinate structures can be calculated using Okuniewski’s equation:88 𝜏4
′ =
𝛽−𝛼
360°−𝜃
+  
180°−𝛽
180°−𝜃
 where β and α are the largest coordination angles and θ is 109.5°, 
the ideal angle of a tetrahedral geometry. A square planar geometry is denoted by a 
value of 0, whereas tetrahedral geometry gives a value of 1. The Zn(II) complex has a 
value of 𝜏4
′ = 0.88 which reveals a distorted trigonal pyramidal (𝜏4
′ = 0.85) coordination 
geometry.  
 
 
 
Figure 2.39. Unit cell of 2.21 
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Scheme 2.17. Reagents and conditions: i) ZnCl2, EtOH, 88% 
The 2:1 Zn(II)  complex 2.22 of ligand 2.13 was synthesized by reacting ZnCl2 with a 
threefold excess of ligand 2.22 in ethanol at room temperature to yield the product 
as a white powder (Scheme 2.17).  The formation of the 2:1 binding of Zn(II) to the 
ligand is confirmed by elemental analysis. The IR spectra exhibits characteristic shifts 
in band from 3430 cm-1 of the free ligand to 3395 and 3158 cm-1 for the νN-H  and νO-H  
stretches and from 1475 cm-1 to 1489 cm-1 representing the νpyr.  This confirms that 
the metal binding occurs through the two chelating nitrogen atoms. As with 2.20, it 
is possible that the compound could exist as either an octahedral 6-coordinate 
complex or a 4-coordinate complex with two chloride counter ions. However, the 
coordination of the chloride cannot be confirmed as the νZn-Cl occurs at a lower 
wavelength than was studied. Given that the IR spectra for 2.20 and 2.22 are almost 
identical (Figure 2.40), it can be assumed that they are symmetrically equivalent and 
therefore exhibit similar coordination geometry. 
 
 
 
 
 
 
 
 
        2.20 
        2.22 
Figure 2.40. IR spectra of 2.20 and 2.22 
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Figure. 2.41. NMR Spectra of 2.21 and 2.22 
 
From the NMR of 2.21 and 2.22, we can see that the 1:1 complex exhibits signals 
downfield of those of the 2:1 complex. This indicates that the the ZnCl2 moeity is 
more electron withdrawing than the [Zn(2.13)]2+ fragment  despite the ligand not 
possessing a negative charge. This could be explained by the shorter Zn-N bond 
length as seen from the crystal structure of 2.21 which could offer better electron 
donation to the metal centre, thereby making it less electron withdrawing. 
 
 
Scheme 2.18. Reagents and conditions: Zn(ClO4)2. 6H2O, EtOH, 62% 
 
2.21 
2.22 
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The perchlorate analogue of 2.22, complex 2.23, was synthesized by a similar method 
utilizing the direct reaction of Zn(ClO4)2.6H2O with an excess of 2.13 at room 
temperature in ethanol. This yielded a hygroscopic brown solid which was collected 
by vacuum filtration (Scheme 2.18). Following lyophilization, the product was 
obtained as a light brown powder. Elemental analysis confirms the 2:1 binding of the 
ligand to the metal and also indicates the presence of one molecule of water.  The 
νN-H shift cannot be determined due to the broad H2O stretch which obscures the 
signal. However, the νC-N occurs as a broad signal at 1247 cm-1 in the ligand which 
shifts to 1222 cm-1. This suggests the coordination of the secondary amine. The νpyr 
stretch exhibits a shift of 13 cm-1, confirming the binding of the pyridine ring to the 
metal. Characteristic strong bands at 623 and 1090 cm-1 indicate the presence of the 
perchlorate anion and the absence of a second perchlorate band in the region of 650 
cm-1 rules out perchlorate coordination to the metal.89 This would suggest the 4-
coordinate structure depicted above as the most likely structure of the complex. 
 
 
Scheme 2.19. Reagents and conditions: i) CuCl2.2H2O, EtOH, 62% 
To see the effect of an alkyl hydroxyl group in place of a phenol group, the alkylated 
N2 ligand 2.14 was reacted in a 1:1 stoichiometry with CuCl2.2H2O to generate 
complex 2.24 as a dark green solid (Scheme 2.19). The elemental analysis of the 
product confirms the 1:1 binding of the ligand and also reveals the presence of one 
water molecule, as was observed for the analogue 2.19. As with ligand 2.13, the νN-H 
and νO-H signals in the IR spectrum are observed as a single broad band at 3306 cm-1. 
In the Cu(II) complex 2.24 these are observed as two distinct bands at 3437 and 3238 
cm-1. This confirms the binding of the secondary amine to the copper whereas the 
νpyr band shifts from 1474 to 1485 cm-1, indicating Cu(II)-NPyr coordination. Crystals 
suitable for X-ray analysis could not be obtained but considering the similarity to the 
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analogous compound 2.19 it could be proposed that the compound adopts a 5-
coordinate square pyramidal geometry. 
 
Scheme 2.20. Reagents and conditions: i) ZnCl2/ Zn(ClO4)2.6H2O/ Zn(NO3)2.6H2O, 
EtOH/ MeOH/ MeCN 
Rather surprisingly, the Zn(II) complex of 2.14 did not form as expected. Several salts 
and solvents were screened and in all cases no precipitation occurred. However, the 
addition of petroleum ether to the reaction mixture precipitated a strongly 
hygroscopic brown solid. A dark oil could also be separated from the reaction solvent 
after cooling in the freezer for several days. Upon lyophilization this yielded a brown, 
strongly hygroscopic solid which could not be satisfactorily characterized. 
 
 
Scheme 2.21. Reagents and conditions: i) CuCl2.2H2O, EtOH, 59% 
Glucosylated ligand 2.15 was reacted with an equimolar amount of CuCl2.2H2O in 
ethanol to produce the complex 2.25 (Scheme 2.21). The 1:1 coordination of the 
ligand to the metal was determined by elemental analysis. Unlike the aglycon 2.19, 
this compound does not show any water of coordination or solvation, which suggests 
a 4-coordinate geometry for the copper centre. The IR spectra reveals a shift in the 
νN-H band, which moves from 3427 cm-1 in the ligand to 3421 cm-1 in the Cu(II) complex 
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while the νpyr occurs at 1475 cm-1 in 2.15 and after complexation this shifts to 1486 
cm-1. This is a similar magnitude to the shift observed upon the formation of the 
aglycon complex 2.25 and indicates the participation of the pyridine ring in the 
coordination with the Cu(II) centre. 
 
Scheme 2.22. Reagents and conditions: i) ZnCl2, EtOH, 52% 
The Zn(II) complex of 2.15 was prepared by the reaction of the ligand with ZnCl2 in 
ethanol to yield a beige precipitate (Scheme 2.22). As with the Cu(II) analogue the IR 
spectrum reveals shifts in the bands for the amine components of the molecule 
indicating their participation in the coordination with the metal with a 40 cm-1 shift 
observed in the νN-H and a shift of 11 cm-1 seen in the νpyr from 1474cm-1 to 1486cm-
1. Elemental analysis confirms the 1:1 binding of the metal with the ligand to form a 
4-coordinate complex which likely adopts a trigonal planar geometry similar to that 
seen for 2.21. 1H NMR studies show a large downfield shifts in the aromatic signals 
caused by the deshielding effects of the Zn(II) cation (Figure 2.42). The Pyr-H signal 
occurring at 7.75 ppm in the free ligand shows a shift of almost 1 ppm upon 
complexation to 8.55, a significantly larger shift than was seen for the aglycon 
complex 2.21 which could suggest a stronger ligand-metal interaction. 
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Figure 2.42. NMR spectra comparison of 2.15 and 2.26 
 
 
Scheme 2.23. Reagents and conditions: i) FeCl2.4H2O, EtOH, 64% 
The Fe(II) complex 2.27 was prepared by reacting ligand 2.15 with a solution of 
FeCl2.4H2O under an inert atmosphere (Scheme 2.23). In order to avoid the possible 
oxidation of the Fe(II) to Fe(III), the reaction was carried out on a Schlenk line using 
degassed solvents and a rigorously air-free environment. The ligand was dissolved in 
anhydrous, degassed ethanol and transferred by cannula to a solution of excess 
FeCl2.4H2O in degassed ethanol using a positive pressure of N2 to immediately yield 
a pale brown precipitate. The reaction was stirred at room temperature for 3 h and 
the solvent was reduced by approximately half in vacuo. The reaction was allowed to 
stand overnight before being filtered under an inert atmosphere to yield a pale 
2.15 
2.26 
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brown solid. A small sample was isolated and immediately analyzed by IR 
spectroscopy and a separate sample was left exposed to air for one week. This 
showed no discoloration and its IR spectrum was identical to that of the sample which 
was analyzed immediately. This suggests that the compound is air stable.  
The IR spectrum reveals changes in the νN-H band from 3427 cm-1 in the ligand to a 
broad band at 3435 cm-1 after the formation of the complex. This corresponds to the 
νN-H and νH2O while the νpyr occurs at 1475 cm-1 in ligand which shifts to 1482 cm-1. 
Elemental analysis suggests that two water molecules are present which are likely 
bound to the Fe(II) to give a 6 coordinate octahedral structure, as this is the most 
stable geometry for Fe(II). This is further supported by the fact that heating the 
complex overnight at 70 °C did not induce any change in the complex by elemental 
analysis. This makes it unlikely that the water molecules observed are simple 
solvating the complex and are more likely coordinating to the metal centre. 
Magnetic moment studies generated a value of 5.16 B.M which indicates a high spin 
d6 configuration. This confirms that the iron species is in the Fe(II) oxidation state and 
no oxidation occurred. Although this is higher than the spin only approximation 
would predict (4.9 B. M), it is in the typical range of octahedral Fe(II) complexes (5.1-
5.7 B. M) and reflects the spin-orbit coupling which the spin only approximation does 
not take into account. 
 
Scheme 2.24. Reagents and conditions: i) FeCl2.4H2O, EtOH, 85% 
When ligand 2.15 was reacted in excess with FeCl2.4H2O under inert conditions 
identical to those used to synthesis 2.27, a green brown precipitate was observed 
which yielded a dark green precipitate upon isolation. Elemental analysis suggests a 
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composition that corresponds to an unusual binuclear species with each Fe(II) 
coordinated to two chloride ligands, a water ligand and a monodentate complexation 
to the ligand. Drying of the complex overnight at 70 °C does not change the  
composition as determined by elemental analysis which suggests that the water 
molecules are directly coordinated to the metal. The binuclear nature of the 
compound is supported by the magnetic properties of the material which exhibits a 
μeff of 9.76 B.M which is close to the spin only predicted value of 9.8 B. M and greatly 
exceeds that of a mononuclear Fe(II) complex. 
The IR spectrum of the compound shows a broad band at 3429 cm-1, corresponding 
to the νH2O which obscures the νN-H band. The corresponding νC-N cannot be assigned 
as it obscured by the strong νC-O signal at 1230 cm-1. The primary νpyr band at 1474 cm-
1 shifts 5 cm-1 upon coordination of the metal. The less pronounced shifts in these 
bands compared to those exhibited by the 2.27 indicate weaker ligand-metal 
interactions. 
It is possible the the complex exists as two 4-coordinate tetrahedral Fe(II) centres as 
depicted in Scheme 2.24 or as a coordination polymer as depicted in Figure 2.43. 
utilising bridging chloride ligands. This would result in the Fe(II) having a larger 
coordination number which is more typical of Fe(II) chemistry.  However, the 
magnetic moment values do not indicate any cooperativity between the two iron 
centres which makes this unlikely. 
 
Figure 2.43. Proposed bridged metallopolymer arising from 2.28 
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Scheme 2.25. Reagents and conditions: i) CuCl2.4H2O, EtOH, 58% 
2.16 was reacted with CuCl2.4H2O in ethanol at room temperature to produce a 
green solid which, interestingly, formed a partial gel of the reaction solution (Scheme 
2.25). The remaining solvent was decanted and the gelled substance was dried under 
high vacuum (0.01 mbar for 24 h). However, this was unsucessful at removing the 
gelled ethanol. The substance was then dried under vacuum using Abderhalden’s 
drying pistol with refluxing acetone as the heat source which was sufficient to 
remove the ethanol to yield the produce as a green solid. This was identified as the 
1:1 complex by elemental analysis, which also indicated the presence of one water 
molecule. As the water remained after thorough drying of the compound both with 
heat and high vacuum, it can be proposed that it is coordinated to the metal to give 
a square pyramidal structure analagous to that observed in aglycon complex 2.19. 
The IR spectrum of 2.16 ligand exhibits a single band at 3412 cm-1, while the ligand 
exhibits two bands in this region at 3442 and 3202 cm-1 corresponding to the νN-H and 
νH2O. The  νpyr band shifts 6 cm-1 from 1477 to 1483 cm-1 upon complexation to the 
metal. This is a smaller shift than is observed upon the formation of the aglycon 
ligand and confirms the participation of the pyridine ring in binding the copper. 
 
Scheme 2.26. Reagents and conditions: i) CuCl2.4H2O, EtOH, 43% 
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The deprotected Cu(II) complex of 2.30 was synthesized by the reaction of 
CuCl2.4H2O with a stoichiometric amount of 2.17 in ethanol, which yielded the 
product as a pale green precipitate (Scheme 2.26). As with the acetylated 2.25, a 1:1 
coordination stoichiometry is revealed by elemental analysis. Unlike the aglycon and 
acetylglucosylated analogues, no water is observed coordinated to the metal centre. 
The IR spectrum of the ligand exhibits a very broad strong signal at 3379 cm-1, 
corresponding to the νO-H and νN-H bands which are observed at 3405 cm-1 in the Cu(II) 
complex. The νpyr band occurs at 1478 cm-1 in 2.17 and after complexation this shifts 
to 1486 cm-1. This is an almost identical shift which is effected by Cu(II) complexation 
to the acetyl protected ligand. 
 
 
Scheme 2.27. Reagents and conditions: i) ZnCl2, EtOH, 23% 
 
Zn(II) complex 2.31 was synthesized by an identical method to 2.30 by the direct 
reaction of equimolar amounts of the ligand 2.17 and metal salt in ethanol (Scheme 
2.27). Elemental analysis revealed the 1:1 coordinaton which would suggest a 4-
coordinate geometry which is typically adopted by Zn(II) complexes. The IR spectrum 
shows a broad strong signal at 3430 cm-1 corresponding to the νO-H and the νN-H bands, 
higher than that observed in the analogous Cu(II) complex. The νpyr band exhibits a 
shift of 8 cm-1 with respect to the ligand which confirms the Zn(II)-Pyr coordination. 
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Scheme 2.28. Reagents and conditions: i) Zn(ClO4)2.6H2O, 55% 
The 2:1 Zn(ClO4)2 complex 2.32 was prepared by the reaction of an ethanolic solution 
of the metal salt with an excess of the ligand 2.17 at room temperature to yield the 
product as a brown hygroscopic precipitate (Scheme 2.28). This produced a brown 
solid upon lyophilization for 24 h. Elemental analysis confirms the 2:1 coordination 
of the ligand to the metal in addition to four water molecules of solvation. The IR 
spectrum reveals a characteristic band at 3430 cm-1 corresponding to νN-H and νH2O 
while a change in the νpyr at 1487 cm-1 confirms the coordination of the pyridine ring. 
Characteristic bands at 625 cm-1  and 1078 cm-1 indicates the presence of the 
perchlorate anion and the lack of a new band in the region of 650 cm-1 confirms that 
this is not coordinated directly to the metal. 
2.3.3   Synthesis of the N2O Series 
 
Unlike the N2 series of compounds, the imines of the N2O series (Figure 2.44) showed 
remarkable stability towards hydrolysis. The imines of the N2O series are stable under 
ambient conditions and require refluxing in the presence of water or acid to effect 
complete hydrolysis.  
 
Figure 2.44. Ligands of the N2O Series 
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This stability can be attributed to the intramolecular hydrogen bond between the 
ortho-phenolic proton and the lone pair of the imine (Figure 2.45). This bond can be 
clearly seen in the X-ray crystal structures of 2.33 and 2.34 and also in the shift of the 
ortho-phenolic group in the 1H NMR spectra. These signals appear in the region of 
13-14 ppm, a resonance frequency typically seen for carboxylic acids. This shows that 
the proton is highly deshielded by both the aromatic ring current and the hydrogen 
bonding to the imine. 
 
Figure 2.45. Hydrogen bonding observed in the N2O series 
The formation of the imine is highly thermodynamically favoured and is produced by 
stirring the aldehyde with 2-picolylamine 2.2 for several hours at room temperature 
without the need for acid catalysis or dehydrating agents. 
Efforts were made to synthesize the corresponding amine N2O ligands however these 
were unsuccessful. The use of hydride based reducing agents such as NaBH4 or LiAlH4 
produced poor conversion and a difficult to separate mixture of starting material, 
degradation products and small amounts of product. This can be attributed to the 
acidic phenolic hydrogen reacting with the basic hydride to generate an electron rich 
delocalized aryl-imine with greatly reduced electrophilicity, which inhibits further 
reaction with hydrides. Catalytic hydrogenation of the imines did not generate the 
same degree of degradation of the starting material. However, even with the rather 
forcing conditions of heating at 50 °C for 48 h with a 15 mol% loading of Pd/C, only 
~40% conversion could be induced. This attests to the high thermodynamic stability 
of the imine ligands. 
 
 
Scheme 2.29. i) EtOH, >98% 
𝛿+ 
𝛿- 
𝛿- 
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Ligand 2.33 (Scheme 2.29) was synthesized by stirring 2,4-dihydroxybenzaldehyde 
2.37 and 2-picolylamine 2.2 in ethanol at room temperature, which formed a bright 
yellow precipitate. This generated the ligand in quantitative yield in 3 to 4 hours, 
which was collected by vacuum filtration and washed with cold ethanol. Crystals of 
the compound were grown by dissolving the compound in warm acetonitrile and 
letting the solution stand for several hours to yield amber, trapezoid-like crystals 
which were analysed by X-ray crystallography (Figure 2.46). 
 
Figure 2.46. X-ray crystal structure of 2.33 
 
 
Figure 2.47. Unit cell of 2.33 
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The compound crystallizes into a monoclinic unit cell which is primarily formed by 
intermolecular hydrogen bonding between the para-phenolic OH group and the 
pyridine nitrogen (Figure 2.47). Secondary intermolecular interactions are formed via 
T shaped π stacking between the electron rich dihydroxyaryl ring and the electron 
deficient pyridine ring. The imine is co-planar with the aryl ring indicating a high 
degree of conjugation while the pyridine ring is 77.69° out of plane with respect to 
this conjugated system.  The compound clearly shows a strong hydrogen bond 
between the ortho-OH and the imine nitrogen with a distance of 1.702 Å, which 
accounts for its greater stability compared to the N2 imine analogue. 
 
 
Scheme 2.30. Reagents and conditions: i) 2-chloroethanol, DBU, TBAI, IPA, 76%; ii) 
EtOH, 86% 
Ligand 2.34 was made in two steps starting from 2,4-dihydroxybenzaldehyde 2.37 
(Scheme 2.30). As with 2.33, the aldehyde was alkylated with 2-chloroethanol using 
a microwave promoted synthesis. Although excess 2-chloroethanol was used, the 
reaction proved to be regiospecific for the para position and did not produce any of 
the ortho-alkylated product. This can be rationalized by steric hindrance from the 
nearby aldehyde and also its electronic effects. As it is moderately strong electron 
withdrawing group, the aldehyde draws electron density away from the phenolic OH 
group, therefore lowing the energy of the HOMO and reducing its nucleophilicity. As 
the para hydroxyl group is further away from the aldehyde, it does not suffer from 
this to the same degree and retains enough nucleophilicity to react with the 2-
chloroethanol to generate 2.38. This aldehyde was then stirred with 2-picolylamine 
2.2 in ethanol at room temperature to yield the ligand as a yellow powder in a 
manner identical to 2.33.  
Single crystals suitable for X-ray analysis were obtained by dissolving the compound 
in hot acetonitrile and allowing it to cool overnight to yield long, needle like crystals. 
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The crystal structure of the compound shows strong similarities to that of 2.33 with 
a monoclinic unit cell and the molecules ordered by way of head to tail hydroxyl-
pyridine hydrogen bonds (Figure 2.48) although there are no significant π stacking 
interactions.
 
Figure 2.48. Crystal structure of 2.34 
As with the 2.33, the compound shows a strong hydrogen bond between the ortho-
phenolic hydrogen and the imine nitrogen with a bond length of 1.695 Å. The imine 
is co-planar with the aryl ring indicating the delocalized electron density. The pyridine 
ring is 49.75° out of this plane, significantly less than the value of 77.69° which was 
observed for the unalkylated compound 2.33. The unit cell shows addition hydrogen 
bonding between the primary alcohol and the pyridyl nitrogen (Figure 2.49). 
 
Figure 2.49. Unit cell of 2.34 
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Scheme 2.31. Reagents and conditions: i) HBr/AcOH, 87%; ii) 2,4-
hydroxybenzaldehyde 2.37, Ag2CO3, 61%; iii) 2-picolylamine 2.2, >98% 
The glucosylated aldehyde 2.35 was synthesized in a manner similar to 2.8 using an 
Ag(I) promoted Koenigs-Knorr glycosylation of tetra-O-acetyl-α-D-glucopyranosyl 
bromide 2.7 (Scheme 2.31). Interestingly, silver carbonate proved to be effective in 
this reaction unlike the reaction using 4-hydroxybenzaldehyde 2.1 as the glucosyl 
acceptor where it did not produce satisfactory conversion (Scheme 4). The aldehyde 
2.39 was obtained in moderate yield and was reacted directly with 2-picolylamine 
2.2 in refluxing ethanol. This yielded the target compound 2.35 as an orange solid in 
quantitative yield upon evaporation of the solvent.  
 
 
Scheme 2.32. Reagents and conditions:  i) 2-chloroethanol, BF3.OEt2, DCM, 55%; ii) 
2,4-dihydroxybenzaldehyde (2.37), DBU, TBAI, MeCN, 64%; iii) 2-picolylamine (2.2), 
78%. 
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Ligand 2.36 was synthesized in a manner similar to 2.16 using the same intermediate 
2.10 (Scheme 2.32). The ether synthesis was accomplished using microwave based 
methodology analogous to 2.38. However, the choice of solvent played a crucial role 
in the success of the reaction. Using IPA as the solvent resulted in the deprotection 
of the acetyl groups on the sugar, in addition to the formation of the ether which was 
observed by NMR and mass spectroscopy. This is due to the DBU catalysed ester 
cleavage of the acetate protecting groups caused by the residual water present in 
the IPA. It was therefore decided to use anhydrous acetonitrile as the solvent which 
mitigated this problem, albeit with a slight reduction in the reaction yield compared 
to the non-glycosylated compound 2.38.  
The imine was then generated by refluxing 2.40 in ethanol with a stoichiometric 
amount of 2-picolylamine for 4 h. Precipitation of the product was induced by 
evaporation of approximately half of the solvent and cooling on ice to yield a bright 
yellow solid. 
2.3.4   Coordination Chemistry of the N2O Series 
 
Initial investigations into the coordination chemistry of the N2O series of ligands using 
the metal chloride salts which were used for the N2 series produced predominantly 
hydrolysis of the ligand and the precipitation of the 2-picolylamine metal complexes. 
Perchlorate salts were therefore used which were less prone to inducing hydrolysis 
during complexation reactions. 
 
Scheme 2.33. Reagents and conditions: i) Cu(ClO4)2.6H2O, EtOH, 40%. 
Direct reaction of the ligand 2.33 with Cu(ClO4)2.6H2O in ethanol produced a dark 
green solid upon cooling (Scheme 2.33). Elemental analysis indicated that it 
contained four water molecules, a perchlorate anion in addition to the ligand and the 
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Cu(II) centre. The presence of one perchlorate anion suggests the 
monodeprotonation of either the ligand or one of the water molecules. Given that 
phenolic protons typically have pKa values in the region of 4-10 and water has a pKa 
of 15, it is most likely that the ligand is deprotonated as these phenolic protons are 
more acidic. This acidity is further increased upon complexation to a metal which 
makes it probable that it is the ortho-phenolic group which participates in binding to 
the metal which is deprotonated.  
The IR spectrum reveals telling changes which identify the interactions of the Cu(II) 
with the ligand. The νO-H band occurs as a medium intensity, relatively sharp signal at 
3435 cm-1 in the ligand. After complexation, there are is a broad band at 3454 cm-1 
and a broad band from 2950 to 3250 cm-1 which could be attributed to νO-H and νH2O. 
The imine νC=N band shifts 11 cm-1 upon complexation from 1622 to 1633 cm-1 
confirming its participation in the metal coordination while the νpyr shows a 10 cm-1 
shift from 1480 to 1490 cm-1. The presence of the perchlorate anion is clearly 
observed by the characteristic bands at 625 and 1088 cm-1 and the lack of a new band 
in the region of 650 cm-1 indicates that the perchlorate is not coordinated to the Cu(II) 
ion. 
a
 
Scheme 2.34. Reagents and conditions: i) Cu(ClO4)2.6H2O, EtOH, 89% 
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Attempts were made to synthesize the 2:1 complex of 2.33 by refluxing three 
equivalents of the ligand with Cu(II) perchlorate and attempting to induce 
precipitation in the same manner as 2.40. However, this did not produce the 
intended product (Scheme 2.34). Instead, hydrolysis of the ligand occurred and the 
2-picolylamine produced reacted with the Cu(II) perchlorate to generate the 
compound 2.42 which precipitated as a lilac powder.  
The structure of the product was identified by the synthesis of the bis-(2-
picolylamine)diperchloratecopper complex 2.42 and a comparison of the IR spectra 
and elemental analyses. Unequivocal proof of the structure was confirmed by X-ray 
crystallography which matched the structure previously reported by Sarma (Figure 
2.50).90 This revealed an octahedral trans-[Cu(2-picolylamine)2(ClO4)2] structure, 
contrary to an earlier report which erroneously identified  it as a square planar [Cu(2-
picolylamine)2].2ClO4 complex.91 The weak Cu-OClO3 interactions do not significantly 
alter the vibrational symmetry of the perchlorate anion and hence do not show easily 
identifiable peaks in the IR spectrum of the complex which would typically be used 
to determine the coordination of the perchlorate anion. This type of interaction has 
been described previously as ‘semi-coordination’.92 Molar conductivity studies were 
also performed by Ramadan et al.91 which indicated the presence of two anions in 
solution. This is likely due to the dissociation and the perchlorate anions upon the 
dissolution of the compound. The weakness of the Cu(II)- ClO4-  interaction is clearly 
seen in the crystal structure by the elongation of the Cu-O bond which has a length 
of 2.597 Å compared to the Cu-N bond lengths of 2.000 and 2.022 Å. The weakness 
of this bond can be attributed to weak coordinating ability of the perchlorate anion 
due to the delocalization of the negative charge across the perchlorate anion and 
also the Jahn-Teller distortion observed in octahedral d9 complexes. This causes 
distortion of the octahedral geometry which in this case elongates the Cu-O bond 
and weakens the interaction. 
The crystal displays a triclinic unit cell (Figure 2.51) which exhibits hydrogen bonding 
between aromatic N-H groups and perchlorate Cl-O groups and also short 
interactions between the perchlorate anion and aromatic C-H. Surprisingly there are 
no π stacking interactions observed. 
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Figure 2.50. Crystal structure of 2.42 
 
Figure 2.51. Unit cell of 2.42 
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Scheme 2.35. Reagents and conditions: i) Zn(ClO4)2.6H2O, 94% 
2.33 was reacted with Zn(ClO4)2.6H2O in refluxing ethanol to produce a hygroscopic 
yellow solid (Scheme 2.35). This was lyophilized to yield a yellow powder which 
elemental analysis revealed to be the 1:1 complex 2.43. Also present was one 
molecule of water present and one perchlorate anion, similar to the product 
observed for the 1:1 Cu(II) complex 2.41. As only one perchlorate anion is present it 
can be deduced that the ortho-phenolic proton dissociated following the 
coordination of the Zn(II) ion. The IR spectrum shows a strong broad band at 3347 
cm-1 corresponding to the νH2O while the νO-H is present at 3307 cm-1. The imine νC=N 
exhibits a sharp band at 1611 cm-1 while the νpyr shows a shift from 1480 to 1489 cm-
1 upon complexation. The perchlorate anion shows bands at 625 and 1089 cm-1 and 
the absence of a new band in the region of 650 cm-1 rules out the possibility of 
coordination with the metal. 
While the compound could be isolated and characterized in the solid state, it proved 
to be very susceptible to hydrolysis in solution. This made it difficult to obtain 
satisfactory 1H NMR data and impossible to obtain 13C NMR data, as the complex 
undergoes hydrolysis over the time necessary to complete the NMR experiment. 
Only the 2, 4-dihydroxybenzaldehyde and [Zn(2-picolylamine)2].2ClO4 complex (2.44) 
were observed. The hydrolysis occurred in all solvents screened, namely in ethanol, 
MeOD, CDCl3, anhydrous CD3CN, d8-THF and d6-DMSO. This sensitivity towards 
hydrolysis is a crucial problem in the synthesis of this compound as the product will 
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hydrolyse with prolonged reaction time. This also made it impossible to generate the 
2:1 Zn(II) complex as was also seen with the analogous Cu(II) complex. As with the 
Cu(II) complex, the [Zn(2-picolylamine)2].2ClO4 complex was synthesized directly and 
the characterization data compared to confirm the composition of the hydrolysis 
product (Scheme 2.36). 
 
Scheme 2.36. Reagents and conditions: Zn(ClO4)2.6H2O, EtOH, 94%. 
The structure of the hydrolysis product was determined by X-ray crystallography of 
crystals which grew from an NMR sample of 2.43 in d8-THF. This revealed the 
formation of 2:1 2-picolylamine Zn(II) complex 2.44 with non-coordinating 
perchlorate anions (Figure 2.52). The structure shows considerable disorder due to 
the multiple orientations of the perchlorate anion, therefore the perchlorate oxygen 
atoms modelled in two positions with occupancies of 69/31%.   
 
Figure 2.52. Crystal structure 2.44 
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The structure reveals a 4-coordinate complex with the two bidentate 2-picolylamine 
ligands coordinated in a syn fashion, unlike the analogous Cu(II) complex where they 
were observed to orientate in an anti orientation. The structure is distorted and has 
a 𝜏4
′  value of 0.70 which suggests a seesaw type geometry (𝜏4
′ = 0.64).93 This is an 
extremely unusual geometry for Zn(II) which has only been reported once in the 
literature to date for a zinc compound which contained Zn(0).94 
 
Figure 2.53. Unit cell of 2.44 
The unit cell displays a tetragonal crystal system and is displayed with only one 
possible orientation of the perchlorate anion for clarity (Figure 2.53). The primary 
intermolecular forces are hydrogen bonds between perchlorate anions and NH2 
groups with close contacts also observed between the perchlorate ion and pyridyl C-
H’s. Parallel displaced π stacking is also observed with a bond distance of 3.805 Å and 
a displacement angle of 15.57°. 
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Scheme 2.37. Reagents and conditions: i) Fe(ClO4)2. xH2O, MeOH, 45 °C 
Attempts were made to synthesize an Fe(II) complex using inert conditions similar to 
those used to generate 2.41 and 2.43 (Scheme 37). Addition of the solution of 
Fe(ClO4)2. xH2O to a solution of excess ligand immediately produced a dark black solid 
which forms a deep brown solution when highly diluted. This colour is more typical 
of Fe(III) complexes and would suggest that oxidation of the Fe(II) has occurred, most 
likely by the redox active phenolic groups as degassed solvent was used. Reaction of 
the product with potassium ferrocyanide does not produce the deep blue colour 
which would be expected of an Fe(II) compound. However, this could be due to 
kinetic or thermodynamic inertness and is not unequivocal proof of the oxidation 
state of the metal. The reaction was repeated using Fe(ClO4)3.H2O and this yielded a 
similarly coloured product, however the IR spectrum and elemental analyses did not 
match those of attempted reaction to form 2.45. 
The IR spectrum indicates a strong interaction between the Fe centre and the imine 
due to the large shift in the νC=N stretch from 1622 to 1607 cm-1 and coordination of 
the pyridine ring is shown by the shift in the νpyr stretch from 1480 to 1475 cm-1. No 
bands corresponding to the perchlorate anion are present in the spectra which 
indicates that the complex has reached neutrality by the deprotonation of the inner 
sphere ligands. The results of the elemental analysis did not correspond to any likely 
complexes of the ligand or hydrolysis products with the metal.  
The material obtained is highly insoluble in all solvents with the exception of DMSO 
and DMF and exhibits a melting point above 300 °C which makes it likely that a 
polymeric material has formed. This is commonly encountered with Fe(III) which 
readily forms oxo and hydroxo bridged structures. Magnetic moment studies reveal 
that the iron is paramagnetic which suggests the presence of high spin Fe(II) or Fe(III) 
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however the molar susceptibility cannot be determined without knowledge of the 
molecular composition. This data does not provide enough evidence to suggest a 
likely structure for the complex formed. Extensive effort was exerted to grow crystals 
suitable for X-ray analysis, however these were unsuccessful. 
 
 
Scheme 2.38. Reagents and conditions: i) Cu(ClO4)2.6H2O, EtOH, 42% 
Upon reaction with an ethanolic solution of an excess of 2.34, Cu(ClO4)2.6H2O   
formed the bridged dimeric complex 1.38 as revealed by X-ray analysis (Scheme 
2.32).  The IR spectrum displays a single band 622 cm-1 with no extra peak observed 
in the region of 650 cm-1 which confirms that there is no interaction between the 
perchlorate ion and the Cu(II) centre. Elsewhere in the spectrum changes can be 
observed in a shift and broadening of the νO-H band found at 3267 cm-1 in the ligand 
which occurs at 3431 cm-1 in the metal complex. This can be attributed the 
interaction of the terminal alcohol with the copper centre. The imine νC=N shifts 12 
cm-1 to 1641 cm-1 while the νpyr shifts from 1479 to 1489 cm-1 confirming its 
coordination with the Cu(II) centre.  
The magnetic moment of the compound is significantly lower than the spin only 
approximation would predict. This can be explained by antiferromagnetic coupling 
between the copper atoms which is commonly observed in bridged polynuclear 
metal complexes. This effect leads to the partial quenching of the paramagnetism of 
the complex due to the close proximity of the metal ions joined by the bridging 
ligands. When the metal centres are ordered in such a close proximity the unpaired 
electrons of neighbouring copper atoms can align themselves in opposing directions, 
thus reducing the net magnetism of the molecule. 
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Crystals were obtained after storing the reaction filtrate in a freezer for one year. 
Upon analysis, this revealed a tetranuclear structure composed of two bridged 
binuclear subunits with two perchlorate counter ions and two water molecules of 
solvation. (Figure 2.54). 
  
 
 
Figure 2.54. Crystal structure of 2.46. Hydrogen atoms omitted for clarity. 
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Figure 2.55. Asymmetric unit of 2.46 showing disorder water molecule position 
(32:49:19% occupancy). Hydrogen atoms omitted for clarity. 
The compound exhibits two distinct 5-coordinate square pyramidal Cu(II) centres 
with N2O3 coordination spheres. One centre (Cu1 in Figure 2.55) is coordinated in a 
tridentate fashion by 2.34 which adopts a planar orientation and displays an N-N bite 
angle of 82.87° and an N-O bite angle of 92.54°. The N-Cu bond lengths are 1.940 and 
1.994 Å which are shorter than those of the corresponding N2 copper complex 
described vide supra which indicates the stronger binding of the metal by this ligand. 
The chelating phenoxide oxygen displays a similar bond length of 1.937°. The fourth 
coordination site of the planar arrangement is occupied by a hydroxide molecule 
which bridges the two Cu(II) centres. This displays a slight asymmetry in its 
coordination to both copper centres with O-Cu bond lengths of 1.919 and 1.934 Å 
and a μ-[Cu-O-Cu] angle of 107.91°. The axial position of the square pyramidal 
structure is occupied by the primary alcohol of another molecule of 2.34 to which 
forms the dimer. As is typically observed for square pyramidal structures, this bond 
is highly elongated with a length of 2.526 Å. The square pyramidal geometry is slightly 
distorted with a geometry index of τ5= 0.21. 
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The other Cu(II) centre present in the crystal (Cu2 in Figure 2.55) presents a similar 
N2O3 square pyramidal coordination sphere. This is comprised of the tridentate 
ligand 2.34, a bridging hydroxide and a bridging phenoxide. Unlike the other Cu(II) 
centre, the phenoxide moiety of this ligand does not show any interaction with the 
other copper centre. The bite angles of the ligand are similar to that observed in the 
other copper centre with an N-N angle of 82.17° and an N-O angle of 94.00°. The 
imino N-Cu bond length is identical to that of the previously described copper centre 
however the pyridyl N-Cu bond is slightly longer with a length of 2.007 Å. As is to be 
expected, the non-bridging phenoxide O-Cu bond is shorter that its counterpart in 
the other coordination centre measuring 1.926 Å. The bridging hydroxide occupies 
the final planar coordination site trans to the imino nitrogen and is bonded at a 
distance of 1.934 Å. 
The axial position of this species is occupied by the bridging phenoxide of the ligand 
chelated to the other Cu(II) centre present in the asymmetric unit. The bond is longer 
than the equatorial bonds with a length of 2.400 Å. However, it is shorter than that 
of the axial interaction observed in the other Cu(II) coordination sphere. The μ-[Cu-
(Ph-O-)-Cu] angle is 16.72° smaller than that of the hydroxide bridge measuring 
91.19°. The coordination geometry of this centre is closer to an ideal square pyramid 
with Addison’s parameter τ5= 0.04. 
The crystal displays a triclinic unit cell and is composed entirely of a single 
tetranuclear complex (Figure 2.56). This forms relatively few intermolecular 
interactions with other molecules in the crystal with only two hydrogen bonds 
observed; perchlorate-μ(OH) and perchlorate-(CH2OH). Other interactions observed 
are hydrophobic interactions between the CH2 chains and the aromatic rings and 
parallel displaced π-π stacking between the pyridine and aryl ring with a distance of 
4.094 Å and a displacement angle of 32.57°. 
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Figure 2.56. Unit cell of 2.46 
 
 
 
Scheme 2.39. Reagents and conditions: i) Zn(ClO4)2.6H2O/ Zn(NO3)2.6H2O/ ZnCl2 
Efforts towards the synthesis of the Zn(II) complex of 2.34 did not prove fruitful. All 
attempts made using different solvents, reaction temperatures and Zn(II) salts such 
as ZnCl2, Zn(ClO4)2.6H2O and Zn(NO3)2.6H2O failed to produce any identifiable 
complex other than the hydrolysis product 2.34. 
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Scheme 2.40. Reagents and conditions: i) Cu(ClO4)2.6H2O, EtOH, 44%. 
The Cu(II) complex of glycosylated ligand 2.35 was synthesized by the reaction of the 
2.35 with Cu(ClO4)2.6H2O in cold ethanol to produce a green precipitate (Scheme 
2.40). The elemental analysis revealed a 1:1 complex with one perchlorate anion and 
four molecules of water, similar to the coordination sphere observed in the aglycon 
2.41. The IR spectrum shows an ill-defined broad band 3465 cm-1 corresponding to 
the νH2O stretch while the imine νC=N exhibits a rather small shift from 1635 to 1628 
cm-1 which is less than that seen upon the formation of 2.41 which could suggest a 
weaker binding interaction. Coordination of the pyridine ring is deduced by the shift 
from 1474 to 1483 cm-1 and the presence of the perchlorate anion is confirmed by 
the appearance of bands at 626 and 1110 cm-1. Examination of the region around 
650 cm-1 does not reveal any new peaks which makes the coordination of the 
perchlorate anion unlikely.  
 
Scheme 2.41. Reagents and conditions: i) Zn(ClO4)2.6H2O, 39% 
2.48 was synthesized by the direct reaction of the ethanolic solutions of the ligand 
2.35 and Zn(ClO4)2.6H2O (Scheme 2.41). The 1:1 coordination was confirmed by mass 
spectroscopy and also elemental analysis. The IR spectrum of the complex is nearly 
identical to that of 2.43 with identical shifts observed in the νH2O, νC=N and νpyr which 
suggests a similar coordination sphere with no coordination of the perchlorate anion 
(Figure 2.57). Both the 1H NMR and 13C NMR spectra showed hydrolysis of the metal 
complex in solution.  
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Figure 2.57. IR Spectra of 2.47 and 2.48 
 
 
Scheme 2.42. Reagents and conditions: i) Cu(ClO4)2.6H2O, 71% 
 
Cu(II) complex 2.49 was synthesized by the reaction of 2.36 with Cu(ClO4)2.6H2O in 
refluxing ethanol and cooling to produce a dark green solid (Scheme 2.42). Elemental 
analysis reveals the formation of the 1:1 complex with one perchlorate anion, 
analogous to the other Cu(II) complexes of the N2O series. The IR spectrum exhibits 
a shift in the νO-H peak from 3467 to 3448 cm-1 which is significantly broader in the 
metal complex due to the overlapping νH2O stretch. The imine νC=N band shows a small 
shift from 1630 to 1627 cm-1 similar to the shift observed in the complexes of the 
ligands featuring direct glycosylation. The coordination of the pyridine ring is inferred 
by the shift in the νpyr band from 1476 to 1489 cm-1. It is proposed that the 
perchlorate anion is not coordinated to the copper centre due to the absence of a 
band in the 650 cm-1 region. 
 
2.47 
2.48 
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Scheme 2.43. Reagents and conditions:  i) Zn(ClO4)2.6H2O. 64%  
As with 2.49, Zn(II) complex 2.50 was synthesized by the reaction of excess ligand 
2.36 and the perchlorate salt in refluxing ethanol (Scheme 2.43). Upon cooling, this 
yielded the product as a white solid in addition to a sticky brown residue. The product 
was isolated by decanting the suspension in order to separate it from the brown 
residue which formed a brown oil upon exposure to air. The product darkened 
slightly to form a beige solid upon lyophilization for 24 h. This was shown by 
elemental analysis to be the 1:1 complex. As with compounds 2.47 and 2.48, IR 
analysis reveals near identical spectra for both the Zn(II) and Cu(II) complexes of 2.36 
with a broad νH2O band at 3446 cm-1 and a shift in the νpyr to 1487 cm-1. The νC=N does 
show a distinct shift to a higher wavenumber of 1436 cm-1 unlike the Cu(II) complex 
which caused it to vibrate at a lower energy. Both the 1H NMR and 13C NMR spectra 
showed hydrolysis of the metal complex in solution. 
 
2.4   Conclusion 
The aim of this work was to synthesize novel ligands and their glucosylated analogues 
and also to investigate their coordination chemistry. Two series of ligands, namely 
the N2 and N2O series, were obtained, characterized and their syntheses optimized. 
Their coordination chemistry with Cu(II), Zn(II) and in some cases Fe(II) was 
investigated and the resulting metal complexes were characterized by IR 
spectroscopy elemental analysis and, where applicable, NMR, magnetic susceptibility 
and X-ray crystallography. 
The initial investigations into the N2 imine ligands did not prove fruitful as the ligands 
were too prone to hydrolysis to be satisfactorily characterized or form stable metal 
complexes. The synthesis of the N2 amine series of ligands was much more successful 
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however, it was not trivial as problems caused by the instability of the imine 
intermediates presented significant challenges. With optimized reaction conditions 
and meticulous attention to the reaction set up, the ligands can be synthesized in 
good yields and high purity. The N2O series on the other hand was quite easily 
synthesized in high yield and purity stemming from the high thermodynamic stability 
of the hydrogen bond stabilized imine and their insolubility in ethanol, which allows 
for the precipitation of the product to drive the reaction to completion.  
While the ligand synthesis presents more difficulty than the N2O ligand series, the 
coordination chemistry of the N2 series offers greater scope developing novel 
compounds. A wide selection of homo and heteroleptic complexes could be obtained 
with both chloride and perchlorate metal salts. The metal complexes are stable and 
could be completely characterized with ease. Several compounds were obtained as 
crystals which allowed for characterization by X-ray crystallography. These 
compounds would be expected to be more attractive as antikinetoplastic agents as 
they have superior stability in the solid and solution phase and therefore, are more 
likely to retain their composition in vivo for a longer time than the complexes of the 
N2O series. 
The coordination chemistry of the N2O is rather limited with only heteroleptic 1:1 
complexes obtained. The Lewis acid promoted hydrolysis of the N2O proved to be a 
significant issue in the synthesis of stable metal complexes. Due to this, no 
homoleptic complexes were obtained and some of the complexes showed instability 
in solution which made complete characterization by NMR impossible. Several 
complexes were hygroscopic, which further presented difficulty in obtaining 
satisfactory characterization data. This instability is highly undesirable for bioactive 
compounds as it is possible that the compound will decompose in vivo before it can 
get to the site of action and the degradation products could present undesired side 
effects. 
To the best of our knowledge, this work presents the first example of glycosylated 
Cu(II) and Zn(II) metallotherapeutics and also the first investigations into this strategy 
for the design of antiparasitic compounds. 
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Chapter 3: Biological Evaluation of Novel Antiparasitic Agents 
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3.1   Aim 
The first aim of this chapter was to perform a preliminary evaluation the biological 
effects of a selection of compounds from the N2 and N2O series of compounds 
described in Chapter 2(Figure 3. 1). Firstly, the compounds were studied to establish 
their in vitro safety in mammalian cells. Following this, their inhibitory effects 
towards the viability of L. amazonensis amastigotes and T. cruzi trypomastigotes 
were investigated in vitro. The compounds which showed the highest inhibitory 
activity were then studied further to gain information about their toxicity in vivo 
using the Galleria mellonella model. The biological evaluations of cytotoxicity and 
antiparasitic activity detailed in Sections 3.2.1, 3.2.2 and 3.2.3 were carried out by 
the group of Prof André Luis Souza dos Santos at the Microbiology Institute Paulo de 
Góes in Universidade Federal do Rio de Janeiro (UFRJ). All experiments were 
performed in triplicate, in three independent experimental sets. The data were 
analysed statistically by means of Student’s t-test using EPIINFO 6.04 computer 
software. P values of 0.05 or less were considered statistically significant.   
 
Following analysis of the data obtained from the above biological testing, it was 
attempted to establish a preliminary structure-activity relationship effected by the 
various modifications to the ligand core, namely glycosylation, alkylation, and 
metalation, on their antiparasitic activity. Finally, to investigate if the glycosylated 
compounds can act as pro-drugs, enzymatic hydrolysis studies were carried out.  
 
 
Figure 3. 1. Structures of compounds selected for biological investigation. 
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3.2   Results and Discussion 
3.2.1   Evaluation of In Vitro Cytotoxicity to Macrophage Cells 
The selected compounds (Figure 3. 1) were initially screened to assess their 
cytotoxicity. This testing was carried out by the group of Prof Santos at URFJ and was 
determined using RAW 264.7 murine macrophage cells. The compounds were 
administered across a range of concentrations and the viability of the macrophage 
cells was determined after 24 h using an MTT assay. The CC50 value, a measure of 
how much of a compound will inhibit the growth of a population of cells by 50%, was 
determined for each of the compounds and the results can be seen in Figure 3. 2 and 
Figure 3. 3.   
 
Figure 3. 2. Cytotoxicity of selected compounds on RAW macrophages. Mammalian 
cells (105 cells) were incubated in a 96-well plate for 48 h (RAW) in the absence (white 
bars) or in the presence of single doses of the compounds at a range of concentrations 
(black bars). Viability was determined spectrophotometrically at 570 nm by MTT 
assay.  
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Figure 3. 3. Cytotoxicity of selected compounds on RAW macrophages. Mammalian 
cells (105 cells) were incubated in a 96-well plate for 48 h (RAW) in the absence (white 
bars) or in the presence of single doses of the compounds at a range of concentrations 
(black bars). Viability was determined spectrophotometrically at 570 nm by MTT 
assay. 
From these results, we can see that the N2 compounds are more cytotoxic that the 
corresponding compounds from the N2O series, for example the aglycon ligand 2.3 is 
almost twice as cytotoxic as the N2O analogue 2.33. This trend can also be observed 
in the metal complexes of these ligands; the Zn(II) complex of 2.3 has a CC50 value of 
118.2 µM while the Zn(II) complex of 2.33 was so well tolerated by the cells that the 
CC50 value was not determined as it was above the concentration range tested. 
However, this compound was found to be unstable in solution so it is likely that the 
tested compound is in fact a hydrolysis product. 
Glycosylation of the N2 ligands proved to be highly effective at decreasing the 
cytotoxicity of the compounds. This is clearly demonstrated by the increase of the 
2.33 
CC50: 307.5 μM 
2.35 
CC50: 196.1 μM 
2.34 
CC50: 296.9 μM 
2.36 
CC50: 240.4 μM 
2.41 
CC50: 132.8 μM 
2.43 
CC50: >400 μM 
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CC50 value of 2.3 from 155.4 µM to 234.5 µM upon glycosylation with peracetylated 
glucose. This effect also occurs in the metal complexes with 2.25 exhibiting a 
cytotoxicity value of 21.4 µM higher than the aglycon analogue. Interestingly, the 
opposite effect was observed for the N2O series of compounds; 2.35 presents with a 
CC50 value more than 100 µM lower than 2.33 while the ligands featuring an ethylene 
group on the phenolic moiety also showed this effect. 2.36 displays a CC50 value of 
240.4 µM, while the parent aglycon is less toxic with a value of 296.9 µM. 
Metalation of the N2 compounds increases their cytotoxicity. The Zn(II) (2.22) and 
Cu(II) (2.20) complexes of 2.3 both exhibited lower CC50 values than the parent ligand 
(118.2 μM and 106.2 μM vs 155.4 μM respectively). This was also seen for the Cu(II) 
complex (2.25) of the glucosylated ligand 2.15 which showed a reduction of 106.9 
μM in the CC50 value. The metal complexes of the N2O series on the other hand 
showed no clearly identifiable trend. The ligand 2.33 possessed a CC50 value of 307.5 
μM while the Fe(II) complex 2.45 showed a similar value of 333.1 μM, the Cu(II) 
complex 2.41 was more cytotoxic with a value of 132.8 μM while the corresponding 
Zn(II) complex was well tolerated across the entire concentration range studied and 
therefore was not determined. CuCl2.2H2O and ZnCl2 did not show any toxicity. 
Overall these results are very promising as they demonstrate that the drugs are well 
tolerated by mammalian cells at relatively high dosages without affecting the viability 
of the cells. This attribute is an essential for drug candidates as it is necessary for 
them to be well tolerated by the host while the dosage is high for the compound to 
exert its therapeutic effect. The CC50 values obtained show that the ligands and metal 
complexes of both the N2 and N2O series do not possess appreciable cytotoxicity and 
therefore could be administered to a mammal without expecting any significant toxic 
effects in vivo. This confirms that the compounds could have potential as agents for 
the treatment of parasitic diseases in humans.  
 
3.2.2   Evaluation of Antileishmanial Activity 
3.2.2.1   In Vitro Studies on L. amazonensis Viability 
In order to assess the ability of the compounds to inhibit the growth of L. 
amazonensis, in vitro studies utilizing L. amazonensis promastigotes were performed 
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by Prof Santos and co-workers at URFJ. Metacyclic promastigotes are one of two 
structural forms of L. amazonensis which occur during the life cycle of the parasite. 
The promastigote form is significantly larger than the amastigote form and possesses 
a flagellum which allows it to be mobile inside the host organism.  This form is present 
in the extracellular matrix and is responsible for the infection and proliferation of the 
parasite inside a mammalian host.95  
All compounds were administered to L. amazonensis promastigotes at an initial 
concentration of 50 µM and the viability was examined after 72 h by motility and the 
lack of Trypan blue staining.96 Of the twelve compounds assayed, seven of them were 
able to significantly inhibit the proliferation of the parasites (Figure 3.4). DMSO, ZnCl2 
and CuCl2.4H2O were used as controls and did not exhibit any antiparasitic activity.  
Following this preliminary investigation, the assay was repeated with compounds 
2.3, 2.22, 2.20, 2.33, 2.43, 2.41, 2.45, 2.34, 2.15, 2.25, 2.35 and 2.36 at a lower 
concentration of 10 µM and the viability of the parasites was quantified. As can be 
seen in Figure 3. 5, five of the compounds assayed retained the ability to effectively 
inhibit the proliferation of L. amazonensis promastigotes (Figure 3. 6). 
 
Figure 3. 4. Effects of selected compounds on the proliferative rate of L. amazonensis 
promastigotes. The proliferation of promastigotes was followed at 28 °C in 
absence/presence of the compounds (50 µM). The viable parasites were counted by 
Trypan blue exclusion and motility in a Neubauer chamber after 72 h of incubation. 
Results are expressed as number of viable cells.  
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Figure 3. 5. Effects of selected compounds on the proliferative rate of L. amazonensis 
promastigotes. The proliferation of promastigotes was followed at 28 °C in 
absence/presence of the compounds (10 µM). The viable parasites were counted by 
Trypan blue exclusion and motility in a Neubauer chamber after 72 h of incubation. 
Results are expressed as number of viable cells. 
 
 
Figure 3. 6. Compounds capable of inhibiting the viability of L. amazonensis at 10 μM. 
 
Once the most efficacious compounds had been identified, their potency was 
determined by administering the compounds across a range of concentrations and 
determining the viability of the parasites. Using this data, the IC50 value for each of 
the five compounds assayed could be determined. Amphotericin B, the current gold 
standard drug for the treatment of leishmaniasis, was also assayed ( 
Figure 3. 7).  
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From these values, it can be seen that the most potent compound is the Zn(II) 
complex 2.22 which is almost 20 times more efficacious than the ligand itself 2.3. This 
non-metallated, aglycon ligand proved to be the least active of the five compounds 
selected for further study. Glucosylation of this ligand 2.15 also increased its activity 
to a lesser degree with a 3.5-fold increase in activity over the aglycon ligand 2.3. Both 
compounds of the N2O series assayed, namely the Zn(II) containing 2.43 or its 
hydrolysis products, and the glucosylated 2.35 showed only moderate antiparasitic 
activity. While all of the compounds assayed showed inferior activity to Amphotericin 
B, the activity of 2.22 exceeds that of the pentavalent antimonial drugs which are 
more commonly used to treat the disease.97  
 
 
Figure 3. 7. IC50 values determined for selected compounds. The viable parasites were 
counted by Trypan blue exclusion and motility in a Neubauer chamber after 24 h of 
incubation. 
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With these IC50 values, it is possible to calculate the selectivity index (SI) for each of 
these compounds. This value describes the ratio between the dose of a compound 
needed to affect its desired pharmacological effect (in this case the inhibition of L. 
amazonensis viability), and the dose which is toxic to healthy mammal cells (RAW 
246.7 murine macrophages). This data is presented in Table 3.1. 
Table 3. 1. Summary of antileishmanial activity and selectivity indices. 
The data shows that all of the five compounds selected have selective antileishmanial 
activity. The least selective of the compounds studied was 2.3 which presented with 
an SI of 6.1 which indicates only a moderate selectivity for antileishmanial activity 
compared to its toxicity to RAW cells. However, its glucosylated analogue 2.15 is over 
5 times more selective with an SI of 33, highlighting the benefit of carbohydrate 
conjugating in improving the tolerance of the compounds by mammalian cells. Of the 
N2O compounds, glucosylated ligand 2.35 showed a moderate selectivity of 10.7. This 
was exceeded by the aglycon Zn(II) complex 2.43, or its hydrolysis products, which 
showed an improved SI of >23.4. However, since the exact CC50 value was not 
determined, an accurate value for the selectivity of the compound cannot be 
deduced. 
Of the compounds assayed, the Zn(II) complex 2.22 is by far the most efficacious. Its 
low IC50 value coupled with its high CC50 value demonstrate that it is a highly selective 
antileishmanial compound with an SI of 90.9. This SI value far exceeds that of the 
compounds currently used to treat Leishmaniasis; miltefosine (SI: 0.2),98 
amphotericin B (SI: 3.1) and paromomycin (SI: 25).99 This is an exceptional result and 
 
Compound 
RAW 
CC50 (μM) 
L. amazonensis 
IC50 (μM) 
RAW/L. 
amazonensis  
SI 
2.3 155.4  25.3 6.1 
2.15 234.5  7.1  33 
2.22 118.2  1.3  90.9 
2.35 196.1  18.4  10.7 
2.43 >400  17.1  >23.4 
Amp. B 37.4 0.012 3.1 
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clearly identifies this compound as worthy of further investigation as a novel 
antileishmanial therapy. 
3.2.2.2   L. amazonensis Promastigote Morphology Studies 
In order to gain an insight into the effects that the compounds have on the parasites, 
L. amazonensis were administered with the most efficacious compounds 2.3, 2.22, 
2.15, 2.43 and 2.35 at IC50 concentrations and their morphology was examined using 
light microscopy after 24 h (Figure 3. 8). These studies were performed by Prof Santos 
and co-workers at URFJ. 
 
Figure 3. 8. Effects of selected compounds on the morphology of L. amazonensis. 
Untreated parasites used as a control show a clearly defined kinetoplast (k), a central 
nucleus (n) and a long flagellum (f) attached to the cell body.  Treatment of the 
parasites with the compounds induced several changes to the morphology of the 
parasites, namely the rounding in shape of the cell body coupled with a reduction in 
cell size (arrow head), swelling of the cell body (black arrow) and the loss of the 
flagellum (white arrow). Parasites were also treated with DMSO which did not cause 
any changes in the morphology. 
Control 2.3 2.15 
2.22 2.35 2.43 
92 
 
The most common morphological change effected by the compounds are a rounding 
in shape of the cell which is coupled with a reduction in the size of the promastigote. 
This would suggest that the compounds are involved in inhibiting the development 
of the kinetoplast cytoskeleton which causes the loss of the elongated cell body that 
the parasites typically display. This change was caused by all of the compounds 
studied which may indicate a general response of the parasites to a toxic event. Both 
Zn(II) compounds 2.22 and 2.43 and the glycosylated N2O ligand 2.35 treated cells 
showed a loss of flagellum by several of the parasites in addition to the reduced cell 
size and loss of cell structure. Interestingly, parasites treated with 2.3 also showed 
swelling of the cell body. This may be related to the damage to the cytoskeleton as 
the cells retain their typical length but lose their defined shape. In addition, the 
parasites appear to lose the distinct structure of the DNA containing nuclei and 
kinetoplasts which could indicate that the compounds act through the disruption of 
DNA replication and localization. This effect has been observed to be caused by 
compounds which are known to interfere with these processes, showing visible 
changes to these organelles.100,101,102,103 However, a more detailed study would need 
to be performed to investigate this in detail. 
While the mode of action cannot be determined from these observations, it does 
demonstrate the significant damage effected by the compounds on the parasites and 
the morphological changes that result from this damage. 
3.2.2.3   Insights Gained from Biological Studies of L. amazonensis 
From these studies, it can be seen that all compounds from the N2 series show potent 
antileishmanial activity with the exception of the copper complexes 2.20 and 2.25. 
The N2O aglycon ligands showed no significant activity however both metalation and 
glycosylation granted these compounds a degree of antileishmanial activity. The 
alkylation of the para phenolic group significantly decreases the activity of the 
compounds. When assayed at 50 µM, the direct glucose conjugate 2.35 showed an 
almost 20-fold improvement in leishmanial inhibition when compared to 2.36, which 
contains an ethylene linker. A similar but less pronounced difference is also observed 
in the aglycon ligands 2.34 and 2.33.  
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The Cu(II) complexes 2.20, 2.25 and 2.41 did not show significant inhibitory affects 
with the exception of 2.41 which showed slightly less than half the proliferation of L. 
amazonensis when compared to the control. Complexation of the antileishmanial 
ligands 2.3 and 2.15 with Cu(II) served to reduce their in vitro activity which suggests 
that this metal interferes with the mechanism by which the N2 compounds exert their 
antileishmanial effects.  
Both Zn(II) complexes 2.22 and 2.43 showed highly enhanced activity over their 
parent ligands 2.3 and 2.33, with 2.22 showing complete inhibition of parasite 
growth at 50 µM and almost complete inhibition at 10 µM. ZnCl2 did not show any 
activity which clearly demonstrates the synergistic effect of complexing the metal 
with the ligand, which possesses only moderate antileishmanial activity in isolation. 
This could occur by three possible mechanisms; 
1) The Zn(II) complexes may act through entirely new mode of action inside the cell 
than the parent ligand. 
2) The complex may increase the uptake of the ligand into the cell and enhance its 
therapeutic effect by enacting its antiparasitic action through the same 
mechanism as the ligand in isolation. 
3) The compounds may behave as ionophores to provide an enhanced uptake of 
the metal into the cell.  The coordination of the metal to an organic ligand 
increases its lipophilicity and therefore its ability to cross the cell membrane by 
passive diffusion. The complex could dissociate inside the cell wherein the ligand 
could affect its antileishmanial effects as seen by 2.3 in isolation with additional, 
synergistic antiparasitic activity coming from the metal ion independent of the 
ligand. 
As discussed in Chapter 2, Zn(II) complexes have successfully been used to treat 
Leishmania infections in vivo. As demonstrated in this study, complexation with Zn(II) 
can be used to enhance the activity of antikinetoplastic compounds. The cause of the 
antileishmanial activity of Zn(II) remains unclear although several modes of action 
have been proposed. Work by the group of Al-Mulla Hummadi has observed that 
Zn(II) complexes possess immunomodulatory properties and increases the number 
and activity of peritoneal macrophages in a murine model infected with L. tropicana 
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and L. major. They propose that this occurs by the activation of NADPH-oxidase 
bound to the surface of the macrophage membrane which causes a respiratory burst, 
leading to increased phagocytosis.104 In addition to this immunoregulatory activity, 
Zn(II) has also been shown to directly inhibit several enzymes associated with the 
Embden-Meyerhof pathway which is responsible for glucose metabolism in a dose-
dependent manner.105 Rice et al have established that for their structurally similar 2-
picolylamine derived Zn(II) complexes, the presence of Zn(II) is essential for the 
uptake of the ligand into the cell, when evaluated using L. major. While they could 
not establish a mode of action, their preliminary experiments lead them to propose 
that it involves the disruption of the parasite membrane.36 Given the similarity of the 
chelating moiety of their compounds to the N2 series of compounds which we 
investigated, it is likely that they share a common mechanism of action.  
Interestingly, the Fe(II) compound 2.45 showed a remarkable increase in the viability 
of the parasites. Promastigotes treated with the compound proliferated at a rate 
thirteen times higher than the control population. This unusual observation can be 
attributed to the fact that iron is an essential nutrient for kinetoplastic parasites. It is 
utilised in the mitochondria of the parasites as a component of both heme and iron-
sulfur clusters which play an essential role in the electron transport chain.106 
Recently, Mittra et al have identified it as a key modulator of the transformation of 
the promastigote form to the amastigote stage of the parasite life cycle. This work 
demonstrated that reducing iron uptake by knocking out a single gene which encodes 
a mitochondrial iron transmembrane transport protein severely limits the growth of 
L. amazonensis.107  
This effect can be explained by the inhibition of iron generated reactive oxygen 
species (ROS) in the cell. ROS, most importantly H2O2, are emerging to be not just 
toxic by-products of cellular respiration, but are in fact a key regulator of cell 
differentiation.108,109 Iron is widely utilized in nature due to its capacity for redox 
activity which allows for Fenton type chemistry that can both form and passivate 
ROS.110  This redox behaviour is essential for the formation of H2O2 in the cell by the 
conversion of O2- into H2O2 by superoxide dismutase. H2O2 has been identified as one 
of the main signalling molecules that induce the formation of infectious forms of L. 
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amazonensis. Most significantly, this has been directly correlated to the levels of iron 
uptake by the parasite.111 It can therefore be proposed that 2.45 increases the uptake 
of iron inside the cell and thereby increases cell differentiation via this H2O2 signalling 
process, however, further investigation is needed to prove this hypothesis. Given 
that 2.45 was well tolerated by RAW cells (CC50: 333.1 μM), it would appear that this 
redox activity occurs as a controlled process inside the cell, as indiscriminate ROS 
generation inside a mammalian cell would cause significant oxidative stress and 
therefore a low CC50 value. 
3.2.2.4   Conclusion of L. amazonensis Studies 
These studies indicate that all the compounds selected for study are well tolerated 
by RAW murine macrophage cells and therefore are expected to be well tolerated in 
a mammalian body. The in vitro studies on the antileishmanial activity identified five 
compounds which warranted further study into their antileishmanial activity. These 
experiments determined the IC50 values and selectivity indices of the chosen 
compounds. The morphological changes that these compounds affect were 
identified using light microscopy and structural defects were characterised. From 
these investigations, we identified Zn(II) complex 2.22 as a highly attractive potential 
therapeutic due to its high potency and its exceptional selectivity which exceeds that 
of the drugs currently used to treat the disease. 
 
3.2.3   Evaluation of Antitrypanosomal Activity 
3.2.3.1   In Vitro Studies on T. cruzi Viability 
As with L. amazonensis, studies were carried out on all of the compounds selected to 
identify any potentially antichagasic activity. The studies were carried out by Prof 
Santos and coworkers at URFJ using T. cruzi metacyclic trypomastigotes. These are 
one of the two forms of the parasite which are present in infected humans and are 
responsible for both the initial infection from the disease vector and for the spread 
of the infection between regions of the body. In this stage of its life cycle, the parasite 
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possesses a long flagellum which allows it to swim inside the bloodstream of the host 
and thereby quickly infect different organ systems within the infected body. 
All compounds were administered to T. cruzi trypomastigotes at an initial 
concentration of 50 µM and the viability was examined after 24 h by motility and the 
lack of Trypan blue staining.96 Of the twelve compounds assayed, seven of them were 
able to significantly inhibit the proliferation of the parasites ( 
 
Figure 3. 9). DMSO, ZnCl2 and CuCl2.4H2O were used as controls and did not exhibit 
any antiparasitic activity.  
 
 
 
Figure 3. 9. Effects of selected compounds on the proliferative rate of T. cruzi 
trypomastigotes. The proliferation of trypomastigotes was followed at 28 °C in 
absence/presence of the compounds (50 µM). The viable parasites were counted by 
Trypan blue exclusion and motility in a Neubauer chamber after 72 h of incubation. 
Results are expressed as number of viable cells. 
 
Compounds 2.13, 2.22, 2.20, 2.41, 2.15, 2.25 and 2.35 were then assayed at a 
concentration of 10 µM and the viability of the trypomastigotes was quantified as 
before (Figure 3.10). From these studies, six compounds were identified which 
showed good antiparasitic activity and could reduce the proliferation of the 
trypomastigotes (Figure 3. 11). 
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Figure 3. 10. Effects of selected compounds on the proliferative rate of T. cruzi 
trypomastigotes. The proliferation of trypomastigotes was followed at 28 °C in 
absence/presence of the compounds (10 µM). The viable parasites were counted by 
Trypan blue exclusion and motility in a Neubauer chamber after 72 h of incubation. 
The results are expressed as number of viable cells. 
 
 
Figure 3. 11. Compounds capable of inhibiting the viability of T. cruzi promastigotes 
at 10 μM. 
With these compounds identified, it was then determined how potent their 
antichagasic activity was by administering them across a range of concentrations and 
examining the viability of the trypomastigotes. From this study, the IC50 value the SI 
of each of the compounds were determined. Benznidazole, a compound currently 
used in the clinic to treat Chagas disease, was also assayed (Figure 3. 12). 
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Figure 3. 12. IC50 values determined for selected compounds. The viable parasites 
were counted by Trypan blue exclusion and motility in a Neubauer chamber after 24 
h of incubation. 
These results show that the antiparasitic activity of the N2 series is superior to that of 
the N2O analogues. Of the N2O compounds assayed, only the Cu(II) complex 2.41 was 
able to inhibit the growth of T. cruzi trypomastigotes and this was only effective at 
the high concentration of 50 μM. The Cu(II) containing compounds 2.20 and 2.25 all 
displayed the highest activity for each of their respective series, which clearly 
demonstrates the importance of Cu(II) to their antiparasitic activity. The highest 
activity was observed for the N2 Cu(II) complex 2.20 which had an IC50 value of 1.7 
μM while its glucosylated analogue 2.25 showed an almost identical value of 1.8 μM. 
Contrary to this, the free ligands showed reduced activity when compared to their 
Cu(II) analogues. The activity of the non-metallated aglycon and glucose conjugate 
2.3 and 2.15 are once again very similar with values of 4.6 μM and 5.3 μM 
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respectively. The Zn(II) N2 complex 2.22 showed inferior activity to both the free 
ligand 2.3 and Cu(II) analogue 2.20 with an IC50 value of 5.2 μM. The results of these 
experiments are very promising as both 2.20 and 2.25 show more than twice the 
activity of benznidazole, the drug currently used to treat Chagas disease.  
Using these IC50 values, the SI values were calculated with respect to RAW cells and 
are presented in Table. 3.1.  
Table 3. 2.  Summary of antitrypanosomal activity and selectivity indices. 
These studies show that all of the compounds display highly selective toxicity 
towards the trypomastigotes when compared to RAW mammalian cells. The Zn(II) 
compound 2.22 showed the least selective T. cruzi inhibition of all the compounds 
studied with a moderate SI of 22.7. The free N2 ligand 2.3 displayed a good selectivity 
of 33.8 which was exceeded by its glucosylated analogue 2.15 which presented a 30% 
improvement in its SI which was determined to be 44.2. The highest selectivity, 
however, was exhibited by the Cu(II) complexes 2.20 and 2.25. While both 2.20 and 
its glucosylated analogue 2.25 show almost identical IC50 values, the SI of 2.25 is 
superior to that of 2.20 with a very high SI of 70.9. The activity of this compound far 
exceeds that of benznidazole in both its IC50 value (3.8 μM vs 1.8 μM) and its 
selectivity (70.9 vs 47.9). These results clearly demonstrate the remarkable activity 
of 2.25 and highlight its potential as a novel antichagasic agent. 
3.2.3.2   T. cruzi Trypomastigote Morphology Studies 
As with L. amazonensis, the effects of the selected compounds on the morphology of 
T. cruzi trypomastigotes was investigated by Santos et al at URFJ. Compounds 2.3, 
 
Compound 
RAW 
CC50 (μM) 
T. cruzi 
IC50 (μM) 
RAW/T. cruzi  
SI 
2.3 155.4  4.6 33.8 
2.15 234.5  5.3  44.2 
2.22 118.2  5.2  22.7 
2.25 127.6  1.8  70.9 
2.20 106.2  1.7  62.5 
Benznidazole 182.1 3.8 47.9 
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2.15, 2.20, 2.25 and 2.22 were administered at their IC50 values and the parasites 
were examined after 24 h using light microscopy.  
 
Figure 3. 13. Effects of selected compounds on the morphology of L. amazonensis 
Untreated parasites used as a control show a clearly defined kinetoplast (k), a central 
nucleus (n) and a long flagellum (f) attached to the cell body.  Treatment of the 
parasites with the compounds induced several changes to the morphology of the 
parasites, namely the rounding in shape of the cell body coupled with a reduction in 
cell size (arrow head), swelling of the cell body (black arrow) and the loss of the 
flagellum (white arrow). Parasites were also treated with DMSO which did not cause 
any changes in the morphology. 
Similar to the studies on L. amazonensis, the most common morphological defect 
seen was the reduction in cell size together with a loss of the typical elongated shape 
of the cell. This structural damage was induced by all of the compounds studied. The 
cells that showed this damage also displayed a loss of distinct kinetoplasts and nuclei 
which would suggest that the production or localization of DNA was inhibited. The 
loss of flagellum was also observed to be caused by all of the compounds studied and 
was only observed in trypomastigotes which also showed a reduction in cell size and 
rounding of the cell body. It could therefore be inferred that the loss of flagellum is 
Control 2.3 2.15 
2.22 2.25 2.20 
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linked to the same underlying biological process which gives rise to the loss of cell 
structural integrity. 
Another effect observed to be caused by 2.3, 2.15, 2.20 and 2.22 was the swelling of 
the cell body of several of the parasites. These parasites retained the distinct 
kinetoplast and nucleus organelles in addition to their flagellum. The swelling is 
localized to the nucleus of the trypomastigote which could support the hypothesis 
that these compounds interfere with the DNA replication process.  
3.2.3.3   Insights Gained from Biological Studies of T. cruzi 
These studies show that the N2 series of compounds are superior antiparasitic agents 
than their N2O counterparts, similar to the results observed for the evaluation of 
antiparasitic activity in L. amazonensis (Section 3.2.2). All of the N2 compounds 
assayed were capable of inhibiting the growth of T. cruzi trypomastigotes at a 
concentration of 10 μM whereas only the Cu(II) containing N2O compound 2.41 and 
the glycosylated 2.35 showed antichagasic activity at the high concentration of 50 
μM. The aglycon ligand 2.33 and its alkylated analogue 2.34 showed no activity which 
highlights the contribution of the glucose moiety to the activity of the compounds. 
Interestingly, the compound which featured an ethylene linker between the 
carbohydrate and the aromatic ring did not show inhibition of the trypomastigote 
growth whatsoever. This mirrors the observed activity of the compounds towards L. 
amazonensis and could suggest that a para phenolic group is essential to the activity 
of the compounds, as it is possible that the compounds conjugated directly to glucose 
(2.15, 2.25, 2.35 and 2.36) could be enzymatically cleaved to reveal the phenolic 
aglycon. 
While all of the N2 compounds showed good activity, there was a clear activity 
enhancement caused by both complexation to Cu(II) and glucosylation of the ligand; 
2.3 showed less activity than the glucosylated compound 2.15 and Cu(II) complex 
2.20. Complexation to Zn(II), however, reduced the activity with 2.22 showing the 
less activity than the free ligand 2.3. The Zn(II) containing N2O complex 2.43 did not 
show any T. cruzi inhibition whatsoever. In addition to enhancing the inhibitory 
effects of the complexes, complexation to Cu(II) significantly increased the SI of the 
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compounds (62.5 vs 33.8 for the aglycon N2 ligands 2.3 and 2.20, and 70.9 vs 44.2 for 
the glucosylated analogues 2.15 and 2.25). The free CuCl2.2H2O salt did not show any 
inhibitory activity however, which proves that the activity does not come from the 
Cu(II) ion alone. This data clearly demonstrates the synergistic effects that arise from 
the combination of the N2 ligand scaffold with Cu(II). This may occur by: 
1) The Cu(II) complexes having a unique antiparasitic mode of action to the free 
ligand such as ROS generation by the redox active Cu(II) centre. 
2) The Cu(II) may not be involved in the antitrypanosomal activity directly but the 
complex may undergo increased uptake into the cell with respect to the ligand 
in isolation. This would lead to an increased uptake inside the cell and therefore 
a higher therapeutic effect than seen for the ligand alone. 
3) The compounds may behave as ionophores to provide an enhanced uptake of 
the metal into the cell with respect to the simple CuCl2.H2O salt.  The 
coordination of the metal to an organic ligand increases its lipophilicity and 
therefore its ability to cross the cell membrane by passive diffusion. This could 
dissociate inside the cell wherein the ligand could affect its antitrypanosomal 
effects in the same mode as 2.3 in isolation, with additional, synergistic 
antiparasitic activity coming from the metal ion independent of the ligand. This 
may not be possible for CuCl2.2H2O as this has extremely poor lipophilicity and 
therefore cannot pass into the cell via passive diffusion. 
The efforts to develop Cu(II) antitrypanosomal drugs and investigations of their mode 
of action has been detailed in Chapter 2. While detailed knowledge on their precise 
mechanism of action is sparse, several biological effects have been determined. 
These include DNA scission,54 inhibition of the farnesyl diphosphate synthase 
enzyme,55 DNA intercalation52 and interactions with proteins involved in cell wall 
synthesis and microtubule formation such as tubulin, fibronectin and integrin.54 The 
data we have obtained is insufficient to establish a likely mode of action but as our 
ligand scaffold varies significantly from the phenanthroline derivatives used by some 
of these authors it is probable that these compounds do not share a common 
mechanism to account for their antitrypanosomal activity. 
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The Fe(II) complex 2.45 did not show any inhibitory activity and in fact increase the 
viability of the parasites by approximately 25%. This is a much less pronounced 
growth enhancement than was observed in the studies of L. amazonensis. Iron is 
known to be an essential and growth rate limiting nutrient for T. cruzi.112,113 Inhibition 
of iron uptake has been shown to inhibit growth of the parasites and this is likely due 
to the fact that T. cruzi utilizes only iron containing superoxide dismutase (Fe-SOD) 
for detoxification of superoxide radicals unlike other organisms which possess Fe-
SOD, Cu/Zn-SOD and/or Mn-SOD.114,115 It can therefore be proposed that compound 
2.45 acts to increase the amount of bioavailable Fe in the growth medium and this 
could explain the increased viability of the trypomastigotes. 
3.2.3.4   Conclusions of T. cruzi Biological Studies 
These studies identified five compounds which showed good antitrypanosomal 
activity. These compounds were studied further and the IC50 values were 
determined. These studies identified the Cu(II) N2 compounds 2.20 and 2.22 as the 
most potent antitrypanosomal agents with almost identical IC50 values of 1.7 μM and 
1.8 μM respectively. The glycosylated compound 2.22, however, showed a superior 
SI value of 70.9 which identifies this as the most attractive compound for further 
study. The morphological changes induced by these compounds were identified 
using light microscopy and structural defects were characterised. The results of these 
studies are remarkable as they indicated that 2.22 is both more potent and more 
selective than benznidazole, the drug currently used to treat the disease. 
3.2.4   In Vivo Immunogenicity in G. mellonella 
3.2.4.1   Galleria Mellonella as a  Toxicology Model for the Analysis of Drug 
Candidates 
Insects are an extremely useful model for the preliminary study of the in vivo toxicity 
of novel drug candidates. This analysis typically employs the use of animal models 
such as mice, rabbits or dogs which is expensive, labour intensive, requires specialist 
training and full ethical approval. Insect models offer a practical alternative for 
preliminary screening as they are cheap, do not require the same ethical approval as 
mammalian trials and the studies can be carried out easily with minimal training. 
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Results are typically obtained in 24-48 h which offers a significant advantage over 
mammalian studies which are typically quite time intensive, making them 
prohibitively expensive for the routine analysis of drug candidates. On the other 
hand, insect based assays can be used to quickly screen a large number of 
compounds with minimal time investment. 
The innate immune systems of G. mellonella and mammals have been shown to bear 
many similarities.116, 117, 118 These include the cuticle, which provides a physical 
barrier which prevents the entry of pathogens into the insect in a similar manner to 
the skin of mammals. The innate immune system also involves a cellular response to 
threats, which in humans occurs by the phagocytosis of pathogens by macrophages 
and neutrophils. In G. mellonella this function is carried out by haemocytes which are 
found in the haemolymph, a fluid which fills the cavity of the insect analogous to 
blood in mammals. These similarities, in addition to many others, have led to the use 
of G. mellonella  as an insect model to investigate drug toxicity.119, 120, 121, 122  
The studies using G. mellonella are very simple to perform; the test solutions are 
administered by injection directly into the haemocoel (body cavity) of the larvae 
through the last left pro-leg. The base of the pro-leg can be opened by applying gentle 
pressure to the sides of the larvae and this opening will close after the removal of the 
syringe without leaving a scar which minimises the chance of bacterial infection that 
could lead to a false positive result for immunogenicity. They are then incubated and 
any immune response can be easily identified by visual inspection of the cuticle 
without the need for any of the blood tests which would be required to gain the same 
information in a mammalian model.  
3.2.4.2   G. mellonella Studies 
Due to the insolubility of 2.43 in purely aqueous solutions, DMSO toxicity studies 
were first performed which established that concentrations of up to 20% could be 
safely administered without showing any toxicity in the larvae. G. mellonella larvae 
were then in occulated with 2.3, 2.15, 2.20, 2.22, 2.25, 2.33, 2.35, 2.41, 2.43 and 2.45 
(Figure 3.14). This was carried out at concentrations of 1, 10 and 100 µM as solutions 
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in PBS buffer with 10% DMSO. The larvae were monitored every 24 h for viability and 
evidence of an immune reaction (Figure 3. 17).   
 
Figure 3. 14. Compounds studied for toxicity in G. mellonella 
 
Figure 3. 15. G. mellonella larvae immediately following inoculation. 
Upon inspection at 24 h and 48 h, all of the larvae studied were found to have 
survived treatment with the compounds and exhibited the behaviour typical of 
healthy larvae (Figure 3. 16). Most significantly, none of the larvae studied showed 
discolouration of their cuticle. This discolouration is caused by a melanisation process 
in the larvae and would indicate a response by their immune system to the presence 
of the compounds. 
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Figure 3. 16. Viability of G. mellonella at 24 h and 48 h 
The results of these experiments are highly encouraging and suggest that these 
compounds are very well tolerated in vivo. The fact that all of the larvae used in the 
study survived together with the fact that none of the compounds tested provoked 
an immune response show that these compounds have extremely low toxicity. 
 G. mellonella has been successfully used as a model to study a variety of in vivo 
properties such as drug efficacy, metabolism, microbial virulence and toxicity and 
these effects have been positively correlated with studies in mice that show similar 
results which validates the use of the G. mellonella model.123, 124 It can therefore be 
expected that these results would also translate to low toxicity in higher organisms 
such as mammals.  
 
 
Figure 3. 17. G. mellonella 48 h after inoculation. 
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These results provide further support to the in vitro studies carried out in RAW 
murine cells. Together these experiments have proven that these compounds have 
low toxicity both in vitro and in vivo. This is a vital step in the development of novel 
therapeutics and the toxicological information gathered from these experiments 
indicate that these compounds show promise for further development as safe 
antiparasitic drugs. 
 
3.2.5   Susceptibility of Compounds to Enzymatic Hydrolysis  
The investigations into the antileishmanial and antitrypanosomal activity of the 
library of compounds showed that the compounds which have an alkyl group on the 
para phenolic group (2.34 and 2.36) did not display any activity. This would indicate 
that a phenolic hydroxyl group at this position is essential to the antiparasitic activity 
of the compounds. While compounds 2.15, 2.25 and 2.35 do not bear a phenolic OH 
group, hydrolysis of the glycosidic bond would result in a hydroxylated sugar residue 
and a redox active phenolic group on the ligand moiety (Figure 3. 18). This prompted 
us to investigate if these glycosides could be acting as pro-drugs. 
 
Figure 3. 18. Enzymatic hydrolysis of glycosylated ligands. 
Glucose conjugation has successfully been used as a pro-drug strategy which takes 
advantage of the glucosidase enzymes that are ubiquitous in nature to cleave a 
glucosylated compound and reveal an active drug moiety.60,125,126,127 To investigate 
whether or not the compounds in question could act in this manner,  their 
susceptibility to cleavage by glucosidase enzymes was studied. In vivo, glucosidase 
recognise per-hydroxylated sugars as the substrate. However, since some of the 
compounds described here bear acetyl protecting groups, we decided to investigate 
both the acetylated compounds 2.15 and 2.25 together with the deprotected 
analogues 2.17 and 2.30. 
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To do this, the compounds were first incubated with phosphate buffer alone at 
physiological pH and temperature as a control to establish the stability of the 
glycosidic bond in aqueous solution. It was found that the products were stable at pH 
7.4 in phosphate buffer as was determined by HPLC analysis. Once the stability was 
determined, the compounds were then incubated with a β-glucosidase enzyme, 
obtained from almonds, for 24 h in phosphate buffer at pH 7.4. Prior to these studies, 
the activity of the enzyme was verified using 4-nitrophenyl-β-D-glucopyranoside, a 
standard compound used for the validation and quantification of activity of β-
glucosidase.128 The resulting solutions were analysed using HPLC and HRMS to detect 
the consumption of the glycoside and to determine the nature of the products, if any, 
that were generated. If hydrolysis of the glycosidic bond occurs, this would be 
confirmed by the presence of the aglycon ligand in solution. HPLC studies were 
carried out using a SunFire C18 5 μm 4.6x 100mm column at room temperature with 
a flow rate of 1 mL/min and a 0-20 % MeCN: H2O mobile phase gradient over 30 min.  
 
3.2.5.1   Results of Enzymatic Hydrolysis Studies 
 
 
Scheme 3. 1. Hydrolysis of 2.15 by β-glucosidase. 
 
The hydrolysis of 2.15 by β-glucosidase would produce the aglycon ligand 2.3 as a 
product (Scheme 3. 1). Thus, the observance of 2.3 after incubation of 2.15 with the 
enzyme would offer proof that the proposed hydrolysis has occurred. However, as β-
glucosidase recognizes per-hydroxylated sugars and 2.15 is per-acetylated, it is 
possible that the enzyme does not recognize this molecule and instead recognizes a 
partially or completely deprotected compound formed by the chemical hydrolysis of 
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the compound in aqueous solution. In a physiological environment, this 
transformation would likely be carried out by esterases which are ubiquitous in the 
cell. 
Figure 3. 19 shows the chromatogram of 2.15 before and after incubation for 24 h 
with β-glucosidase. From these chromatograms, it can be seen that the peaks at 11.2 
min and 12.7 min which correspond to 2.15 have almost entirely disappeared upon 
reaction with the enzyme. This could suggest that this compound is susceptible to 
the action of β-glucosidase. While the initial trace of 2.15 shows more than one 
species in solution, this is to be expected as the compound is in aqueous solution at 
pH 7.4 and therefore exists as an equilibrium of protonated and unprotonated 
species.   
 
 
Figure 3. 19. HPLC traces of 2.15 A) before and B) after incubation with β-
glucosidase. 
From the HRMS data of the solution after enzymatic treatment (Figure 3. 20), we can 
see that the most abundant ions detected correspond to the ligand 2.15 (m/z= 
545.213) and its deacetylation products. However, the aglycon 2.3 is present in the 
sample which confirms that hydrolysis of the glycosidic bond has occurred to some 
extent. It can be inferred that i) the acetylated compound is only weakly susceptible 
to the action of β-glucosidase or ii) 2.15 must be partially or completely deacetylated 
before hydrolysis can take place. As the HPLC trace indicates that 2.15 has 
disappeared, it is likely that this is due to both the hydrolysis of the glycosidic bond, 
which is confirmed by the presence of 2.3, in the mass spectrum, deacetylation of 
2.15, or degradation. 
 
A) 2.15  B) 2.15 after 24 H  
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m/z600550500450400350300250200
419.180.
420.184.
461.192.
503.202.
545.213.
546.215.
567.193.
568.197.ESI+
 
Figure 3. 20. ESI+ HRMS spectrum of 2.15 following incubation with β-glucosidase. 
 
 
 
Scheme 3. 2. Hydrolysis of 2.25 by β-glucosidase. 
 
Cu(II) complex 2.25 treated with β-glucosidase under the same conditions as 2.15 
(Scheme 3. 2). The HPLC trace of Cu(II) complex 2.25 shows multiple species in 
solution which could be due to hydrolysis of the chloride ligands on the metal (Figure 
3.21). Following incubation with the enzyme, the peaks at 0.9 and 1.2 min 
disappeared completely from the trace. This could indicate a reaction of the 
compound with the enzyme or deacetylation products. 
2.15 + H+ 
(2.15 – OAc) + H+ 
(2.15 – 2OAc) + H+ 
2.3 + H+ 
2.15 + Na+ 
(2.15 – 3OAc) + H+ 
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Figure 3.21. HPLC traces of 2.25 A) before and B) after incubation with β-
glucosidase. 
The HRMS data from the experiment utilizing 2.25 shows peaks corresponding to 
hydrolysis products (Figure 3. 22). The non-metallated aglycon species 2.3 is 
observed which indicates that the metal complex has dissociated, either in the 
aqueous solution or by ionisation inside the mass spectrometer. 
m/z600550500450400350300250200
215.117.
346.949.
365.106.
486.042.
545.149.
ESI+
Figure 3. 22. ESI+ HRMS spectrum of 2.25 following incubation with β-glucosidase. 
While the starting material 2.25 was not observed, the free ligand 2.15 was observed 
in the mass spectrum, indicating that the metal complex had partially dissociated. 
The incomplete hydrolysis of the ligand could be attributed to the presence of Cu(II) 
in solution which is known to inhibit the activity of β-glucosidase.129 
B) 2.25 after 24 H  A) 2.25  
2.15 + H+ 2.3 + H+ 
2.20+ - H2O 
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Scheme 3. 3. Hydrolysis of 2.26 by β-glucosidase. 
 
Zn(II) complex 2.26 was studied to assess whether the metal present has an effect on 
the susceptibility of the complex to hydrolysis as Zn(II) has also been shown to inhibit 
the activity of β-glucosidase.129 The HPLC trace of 2.26 shows a single peak at t= 2.5 
min which disappears entirely upon reaction with β-glucosidase for 24 h (Figure 
3.23). 
Analysis by HRMS of the solution following incubation with β-glucosidase reveals the 
presence of the aglycon ligand 2.3 (Figure 3. 24). This could indicate that the 
compound has been hydrolysed as Scheme 3. 3. None of the glycosylated metal 
complex 2.26 or free ligand 2.15 could be observed in the spectrum which indicates 
would suggest this compound is highly susceptible to the action of β-glucosidase. 
 
 
 
Figure 3. 23. HPLC traces of 2.26 A) before and B) after incubation with β-
glucosidase. 
B) 2.26 after 24 H  A) 2.26 
113 
 
m/z550500450400350300250200150
142.936.
153.126.
164.918.
215.105.
365.094.
377.159.
485.056.
491.140.
493.134.
ESI+
Figure 3. 24.  ESI+ HRMS spectrum of 2.26 following incubation with β-glucosidase. 
 
 
Scheme 3. 4. Hydrolysis of 2.25 by β-glucosidase. 
 
 
As was seen with the acetylated analogue 2.15, the HPLC trace of deprotected ligand 
2.17 showed multiple species in solution, likely due to multiple protonation states as 
for its acetylated analogue (Figure 3. 25). These are rapidly eluted due to the highly 
polar nature of deprotected molecule and hence the peaks show very similar 
retention times but are sufficiently well resolved to be clearly distinguished. 
 
Figure 3. 25. HPLC traces of 2.17 A) before and B) after incubation with β-
glucosidase. 
A) 
2.17 
B) 2.17 after 24 
h 
2.3 + H+ 
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The mass spectrum of 2.17 reveals that the primary ion detected is the aglycon 2.3 
which confirms that the glycoside 2.17 is a substrate for the β-glucosidase enzyme 
(Figure 3. 26). No adducts of starting glycoside could be detected, unlike the reaction 
with the acetylated analogue 2.15, which would suggest that compound has been 
completely hydrolysed after 24 h.  
 
m/z420400380360340320300280260240220200180160
215.118..
ESI+
 
Figure 3. 26. ESI+ HRMS spectrum of 2.17 following incubation with β-glucosidase. 
 
 
Scheme 3. 5. Hydrolysis of 2.30 by β-glucosidase. 
 
Incubation of the per-hydroxylated Cu(II) complex 2.30 with β-glucosidase for 24 h 
resulted in an almost complete disappearance of the peak corresponding to 2.30 in 
the HPLC chromatogram (Figure 3. 27). This suggests 2.30 has been completely 
hydrolysed by the enzyme (Scheme 3. 5). As with the free ligand 2.17, 2.30 is rapidly 
eluted due to the highly polar nature of the molecule. 
 
2.3 + H+ 
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Figure 3. 27. HPLC traces of 2.30 A) before and B) after incubation with β-
glucosidase. 
Analysis by HRMS (Figure 3. 28) shows the presence both the aglycon Cu(II) complex 
2.20 and the free aglycon ligand 2.3 which confirms that hydrolysis of the glycosidic 
bond has occurred. Also observed are peaks corresponding to the starting 
compound, one which shows the presence of a water adduct of 2.30 which has lost 
a chloride ligand (m/z= 491.149) and another of the free ligand 2.17 (m/z= 377.171). 
 
m/z520500480460440420400380360340320300280260240220
215.117. 365.105.
377.171.
491.149.
492.427.
ESI+
  
 Figure 3. 28. ESI+ HRMS spectrum of 2.30 following incubation with β-glucosidase. 
 
A) 2.30 
B) 2.30 after 24 h 
(2.30 + H2O) - Cl 
2.20 + H+ 
2.3 + H+ 
2.17+ H+ 
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Scheme 3. 6. Hydrolysis of 2.31 by β-glucosidase. 
 
The deprotected Zn(II) complex 2.31 was incubated with β-glucosidase for 24 h 
(Scheme 3. 6). The HPLC trace of 2.31 shows a single peak at t= 1.2 while the trace of 
the sample taken after incubation with the enzyme shows three major peaks at t = 
1.1, 13.0 and 25.2 min (Figure 3. 29). While the retention time is not identical, the 
peak at t= 1.1 min in the hydrolysis study could correspond to the starting material 
which occurred at 1.2 min which would indicate that complete hydrolysis of the 
compound has not occurred. The variation in retention times could be explained by 
a variation in the temperature of the column between the two runs. 
The HRMS spectrum shows the most abundant ion detected corresponds to the 
aglycon ligand 2.3, indicating that hydrolysis of the ligand and dissociation of the 
metal complex has occurred (
Figure 3. 30). None of the starting complex 2.31 or the free ligand 2.17 can be 
observed in the spectrum which demonstrates that the compound is in fact highly 
susceptible to the action of β-glucosidase. 
 
117 
 
 
Figure 3. 29. HPLC traces of 2.31 A) before and B) after incubation with β-
glucosidase. 
Figure 3. 30. ESI+ HRMS spectrum of 2.31 following incubation with β-glucosidase. 
 
 
Scheme 3. 7. Hydrolysis of 2.35 by β-glucosidase. 
HPLC analysis of the N2O ligand 2.35 shows a single peak in the chromatogram which 
disappears entirely upon reaction with β-glucosidase for 24 h (Figure 3. 31). This may 
suggest that the compound is susceptible to the action of β-glucosidase or that 
hydrolysis of either the ester protecting groups or imine bond has occurred (Scheme 
3. 7). 
B) 2.31 after 24 h A) 2.31 
2.3 + H+ 
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Figure 3. 31. HPLC traces of 2.35 A) before and B) after incubation with β-
glucosidase. 
 
The analysis of the mass spectrum presents a significant challenge due to the large 
number of species present (Figure 3. 32). None of the most abundant peaks 
correspond to adducts of the starting material, products of hydrolysis the glycosidic 
bond, deacetylation of the ligand or hydrolysis of the imine bond. However, closer 
examination of spectrum can lead to some tentatively assignments which correspond 
to expected products (Figure 3. 33). If 2.35 has been hydrolysed by the enzyme, it is 
expected that adducts of the aglycon 2.20 would be observed in the mass spectrum 
(Scheme 3. 7). While the abundance of the ions is low, masses corresponding to 2.33 
+ Na+, 2.33 + K+ and 2.33 + 2Na+-H+ can be observed in the spectrum.  Coupled with 
the HPLC analysis which demonstrated that the none of the starting material 
remains, this could suggest that this compound is susceptible to the action of 
glucosidases. 
 
m/z950900850800750700650600550500450400350300250200150100
ESI+
 
Figure 3. 32. ESI+ HRMS spectrum of 2.35 following incubation with β-glucosidase. 
 
A) 2.35 B) 2.35 after 24 h 
0.941 
142.948 
164.930 
213.107 
274.163 
365.105 
382.866 
485.664 
622.784 
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Figure 3. 33. ESI+ HRMS spectrum of 2.35 following incubation with β-glucosidase, 
247-280 m/z. 
3.2.5.2   Conclusion of Glucosidase Studies 
These studies indicate that the glycosylated compounds 2.15, 2.17, 2.25, 2.26, 2.30, 
2.31 and 2.35 undergo hydrolytic reactions upon treatment with glucosidase 
enzymes at physiological pH and temperature. The presence of the aglycon ligand in 
solution after 24 h incubation was detected by HRMS analysis and the disappearance 
of the starting compound was determined by HPLC. These observations suggest that 
the glycosylated compounds could potentially be cleaved in vivo to produce the 
aglycon ligands and metal complexes. It was not clear that acetylated compounds 
2.15 and 2.25 were as susceptible to hydrolysis as their deprotected analogues 2.17 
and 2.30. This is to be expected given that the natural substrates for the enzyme are 
per-hydroxylated glycosides. This study indicates that these compounds have 
undergone hydrolysis by β-glucosidase. Once administered to the parasite, it is 
possible that these compounds may inhibit the viability of T. cruzi and L. amazonensis 
by a pro-drug mechanism involving the enzymatic hydrolysis of the sugar moiety. 
3.3   Conclusion 
The aim of this chapter was to perform a preliminary evaluation of the biological 
effects of a selection of compounds from the N2 and N2O series of compounds. The 
toxicity of the compounds was investigated in vivo in RAW mammalian cells which 
found that they were well tolerated with minimal toxicity. Selected compounds were 
studied in vivo using the G. mellonella model which further demonstrated that the 
2.33 + Na+ 
2.33 + K+ 
2.33 - H+ + 2Na+ 
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compounds are not cytotoxic at the concentrations required for them to exert their 
antiparasitic effects.  
The inhibitory effects towards L. amazonensis amastigotes and T. cruzi 
trypomastigotes were investigated in vitro. From this study, we identified two 
compounds which show exceptional activity as antikinetoplastic agents. Zn(II) 
complex 2.22 was shown to be more potent and selective than the currently used 
miltefosine and pentavalent antimonial therapies. While its potency was inferior to 
amphotericin B, it possesses superior selectivity.  Considering that 2.22 is not 
structurally related to any of the currently used antileishmanial therapies, it is not 
expected to share any common resistance. This fact, together with the multitude of 
problems associated with the use of amphotericin B, demonstrate that 2.22 is a 
highly attractive candidate for further investigation as a novel therapy for 
Leishmaniasis.  
The investigations into the antichagasic activity of these compounds found that the 
Cu(II) complex 2.25 shows exceptional activity towards T. cruzi trypomastigotes. Both 
its potency and selectivity exceed that of Benznidazole which clearly identifies this 
compound as a promising lead compound for further development of novel 
antichagasic therapies. 
The studies into the antiparasitic activity of these compounds yielded vital 
information about the structure-activity relationships relevant to their activity. The 
N2 series of compounds was discovered to be far superior than the corresponding 
N2O analogues as antiparasitic agents. Glycosylation was identified as a modulator of 
both antiparasitic activity and as a means to increase selectivity of the compounds 
by making them less cytotoxic to RAW cells. Metal complexation was also discovered 
to significantly increase their ability to inhibit the growth of T. cruzi and L. 
amazonensis. Interestingly, it was discovered that the activity of the compounds 
could be tuned by the choice of metal; Zn(II) was found to increase the activity and 
selectivity towards L. amazonensis while the Cu(II) compounds showed increased 
activity towards T. cruzi. 
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The functionalization of the para phenoxy group with a non- enzymatically labile 
group was found to inhibit the activity of the compounds. The susceptibility of 
selected phenolic glycoconjugates compounds towards enzymatic hydrolysis was 
therefore determined. This established that it is possible for these compounds to  be 
hydrolysed by β-glucosidase and therefore it is plausible that they can act as pro-
drugs.
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Chapter 4: Studies Towards the Synthesis of a Galactosyl-
1,2,3-Triazolyl Derived Macrocycle 
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4.1   Introduction 
4.1.1   Carbohydrate functionalized macrocycles 
Macrocycles are rather loosely defined by IUPAC as being large cyclic molecules.130 
They are highly attractive compounds because of their interesting biological and 
physicochemical properties which stems from the conformational restriction caused 
by the macrocyclic ring.131,132,133 In particular, macrocycles containing carbohydrates 
have attracted considerable attention, both as pendant groups and as constituents 
of the macrocyclic ring.134, 135, 136 This attention stems from the widespread 
occurrence of  carbohydrates in nature for recognition and cell signalling and also 
their utility in synthesis; they are cheap, abundant, stereochemically pure starting 
materials that offer substantial structural versatility. A single carbohydrate can adopt 
several different forms, namely open chain, α/β-furanose and α/β pyranose and this 
array of functional diversity grants carbohydrates significant utility in the design and 
synthesis of functional macrocyclic compounds. 
4.1.2   Carbohydrates as Pendant Groups 
Carbohydrates are commonly seen as pendant groups appended to macrocyclic rings 
such as porphyrins, crown ethers and polyene-lactones. Carbohydrates are attractive 
as pendant groups due to the relative ease of modification of the macrocycle. Upon 
the formation of the macrocycle, different sugar motifs can be attached to the 
macrocyclic core and allow late stage diversification in the synthesis.68, 137, 138 
Glycosylated macrocycles often display potent biological activities. For example, the 
macrolide class of antimicrobial drugs features a macrocyclic lactone ring and 
pendant deoxy saccharide groups. This includes the commonly prescribed antibiotics 
amphotericin B and erythromycin (Figure 4. 1). While these typically act by binding 
to sterols on the cell surface and forming pores which disrupt membrane integrity, 
they are also known to act as immunomodulators.139,140,141  Studies have suggested 
that they may function through several different mechanisms including coordination 
to endogenous metals, ROS generation and electron transfer.142,143  
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Figure 4. 1. Chemical structures of Amphotericin B and Erythromycin.      
As was discussed in Chapter 2, carbohydrate conjugation is often employed as a 
means to improve solubility and drug targeting in cells. This strategy has been 
investigated using carbohydrates appended to macrocyclic rings. In one example, 
work by Vicente and co-workers appended various carbohydrates to a porphyrin ring 
using the copper promoted azide-alkyne cycloaddition (CuAAC). The metal 
complexes of these macrocycles were investigated for the potential use as  targeted 
photosensitizing anticancer therapeutics.144 They found that the galactose conjugate 
was selectively taken up by HEp2 cells and localized preferentially in the cells 
lysosome. 
 
Figure 4. 2. Structure of galactose conjugated porphyrin synthesized by Vincente 
and co-workers.144 
Stephan and co-workers have successfully functionalized 14-azacrown-4 with various 
carbohydrate moieties (Figure 4. 3).145 This was done to improve the binding of the 
molecule to concanavalin A, a lectin, with the aim of developing a targeting ligand for 
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use with metals such as 99mTc, 90Y and other metals commonly used for 
radiopharmaceutical therapeutics and diagnostics.  
 
Figure 4. 3. Example of glucose functionalized azacrown synthesized by Stephan and 
co-workers.145 
From this work, they were able to quantify the change in binding affinity of different 
compounds based on the glycosylation motifs appended to the macrocyclic ring. 
These glycosylated macrocycles were found to bind much more strongly to 
concanavalin A than glucose, an observation attributed to the glycoclustering effect.  
4.1.3   Carbohydrates as Internal Ring Constituents 
Carbohydrates are commonly used as scaffolds upon which to build a macrocycle. 
This has many benefits as the rigid conformation of the carbohydrate, typically a 4C1 
conformation for a pyranose sugar, can offer a degree of preorganization to the open 
chain precursor and allow for a more efficient macrocyclization reaction than a purely 
linear chain molecule. The multifunctional nature of carbohydrates allows the 
possibility of linkage through any of the hydroxyl groups to generate structural 
diversity. The chiral nature of the sugar permits the synthesis of chiral cavities which 
offers potential for use of the molecules as asymmetric catalysts and chiral 
recognition. 
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As with the pendant carbohydrate macrocycles detailed above, molecules which 
have carbohydrates embedded in the macrocycle ring often display attractive 
biological profiles stemming from their conformational rigidity and dense 
functionality.  
One such example of this is the macrocyclic analogue of Sialyl Lewis X (SLeX) 
synthesized by Tsai and co-workers.146 SLeX is a tetrasaccharide often found on 
glycoproteins and serves as a ligand for selectins. These are carbohydrate recognising 
proteins that are involved in several important immunological processes including 
neutrophil extravasation, lymphocyte recirculation and platelet adhesion.147 By 
synthesizing a macrocyclic scaffold,  all the recognition elements are pre-organized 
in a defined manner which lowers the entropy upon binding with selectin. This 
proved to have a dramatic effect as the macrocycle was found to be 1000 times more 
potent than natural SLeX at binding P-selectin. 
 
Figure 4. 4. SLeX mimic synthesized by Tsai and co-workers. 
Carbohydrate macrocycles have been investigated for their host-guest chemistry. 
Kessler et al synthesized macrocycles based on a glucosyluronic acid methylamine 
framework (Figure 4. 5). This is a dipeptide isostere that mimics a Gly-Ser sequence 
held in a β-turn conformation.148 They found that the ring closing amide coupling 
reaction formed dimer, trimer, tetramer and hexamer macrocycles. Binding studies 
of the hexameric species with p-nitrophenol and benzoic acid were carried out using 
NMR titrations and found that the host-guest behaviour of the compound closely 
mimicked that of α-cyclodextrin. 
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Figure 4. 5. Cyclodextrin mimic synthesized by Kessler and co-workers.149 
Carbohydrates have been widely used as scaffolds to synthesize chiral crown ethers 
incorporating two adjacent sugar hydroxyl groups as part of the cavity. These are 
attractive as chiral catalysts in their own right or as metal chelators. This 
methodology was exploited by Bakó and co-workers who synthesized several 
carbohydrate derived lariat crown ethers (Figure 4. 6), and studied their influence on 
the stereochemical outcome of the Darzens reaction (Figure 4. 7).150 
 
Figure 4. 6. Glucose derived crown ether investigated by Bakó and co-workers.150 
They found that the compounds could successfully catalyse the reaction to give ee 
values between 43% and 96 %. Interestingly, they found that by replacing the glucose 
catalyst with one derived from mannose, which possesses inverted stereochemistry 
at the C-2 position, they could alter the enantioselectivity of the reaction and 
preferentially obtain the opposite enantiomer. This result clearly demonstrates the 
utility of carbohydrate macrocycles as highly effective and tunable catalysts.  
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Figure 4. 7. Darzens reaction studied by Bakó. 
4.1.4   Carbohydrate Macrocycles Containing Triazole Rings 
The CuAAC reaction has been widely applied to the synthesis of macrocycles. The 
popularity of the reaction stems from its mild conditions, high functional group 
tolerance and high reliability. This makes it an ideal reaction for the ring closing step 
of a macrocycle synthesis. 
Fields and co-workers have synthesized a collection of galactose derived macrocycles 
using CuAAC methodology and investigated their susceptibility to the action of 
enzymatic sialylation using T. cruzi trans-sialidase.151  
 
Figure 4. 8. Synthesis of triazole containing macrocycles used by Field and co-
workers.151 
This reaction was carried out in a microwave and produced macrocycles consisting 
of 2-5 saccharide subunits which were separated by HPLC. The reaction temperature, 
catalyst loading and reaction time were varied but they found that this had little 
effect on the yield and ratio of the macrocycles produced in the reaction. The 
concentration of the reactants however, did influence the amount of larger oligomer 
produced in the reaction, which increased with higher concentrations. These 
macrocycles were subject to sialylation with T. cruzi trans-sialidase. The researchers 
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found that the macrocycles consisting of 2 and 3 sugar subunits could be successfully 
sialylated using this enzymatic methodology.  
The Gin research group has investigated using the CuAAC methodology to synthesize 
cyclodextrin mimics.152 They used an α(14) linked trimannose unit as their central 
building block to synthesize a macrocycle containing 6 sugar subunits.  
 
Figure 4. 9. Cyclodextrin mimic synthesized by Gin and coworkers.152 
This work found that the trimannose unit form the dimerized hexasaccharide 
macrocycle preferentially under CuAAC reaction conditions. Studies on the host-
guest chemistry of the macrocycle found that it mimicked the behaviour of β-
cyclodextrin to bind 8-anilino-1-naphthalenesulfonate, a fluorescent dye. 
Listokowski and co-workers have used sucrose as a scaffold to build triazole linked 
macrocycles. They found that by using CuAAC methodology they could synthesize 
both the desired disucrose macrocycle together with two monomeric macrocycles.153 
Rather surprisingly, they found that both 1,4 and 1,5 substituted triazoles were 
formed under these conditions. By performing the reaction under thermal conditions 
without any catalysis, they found that they could produce the dimeric macrocycle 
exclusively without the formation of the monomeric species. 
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Figure 4. 10. Macrocycles prepared by Listkowski and coworkers.153 
  
4.1.5   Macrocyclization Strategies 
There are numerous approaches that can be followed for the synthesis of 
macrocycles. The ring closing reaction to complete the macrocycle is typically the 
most difficult due to the entropy barrier that must be overcome to favour the 
intramolecular collision of the two reacting functional groups, as there are more 
conformations that result in intermolecular reactions than intramolecular ones. This 
intramolecular reaction is in competition with the intermolecular reaction that would 
produce dimers, trimers and oligomers which must be avoided. Due to the 
conformational constraint of the ring, the larger dimers and trimers are typically 
more favourably formed than monomeric species. In addition to the bond strain 
caused by the deviation of bond angles from their lowest energy conformation, Pitzer 
strain, also known as torsional strain, can often occur in macrocycles.154 This is 
repulsion caused by the adoption of an eclipsed conformation of two adjacent 
substituents instead of the more stable staggered conformation. It is for these 
reasons that the formation of macrocyclic compounds is highly unfavourable with 
respect to the formation of their respective linear oligomers and hence present 
difficult synthetic targets. 
To form the macrocyclic ring, it is therefore preferable to use a reaction that is 
reliable, high yielding and occurs in one step in a non-reversible manner. This ensures 
that the monomeric macrocycle, can be obtained in preference to the 
thermodynamically favoured oligomers. To this end a wide variety of reactions have 
been investigated such as esterification,155,156 Pd catalysed coupling reactions,157,158 
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olefin metathesis159 and CuAAC reactions.160,161 The CuAAC reaction is an important 
approach for the synthesis of non-naturally occurring macrocycles. This is due to the 
high reliability of the reaction, mild reaction conditions and high functional group 
tolerance which grants it a very wide substrate scope.162  
This reaction has two possible reactions pathways; one featuring a mononuclear σ-
bonded copper acetylide and the other which proceeds via a binuclear intermediate. 
This binuclear complex has a σ-bonded acetylide in addition to an additional π-bond 
to another copper centre which is also bonded to the σ-bonded copper centre.163 It 
is this binuclear pathway which is believed to be the primary pathway which the 
reaction proceeds through (Figure 4. 11). This is due to the increased polarity of the 
triple bond and therefore it exhibits increased reactivity with the azide dipole. In 
addition to this, the  N3-Cu interactions direct the approach of the alkyne to azide 
moiety and control the regiochemistry of the reaction which forms the 1,3 
disubstituted triazole exclusively.164 
 
 
Figure 4. 11. Mechanism of the CuAAC.163 
Often the structure of a macrocycle will present more than one possible point for 
ring closure. When developing a synthetic route to a target, factors such as 
preorganisation must be considered.165 This can occur in either the starting molecule 
or the reaction intermediate through hydrogen bonding, dipole-dipole interactions, 
π stacking or anion/cation templating. Choice of solvent can also play a crucial role 
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in stabilizing favourable transition states through hydrogen bonding which can alter 
the ratio of monomer to oligomers formed in the reaction. 
One common strategy to increase the probability of an intramolecular reactions, and 
therefore avoid the formation of dimers, trimers and oligomers, is to use pseudo-
high dilution conditions. High dilution is known to favour the production of cyclic 
products over linear molecules as it minimizes the likelihood of intermolecular 
collisions. The intramolecular reaction is first order as both reactants are present in 
the same molecule with a rate law of r=k[A], where r is the rate of reaction, k is the 
rate constant and [A] is the concentration of the uncyclized starting material. The 
intermolecular reaction is dependent on the reaction of two discrete molecules in 
solution and is therefore a second order reaction with a rate law of r=k[A]2. As the 
rate of this reaction is proportional to the square of the concentration of the 
substrate, dilution has greater effect on reducing the rate of the bimolecular reaction 
compared to the monomolecular reaction. This difference can be exploited to favour 
the intramolecular reaction.166 Pseudo-high dilution utilizes the dropwise addition of 
the open chain reactant into a solution of reaction promotor. A single drop of 
reactant is therefore diluted in the volume of the promotor and is present in an 
extremely low effective concentration. This provides a much high dilution than 
dissolving the entire quantity of the starting material in the same volume of solvent 
at once. 
4.2   Aim 
The aim of this work was to investigate the synthesis of a conformationally 
constrained macrocycle built upon a carbohydrate scaffold with CuAAC 
methodology. We envisage that this can be accomplished by the functionalization of 
the carbohydrate with an alkyne moiety in the C-6 position and a unit bearing an 
azide group in the C-1 position. This would allow for the use of the CuAAC reaction 
to close the ring in a high efficient manner.  
As outlined above, small, conformationally restricted macrocycles are attractive due 
to their unique chemical and biological properties, stemming from their high degree 
of preorganization and rigidity. For our synthesis, galactose was chosen as the core 
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carbohydrate given the ease of regioselective manipulation of the C-6 position and 
the possibility to stereoselectively generate the β-glycoside of the azide containing 
fragment with participating protecting groups. This is important as it would leave 
both the alkyne and azide fragments orientated with a syn relationship with respect 
to the carbohydrate ring. This should allow for a lower energy conformation with the 
alkyne and azide moieties in close proximity which is necessary for the cycloaddition 
to generate the target macrocycle to occur.  
 
 
Figure 4. 12. Route to the target macrocycles 4.1a and 4.1b. The galactose unit shown 
in red, the ethylene moiety in green and the alkyne derived unit in blue. 
The preliminary investigations focused on the intramolecular cycloaddition of 2-
aziodoethyl to form the desired macrocycles 4.1a and 4.1b (Route A). Alternatively, 
an intramolecular glycosylation route could be followed which entails the tethering 
of the glycosyl acceptor to the C-6 position and then using a glycosylation reaction to 
form the macrocycle (Route B) 
Two different types of acceptors were investigated. Initially, the glycosylation of N-
Fmoc-L-serine methyl ester was explored. These derivatives would lead to 
macrocycles bearing a methyl ester which could be further functionalized. 
Structurally simpler 2-azidoethanol derivatives were also investigated, in order to 
establish the most favourable route to macrocyclization. 
 
 
 
Route A 
Route B 
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4.3   Results and Discussion 
4.3.1   Investigations into the Synthesis of a Serine Derived Macrocycle 4.1a 
4.3.1.1   Synthesis of Peracetylated Galactosyl Donor 4.2 
 
Scheme 4. 1. Reagents and conditions: Acetone, FeCl3, 75% 
The first reaction of the sequence is the protection of galactose with isopropylidene 
groups (Scheme 4. 1).167 Isopropylidene protecting groups are extremely useful in 
carbohydrate chemistry as they allow selective manipulation of a single hydroxyl 
group by spanning two different pairs of hydroxyl groups in the saccharide. In the 
case of galactose, this strategy allows the regioselective reaction of the C-6 hydroxyl 
group.  
This selectivity arises from the preference of acetone to form cyclic 5-membered 
rings with vicinal diols. For this to occur with a cyclic carbohydrate it is necessary for 
the two hydroxyl groups on the ring to be in a cis orientation to each other. The trans 
configuration generates ring strain in the isopropylidene ring and the conformational 
rigidity of the pyranose prevents the twisting of the ring to adopt a more favourable 
conformation. As a result, galactose forms two isopropylidene rings; one spanning 
the C-1 and C-2 hydroxyl groups and the other formed between the C-3 and C-4 
positions leaving the C-6 hydroxyl group unprotected. 
Acetonide protection requires acid catalysis and to this end a range of catalysts were 
screened for the generation of diacetone galactose including H2SO4,168 ZnCl2,169 and 
I2.170 While these did successfully generate the target compound, they showed 
problems with reproducibility when performed on a multigram scale. FeCl3 proved to 
be the most efficient catalyst for the protection reaction and produces the protected 
compound 4.4 on scales up to 7 g with a consistent yield of 70-75%.167 
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Scheme 4. 2. Reagents and conditions: Propargyl bromide, NaH, TBAI, 89%  
The functionalization of the C-6 hydroxyl group to form 4.5 was carried out by the 
reaction of the isopropylidene protected compound with propargyl bromide utilizing 
TBAI as a catalyst (Scheme 4. 2).171 Initial reactions were carried out using sodium 
hydroxide as the base however these did not affect satisfactory conversion so it was 
decided to investigate the use of sodium hydride. Despite having a pKAH that 
drastically exceeds that of the alkyne (42 vs ~26), the reaction proceeds smoothly 
using a threefold excess of base to form the product in high yield of 89%. The product 
can be purified by simple filtration through a silica plug with no trace of side products 
generated by the deprotonation of the alkyne starting material. 
 
Scheme 4. 3. Reagents and conditions: TFA/H2O, 97% 
Compound 4.5 was then deprotected under acidic conditions (Scheme 4. 3). Various 
conditions were screened including catalytic TFA, Dowex H+ and HCl. However, the 
isopropylidene protecting groups proved to be very resistant to hydrolysis and these 
attempts unsuccessful. The reaction was eventually effected in high yield using the 
very forcing conditions of 66 % TFA in H2O to generate 4.6 without any degradation 
observed.151 
Following the rigorous drying of the deprotected saccharide 4.6 to ensure the 
removal of as much water as possible, the remaining hydroxyl groups were then 
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protected with acetyl groups to generate 4.2. The acetylation reaction was carried 
out at 80 °C in acetic anhydride utilizing sodium acetate as a base. These conditions 
favour the formation of the β-anomer over the more thermodynamically stable α-
anomer.  
The selectivity of this reaction arises from the relative rate of mutarotation at the 
anomeric centre and the rate of acetylation. When acetic anhydride and a weak, non-
nucleophilic base are used, the rate of mutarotation between the α and β-hydroxyl 
anomers is faster than the acetylation reaction. As the equatorial hydroxyl group is 
more nucleophilic than the axial α anomer, the kinetic β-product can be obtained 
preferentially over the thermodynamic α- product (Figure 4. 13)  
 
 
 
 
Figure 4. 13. Diastereoselective acetylation of 4.4. 
This reaction produced 4.2 in moderate yield of 74% in an α/β ratio of approximately 
16:84% as determined by NMR spectroscopy. All though the compound has been 
reported as the pure β-anomer,151 these diastereomers did not prove separable by 
column chromatography. It was therefore decided to use the mixture of anomers for 
the next steps of the synthesize and purify the mixture upon further derivatization. 
 
4.2-β 
β-anomer is the major product 
(Kinetic) 
4.2-α 
α-anomer is the major product 
(Thermodynamic) 
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4.3.1.2   Glycosylation Studies with N-Fmoc-L-Serine Methyl Ester 
4.3.1.2.1   Acetyl Donor 
 
Scheme 4. 4. Reagents and conditions: BF3.OEt2, 0-25 °C, 18h. 
The glycosylation of 4.2 presented significant challenges. The reaction of N-Fmoc-L-
serine methyl ester 4.7 with donor 4.2 utilizing BF3.OEt2 as the reaction promotor did 
not affect the desired conversion to the target galactoside (Scheme 4. 4). Instead, 
acetyl transfer was observed from the donor 4.2 to the amino acid acceptor to 
generate the O-acetyl ester 4.9 (Figure 4. 14), in addition to the formation of 
dehydroalanine 4.10.  
 
Figure 4. 14. Structure of O-acetylated by product 4.9 and elimination product 4.10. 
 
This is formed by the Lewis acid promoted elimination of the hydroxyl group, made 
possible by the presence of the electron withdrawing N-Fmoc and methyl ester 
groups which increase the acidity of the α-hydrogen. This proceeds through an E2 
mechanism considering that the molecule is a primary alcohol which cannot form a 
stable cation necessary for an E1 and the lack of base prevents the E1cb pathway 
(Scheme 4. 5). 
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Scheme 4. 5. Formation of dehydroalanine product 4.10 by BF3. 
Extensive efforts were made to avoid these side reactions including varying reaction 
temperatures, stoichiometries and order of addition, however, these difficulties 
persisted. SnCl4 was also screened as a reaction promotor but this too was unable to 
effectively produce the desired galactoside. It was reasoned that the source of these 
problems were caused the disarmed character of the acetylated donor together with 
the poor nucleophilicity of the serine acceptor. Acetylated donors are known to be 
deactivated coupling partners in chemical glycosylation due to the electron 
withdrawing nature of the acetyl group which destabilizes the cationic oxocarbenium 
intermediate and therefore inhibits its formation. Serine derivatives are also a poor 
nucleophile due to the internal hydrogen bond between the hydroxyl group and the 
carboxyl lone pair. This forms a stable 5-membered ring and reduces the ability of 
the oxygen to behave as a nucleophile (Figure 4. 15).  
 
Figure 4. 15. Hydrogen Bonding in 4.7. 
 
4.3.1.1.2   Thioglycoside Donors 
Due to these drawbacks, it was decided to explore the use of more reactive glycosyl 
donors. Thioglycosides are a very attractive class of glycosyl donors due to their high 
reactivity, mild activation conditions and stability. Since their first use by Ferrier and 
co-workers in 1973,172 thioglycosides have become extremely popular in 
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carbohydrate chemistry for the construction of a wide variety of oligosaccharides and 
glycoconjugates.173 They  are typically prepared from the corresponding acetyl donor 
utilizing Lewis acid promotors such as BF3.OEt2 or SnCl4 and either an alkyl or aryl 
thiol. While a multitude of activating methods have been developed, these can be 
divided into three broad categories: 1) Metal salts; 2) halonium reagents; 3) 
organosulfur reagents. 
1) Metal salts 
The first usage of thioglycoside donors utilized soft, thiophilic cations such as Hg(II) 
and Ag(I).172 These salts are often toxic and typically require stoichiometric amounts 
to effect complete conversion of the donor. The use of these salts as promotors 
necessitates high reaction temperatures which can lead to the formation of complex 
side products and therefore these salts are rarely used in glycosylation reactions.  
2) Halonium Reagents: 
Cationic halogen species such as Br+ and I+ are highly thiophilic and as a result have 
found widespread use as activators for thioglycosides under much milder conditions 
than the previously used metal salts. This approach was first introduced by Nicolaou 
in 1983 when he reported the successful activation of a selection of thioglycosides 
using NBS.174 Iodinium based systems employing NIS/TfOH or NIS/AgOTf have been 
shown to be more efficient activators of thioglycosides, likely due to the softer nature 
of the I+ cation. These systems were developed by the groups of Fraser-Reid and van 
Boom and since their publication in 1990 they have become the standard methods 
for the activation of thioglycosides in carbohydrate chemistry.175,176  
3) Organosulfur Reagents: 
Another widely used method for the activation of thioglycosides is organosulfur 
reagents. These utilize a cationic sulfur containing molecule, usually generated in 
situ, to act as a soft electrophile to activate the thioglycoside. The first reported 
example of this was by Fügedi who used dimethyl(thiomethyl)sulfonium triflate 
(DMTST)  as a reaction promotor to generate a selection of disaccharides.177,178 This 
reagent is generally used freshly prepared by the reaction of dimethyl disulfide and 
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methyl trifluoromethanesulfonate due to its high reactivity and hydroscopic nature. 
The safety hazards associated with using methyl trifluoromethanesulfonate has led 
researchers to develop alternative activating agents based on the same principle as 
DMTST. Commonly used substitutes include dimethyl(thiomethyl)sulfonium 
tetraaflouroborate (DMTSF), dimethyl disulphide/ triflic anhydride (Me2S2/ Tf2O) and 
S-(4-Methoxyphenyl) benzenethiosulfinate/ trifluoromethanesulfonic 
anhydride.179,180 A variety of organoselenium promoters have also been 
investigated.181,182 
4.3.1.1.2.1   Glycosylation Studies of N-Fmoc-L-Serine Methyl Ester Utilizing 
Thiophenyl Glycosides 
A thiophenol based galactose donor 4.11 (Scheme 4. 6) was initially investigated for 
its reactivity with N-Fmoc-L-serine methyl ester. To generate the thioglycoside from 
4.2, it was reacted with thiophenol using SnCl4 as a promotor using conditions 
identical to those used to generate the thiophenol donor from the peracetylated 
analogue.183 These proved unsuccessful and a mixture of starting material and 
degradation products were observed upon workup. Interestingly, a deep red colour 
developed during the reaction which is not generally observed during glycosylations 
using SnCl4. As the colour change is not seen for the analogous reaction of 
peracetylated galactose with thiophenol, it is unlikely that it arises from the 
displacement of the chloride ligands by thiophenol and instead arises from an 
interaction between the Sn(IV) and the alkyne moiety of the saccharide. This colour 
disappears upon quenching the reaction with a saturated aqueous solution of 
NaHCO3 which would suggest that this is a weak interaction and that all of the tin is 
converted to SnO2.  
 
Scheme 4. 6. Reagents and conditions: Thiophenol, BF3.OEt2, 0-25 °C, 61% 
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Galactosyl 4.11 was instead obtained in good yield using BF3.OEt2 as the reaction 
promotor, without the production of the degradation products observed as was the 
case when SnCl4 was used (Scheme 4. 6). 
4.11 was then subject to glycosylation with N-Fmoc-L-serine methyl ester 4.7 using 
the NIS/TfOH activating system. While the intended glycoside could be detected by 
mass spectrometry, it was formed in trace amounts and the bulk of the material 
recovered consisted of starting material 4.11, the galactose hemiacetal and 
unidentifiable complex by-products. A range of stoichiometries were screened, as 
were the reaction temperature however no significant improvement could be 
obtained (Scheme 4. 7). 
 
 
Scheme 4. 7. Reagents and conditions: NIS/TfOH, 0-25 °C 
It was postulated that a possible cause of the side reactions and poor reactivity was 
the formation of an iodinium species between the alkyne moiety and the I+ generated 
from the activator solution.  We therefore conducted studies using a thiophenol 
galactose donor bearing an acetate group at the C-6 position in place of the intended 
alkyne.183 
 
Scheme 4. 8. Reagents and conditions: Thiophenol, SnCl4, 0-25 °C, 94% 
This was prepared as per literature methods and reacted with N-Fmoc-L-serine 
methyl ester using the NIS/TfOH activator system (Scheme 4. 9). While the reaction 
mixtures did produce a less complex mixture of products as determined by thin layer 
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chromatography (TLC), it was not successful at generating the glycosylation product 
4.8. As with the alkyne functionalized donor, various stoichiometries and reaction 
temperatures were screened, however, these too were not able to generate the 
desired product. 
 
Scheme 4. 9. Reagents and conditions: NIS/TfOH, 0-25 °C 
It was reasoned that the disarmed nature of 4.11 was impeding the reaction and that 
a stronger activator might overcome this problem. The Me2S2/Tf2O system, initially 
developed by Fügedi and co-workers, was explored, as it is known to be highly active 
and can completely activate disarmed donors at temperatures as low as -78 °C.180 
This activity is due to the higher thiophilicity of the sulfonium cation generated by 
the activator solution, which is more readily attacked by the anomeric thiol (Scheme 
4. 10).   
 
Scheme 4. 10. Mechanism of activation by the dimethyl disulphide/triflic anhydride 
system. 
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Reacting thiophenyl galactoside 4.11 with N-Fmoc-L-serine methyl ester using freshly 
prepared Me2S2/Tf2O at -42 °C produced a complex mixture of by-products and 
starting materials, similar to the studies utilizing acetyl based donors (Scheme 4.11). 
While trace amounts of the intended product could be observed by mass 
spectrometry, it was not formed in sufficient amounts to allow isolation. This 
reaction was repeated several times with increasing stoichiometries of activator and 
N-Fmoc-L-serine methyl ester 4.7, however, no improvement could be achieved. 
Conducting the reaction at the comparatively high temperature of 0 °C and allowing 
longer reaction times were also insufficient to allow for the generation of the target 
glycoside 4.8. Studies using the Me2S2/Tf2O system were also carried out using the 
peracetylated galactose thiophenyl donor 4.1 lacking the alkyne functionality at the 
C-6 position with identical results the studies using 4.11. 
 
 
 
Scheme 4. 11. Reagents and conditions: Me2S2/Tf2O, 0 °C or -42 °C, no product 
recovered. 
 
4.3.1.1.2.2   Glycosylation Studies of N-Fmoc-L-Serine Methyl Ester Utilizing 
Thioethyl Glycosides 
The poor results of this approach demonstrated that the thiophenyl donor is not 
reactive enough to form the desired galactoside 4.8 with N-Fmoc-L-serine methyl 
ester. In efforts to achieve a reactive glycosylation partner while still retaining the 
disarming acetyl protecting groups at the C-2 position to control the stereochemistry 
of the glycosylation, we therefore decided to investigate a thioethyl galactoside 
donor 4.15 (Figure 4. 16). Thioethyl based  donors are known to be more than twice 
as reactive as glycosyl donors than their thiophenyl analogues.184  
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Figure 4. 16. Reagents and conditions: EtSH, BF3.OEt2, 0-25 °C, 45% 
The synthesis of the thioethyl donor presented significant difficulty. Standard 
glycosylation conditions using BF3.OEt2 or SnCl4 produced only very small amounts of 
the intended product 4.15 when 4.2 was reacted with thioethanol, even with 
prolonged reaction times and activation of the donor at room temperature. The 
majority of the material recovered was the unreacted acetyl donor 4.2 which 
suggests that the activation of the anomeric acetyl was being inhibited by the 
presence of thioethanol in the reaction mixture, most likely by the formation of a 
BF3.SEt adduct which is unreactive towards 4.2. After extensive optimization, a pre-
activation protocol was developed. This entails the activation of 4.2 by the slow 
addition of a 50% solution of BF3.Et2O in DCM at 0 °C over 15 mins and stirring for a 
further 15 mins to ensure the activation of the anomeric acetate. Thiophenol is then 
added dropwise over 15 min and the reaction is allowed to warm to room 
temperature and stir overnight. This protocol was able to effect complete reaction 
of 4.2 however, the reaction did produce significant amounts of by-products which 
presented challenges during purification. Using this method, thioethyl galactoside 
4.15 was successfully obtained in a moderate yield of 45%. 
4.15 was then reacted with N-Fmoc-L-serine methyl ester 4.7 using the NIS/TfOH 
activating system. As with the thiophenyl derived donor 4.11, no product could be 
recovered from the reaction (Scheme 4. 12). Unlike the reactions using 4.11, very 
little of the unreacted donor was recovered indicating that the thioethyl donor was 
indeed more active. 
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Scheme 4. 12. Reagents and conditions: NIS/TfOH, 0-25 °C, No product recovered. 
The reaction was studied using the Me2S2/Tf2O promotor system and analysis of the 
reaction crude showed more promise; the intended glycoside 4.8 could be observed 
by mass spectroscopy and complete activation of the donor was observed by TLC 
analysis. Despite extensive efforts to optimize the reaction further, the target 
molecule could only be generated in trace amounts. Increasing reaction time lead to 
the generation of dehydroalanine 4.10, likely caused by either the reaction of 
residual Tf2O with the N-Fmoc-L-serine methyl ester 4.7 to promote elimination or 
the direct reaction of the hydroxyl group of 4.7 with the activated sulfonium present 
in the reaction promotor solution. A reaction utilizing first the Me2S2/Tf2O activator 
system followed by the later addition of NIS/TfOH was performed to see if a mixed 
activator strategy would show more success, however this did not yield any 
improvement over either activation strategy in isolation (Scheme 4. 13). 
 
Scheme 4. 13. Reagents and conditions: Me2S2/Tf2O, 0 °C or -42 °C, no product 
recovered. 
 
Scheme 4. 14. Reagents and conditions: Thioethanol, BF3.OEt2, 0-25 °C, 92% 
As with previous investigations, the reaction with a peracetylated thiopethyl 
galactose donor lacking the alkyne functionality at the C-6 position was also 
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investigated (Donor 4.16, Scheme 4. 14).185 These studies however, did not reveal 
any improved outcome over the reactions utilizing 4.12. 
The attempted glycosylation studies of 4.7 are summarized in Table 5. 1. It became 
evident that the primary problem lay not with the reactivity of the galactosyl donor, 
but with the poor reactivity of the N-Fmoc-L-serine methyl ester acceptor 4.7. The 
poor nucleophilicity of the serine hydroxyl group is caused by the hydrogen bond 
with the nitrogen of the carbamate group. This hydrogen bond severely hampers its 
reactivity even when reacted with thioethyl donors utilizing the strong glycosylation 
promotor system of Me2S2/Tf2O.  
 
Scheme 4. 15. Attempted routes to 4.8. 
Table 5. 1. Summary of N-Fmoc-L-Serine Methyl Ester Glycosylation Studies 
R R’ Activation Outcome 
OAc Ac (4.12) 
CH2C≡CH (4.2) 
BF3.OEt2 No product recovered. Acyl migration 
and elimination observed. 
OAc Ac (4.12) 
CH2C≡CH (4.2) 
SnCl4 No product recovered. Elimination 
observed. 
SPh Ac (4.13) 
CH2C≡CH (4.11) 
NIS/ TfOH No product recovered. 
SPh Ac (4.13) 
CH2C≡CH (4.11) 
Me2S2/ Tf2O No product recovered. 
SEt Ac (4.16) 
CH2C≡CH (4.15) 
NIS/ TfOH No product recovered. 
SEt Ac (4.16) 
CH2C≡CH (4.15) 
Me2S2/ Tf2O Trace conversion observed. Elimination 
observed. 
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The use of this acceptor is further complicated by the acidity of the α-hydrogen of 
the molecule. Due to the presence of the electron withdrawing methyl ester and the 
Fmoc carbamate groups, the proton is readily deprotonated which allows for the 
elimination of the hydroxyl group when it is activated by either a Lewis acid or an 
electrophile, both of which are utilized for the activation of acetyl, thiophenyl and 
thioethyl donors. The substitution of the Fmoc protecting group was considered but 
carbamate groups such as Boc or Cbz are also electron withdrawing and likely to 
allow the elimination reaction to proceed. Less electron withdrawing groups such as 
Bn or Tr were also contemplated but given the difficulty in removal that these groups 
can present, it was decided to abandon the pursuit the N-Fmoc-L-serine methyl ester 
galactoside.  
4.3.2   Investigations into the Synthesis of a 1, 2, 3-Triazolyl-Ethylene Derived 
Macrocycle 
Given the problems encountered with the glycosylation of N-Fmoc-L-serine methyl 
ester discussed above, it was decided to simplify the glycosyl acceptor in the hopes 
that this would be more amenable to glycosylation. To this end, we decided to use 2-
azidoethanol as it would generate the same 12-membered sized macrocyclic ring, but 
it lacks the functional groups that reduce the nucleophilicity of N-Fmoc-L-serine 
methyl ester in glycosylation reactions. Furthermore, the use of the azide 
functionality on the molecule does not require the use of electron withdrawing 
protecting groups which reduces the likelihood of an elimination reaction occurring, 
particularly when the electron withdrawing ester group is also absent. Our new 
target therefore became 4.1b (Figure 4. 17). 
 
  
Figure 4. 17. Azidoethanol derived macrocycle 4.1b. 
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4.3.2.1   CuAAC Macrocyclization Approach (Route A) 
 
Scheme 4. 16. Reagents and conditions: 1) BF3.OEt2, 2-chloroethanol, 0-25 °C, 49%, 
2) NaN3, 80°C, 83% 
Acetylated donor 4.2 was glycosylated with 2-chloroethanol in DCM using a 50% 
solution of BF3.OEt2 in DCM. Following purification, this yielded 4.17 
stereospecifically as the β-anomer in a moderate yield of 49%. This was then 
subjected to azide-halide exchange (Scheme 4. 16). 4.17 was reacted in DMF for 2 
days at 80 °C in order to achieve sufficient conversion of the starting material to yield 
the product with a yield of 83%. This reaction is typically carried out at higher 
temperatures and frequently utilizes catalytic iodide. However these conditions were 
not used in order to avoid the possibility of a thermally promoted Huisgen 
cycloaddition which can occur at temperatures of 100 °C and above.186  
 
Scheme 4. 17. Reagents and conditions: Sodium Ascorbate, CuSO4. 
With the azide/alkyne precursor 4.18 in hand, the cyclization of the compound was 
performed. This was carried out using CuSO4.5H2O/ sodium ascorbate as the reaction 
catalyst (Scheme 4. 17). Pseudo-high dilution conditions were used and the substrate 
4.18 (0.025M solution in MeCN) was added dropwise (approximately one drop every 
5 seconds) to the solution of catalyst and reaction was allowed to stir at room 
temperature for 10 days before being worked up. Analysis of the crude mixture by 
TLC proved impossible, as the products were strongly retained by the TLC plate. 
However, conversion of the starting glycoside 4.18 was complete as determined by 
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TLC analysis. Attempts to purify the compound by crystallization, trituration or 
chromatography in strongly eluting mobile phases proved unsuccessful.  
 
Figure 4. 18. 1H NMR spectra of 4.18 (blue) and the products of the cyclization 
reaction (red). 
The 1H NMR spectrum of the reaction crude is quite poorly resolved with broad 
signals compared to that of 4.18 (Figure 4. 18). This is likely due to the mixture of 
compounds present in the sample. The 7.5-7.8 ppm region shows a large number of 
new peaks corresponding to triazole C-H signals which clearly demonstrates that a 
number of products was formed during the reaction. A range of 13C spectra, 
homo/heteronuclear 2D experiments, 1H decoupled experiments and DOSY NMR 
experiments were carried out in an effort to try and elucidate the nature and number 
of species present in the sample but these did not provide any data that could 
determine the products generated with any degree of certainty. 
From the mass spectrum obtained from the crude reaction product, it is clear that a 
mixture of products had formed (Figure 4. 19). Strong signals corresponding to the 
monomeric product (4.1b, [M+Na]+: 436.134 m/z), dimer (4.19, [2M+H]+: 827.294 
m/z), trimer (4.20, [3M+2H]2+: 620.725 m/z) and pentamer (4.21, [5M+2H]2+: 
1034.366 m/z), which could be present as cyclic or open chain oligomers, are clearly 
Cyclization Products 
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observable. This indicates that the formation of the monomeric macrocycle is not 
highly favourable, even under the highly dilute conditions used.  
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Figure 4. 19. ESI+ mass spectrum of cyclization crude. 
To confirm that the observed base peak was the monomeric macrocycle and not a 
dimer+2H+ signal, we inspected the isotopic distribution (Figure 4. 20). This can be 
used to identify signals which correspond to dimeric and trimeric products which 
generate the same mass as the monomer when their charge is equal to the number 
of monomer units which make up the molecule. When a dimer is present, a signal 
with a m/z of [M+X+] +0.502 is expected, due to the presence of a single 13C atom in 
place of a 12C in the molecule.187, 188 
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Figure 4. 20. ESI+ mass spectrum of cyclization crude, 410-455 m/z range. 
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From this data, we can see that a signal corresponding to [4.1b+H +] +0.502 is present 
at 414.655 m/z, indicating the presence of dimer 4.19 +2H+. This value means that we 
cannot accept the m/z value of 414.153 as conclusive evidence of the monomer as 
this could also indicate 4.19+2H+. However, analysis of the more abundant Na+ 
adduct does not show an ion corresponding to [4.1b+Na+] +0.502. This isotope 
pattern provides definitive proof that a mass corresponding to the monomeric 
macrocycle is present in the sample. As the 4.18 is not observable by TLC or NMR, we 
can be confident that this is indeed the macrocyclic product and not unreacted 
starting material. 
Inspection of the 826-860 m/z range of the spectrum yields similar results (Figure 4. 
21). The proton adducts of the dimer 4.19 also show the presence of a peak with a 
m/z value of [4.19+H+] +0.502, indicating the that a tetramer, 4.22, is present in the 
product. The K+ adduct is present also but does not show a signal corresponding to 
[4.19+K+] +0.502 so we can conclude that the dimer 4.19 is present. 
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Figure 4. 21. ESI+ mass spectrum of cyclization crude, 826-860 m/z range. 
 
A similar analysis of the 1033-1038 m/z range indicates the presence of the 
pentameric product 4.21 in the reaction mixture. While the monocationic adducts of 
4.21 are too large to be observable in the mass range studied, the formation of this 
compound can be determined by the observation of dicationic fragments seen in this 
m/z region (Figure 4. 22). This shows the expected masses of the diprotic adduct and 
the diprotic adduct of a molecule containing an atom of 13C. Interestingly, it also 
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4.22 (13C) +2H+ 
4.19 (13C) +K+ 
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shows a m/z of [4.21+H+] +0.502, thus showing that decamer has formed during the 
reaction. 
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Figure 4. 22. ESI+ mass spectrum of 4.16, 1033-1038 m/z range. 
Finally, the upper range of the spectrum was analysed to glean more information 
about the compounds produced during the reaction (Figure 4. 23). Similar to the 
other ions studied, the protic adducts of the trimer 4.20 show the presence of a 
compound with m/z of [4.20+H+] +0.502, indicating that a hexamer is present.  
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Figure 4. 23. ESI+ mass spectrum of cyclization crude, 1230-1330 m/z range. 
This mass spectral data, together with the NMR data, shows that this route to the 
macrocycle is highly problematic. The abundance of oligomeric products observed 
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show that this route does not favour the formation of the desired monomeric 
macrocycle. A closer evaluation of the mechanism of the reaction can be used to 
explain this (Figure 4. 24). 
 
Figure 4. 24. Mechanism for the formation of 4.16. Reagents and conditions: 4.18, 
CuSO4.6H2O, sodium ascorbate. 
The formation of a dicopper species is necessary for the cycloaddition to occur. As 
can be seen from Figure 4. 24, this would place one of the copper atoms, together 
with its inner sphere ligands, inside the cavity of the macrocycle. While some 
stabilization may occur from the interactions between the Cu(I) ion and the lone pairs 
present on the oxygen atoms of the ring, it is likely that the steric bulk of the copper 
complex would disfavour the ring closing in such a manner and would instead form 
the larger oligomers observed in the mass spectrum of the reaction product.  
In addition to the steric effects preventing the intramolecular closure of the ring, 
there are electronic effects that must be considered. The macrocyclic ring has three 
oxygen atoms, two of which are bonded to the same carbon atom, and these each 
bear lone pairs of electrons (Figure 4. 24). Each of these oxygen atoms possesses a 
dipole moment associated with this electron density and this causes electronic 
repulsion between these groups. This repulsion would likely raise the energy of a 
conformation in which the azide and alkyne groups are in close enough proximity to 
react in an intramolecular manner, especially considering that the reaction was 
carried out at room temperature.   
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The data presented above is taken from a single macrocyclization reaction. Attempts 
were made to obtain the target macrocycle by varying the solvent and catalyst 
loadings however these did not produce any significant change in the outcome of the 
reaction. 
4.3.2.2   Intramolecular Glycosylation Route (Route B) 
Owing to these difficulties, we decided to explore alternative strategies to obtain the 
target macrocycle. We also decided to investigate the feasibility of using an 
intramolecular glycosylation reaction to form the macrocyclic ring (Scheme 4. 18). 
4.3.2.2.1   Studies Using Acetyl Donor 4.23 
 
Scheme 4. 18. Route to macrocycle using a ring closing glycosylation. 
The initial attempts used acetyl galactosyl donor 4.2. This was first reacted with 2-
azidoethanol to generate the triazole- alcohol compound 4.23 which could then take 
part in an intramolecular glycosylation reaction to give the target 4.1b (Scheme 4. 
18). 
 
Scheme 4. 19. Reagents and conditions: Sodium azide, 80 °C, 48 h, 3.07 g.189  
2-azidoethanol 4.22 was generated from the reaction of 2-chloroethanol with 
sodium azide in refluxing water for 2 days (Scheme 4. 19). Despite longer reaction 
times, full conversion of chloride to the azide derivative could not be achieved. This 
could be explained by the volatile nature of 2-chloroethanol which means that a 
fraction would be in the vapour phase and therefore unable to react with the 
aqueous azide solution.  Due to the explosive nature of low molecular weight azides, 
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it was decided to avoid distilling the reaction mixture and instead use the mixture of 
compounds for the next reaction as 2-chloroethanol will not participate in the CuAAC 
reaction. The unreacted 2-chloroethanol was then safely removed by high vacuum 
upon completion of the reaction.    
 
Scheme 4. 20. Reagents and conditions: CuSO4/ Sodium Ascorbate, 96 %, 2) 
BF3.OEt2, 0-25 °C, 81% based on recovered material. 
2-azidoethanol was then reacted with 4.2 utilizing catalytic CuSO4.5H2O and sodium 
ascorbate to promote the cycloaddition between the azide and alkyne. The reaction 
went smoothly with the total conversion of the starting material observed by TLC. As 
was observed with the previously studied triazole compounds, the product 4.23 
showed an Rf value of 0 in TLC unless extremely polar eluents were used, such as 70% 
MeOH in DCM with triethylamine. In these cases, extreme streaking on the plate was 
observed. This prevented the separation by column chromatography of the α and β-
anomers present in the CuAAC product, as the starting material contained both the 
α and β-anomeric acetyl group. Attempts to isolate the β-anomer by crystallization 
were unsuccessful.  
With the triazole precursor 4.23 in hand, we attempted the synthesis of the 
macrocycle by intramolecular glycosylation. The reaction was carried out under 
pseudo-high dilution conditions by the dropwise addition of the substrate to a 
solution of BF3.OEt2. A 0.042 M solution of 4.23 in DCM was added dropwise at a rate 
of approximately 0.05 ml/min to a 0.21 M solution of 3 equivalents of BF3.OEt2 in 
DCM at 0 °C under anhydrous conditions and was stirred for 48 h. This produced a 
complex mixture of products which, as with previous efforts to synthesize the 
macrocycle, proved to be inseparable by chromatography. Attempts to purify the 
mixture by trituration and crystallization were also unsuccessful.  
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Analysis of the 1H NMR spectrum of the reaction crude clearly indicates the presence 
of multiple products in the sample which complicates the analysis, however, it does 
reveal significant information about the outcome of the reaction. The Hβ-1 of the 
acetyl donor 4.23 can be seen as a doublet at 5.65 ppm in (Figure 4. 25). In the 
reaction crude, this peak has almost entirely disappeared, indicating that a small 
amount of the starting material was not activated during the reaction. Most 
importantly however, are the new peaks in the 7.5-7.8 ppm region which correspond 
to the triazolyl C-H signal. This presents as a single sharp peak in 4.23 at 7.62 ppm 
whereas the spectrum of the reaction crude shows at least 5 poorly defined peaks 
indicative of a mixture of species. While one of these can be attributed to the starting 
material 4.21, the nature of the rest cannot be determined. The signals which occur 
upfield from this region are poorly defined and cannot be assigned with any 
confidence. Analysis of the 13C spectra, homo/heteronuclear 2D experiments, 1H 
decoupled experiments and DOSY NMR suggested some tentative assignments, 
however, no information into the precise structure of the compounds present could 
be determined with any degree of certainty.  
 
Figure 4. 25. 1H NMR of 4.23 (blue) and the cyclization crude (red). 
Analysis of the mass spectrum of the reaction crude shows an m/z signal 
corresponding to 4.1b which confirms the formation of the desired macrocycle.  Only 
trace amounts of dimer and trimer could be observed in the mass spectrum of the 
compound with a total ion counts of 0.3% and 0.1% respectively (Figure 4. 26).  
 
Cyclization Crude 
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Figure 4. 26. ESI+ mass spectrum of the intramolecular glycosylation crude. 
To confirm that the observed base peak was the monomeric macrocycle and not a 
dimer+2H+ signal, we inspected the isotopic distribution as before. No signal 
corresponding to a m/z of M+ 0.5017 was detected in the spectra and we can 
therefore be confident that the desired macrocycle was formed (Figure 4. 27). 
 
Retention Time:  3.512 Ion Mode: ESI+
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414.153.
415.155.
ESI+
 
Figure 4. 27. ESI+ mass spectrum of intramolecular glycosylation crude, 423-423 
m/z range. 
The complicated spectrum could arise not just from the presence of a mixture of 
monomer, dimer, trimer and starting material, it is also possible that different 
conformers of the monomer could be present in the mixture. It was hypothesized 
that due to the rigidity of the monomeric macrocycle, multiple conformations could 
be formed which could be conformationally locked at room temperature due to the 
small cavity which could restrict rotation. 
In order to investigate this, we undertook variable temperature NMR studies. At high 
temperatures, the macrocycle would have enough energy to convert between 
different conformations, thus any possible conformers would appear equivalent and 
4.1b +H+ 
 
4.23 +H+ 
4.19 +H+ 
 
4.1b +Na+ 
 
 4.20 +NH4+ 
4.1b +H+ 
 
4.1b (13C) +H+ 
 
4.23 +Na+ 
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the signals corresponding to different conformations would coalesce into a single 
peak. Conversely, at lower temperatures the signals should appear more defined as 
intermolecular collisions are reduced and each conformer should be locked in its 
lowest energy state. We therefore examined the NMR spectra of the mixture at 40 
°C and -60°C (Figure 4. 28). These appeared to be almost identical and therefore we 
can conclude that this hypothesis is incorrect. 
 
Figure 4. 28. 1H NMR spectra of 4.16 at 40 °C (red) and -60°C (blue). 
 This route showed great promise as far fewer oligomeric products were produced 
than the previously studied CuAAC Route A. However, the reaction still produced a 
number of different compounds and did not go entirely to completion. In an effort 
to investigate whether or not a more active donor would give a cleaner reaction, we 
decided to study the same ring closing glycosylation route using a thiogalactoside 
donor. To this end, we investigated the thioethyl donor 4.12 as a coupling substrate 
for macrocyclization. 
4.3.2.2.2   Thioglycoside Donor 
 
Scheme 4. 21. Reagents and conditions: CuSO4, Na ascorbate, 96 % 
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As with the analogous acetyl donor, 4.15 was reacted with 2-azidoethanol using 
catalytic CuSO4.6H2O and sodium ascorbate. This product was also unsuitable for 
isolation by column chromatography due to high retention to silica, as was observed 
for the other triazole compounds.  
 
 
Scheme 4. 22. Reagents and conditions: Me2S2, Tf2O, -42°C. 
 
Triazole-thiogalactoside 4.25 was then cyclized using the Me2S2/Tf2O reaction 
promotor described vide supra under pseudo-high dilution conditions at -42 °C. As 
with the acetyl donor 4.23, a complex mixture of products was formed. These were 
inseparable by column chromatography, trituration and crystallization. 
Comparison of the 1H NMR spectra of starting material 4.25 and the crude reaction 
mixture shows a single peak at 7.57 ppm in 4.25 corresponding to the triazole C-H 
(Figure 4. 29). Upon glycosylation, this signal has disappeared and instead becomes 
a broad signal with at least 4 discernible peaks (Figure 4. 30). Similar to the spectra 
obtained from the cyclization of the acetyl donor 4.23, the 3-6 ppm region was too 
poorly resolved due to the overlapping peaks to yield any reliable information into 
the nature of the products formed. Analysis of the 13C spectra, homo/heteronuclear 
2D experiments, 1H decoupled experiments and DOSY NMR did not present any 
definitive evidence on the nature or number of the species formed during the 
reaction. Glycosylation reactions of the macrocycle utilizing higher reaction 
temperatures such as 0 °C did not produce any significant differences in the reaction 
outcome. 
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Figure 4. 29. 1H NMR spectrum of 4.25 
 
 
Figure 4. 30. 1H NMR spectrum of 4.1b formed by cyclization of 4.25. 
Analysis of the mass spectrum of the reaction crude proved to be more fruitful. From 
this, we can see that 4.1b was formed by the m/z peak of 414.152, corresponding to 
4.1b + H+ (Figure 4. 31). The nature of this signal was determined to be the 
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monomeric macrocycle and not the dimer+2H+ by the absence of a m/z of 4.16+ 
0.502. Also present in the spectrum is a peak corresponding to 4.19 +K+ with an ion 
count of 21.5% relative to 4.16. While high molecular weight ions were observed, 
these did not correspond to the trimeric product 4.20. 
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Figure 4. 31. ESI+ spectrum of the reaction crude of the intramolecular glycosylation 
of 4.25. 
 
The results of these studies suggest that the intramolecular glycosylation could be 
more favourable for the generation of the monomeric macrocycle. For both donors 
studied, 4.23 and 4.25, this route generated far fewer oligomeric products, as 
determined by HRMS, however a number of reaction products is evident by NMR 
spectroscopy. This would suggest that it possesses a degree of selectivity for the 
intramolecular reaction rather than the intermolecular reaction that generates the 
oligomeric products. An examination of the intermediate generated during the 
reaction may explain this (Scheme 4. 23).  
4.1b +H+ 
4.19 +K+ 
4.1b +Na+ 
849.283 
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Scheme 4. 23. Proposed intermediate formed during the glycosylation of 4.23. 
Upon the formation of the oxocarbenium ion, the anomeric position adopts a sp2 
geometry which forces the pyranose ring to adopt a 4E envelope conformation.190 In 
non-polar solvents, such as DCM, a close contact ion pair (CCIP) is formed between 
the oxocarbenium ion and the anion, in this case triflate.3 It could be proposed that 
the electrostatic interactions between the oxocarbenium ion and the triazole N lone 
pair of electrons acts to tether the chain over the pyran ring. The triflate ion (or 
acetate in the case of the reaction of 4.23) could then form a hydrogen bond with 
the hydroxyl group to bring it in close proximity to the anomeric centre. This 
hydrogen atom could also hydrogen bond to a second nitrogen present on the 
triazole ring. With the hydroxyl group tethered in such a fashion in proximity to the 
anomeric centre, it would favour the intramolecular reaction to a greater degree 
than the CuAAC route which does not possess any favourable preorganization of the 
cavity. 
4.4   Conclusion 
The aim of this chapter was to investigate the synthesis of a conformationally 
constrained macrocycle built upon a carbohydrate scaffold. Initial investigations into 
a galactose-serine derived macrocycle did not yield any successful macrocyclization 
reactions but important information was gained into the reactivity of this system. 
The disarming nature of acetyl protecting groups is too great to allow the reaction of 
the galactoside donors with the serine acceptor, even when the thiogalactoside 
donors were reacted with the strongly activating Me2S2/Tf2O promotor system. A 
further complication that prevents the synthesis of the target galactoside is the 
competing elimination reaction to form dehydroalanine ester 4.10. This occurs in the 
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presence of Lewis acids such as BF3.OEt2 and SnCl4 or electrophiles such as 
dimethylsulfide-sulfonium triflate generated by the Me2S2/Tf2O activating system. In 
order to achieve this target glycoside, less deactivating protecting groups should be 
used together with a donor group that does not require stoichiometric amounts of 
Lewis acid or strongly electrophilic reagents to react. 
Investigations into the synthesis of a 2-azidoethanol derived macrocycle showed 
more success. Two routes were explored; Route A used a CuAAC reaction to form the 
ring and Route B used an intramolecular glycosylation. The studies using the CuAAC 
presented a wide variety of oligomers formed which suggests that this route does 
not offer any selectivity for the desired macrocycle. In addition, to the difficulties 
with the purification of the products and the identical mass of the cyclic and linear 
species, the presence of the target macrocycle cannot be conclusively proved. 
The intramolecular glycosylation route proved to be the most promising route. This 
present fewer oligomeric products than the CuAAC route as suggested by HRMS 
analysis and a plausible hypothesis to explain this selectivity is presented. 
Importantly, this route allows for the unequivocal proof of the existence of the 
monomeric macrocycle by HRMS which is not possible for the CuAAC route.  This 
work has generated the preliminary synthetic methodology for the successful 
synthesis of a conformationally constrained 12-membered macrocycle built upon a 
galactose scaffold. Further work remains, however, for the optimal employment of 
this strategy and the purification and complete characterization of these macrocyclic 
structures. 
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Chapter 5: Investigations into the Fluorescent Properties of 
Functionalized Imino-Pyridyl Compounds 
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5.1   Introduction 
5.1.1   Fluorescence Spectroscopy 
Fluorescence is defined as the emission of light from a compound in an electronically 
excited singlet state.191 A singlet excited state is one where the excited electron is 
spin paired to an electron in the ground state. This differs from phosphorescence 
which involves a triplet excited state, in which the excited electron has the same spin 
orientation as the unpaired electron in the ground state.  
Under standard conditions, a molecule will occupy the lowest vibrational level (ν0) of 
their ground state electronic configuration (S0). Upon absorption of a photon of 
appropriate energy, the molecule is elevated to occupy an excited electronic state 
(Sn, n> 0). For each excited state, there are also a number of vibrational states. After 
absorbing energy and reaching one of the higher vibrational levels of an excited state, 
the molecule will then lose vibrational energy and fall to the lowest vibrational level 
of the excited state. If the molecule occupies an electronic state higher than S1, it will 
undergo internal conversion and pass from the lowest vibrational level of the upper 
state to a higher vibrational level of a lower excited state without the emission of 
light. This process will repeat until the lowest vibrational level of the first excited 
state is reached (S1, ν0). The relaxation between different excited state species can 
occur through a number of different processes such as internal conversion, 
intramolecular charge transfer, molecular collisions and conformational change. 
Upon reaching the lowest vibrational state of S1, it can then return to the ground 
electronic state S0 together with the fluorescent emission of light.192 
Intersystem crossing (ISC) is another possible process that can occur when a molecule 
is in an excited state. ISC involves a ‘forbidden’ transition from a singlet excited state 
to a triplet excited state (Sn Tn, n> 0). This triplet excited state can undergo radiative 
emission upon relaxation to S0 in a process known as phosphorescence. 
Phosphorescence is a slow process and typically occurs over timescales of 10-3 to 103 
seconds, this differs significantly from fluorescence which occurs over 10-9 to 10-7 
seconds. Phosphorescence is not usually seen in solution as there are many 
competing, non-radiative relaxation mechanisms. For this reason, the observed 
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phosphorescent intensity is typically significantly weaker than fluorescent 
emission.192 These various processes can be represented using a Jablonski diagram 
(Figure 5. 1).193 
Figure 5. 1. Jablonski diagram depicting the electronic transitions giving rise to 
absorption, fluorescence and phosphorescence.192  
 
The energy of the emitted photon is typically less than that of the absorbed photon, 
as can be seen from Figure 5. 1, and therefore fluorescence occurs at longer 
wavelengths than the excitation light. This phenomenon was first observed by 
George Stokes in 1852 and allows for the distinction between the absorbed and 
emitted photons.194 The difference between the band maxima of absorption and 
emission in a spectrum of the same electronic transition in a spectra is known as the 
Stokes shift in his honour.195 
5.1.2   Structural Attributes of Fluorophores 
A fluorophore is a molecule or moiety that can exhibit fluorescence following 
excitation with light of an appropriate wavelength. These typically contain several 
fused aromatic rings such as those seen in the common fluorophores fluoroscein, 
pyrene and anthracene. Another structural feature frequently found in fluorophores 
is a long chain of conjugated double bonds such as those present in cyanine 
fluorescent dyes ( 
Figure 5. 2).195 
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Figure 5. 2. Structures of common fluorophores. 
The reason that highly conjugated and aromatic compounds often display 
fluorescence is due to their electronic structure. By virtue of their large, delocalized 
HOMO orbitals, these molecules have low lying π  π* transitions. These transitions 
are characterized by high molar absorption coefficients and high fluorescent yields. 
However, when a heteroatom such as O or N is present in the π system, the lowest 
energy transition may be a n  π* transition. The transitions of this type generally 
have molar absorption coefficients 102 lower than π  π* transitions and have longer 
radiative lifetimes. Due to these longer radiative lifetimes, the observed fluorescent 
intensity is generally much lower than π  π* transitions because of the competing 
non-radiative relaxation processes that occur. This effect is often observed in 
pyridine derived fluorophores.192 
5.1.3   Fluorescent glycosides 
Glycosylated fluorophores are an attractive tool for the investigation of a wide 
variety of biological processes such as glycosidase activity,128 antigen binding,196 and 
the metabolism of sphingolipids.197 These approaches take advantage of the low 
detection limit of fluorescent compounds and the highly sensitive nature of 
fluorometry to elucidate the details of these processes in vitro. 
 
Fluoroscein Pyrene Anthracene 
Cyanine 
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This approach has become a routine method for the analysis of glycohydrolase 
enzymes. Some of the most common substrates used are glycosides of 4-
methylumbelliferyl (Figure 5. 3).  
 
Figure 5. 3. 4-methylumbelliferyl-β-D-glucopyranoside.198 
These offer an improvement over chromogenic substrates such as 4-nitrophenol 
glycosides as they have a significantly lower limit of detection.198 This class of 
fluorescent probes have been commercially available since the 1960’s and have been 
used to identify, characterize and determine the kinetics of a range of glycosides.199, 
200, 201, 202 4-methylumbelliferone is released upon hydrolysis of the glycosidic bond 
of these probes and can be detected by fluorescent spectroscopy. This fluorophore 
is characterized by an 89 nm Stokes shift and is most effectively detected at basic 
pH’s, as the phenolate is more electron donating and, together with the electron 
withdrawing lactone, constitutes a ‘push-pull’ system. Push-pull systems are 
frequently employed as fluorophores as they undergo intramolecular charge transfer 
from their neutral to zwitterionic state, a process that involves a low energy HOMO 
 LUMO transition.203, 204, 205 
Due to the high pH requirement for the low-level detection of 4-methylumbelliferyl 
glycosides, researchers have developed fluorophores that retain high fluorescence 
under acidic conditions. Kaneski et al synthesized a lysomotropic galactoside for the 
intracellular study of enzymatic activity.206 To this end, they utilized a dicyano-
hydroquinonyl unit as the fluorophore of their probe (Figure 5. 4). 
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Figure 5. 4. Fluorescent probe synthesized by Kaneski et al.206 
They found that this molecule exhibits the same maximum emission wavelength 
across the entire pH range while the excitation wavelength varied dependent on the 
protonation state of the phenol, revealed upon hydrolysis of the glycosidic bond. This 
indicates that emitting excited state is identical for both the phenol and phenolate 
state of the fluorophore. While the glycoside did show a degree of fluorescence, it 
was found that this did not occur at the maximum emission wavelength of the 
aglycon fluorophore. This allows it to be used as a probe for β-galactosidase activity, 
with the transition of interested showing a Stokes shift of 75 nm. The use of this 
probe to monitor β-galactosidase activity was validated in vitro using human 
lysosome homogenate.206 
Work by the Brumer group has led to the development of resorufin based probes for 
glycosidase activity (Figure 5. 5).207 These were developed to fulfil the need for 
probes for the direct analysis of endogenous glycoside hydrolases and 
transglycosidases responsible for cell wall remodelling in plants. 
 
Figure 5. 5. Xylogluco-oligosaccharide probe developed by Brumer et al.207 
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The group used xylogluco-oligosaccharide, a substrate for xyloglucan endohydrolase, 
functionalized with resorufin as a fluorescent probe. Upon glucohydrolysis, the 
resorufin aglycon is released and exists in its deprotonated state in the plant 
apoplast. Similar to the 4-methylumbelliferone fluorophore, the deprotonated 
resorufin fluorophore is an example of a push-pull system. This fluorophore has a 
high fluorescent intensity and a Stokes shift of 14 nm. Importantly, the 
absorption/emission occurs at relatively long wavelengths of 571/585 nm which are 
longer than the wavelengths of autofluorescence observed in living tissue (< 400 nm). 
This makes the probe suitable for use in biological tissue and was successfully used 
by the group to monitor xyloglucan endohydrolase in plant tissue extracts. 
Vocadlo et al have recently published a fluorogenic glycoside substrate for imaging 
glucocerebrosidase activity in living human cells.208 Their probe is initially non-
fluorogenic but upon glucohydrolysis it becomes photochemically active. This is due 
to the design which incorporates a BODIPY fluorophore together with a Black Hole 
Quencher 2 moiety (Figure 5. 6). This group functions to quench the fluorescence of 
the BODIPY fluorophore by Förster Resonance Energy Transfer (FRET). 
FRET occurs when the absorption band of a quenching molecule overlaps with the 
emission band of a fluorophore. The quenching group therefore absorbs the emitted 
energy of the fluorophore and disperses it through non-radiative processes, 
ultimately quenching the fluorescence of the system. This process requires both the 
emitting and quenching groups to be close to each other, such as this probe where 
they are appended to the same glucose scaffold. Upon cleavage of the quenching 
group, it disperses in solution and can no longer quench the fluorescence of the 
BODIPY fluorophore as it is no longer in close proximity to it. 
Using this probe, the group were able to image and monitor the activity of 
glucocerebrosidase in human cells by the detection of the fluorophore which is 
rendered active by the activity of the enzyme. This is significant as the study of the 
activity of this enzyme in the lysosome has proven difficult to date. Given that this 
enzyme plays a central role in the mechanism of Gaucher’s disease, this probe 
presents an important new tool for the study of the disease. 
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Figure 5. 6. Probe synthesized by Vocadlo et al.208 
Panza et al have investigated the CD1a antigen binding properties using a dansyl-
functionalized sulfatide probe.196 Sulfatides are a class of galactose derived 
glycolipids containing a sulfate group and are involved in the adaptive immune 
response. They function by first binding to CD receptors to form a complex which can 
then be recognised as an antigen by T-cells. 
 
 
Figure 5. 7. CD1a probe investigated by Panza et al.196 
Using recombinant sCD1a immobilized on magnetic beads, the group found that the 
incorporation of the dansyl fluorophore at the C-6 position of the sugar did not inhibit 
its binding to the CD1a receptor. Furthermore, they established that the binding of 
the probe to the receptor is specific, as it can be displaced by unlabelled sulfatide but 
not by tripalmitin, a lipid unable to bind to CD1a. The detection of the fluorophore 
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was established by irradiating the compound at 351 nm and detecting emission at 
530 nm, giving the probe a Stokes shift of 179 nm. 
A similar approach was used by Bonin et al to investigate the localization of an α-
galactosylceramide fluorescent probe.209 α-galactosylceramides are a class of 
immunomodulatory compounds which are capable of activating natural killer cells 
(NKT), a type of T-lymphocyte. They synthesized a BODIPY functionalized α-
galactosylceramide and administered this to mice by intraperitoneal injection and 
monitored the activation-induced disappearance of NKT cells (Figure 5. 8). 
 
Figure 5. 8. α-galactosylceramide probe used by Bonin et al.209 
They found that this probe had similar immunomodulatory activity to the known α-
galactosylceramide immunomodulator KRN7000. Using fluorescent microscopy to 
inspect liver tissue taken from the mice administered with the probe, they were able 
to establish the localization of the compound within the liver. They found that the 
compound accumulated primarily in spleen and liver antigen presenting cells and, 
significantly, was not associated with NKT cells. 
The Mitkovski group has used fluorescent probes to investigate the distribution of a 
galactoside analogue of the known cytotoxic compound duocarmycin (Figure 5. 9).210 
This molecule incorporates a coumarin based moiety which serves as both a 
fluorophore and a DNA intercalator.  They then studied the cytotoxicity and 
localization of the galactoside prodrug and its aglycon in human lung cancer cells. 
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Figure 5. 9. Galactoside studied by Mitkovski et al.210 
From these studies, they found that both the galactoside and its aglycon displayed 
almost identical IC50 values. Using confocal laser scanning microscopy, they studied 
how these compounds are absorbed and localized within the cell. These studies 
showed that both the galactoside and aglycon penetrate the cell membrane within 
seconds and after several minutes accumulate within the mitochondria and 
ultimately cause cell death. 
5.2   Aim 
During the synthesis of 2.35 (Chapter 2), it was noticed that solutions of this 
compound appeared fluorescent when viewed under UV light at 254 nm. This effect 
was not observed for the corresponding aglycon 2.33. Given that the compound does 
not feature a large, extended conjugated system typically present in other 
fluorescent moieties such as pyrene and anthracene, we hypothesized that this 
fluorescence could arise from the presence of the acetal functionality present in the 
glycosidic bond. Therefore, the aim of this work was to synthesize a selection of 
analogues of 2.35 and investigate their fluorescent properties. 
The influence of several structural attributes on the photochemical properties of the 
system was explored by synthesising and studying the fluorescence of several 
analogues (Figure 5. 10). To do this, we sought to first investigate the nature of the 
glycoside attached to the ligand core. The aforementioned 2.35 features a β-
glycosidic linkage and each acetyl group is in an equatorial configuration. We 
reasoned that the inversion of this chiral centre to an α-mannoside 5.1 could have a 
significant effect on the fluorescence, as this would change the orientation of the 
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lone pairs present on both oxygen atoms and therefore change the overall electronic 
structure of the bond. In addition, we wanted to investigate the effect that the 
retention of the β-glycosidic linkage with the inversion of a stereocenter at a position 
remote to the anomeric centre would have on the fluorescent behaviour. This could 
be achieved by studying a β-galactoside 5.2 which is the C-4 epimer of glucose.  
To assess if the observed enhancement of fluorescence is unique to glycosides, we 
also aimed to explore a non-glycosidic groups appended to the N2O core; the 
alkylated compound 2.34, the acetal containing tetrahydropyran (THP) compound 
5.3 and the ether linked menthol conjugate 5.4.  
Finally, DFT calculations were obtained in order to assist with the interpretation of 
the data obtained from the fluorescence studies. The calculations were performed 
by Dr C. Henchy (Dept. of Chemistry, Maynooth University). 
 
 
Figure 5. 10. Compounds Investigated for the Photochemical Behaviour.  
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5.3   Results and Discussion  
5.3.1   Synthesis 
5.3.1.1   Synthesis of Mannoside 5.1 
 
 
Scheme 5. 1. Reagents and conditions: i) HBr/AcOH, >98%; ii) 2,4-
hydroxybenzaldehyde 2.37, Ag2CO3, MeCN,  72%; iii) 2-picolylamine, EtOH, >98% 
Mannoside 5.1 was synthesized in a manner analogous to the glucososide 2.35 
described in Chapter 2 (Scheme 5. 1). Mannose pentaacetate 5.5 was brominated 
using HBr/AcOH to generate the bromide mannosyl donor 5.6.211 This was then 
subject to Koenigs-Knorr glycosylation conditions with 2.37 to yield the galactoside 
5.7 in good yield. Unlike the Koenigs-Knorr glycosylation of 2.39 which produced the 
β-glucoside, the reaction utilizing 5.6 produces 5.7 as the α-anomer 
stereospecifically. This arises because the acetyl group on the C-2 position is in the 
axial configuration unlike glucose and galactose. When the oxocarbenium ion is 
formed, the acetoxonium ring is therefore formed on the top face of the sugar 
(Scheme 5. 2). The nucleophile therefore can only attack from the bottom face of the 
pyranose ring to form the α-anomer exclusively. The stereochemistry was confirmed 
by the chemical shift of the anomeric proton in 1H NMR and the 3J1,2 coupling 
constant of 1.7 Hz, which is characteristic of cis-glycosidic bonds. 
The imine 5.1 was then prepared by refluxing 5.7 in anhydrous ethanol with 2-
picolylamine overnight and reducing to dryness to produce a yellow oil. 
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Scheme 5. 2. Mechanism for the formation of 5.7. 
 
5.3.1.2   Synthesis of Galactoside 5.2 
 
 
Scheme 5. 3. Reagents and conditions: i) HBr/AcOH, 89%; ii) 2,4-
hydroxybenzaldehyde 2.37, Ag2CO3, MeCN, 66%; iii) 2-picolylamine, EtOH, >98% 
The galactoside 5.2 was synthesized following the same route as the glucoside and 
mannoside 2.35 and 5.1, respectively (Scheme 5. 3). Galactose pentaacetate 5.8 was 
brominated using HBr/AcOH to generate the aldehyde 5.10 as the expected β-
anomer, as evidenced by the chemical shift of the H-1 proton.212 The target imine 5.2 
was synthesized in quantitative yield by the reaction of 5.10 with 2-picolylamine in 
refluxing EtOH and the complete evaporation of the solvent.  
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5.3.1.3   Synthesis of THP Derivative 5.3 
 
 
Scheme 5. 4. Reagents and conditions: i) 2,4-hydroxybenzaldehyde 2.37, PPTS, DCM, 
90%; iii) 2-picolylamine, EtOH, >98% 
The THP derived compound 5.3 was synthesized by first forming the THP conjugated 
aldehyde 5.12 (Scheme 5. 4). This was carried in anhydrous dichloromethane using 
catalytic pyridinium p-toluenesulfonate (PPTS) to produce the target compound as a 
racemic mixture in excellent yield.213 This aldehyde was refluxed in ethanol overnight 
with 2-picolylamine to produce the target compound 5.3 in quantitative yield upon 
evaporation of the solvent. 
5.3.1.4   Synthesis of Menthol Derivative 5.4 
 
 
Scheme 5. 5. Reagents and conditions: i) 2,4-hydroxybenzaldehyde 2.37, DIAD, PPh3, 
THF, 16 %; iii) 2-picolylamine, EtOH, >98 % 
Our initial attempts to synthesize a sterically bulky ether had focused on an 
adamantane derivative. This could not be synthesized however, due to the 
structurally demanding nature of the bromoadamantane used in the reaction. This 
could not undergo SN2 substitution due to the steric hindrance which prevents back 
side attack of the nucleophile. On the other hand, an SN1 reaction cannot take place 
as the rigidity of the compound prevents the formation of a planar, sp2 hybridized 
cation necessary for this reaction to occur. As an alternative to this sterically 
demanding conjugate, the menthol derivative 5.4 was investigated. 
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The synthesis of the menthol functionalised imine 5.4 begins with the Mitsunobu 
reaction of (-)-menthol with 2,4-dihydroxybenzaldehyde (Scheme 5. 5). This reaction 
proceeds with the inversion of stereochemistry at the C-O stereocenter of the 
menthol ring. This occurs because the hydroxyl group is eliminated in an SN2 fashion 
after activation by DIAD/PPh3 (Scheme 5. 6). 
The reaction is quite low yielding (16 %), however, this is unsurprising due to the 
nature of reactants. Typically, a Mitsunobu reaction is conducted with both reactants 
in solution when the PPh3/DIAD is added. The more acidic hydroxyl group, often a 
carboxylic acid, is deprotonated by the phosphonium-amide betaine and is ultimately 
eliminated by the nucleophilic attack of the less acidic hydroxyl group.214 As the more 
acidic hydroxyl group, the phenol, is also the nucleophile in our intended reaction, a 
protocol involving the activation of the secondary hydroxyl group before the addition 
of the phenol was followed. Under these conditions, a (I) phosphonium-alkoxide 
betaine is generated, which is in equilibrium with the dialkoxyphosphorane (II).215 
Upon addition of 2.37, the activated phosphonium-oxide (I) is then displaced and a 
molecule of menthol is regenerated, requiring two equivalents to be used in the 
reaction. 
 
Scheme 5. 6. Mechanism of the Mitsunobu Reaction.215  
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5.14 was then reacted with 2-picolylamine in refluxing ethanol to produce the target 
imine in quantitative yield as an orange oil. 
5.3.2   Fluorescence Studies 
With compounds 2.33, 2.34, 2.35, 5.1, 5.2, 5.3 and 5.4 successfully synthesized and 
characterized, their photochemical behaviour was investigated. This was done by 
first determining the λmax, the frequency that the molecule absorbs the most energy, 
and then examining the fluorescent emission of the molecule at this wavelength. This 
was carried out using both methanol and acetonitrile as solvents.  
5.3.2.1   Fluorescence Studies of 2.33 
 
 
Solutions of 2.33 in acetonitrile and methanol were excited with light at λmax 
frequencies and the resulting emission spectra were obtained (Figure 5. 11 and 
Figure 5. 12). From these spectra, it can be seen the  compound exhibits very weak 
emission. The 10μM solution of 2.33 in acetonitrile shows a negligible emission of 
1.706 a.u. at 296 nm when excited at 268 nm. 
An identical solution of 2.33 in methanol was excited at 272 nm and the emission 
spectrum was collected. This did not show any fluorescence whatsoever. 
 
Figure 5. 11. Emission spectrum of 2.33 in acetonitrile. 
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Figure 5. 12. Emission spectrum of 2.33 in methanol. 
5.3.2.2   Fluorescence Studies of 2.34 
 
 
 
 
The alkylated ether compound 2.34 was investigated in a manner identical to 2.33 at 
wavelengths of 275 nm (methanol, Figure 5. 13) and 279 nm (acetonitrile, Figure 5. 
14). These studies found that the compound does not show any fluorescent 
behaviour in either acetonitrile or methanol. 
 
Figure 5. 13. Emission spectrum of 2.34 in acetonitrile. 
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Figure 5. 14. Emission spectrum of 2.34 in methanol. 
 
5.3.2.3   Fluorescence Studies of 2.35 
 
 
 
 
The glucoside 2.35 was studied in both acetonitrile and methanol at a concentration 
of 10 μM (Figure 5. 15 and Figure 5. 16). The acetonitrile solution was excited at 270 
nm and the emission spectrum was collected. This showed a broad emission band 
centred at 428 nm, presenting a Stokes shift of 158 nm, with an intensity of 15.88 
a.u. The solution in methanol showed a similar emission with the band centred at a 
slightly lower wavelength of 427 nm and a weaker emission intensity of 10.83 a.u. 
This has a similar Stokes shift of 155 nm, showing that the solvent has very little effect 
on the fluorescence of the compound. 
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Figure 5. 15. Emission spectrum of 2.35 in acetonitrile. 
 
 
Figure 5. 16. Emission spectrum of 2.35 in methanol. 
 
5.3.2.4   Fluorescence Studies of 5.1 
 
 
 
 
The mannose appended compound 5.1, containing an α-glycosidic bond, did not 
show any fluorescent activity comparable to that of the β-glycosylated compounds 
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2.35 and 2.51. When excited at its λmax frequency of 269 nm in acetonitrile, it showed 
two broad emission bands centred at 310 nm and 437 nm (Figure 5. 17). These have 
very low intensities of 2.57 a.u. and 1.49 a.u. The presence of two emission bands 
suggests that there are two distinct excited states adopted upon irradiation. When 
the experiment is repeated using methanol as a solvent, no fluorescence is detected 
(Figure 5. 18).  
 
Figure 5. 17. Emission spectrum of 5.1 in acetonitrile. 
 
Figure 5. 18. Emission spectrum of 5.1 in methanol. 
5.3.2.5   Fluorescence Studies of 5.2 
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The galactoside 5.1, possessing an axial C-4 hydroxyl group, showed fluorescent 
behaviour similar the glucoside 2.35. When excited at 297 nm in acetonitrile, the 
compound showed a broad emission centred at 371 nm with an intensity of 20.22. 
This has a Stokes shift of 74 nm, less than half that of 2.35. When the compound was 
excited at the same wavelength in methanol, it showed an emission band at the 
lower wavelength of 437 nm, giving it a Stokes shift of 140 nm which is similar to that 
of 2.35. The intensity of the emission, however, was weaker than that observed in 
acetonitrile. 
 
Figure 5. 19. Emission spectrum of 5.2 in acetonitrile. 
 
 
Figure 5. 20. Emission spectrum of 5.2 in methanol. 
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5.3.2.6   Fluorescence Studies of 5.3 
 
 
 
The THP derived compound 5.3 was studied as the acetal linkage, while racemic, is 
identical to that of the glycosidic bond, but compound lacks the functionality on the 
pyran ring found on the glycosides. When 5.3 was studied in acetonitrile, a sharp, 
weak emission band was observed (Figure 5. 21). The Stokes shift of this emission is 
much larger than that observed for the glycosylated compounds with a value of 265 
nm. The intensity of this emission is very low with a value of 2.23 a.u. The 
corresponding experiment in acetonitrile (Figure 5. 22) did not show this emission. 
 
Figure 5. 21. Emission spectrum of 5.3 in acetonitrile. 
 
Figure 5. 22. Emission spectrum of 5.3 in methanol. 
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5.3.2.7   Fluorescence Studies of 5.4 
 
 
 
5.4 was studied to investigate the effect of a sterically bulky, non-glycosidic ether 
linked group on the photochemical behaviour of the compound. When irradiated 
with light at 266 nm in acetonitrile, a broad, weak emission band is observed at 425 
nm with an intensity of 2.77 a.u. (Figure 5. 23). This has a Stokes shift of 159 nm, 
almost identical to that of 2.35 which was 158 nm. The intensity, however, is weaker 
than either of the β-glycosides studied. The same experiment repeated in methanol 
showed two, extremely broad emissions at 331 nm and 437 nm with intensities of 
1.83 a.u. and 1.51 a.u. respectively (Figure 5. 24). These are extremely weak and it 
can be concluded that this compound does not exhibit significant fluorescent 
behaviour.  
 
Figure 5. 23. Emission spectrum of 5.4 in acetonitrile. 
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Figure 5. 24. Emission spectrum of 5.4 in methanol. 
 
In summary, these fluorescence studies show that only the β-glycosylated 
compounds, 2.35 and 5.1, show significant fluorescent activity (Figure 5. 25). This 
observation can be correlated with the fact that β-vanillin glucosides, a class of plant 
metabolites, also display fluorescence.216 The α-linked mannoside 5.2 showed 
extremely weak fluorescence in acetonitrile and none in methanol. The acetal linked 
5.3, analogous to a glycosidic bond, showed only very weak fluorescence in 
acetonitrile. Neither the phenolic compound 2.33 nor the ether functionalised 2.34 
showed significant photochemical activity while the ether linked menthol 5.4 showed 
a weak fluorescent emission. These results indicate that, while a β-glycoside moiety 
appears to grant a significant increase in the fluorescence of the N2O scaffold, 
fluorescence of this moiety is not exclusive to β-glycosides as was proved by the weak 
but clearly identifiable fluorescent emission of 5.4. This would indicate that the 
fluorescent activity arises not just from the electronic properties of the β-glycosidic 
bond but also the steric contribution of the appended group.  
In addition, the solvent appears to play a role in the fluorescence of the compounds. 
The compounds which showed fluorescence presented with more intense emission 
in acetonitrile when compared to methanol. While acetonitrile and methanol are 
both water-miscible, polar solvents, methanol can function as a H-bond donor while 
acetonitrile cannot. As the compounds contain several H-bond acceptors, this means 
that the compounds will differ in their solvation shell in both solvents. It is therefore 
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likely that the compounds will adopt different conformations which can affect the 
electronic structure of the compounds and therefore change their fluorescent 
properties This effect is well documented in pyridine type fluorophores.192,217,218 
 
 
Figure 5. 25. Fluorescent emission of compounds studied in acetonitrile. 
 
5.3.3   DFT Studies 
In an effort to gain an insight into the electronic effects that are responsible for the 
differences observed in the fluorescent activity of 2.33, 2.34 and 2.35, a preliminary 
investigation of the electronic structure of these molecules was carried out using 
density functional theory (DFT). These studies were performed by Dr Christopher 
Henchy at Maynooth University using the Gaussian-03 software suite,219 utilizing the 
B3LYP functional and 6-311++g(2d,2p) basis set. Excited states and electronic 
transitions were studied using Time-Dependent DFT calculations. 
Taking the conformation found from the X-ray crystal structure of 2.3 as the ground 
state conformation (Figure 5. 26, A), the molecular orbital structure was generated. 
Once this was done, the vibrational structure and electronic transitions could be 
modelled. As expected, this found that the primary absorption involves the 
promotion of an electron from the HOMO orbital, molecular orbital 60 (MO-60) 
(Figure 5. 26, B), into the LUMO orbital (MO-61) (Figure 5. 26, C). These structures 
can give an insight into why this molecule lacks strong fluorescence. 
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As described above, fluorescence is typically observed in molecules that have 
extended networks of conjugated double bonds, as this gives a larger, extended 
HOMO. Due to this extended electronic network, both the HOMO energy and energy 
gap between the HOMO and LUMO is reduced, therefore making it more probable 
that an electronic transition will occur. Figure 5. 26, B shows that the major 
contributor to the HOMO of the molecule is the phenolic ring and imine functional 
group. Only a very slight contribution of electron density comes from the pyridine 
ring. This means that the HOMO effectively extends from the p-phenolic group to the 
end of the pyridine ring, giving it a much smaller HOMO than typical fluorophores 
such as anthracene or fluorescein, which have HOMOs that extend across several 
aromatic rings. The reason that the HOMO does not extend across the pyridine ring 
is likely due to the non-planar orientation of the pyridine ring with respect to the aryl 
ring, having a torsion angle of 81.87 ° as determined from the X-ray crystal structure. 
The orbitals of the pyridine ring, therefore, do not align well with those of the aryl 
ring and as a result, the HOMO does not extend across both rings. 
 
 
 
Figure 5. 26. A) Molecular structure of 2.33; B) HOMO, MO-60; C) LUMO, MO-61 
A B 
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As with 2.33, the ground state geometry of 2.34 was taken from the crystal structure 
of the compound. From this the molecular orbital structure and electronic transitions 
were generated. The principle electronic transition of this molecule is from the 
HOMO (MO-72) to LUMO (MO-73). The molecular orbital structure of 2.34 is very 
similar to that of 2.33; the HOMO extends from the p-phenolic oxygen atom, across 
the aryl ring and terminates at the m-carbon atom of the pyridine ring. It is 
unsurprising, therefore, that the molecule does not exhibit fluorescence, as the 
HOMO is not significantly delocalized. This observation mimics the results obtained 
for 2.33. 
 
 
 
 
Figure 5. 27. A) Molecular structure of 2.34; B) HOMO, MO-72; C) LUMO, MO-73 
 
To analyse glucosylated compound 2.35, the ground state geometry was first 
determined as no crystal structure could be obtained (Figure 5. 28, A). After the 
ground state geometry was validated using vibrational analysis, the electronic 
structure was generated in the same manner as above. The strongest predicted 
electronic transition was from the HOMO (Figure 5. 28, B) to the LUMO (Figure 5. 28, 
A B 
C 
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C), as was the case for the 2.33 and 2.34. The electronic structure of 2.35 shows 
striking differences to those described above. The HOMO of 2.35 is significantly 
larger, extending from the pyran oxygen atom, through the glycosidic bond and 
across both the aryl and pyridine ring. This extended electronic structure explains 
why this molecule exhibits fluorescence while the aglycon 2.33 does not, and could 
be attributed to the more planar arrangement of the two aromatic rings in 2.35, 
which is predicted to be 33.21 °.   
Interestingly, this structure reveals that the oxygen atom present in the pyranose ring 
contributes to the HOMO of the molecule, suggesting that the acetal functionality 
present in the glycosidic bond is an important contributor to the fluorescence of the 
molecule. As the acetal containing 5.3 did not show fluorescence while the ether 
linked 5.4 did, it is apparent that the glycosidic bond is not the only factor that 
influences the fluorescence. Steric bulk may contribute to the ground state 
conformation and allow for a more planar arrangement between the two aromatic 
rings. This could explain why the bulky, ether linked 5.4 exhibited fluorescence, albeit 
weak, while the acetal linked 5.3 compound did not. Further study is required to 
confirm this hypothesis.  
             
 
 
Figure 5. 28. A) Geometry optimized molecular structure of 2.35; B) HOMO; C) 
LUMO. 
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5.4   Conclusion 
The aim of this work was to synthesize and carry out a preliminary investigation of 
the fluorescent activity of a selection of N2O derivatives. To this end a galactose, 
mannose, THP and menthol analogues of 2.35 were synthesized and characterized. 
These compounds, along with the previously described 2.33, 2.34 and 2.35, were 
studied by spectroflourometry.  
These studies found that the β-glycoside functionalized molecules 2.35 and 5.1 
showed moderate fluorescence, while compounds 2.33, 2.34, 5.2, 5.3 and 5.4 
showed little to no fluorescence. In addition, the solvent used for analysis played a 
minor role in the fluorescence of the solutions. Solutions that used acetonitrile as the 
solvent showed an improved intensity of emission compared to those of methanol. 
To aid in the analysis of these results, DFT studies were used to analyse the electronic 
structure of the molecules. These found that the HOMO orbital of 2.35, which was 
found to be fluorescent, is comprised of electron density contributed by both 
aromatic rings and, importantly, the β-glycosidic bond. Conversely, 2.33 and 2.34, 
which were not fluorescent, did not show this extended HOMO orbital. This 
difference in the electronic structure may explain the difference fluorescent activity 
between the glycosylated and non-glycosylated compounds. 
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Chapter 6: Experimental Details 
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6.1   General Procedures 
All chemicals purchased were reagent grade and used without further purification 
unless stated otherwise. Anhydrous dichloromethane and acetonitrile were freshly 
distilled over CaH2 prior use. Ethanol was dried over 3 Å molecular sieves, which were 
flame dried prior to use. Reactions were monitored with thin layer chromatography 
(TLC) on Merck Silica Gel F254 plates. Detection was effected by UV, charring in a 
mixture of 5 % sulfuric acid-ethanol or 6 % vanillin-ethanol. All glassware used for 
anhydrous reactions was flame dried under vacuum prior to use. NMR spectra were 
obtained on a Bruker Ascend 500 or a Bruker Avance 300 spectrometer using the 
residual solvent peak as internal standard. Chemical shifts are reported in ppm. 
Proton and carbon assignments were made with the aid of 1D and 2D NMR 
experiments (COSY, DEPT, HSQC, HMBC, NOESY, PSYCHE and TOCSY). Flash 
chromatography was performed with Merck Silica Gel 60. Microwave reactions were 
carried out using a CEM Discover Microwave Synthesizer. Optical rotations were 
obtained from an AA-100 polarimeter. [α]D values are given in 10
−1 cm2·g−1. The 
melting points were obtained using a Stuart Scientific SMP1 melting point apparatus 
and are uncorrected. Purity was confirmed by elemental analysis using a FLASH EA 
1112 Series Elemental Analyzer with Eager 300 operating software. High resolution 
mass spectrometry was performed on an Agilent-LC 1200 Series coupled to a 6210 
Agilent Time-Of-Flight (TOF) mass spectrometer equipped with an electrospray 
source in both positive and negative (ESI+/−) modes. Magnetic susceptibility 
measurements were carried out at room temperature using a Johnson Matthey 
Magnetic Susceptibility Balance with [HgCo(SCN)4] as reference. Infrared spectra 
were obtained as a film on NaCl plates or as KBr disks in the region 4000–400 cm−1 
on a Perkin Elmer Spectrum 100 FT-IR spectrophotometer. The X-ray intensity data 
were measured using an Oxford Cryosystems low temperature device using a 
MiTeGen micromount and solved using the Bruker APEX Software Package. The X-ray 
crystal structures were analysed using Mercury 3.8 software. 
Caution: Although not encountered in our experiments, perchlorate salts of metal 
ions are potentially explosive and should be manipulated with care. 
195 
 
6.2   Chapter 2 
6.2.1   N2 Series 
 
 
 
To a solution of 4-hydroxybenzaldehyde (1 g, 0.0082 mol) and DBU (1.35 mL, 0.009 
mol) in IPA (10 mL) was added a solution of 2-chloroethanol (1.65 mL, 0.0246 mol) 
and NaI (1.23 g 0.0082 mol) in IPA (15 mL) and heated to 120 ˚C in a microwave for 4 
h. The solvent was removed in vacuo and the residue was suspended in EtOAc (30 
mL) and washed with saturated sodium dithionite solution (30 mL), H2O (2x30 mL), 
saturated NaHCO3 solution (2x30 mL) and brine (30 mL). The organic solution was 
dried over Na2SO4 and the solvent was removed in vacuo to yield a heavy yellow oil. 
This was purified by column chromatography (3:2 Pet. Ether/EtOAc, Rf: 0.29) to yield 
the product as a clear oil (0.804 g, 59 %). 1H NMR (500 MHz, CDCl3) δ 9.88 (s, 1H, 
HC=O), 7.84 (d, J = 8.8 Hz, 2H, ArH), 7.02 (d, J = 8.8 Hz, 2H, ArH), 4.17 (t, J = 4.8 Hz, 
2H, ArOCH2), 4.01 (t, J = 4.8 Hz, 2H, CH2OH), 2.16 (bs, 1H, OH). 13C NMR (126 MHz, 
CDCl3) δ 190.9 (C=O), 163.8 (Ar), 132.2 (Ar), 130.4 (Ar), 114.9 (Ar), 69.7 (ArO-C), 61.3 
(C-OH). IR (NaCl Plate): 3420, 2939, 2874, 2745, 1681, 1603, 1578, 1510, 1315, 1261, 
1164, 1080, 1045, 833 cm-1. HRMS m/z (ESI+): 167.0703 (C9H10O3: [M+H]+ requires 
167.07082) 
The NMR data is in agreement with that reported in the literature.220 
 
 
 
2.4 
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Glucose pentaacetate (5 g, 0.0128 mol) was dissolved in HBr/AcOH (15 mL) with 
acetic anhydride (2 mL) under N2 and stirred for 4 h at room temperature. This was 
diluted with DCM (30 mL) and washed with water (3 x 20 mL), saturated NaHCO3 
solution (30 mL) and brine (30 mL) before being dried with Na2SO4. The solvent was 
removed in vacuo to yield a clear oil which was diluted in Et2O (20 mL) and 
cyclohexane (70 mL) was added. The solution was cooled on ice to precipitate the 
product as a white solid (4.525 g, 87 %). 1H NMR (500 MHz, CDCl3) δ 6.61 (d, J = 4.0 
Hz, 1H, H-1), 5.56 (appt, J = 9.7 Hz, 1H, H-3), 5.16 (appt, J = 9.8 Hz, 1H, H-4), 4.84 (dd, 
J = 10.0, 4.1 Hz, 1H, H-2), 4.40 – 4.25 (m, 2H, H-5,H-6), 4.16 – 4.09 (m, 1H, H-6’), 2.10 
(s, 3H, OAc), 2.10 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03 (s, 3H, OAc). 13C NMR (126 MHz, 
CDCl3) δ 170.6 (C=O), 169.9 (C=O), 169.8 (C=O), 169.54 (C=O), 86.65 (C-1), 72.2 (C-5), 
70.7 (C-2), 70.3 (C-3), 67.3 (C-4), 61.0 (C-6), 20.7 (OAc), 20.7 (OAc), 20.7 (OAc), 20.6 
(OAc). 
The NMR data is in agreement with the data reported in the literature.221 
 
  
 
 
2.7 (5.68 g, 0.0138 mol), 4-hydroxybenzaldehyde (3.374 g, 0.0176 mol) and Ag2O (8 
g, 0.0345 mol) were dissolved in freshly distilled MeCN (80 mL) under N2 in the dark 
and allowed to stir at room temperature for 17 h with approximately 1 g of molecular 
sieves. The solvent was removed in vacuo and the residue was then dissolved in 
EtOAc and filtered through a Celite plug. The solution was then washed with 1M HCl 
2.7 
2.8 
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(100 mL), NaHCO3 solution (2x100 mL), brine (100 mL) and dried over Na2SO4. The 
solvent was removed in vacuo to yield an orange solid which was recrystallized from 
EtOH to yield the product as a white solid (3.933 g, 63 %). 1H NMR (500 MHz, CDCl3) 
δ 9.93 (s, 1H, C(=O)H), 7.85 (d, J = 8.7 Hz, 2H, Ar-H), 7.10 (d, J = 8.7 Hz, 2H, Ar-H), 5.41 
– 5.26 (m, 2H, H-2, H-3), 5.27 – 4.88 (m, 2H, H-1, H-4), 4.29 (dd, J = 12.3, 5.5 Hz, 1H, 
H-6), 4.18 (dd, J = 12.3, 2.4 Hz, 1H, H-6’), 3.93 (ddd, J = 9.9, 5.5, 2.4 Hz, 1H, H-5), 2.07 
(s, 3H, OAc), 2.06 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.05 (s, 3H, OAc). 13C NMR (126 MHz, 
CDCl3) δ 190.8 (C(=O)H), 170.6 (C=O), 170.3 (C=O), 169.5 (C=O), 169.3 (C=O), 161.3 
(Ar),  131.9 (Ar), 131.8 (Ar), 116.9 (Ar), 98.2 (C-1),  72.7 (C-2), 72.5 (C-5) 71.2 (C-3), 
68.3 (C-4), 62.1 (C-6), 20.8 (OAc), 20.7 (OAc), 20.7 (OAc), 20.7 (OAc). IR (KBr Disk): 
2963, 2850, 2747, 1754, 1692, 1505, 1422, 1380, 1233, 1038 cm-1. HRMS m/z (ESI+): 
475.1201 (C21H24O11: [M+Na+]+ requires 475.1201). Mp: 145-146 ˚C. [α]D
25: -0.17 (c 1, 
CH2Cl2) 
 The  NMR characterisation data is in agreement with that reported in the 
literature.222 
 
 
 
Glucose pentaacetate (2 g, 0.00512 mol) and 2-chloroethanol (1.03 mL, 0.01536 mol) 
were dissolved in DCM (15 mL) at 0 ˚C. A solution of BF3.OEt2 (1.89 mL, 0.01536 mol) 
in DCM (1.89 mL) was added dropwise via cannula over 8 min and the reaction was 
allowed to warm to room temperature and stirred for 17 h. This was then transferred 
to a separating funnel and washed with saturated NaHCO3 solution (2 x 20 mL), H20 
(20 mL) and the combined aqueous layers were extracted with DCM (20 mL). The 
combined organic layers were then washed with brine (30 mL) and dried with Na2SO4 
before the solvent was removed in vacuo to yield a transparent yellow oil. This was 
then recrystallized from hot ethanol (20 mL) to yield the product as a white solid 
(1.1633 g, 55 %). 1H NMR (500 MHz, CDCl3) δ 5.22 (t, J = 9.5 Hz, 1H, H-3), 5.09 (t, J = 
2.10 
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9.7 Hz, 1H, H-4), 5.02 (dd, J = 9.6, 8.0 Hz, 1H, H-2), 4.58 (d, J = 8.0 Hz, 1H, H-1), 4.26 
(dd, J = 12.3, 4.8 Hz, 1H, H-6), 4.15 (dd, J = 12.3, 2.4 Hz, 1H, H-6’), 4.13 – 4.06 (m, 1H, 
OCH), 3.80 – 3.73 (m, 1H, OCH), 3.71 (ddd, J = 9.9, 4.7, 2.4 Hz, 1H, H-5), 3.62 (t, J = 5.7 
Hz, 2H, CH2Cl), 2.09 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.01 (s, 3H,OAc). 
13C NMR (126 MHz, CDCl3) δ 170.7 (C=O), 170.4 (C=O), 169.5 (C=O),  169.5 (C=O),  
101.2 (C-1), 72.7 (C-3), 72.0 (C-5), 71.1 (C-2), 70.0 (OCH2), 68.4 (C-4), 61.9 (C-6), 42.6 
(CH2Cl), 20.8(OAc), 20.8(OAc), 20.7(OAc), 20.7 (OAc). IR (KBr Disk): 2969, 1749, 1434, 
1380, 1223, 1173, 602cm-1. HRMS m/z (ESI+): 411.1060 (C16H24ClO10: [M+H]+ requires 
411.10580).  Mp: 114 C Anal. Calcd for C16H23ClO10: C, 46.78; H, 5.64. Found: C, 
46.74; H, 5.63.[α]𝐷
22: -15˚ (c= 4, CHCl3) 
The characterisation data is in agreement with that reported in the literature.223 
 
 
2.10 (6.278 g, 0.015 mol), 4-hydroxybenzaldehye (3.733 g, 0.03 mol), TBAI (1.1 g, 
0.003 mol) and K2CO3 (2 g, 0.015 mol) were dissolved in anhydrous DMF (80 mL) 
under N2 in the dark with 3 Å molecular sieves. This was heated to 110 ˚C for 18 h 
and the solvent was removed in vacuo in the dark to yield a brown residue. The 
residue was diluted with EtOAc (80 mL) and washed with saturated sodium dithionite 
solution (50 mL), H2O (2x50 mL), saturated NaHCO3 (2x50 mL) and brine (50 mL). This 
was dried over Na2SO4 and the solvent was removed in vacuo to produce an orange 
oil which was purified by column chromatography (3:1 Pet. Ether/ EtOAc, Rf: 0.33) to 
yield the product as a yellow oil (6.479 g, 87 %). 1H NMR (500 MHz, CDCl3) δ 9.89 (s, 
1H, HC=O), 7.84 (d, J = 8.6 Hz, 2H, Ar-H), 7.00 (d, J = 8.6 Hz, 2H, Ar-H), 5.23 (appt, J = 
9.5 Hz, 1H, H-3), 5.10 (appt, J = 9.7 Hz, 1H, H-4), 5.02 (appt, J =10Hz, 1H, H-2), 4.67 
(d, J = 8.0 Hz, 1H, H-1), 4.27 (dd, J = 12.3, 4.7 Hz, 1H, H-6), 4.24 – 4.09 (m, 4H, H-6’, 
CHCH2OAr,), 3.97 (ddd, J = 10.7, 6.6, 4.1 Hz, 1H,CHCH2OAr), 3.74 (ddd, J = 9.9, 4.4, 2.3 
Hz, 1H, H-5), 2.08 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.92 (s, 3H, OAc). 
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13C NMR (126 MHz, CDCl3) δ 190.7 (C=O), 170.6 (OAc), 170.2 (OAc), 169.4 (OAc), 169.3 
(OAc), 163.6 (Ar), 132.0 (Ar), 130.2 (Ar), 114.8 (Ar), 101.05 (C-1), 72.7 (C-3), 71.9 (C-
5), 71.1 (C-2), 68.3 (C-4), 67.92 (CH2CH2OAr), 67.4 (CH2CH2OAr), 61.9 (C-6), 20.7 
(OAc), 20.6 (OAc), 20.6 (OAc), 20.5(OAc). HRMS m/z (ESI+): 497.1654 (C23H29O12: 
[M+H]+ requires 497.16590). IR (KBr Disk): 2977, 2953, 2926, 2890, 1744, 1700, 1609, 
1578, 1511, 1448, 1377, 1255, 1228, 1170, 1137, 1043, 924, 839, 610, 520cm-1. [α]D
24: 
-0.09 (c 0.5, CH2Cl2) 
 
 
4-hydroxybenzaldehyde (10 g, 0.0818 mol), 2-aminomethylpyridine (8.76 mL, 0.085 
mol and Na2SO4 (15 g, 0.1 mol) were refluxed overnight in diethyl ether (200 mL). This 
was reduced to approximately 40 mL and cooled to -10 ˚C in an ice/acetone/NaCl 
bath and EtOH (100 mL, dried over molecular sieves) was added. NaBH4 (9 g, 0.2379 
mol) was added portion wise over 30min and allowed to warm to room temperature 
and stir overnight. The reaction was quenched with water (approximately 40 mL) and 
stirred until no more gas was generated. The EtOH was removed in vacuo and the 
reaction was extracted with 5 x 50 mL diethyl ether and the combined organic layers 
were washed with water (100 mL), brine (100 mL) and dried over Na2SO4. The solvent 
was removed in vacuo to yield the product as a heavy brown oil (12.411 g, 71 %). 1H 
NMR (300 MHz, CDCl3) δ 8.52 (d, J = 5.4 Hz, 1H, pyr-H), 7.64 (td, J = 7.7, 1.7 Hz, 1H, 
pyr-H), 7.32 (d, J = 7.7 Hz, 1H, pyr-H), 7.18 (dd, J = 7.0, 5.4 Hz, 1H, pyr-H), 7.04 (d, J = 
8.4 Hz, 2H, Ar-H), 6.62 (d, J = 8.4 Hz, 2H, Ar-H), 6.54 (s, 2H, N-H, O-H), 3.92 (s, 2H, 
CH2), 3.72 (s, 2H, CH2).13C NMR (126 MHz, CDCl3) δ 158.8 (Pyr), 156.3 (Ar), 148.9 (Pyr), 
137.2 (Pyr), 129.9 (Ar), 123.0 (Pyr), 122.5 (Pyr), 115.8 (Ar), 115.5 (Ar), 53.5 (PyrCH2), 
52.8 (ArlCH2). IR (KBr Disk): 3430, 3204, 3015, 2926, 1613, 1595, 1571, 1514, 1436, 
1365, 1247, 1171, 831, 761, 564, 509 cm-1. HRMS m/z (ESI+): 215.1187, (C13H14N3O: 
[M+H]+ requires 215.1184). Elemental analysis calculated (%) for C13H14N2O: C 72.87,   
H 6.59, N 13.07. Found: C 72.76, H 6.88, N 12.96. 
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Synthesized as per Brunner et al, however incomplete spectroscopic data was 
presented.85 
 
 
 
2.4 (1.523 g, 0.00916 mol) and 2-picolylamine (1.04 mL, 0.1 mol) were dissolved in 
EtOH (25 mL, dried over 3 Å molecular sieves) and refluxed for 3 h with MgSO4 (2.21 
g, 0.0183 mol) under N2. This was cooled to -10 ˚C under Ar and solution of NaBH4 
(1.386 g, 0.0366 mol) in EtOH (20 mL, dried over molecular sieves) was added 
dropwise and the reaction was allowed to warm to room temperature and stir 
overnight. H2O (approximately 25 mL) was added and the solution was heated to 80 
˚C for 30 min. The solvent was removed in vacuo and the residue was suspended in 
water to yield an orange solution the product was extracted with 5x30 mL portions 
of DCM. The combined organic layers were washed with brine, dried over Na2SO4 and 
the solvent was removed in vacuo to yield a heavy brown oil. By-products were 
removed by short path distillation (175 ˚C at 0.08 mbar) and the residue was further 
purified by column chromatography (0.8% MeOH in DCM, basic alumina stationary 
phase) to yield the product as a brown oil (1.609 g, 68 %). 1H NMR (500 MHz, CDCl3) 
δ 8.54 (d, J = 4.4 Hz, 1H, Pyr-H), 7.63 (apptd, J = 7.7, 1.7 Hz, 1H, Pyr-H), 7.35 – 7.28 
(m, 1H, Pyr-H), 7.25 (d, J = 8.5 Hz, 2H, Ar-H), 7.15 (dd, J = 6.9, 5.3 Hz, 1H, Pyr-H), 6.83 
(d, J = 8.6 Hz, 2H, Ar-H), 4.03 – 3.99 (m, 2H, CH2OAr), 3.90 (s, 2H, CH2Pyr), 3.90 – 3.87 
(m, 2H, CH2OH), 3.76 (s, 2H, CH2Ar), 3.05 (bs, 2H, NH, OH ).IR (NaCl Plate): 3306, 2928, 
2862, 1610, 1594, 1570, 1511, 1474, 1454, 1435, 1367, 1301, 1247, 1175, 1085, 1051, 
917, 985, 829, 761 cm-1. HRMS m/z (ESI+): 259.1440 (C15H18N2O2: [M+H]+ requires 
259.14465). Elemental analysis calculated (%) for C15H18N2O2: C 69.74, H 7.02, N 
10.84. Found: C 69.38, H 7.09, N 10.77 
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2.8 (1 g, 0.0022 mol) and 2-picolylamine (0.24 mL, 0.0022 mol) were stirred in EtOH 
(25 mL, dried over 3 Å molecular sieves) with MgSO4 (3eq) for 4 h at 50 ˚C under N2. 
This was filtered and cooled to approximately -10 ˚C in an ice/acetone/ salt bath 
under N2 and AcOH (0.1 mL, 0.002 mol) was added immediately before the dropwise 
addition of a solution of NaBH4 (0.333 g, 0.0088 mol) in EtOH (30 mL, dried over 3 Å 
molecular sieves). The solution was allowed to warm to room temperature and was 
stirred overnight before being quenched by the addition of water heating to 80 ˚C for 
30 min until the precipitation of white boron salts had ceased. The solution dried in 
vacuo to yield a brown residue which was dissolved in water and extracted with 
EtOAc (5x40 mL). The combined organic layers were washed with brine (100 mL), 
dried with Na2SO4 and the solvent was removed in vacuo to yield the product as a 
heavy brown oil (0.934 g, 76 %). 1H NMR (500 MHz, CDCl3) δ 8.55 (d, J = 3.5 Hz, 1H), 
7.67 (td, J = 7.6, 1.7 Hz, 1H), 7.33 – 7.28 (m, 3H), 7.21 (dd, J = 6.6, 5.1 Hz, 1H), 6.95 (d, 
J = 8.5 Hz, 2H), 5.27 (p, J = 9.4 Hz, 2H), 5.16 (t, J = 9.4 Hz, 1H), 5.06 (d, J = 7.3 Hz, 1H), 
4.90 (s, 1H), 4.28 (dd, J = 12.2, 5.2 Hz, 1H), 4.22 – 4.12 (m, 1H), 3.99 (s, 2H), 3.88 (s, 
2H), 3.86 – 3.79 (m, 1H), 3.70 (q, J = 7.0 Hz, 2H), 2.07 (s, 2H), 2.05 (s, 3H), 2.04 (s, 3H), 
2.02 (s, 4H). 13C NMR (126 MHz, CDCl3) δ 170.7 (C=O), 170.4 (=O), 169.5 (C=O), 169.4 
(C=O), 159.5 (Pyr-C), 156.2 (Ar-C), 149.4 (Pyr-CH), 136.6 (Pyr-CH), 129.7 (Ar-C), 128.6 
(Ar-CH), 122.6 (Pyr-CH), 122.2 (Pyr-CH), 117.2 (Ar-CH), 99.5 (C-1), 72.9 (C-4), 72.2 (C-
5), 71.4 (C-3), 68.5 (C-2), 62.1 (C-6), 54.3 (PyrCH2), 52.8 (ArCH2), 20.8 (OAc), 20.8 
(OAc), 20.7 (OAc), 20.7 (OAc). HRMS m/z (ESI+): 545.2139 (C27H32N2O10: [M+H+ ]+ 
requires 545.2135) IR (KBr Disk): 3427, 2945, 3922, 1751, 1610, 1592, 1511, 1474, 
1435, 1369, 1235, 1214, 1069, 1042, 908, 831, 761, 600cm-1.[α]D
22: -0.07 (c 0.5, 
CH2Cl2), Elemental analysis calculated (%) for C27H32N2O2: C 59.55, H 5.92, N 5.14. 
Found: C 59.27, H 6.10, N 5.03. 
2.15 
202 
 
 
2.11 (6.436 g, 0.0129 mol) and 2-picolylamine (1.336 mL, 0.0129 mol) were refluxed 
in EtOH (25 mL, dried over 3 Å molecular sieves) with MgSO4 (3.6 g) for 4 h under N2. 
This was cooled to approximately -10 ˚C in an ice/acetone/ salt bath under N2 and 
AcOH (0.74 mL, 0.0129 mol, dried over 3 Å molecular sieves) was added immediately 
before the dropwise addition of a solution of NaBH4 (1.475 g, 0.0387 mol) in EtOH 
(30 mL, dried over 3 Å molecular sieves). The solution was allowed to warm to room 
temperature and was stirred overnight before being quenched by the addition of 
water heating to 80 ˚C for 30 min until the precipitation of white boron salts had 
ceased. The solution dried in vacuo to yield a brown residue which was dissolved in 
water and extracted with EtOAc (5x40 mL). The combined organic layers were 
washed with brine (100 mL), dried with Na2SO4 and the solvent was removed in vacuo 
to yield the product as an orange oil (3.229 g, 42.5%). 1H NMR (500 MHz, CDCl3) δ 
8.56 (d, J = 4.0 Hz, 1H, Pyr-H), 7.64 (appt, J = 7.1 Hz, 1H, Pyr-H), 7.37 (appt, J = 8.6 Hz, 
1H, Pyr-H), 7.26 (d, J = 6.5 Hz, 2H, Ar-H), 7.20 – 7.10 (m, 1H, Pyr-H), 6.87 (d, J =6.5Hz, 
2H, Ar-H), 5.22 (appt, J = 9.5 Hz, 1H, H-3), 5.10 (appt, J = 9.7 Hz, 1H, H-4), 5.04 – 4.97 
(m, 1H, H-2), 4.68 (d, J = 8.0Hz, 1H, H-1), 4.26 (dd, J = 12.1, 3.8 Hz, 1H, H-6), 4.17 – 
4.09 (m, 3H, H-6’, OCH2CH2OAr), 3.91 (s, 2H, Pyr-CH2), 3.78 (s, 2H, Ar-CH2), 3.72 (ddd, 
J = 9.8, 4.4, 2.2 Hz, 1H, H-5), 3.64 – 3.55 (m, 1H, OCH2CH2OAr), 3.49-3.53 (m, 1H, 
OCH2CH2OAr), 2.07 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.93 (s, 3H, OAc). 
13C NMR (126 MHz, CDCl3) δ 170.7 (C=O), 170.3 (C=O), 169.4 (C=O), 169.4 (C=O), 
159.4 (Pyr), 158.6 (Ar), 157.7 (Ar), 149.3 (Pyr), 136.5 (Pyr), 131.9 (Ar), 127.9 (Pyr), 
122.5 (Pyr), 114.2 (Ar), 101.2 (C-1), 72.8 (C-3), 71.9 (C-5), 71.2 (C-2), 68.4 (C-4), 68.3 
(CH2Pyr), 67.3 (OCH2CH2OAr), 61.9 (C-6), 61.0 (OCH2CH2OAr, 60.9 (CH2Ar), 20.9 (OAc), 
20.7 (OAc),  20.6 (OAc), 20.5 (OAc). IR (NaCl Plate): 3385, 2970, 2932, 2883, 1755, 
1611, 1512, 1435, 1367, 1231, 1070, 1040, 910, 832, 760, 596cm-1.  HRMS m/z (ESI+): 
589.2407(C29H37N2O11: [M+H]+ requires 589.2392).[α]D
23: -0.14 (c 0.5, MeOH). Anal. 
Calcd for C29H36N2O11: C,59.18; H, 6.16; N, 4.76 Found: C, 59.17; H, 6.11; N, 4.45%  
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2.13 (2.656 g, 0.00487 mol) was dissolved in MeOH/H2O (40/5 mL) and a drop of 5.4 
M NaOMe solution was added. The reaction was stirred at room temperature for 1 
hr and the pH was adjusted to approximately 9 using Dowex H+. The reaction was 
filtered and the solvent removed in vacuo to yield a brown oil which gave product as 
a light brown solid after lyophilisation for 48 h (1.836 g, quantitative yield). IR (KBr 
Disk): 3379, 2969, 2875, 1611, 1596, 1571, 1511, 1478, 1437, 1367, 1303, 1234, 1177, 
1075, 1046, 1015, 896, 832, 763, 630, 559cm-1. HRMS m/z (ESI+): 377.1697 
(C19H25N2O6: [M+H]+ requires 377.1707).[α]D
24: -0.11 (c 0.5, H2O). Mp: 86-87 ˚C. Anal. 
Calcd for C19H24N2O6: C,60.63; H, 6.43; N, 7.44 Found: C, 60.39; H, 6.56; N, 7.24% 
 
  
2.13 (0.438 g, 0.002 mol) was dissolved in EtOH (10 mL) and a CuCl2.6H2O solution 
(0.348 g, 0.002 mol in 10 mL EtOH) was added. A blue/green precipitate was formed 
and the reaction was allowed to stir at room temperature overnight. The solvent was 
reduced by half in vacuo and cooled on ice for 30 min and a green/blue solid was 
collected. This was washed with cold EtOH and dried under vacuum (0.525g, 69 %). 
IR (KBr Disk): 3495, 3377, 3198, 2970, 2918, 2873, 1610, 1516, 1484, 1444, 1234, 
1217, 1049, 823, 768, 579, 510 cm-1. Anal. Calcd for C13H16N2Cl2O2Cu: C, 42.58; H, 
4.40; N, 7.64. Found: C, 42.66; H, 4.39; N, 7.30%. Mp: 178 ˚C. μeff: 1.78 B.M. 
2.17 
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Crystals suitable for X-ray analysis were obtained from a solution of the ligand in 
acetonitrile. 
Empirical formula  C56H62Cl8Cu4N10O4 
Formula weight  1476.91 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  Pī 
Unit cell dimensions a = 11.9914(6) Å           α= 113.9980(10)°. 
 b = 12.6755(6) Å           β= 96.5800(10)°. 
 c = 12.6960(6) Å            γ= 115.3470(10)°. 
Volume 1492.64(13) Å3 
Z 1 
Density (calculated) 1.643 Mg/m3 
Absorption coefficient 1.819 mm-1 
F(000) 752 
Crystal size 0.230 x 0.180 x 0.120 mm3 
Theta range for data collection 1.874 to 30.211°. 
Index ranges -16≤h≤16, -17≤k≤17, -17≤l≤17 
Reflections collected 58825 
Independent reflections 8816 [R(int) = 0.0282] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7460 and 0.6898 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8816 / 0 / 381 
Goodness-of-fit on F2 1.030 
Final R indices [I>2σ(I)] R1 = 0.0223, wR2 = 0.0542 
R indices (all data) R1 = 0.0292, wR2 = 0.0572 
Largest diff. peak and hole 0.423 and -0.420 e.Å-3 
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2.13 (0.613 g, 0.0028 mol) was dissolved in EtOH (10 mL) and a CuCl2.6H2O solution 
(0.163 g, 0.00093 mol, 0.33eq in 10 mL EtOH) was added. A green precipitate was 
formed and the reaction was allowed to stir at room temperature overnight. The 
solvent was reduced by half in vacuo and cooled on ice for 30 min and a green/blue 
solid. This was washed with cold EtOH and dried under vacuum (0.489 g, 62%). IR 
(KBr Disk): 3340, 3161, 3079, 2947, 2883, 1610, 1594, 1515, 1489, 1446, 1273, 1235, 
1179, 1053, 828, 761, 585, 505 cm-1 . HRMS m/z (ESI+): 491.1523, (C26H28N4O2Cu: 
[M*]+ requires 491.1508). Mp: 162-163˚C. Anal. Calcd for C26H28N4Cl2O2Cu: C, 55.47; 
H, 5.01; N, 9.95 Found: C, 55.46; H, 5.21; N, 9.73%. μeff: 1.89 B.M. 
 
 
 
2.13 (0.425 g, 0.00198 mol) was dissolved in EtOH (10 mL) at and a solution of ZnCl2 
(0.270 g, 0.00198 mol in 10 mL EtOH) was added. A white precipitate was formed 
after several minutes stirring at room temperature and the reaction was allowed to 
stir overnight. This was reduced in vacuo by approximately half and cooled on ice to 
yield a brown precipitate. This was collected by filtration and washed with cold EtOH 
to yield a brown solid upon drying (0.349 g, 52 %). IR (KBr Disk): 3415, 3233, 3211, 
3228, 1610, 1572, 1520, 1438, 1207, 1030, 835, 767, 509 cm-1.  Mp: 169-170 ˚C Anal. 
Calcd for C13H16N2Cl2O2Zn: C, 44.54; H, 4.03; N, 7.99. Found: C, 44.01; H, 4.27; N, 7.79 
%. 
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Crystals suitable for X-ray analysis were grown by slow evaporation of the filtrate 
over several weeks to yield pale brown rhombic crystals. 
Empirical formula  C13H14Cl2N2OZn 
Formula weight  350.53 
Temperature  99.92 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.7884(7) Å                  α= 90°. 
 b = 8.3147(5) Å β= 92.337(2)°. 
 c = 13.8733(7) Å γ= 90°. 
Volume 1473.94(14) Å3 
Z 4 
Density (calculated) 1.580 Mg/m3 
Absorption coefficient 2.021 mm-1 
F(000) 712 
Crystal size 0.2 x 0.2 x 0.13 mm3 
Theta range for data collection 2.857 to 28.420°. 
Index ranges -16≤h≤17, -11≤k≤7, -18≤l≤18 
Reflections collected 13564 
Independent reflections 3684 [R(int) = 0.0487] 
Completeness to theta = 26.000° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.6619 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3684 / 0 / 180 
Goodness-of-fit on F2 1.019 
Final R indices [I>2σ(I)] R1 = 0.0323, wR2 = 0.0596 
R indices (all data) R1 = 0.0548, wR2 = 0.0671 
Largest diff. peak and hole 0.389 and -0.435 e.Å-3 
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2.13 (0.858 g, 0.004 mol) was dissolved in EtOH (15 mL) at and a solution of ZnCl2 
(0.177 g, 0.0013 mol in 10 mL EtOH) was added. A white precipitate was formed after 
several minutes stirring at room temperature and the reaction was allowed to stir 
overnight. The solvent was reduced in vacuo by approximately half and the solution 
was cooled on ice for 30 min. A white precipitate was collected by filtration and 
washed with cold EtOH (0.703 g, 90 %). IR (KBr Disk): 3395, 3158, 3125, 3090, 2900, 
1611,1592, 1574, 1516, 1489, 1445, 1366, 1274, 1236, 1176, 1085, 981, 828, 759, 
506 cm-1. Mp: 178-179 ˚C. Anal. Calcd for C26H30N4Cl2O3Zn: C, 54.24 H, 5.56; N, 9.37. 
Found: C, 54.18; H, 5.19; N, 9.65%. 1H NMR (500 MHz, DMSO) δ 9.32 (s, 1H, N-H),  
8.51 (s, 1H, Pyr-H), 7.91 (t, 1H, Pyrr-H), 7.52 (ds, H, Pyr-H), 7.41 (bs, 1H, Pyr-H), 7.16 
(d, 2H, Ar-H), 6.71 (d, 2H, Ar-H), 3.84 (s, 2H, Pyr-CH2), 3.65 (s, 2H, Ar-CH2). 13C NMR 
(126 MHz, DMSO) δ 157.1 (Pyr-C), 149.2 (Ar-C), 145.3 (Pyr-CH), 141.4 (Pyr-CH), 131.5 (Pyr-
CH), 130.2 (Ar-CH), 125.4 (Ar-CH), 115.4 (Ar-CH), 56.8 (CH2), 52.0 (CH2).   
 
 
 
To a solution of 2.13 (0.397 g, 0.00185 mol) in EtOH (10 mL) was added a solution of 
Zn (ClO4)2.6H2O (0.229 g, 0.00061 mol) in EtOH (10 mL) at room temperature to 
immediately yield a beige precipitate. This was stirred for 5 h and the precipitate was 
collected by vacuum filtration to yield the product as a hygroscopic brown solid which 
was then freeze dried to yield the product as a brown powder (0.207 g, 62 %). 1H 
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NMR (500 MHz, CD3CN) δ 8.11 (bs, 2H, Ar-H), 8.05 – 8.00 (m, 2H, Ar-H), 7.49 (bs, 4H, 
Ar-H), 7.09 (bs, 4H, Ar-H), 6.77 (bs, 4H, Ar-H), 3.91 (bs, 4H, Pyr-CH2), 3.64 (bs, 4H, Ar-
CH2). 13C NMR (126 MHz, DMSO) δ 157.1 (Pyr-C), 148.1 (Ar-C), 147.3 (Pyr-CH), 140.4 
(Pyr-CH), 130.5 (Pyr-CH), 130.2 (Ar-CH), 124.1 (Ar-CH), 115.7 (Ar-CH), 56.6 (CH2), 52.0 
(CH2).  IR (KBr Disk): 3430, 2935, 2968, 1613, 1574, 1517, 1489, 1446, 1375, 1269, 
1222, 1177, 1108, 1051, 928, 833, 764, 623, 509cm-1. Mp: 161-163 ˚C. Anal. Calcd for 
C26H30N4Cl2O11Zn: C, 43.93; H, 4.25; N, 7.88. Found: C, 44.02; H, 4.49; N, 8.20% 
 
 
 
2.14 (0.200 g, 0.00077 mol) was dissolved in EtOH (10 mL) at room temperature and 
a solution of CuCl2.2H2O (0.158 g, 0.00092 mol) in EtOH (8 mL) was added to yield a 
green precipitate. This was stirred for 4 h and the product was collected by vacuum 
filtration and dried to yield the product as a dark green solid (0.189 g, 62.5 %). 
IR (KBr Disk): 3437, 3238, 2941, 2868, 1609, 1583, 1512, 1485, 1448, 1308, 1250, 
1183, 1079, 1053, 918, 895, 841, 816, 767, 646, 598, 542cm-1. Anal. Calcd for 
C15H20Cl2CuN2O3: C, 43.86; H, 4.91; N, 6.82. Found: C, 43.34; H, 4.69; N, 6.29%. μeff: 
1.86 B.M 
 
 
2.15 (0.294 g, 0.00054 mol) was dissolved in EtOH (10 mL) at room temperature and 
a solution of CuCl2.2H2O (0.110 g, 0.00065 mol) in EtOH (10 mL) was added and the 
reaction was allowed to stir overnight. The resulting green solution was allowed to 
stand for 3 days and a green precipitate was collected. This was washed with cold 
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EtOH and dried in vacuo to yield a green powder (0.216 g, 59 %). IR (KBr Disk): 3421, 
2998, 2924, 2887, 1753, 1628, 1610, 1512, 1486, 1447, 1431, 1376, 1231, 1045, 908, 
769, 600cm-1. Mp: 146-147 ˚C. Anal. Calcd for C27H32N2Cl2O10Cu: C, 47.76; H, 4.75; N, 
4.13. Found: C, 47.46; H, 4.85; N, 3.82%. μeff: 1.71 B.M 
 
 
2.15 (0.200 g, 0.00036 mol) was dissolved in EtOH (15 mL) at room temperature and 
a solution of ZnCl2 (0.049 g, 0.00036 mol) in EtOH (5 mL) was added which 
immediately formed a beige precipitate. The reaction was stirred for 4 h and the solid 
was filtered and washed with cold ethanol to yield the product as a beige solid (0.127 
g, 52 %). 1H NMR (500 MHz, DMSO) δ 8.57 (bs, 1H, Pyr-H), 8.02 (t, J = 7.5 Hz, 1H, Pyr-
H), 7.59-7.53(m, 2H, Pyr-H), 7.36 (d, J= 7.9 Hz, 2H, Ar-H), 6.98 (d, J = 7.8 Hz, 2H, Ar-
H), 5.57 (d, J = 8.9 Hz, 1H, H-1), 5.43 (t, J = 7.9 Hz, 1H, H-4), 5.07 (at, J = 7.3 Hz, 1H, H-
2), 5.03 (at, J = 7.5 Hz, 1H, H-3), 4.27-4.23 (m, 1H, H-5), 4.19 (dd, J = 9.3, 3.9 Hz, 1H, 
H-6), 4.08 (ad, J = 4.0 Hz, 1H, H-6’), 3.88 (s, 2H, PyrCH2), 3. 3.79 (bs, 2H, ArCH2),  2.03 
(s, 3H, OAc), 2.03 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.98 (s, 3H, OAc). 13C NMR (126 MHz, 
DMSO) δ 170.4 (C=O), 170.0 (=O), 169.8 (C=O), 169.6 (C=O), 156.2 (Pyr-C), 148.2 (Ar-
C), 140.2 (Pyr-CH), 132.2 (Pyr-CH), 130.8 (Ar-C), 124.4 (Ar-CH), 124.2 (Ar-CH),  123.9 
(Pyr-CH), 116.7 (Pyr-CH), 97.5 (C-1), 72.4 (C-4), 71.2 (C-5), 71.2 (C-3), 68.5 (C-2), 62.1 
(C-6), 51.9 (PyrCH2), 51.0 (ArCH2), 20.9 (OAc), 20.8 (OAc), 20.8 (OAc), 20.7 (OAc). IR 
(KBr Disk): 3460, 3264, 2961, 2941, 1752, 1610, 1574, 1512, 1486, 1446, 1370, 1231, 
1065, 1044, 910, 836, 768, 599cm-1. Mp: 123-124 ˚C. Anal. Calcd for 
C27H32N2Cl2O10Zn: C, 47.63; H, 4.74; N, 4.11. Found: C, 47.26; H, 4.81; N, 4.04% 
2.26 
210 
 
 
 
 
This reaction was carried out on a Schlenk line under a positive pressure of nitrogen. 
Flame dried glassware was used and the ethanol was dried over 3 Å molecular sieves 
and degassed using the freeze-pump-thaw method. 
2.15 (0.366 g, 0.00067 mol) was dissolved in EtOH (10 mL) at room temperature to 
which a solution of FeCl2.4H2O (0.04 g, 0.00022 mol) in EtOH (5 mL) was added 
dropwise via cannula. This formed a deep green solution which was allowed to stir 
for 3 h before the solvent was reduced by approximately half in vacuo and left to 
stand overnight. This was then filtered under a flow of nitrogen to yield the product 
as an air stable green/grey solid (0.112 g, 60%). IR (KBr Disk): 3429, 2913, 1752, 1607, 
1510, 1479, 1437, 1369, 1231, 1038, 1046, 909, 835, 766, 601 cm-1. Mp: 149-150 ˚C. 
Anal. Calcd for C27H36N2Cl4O12Fe2: C, 38.88; H, 4.35; N, 3.36. Found: C, 38.89; H, 4.04; 
N, 3.30%. μeff : 9.76 B.M 
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This reaction was carried out on a Schlenk line under a positive pressure of nitrogen. 
Flame dried glassware was used and the ethanol was dried over 3 Å molecular sieves 
and degassed using the freeze-pump-thaw method. 
2.15 (0.266 g, 0.00048 mol) was dissolved in EtOH (10 mL) and was added dropwise 
via cannula to a solution of FeCl2.4H2O (0.116 g, 0.00057 mol) in EtOH (8 mL) which 
immediately produced a yellow brown precipitate. This was stirred for 3h at room 
temperature and the solvent was reduced in vacuo by approximately half and the 
solution was allowed to stand overnight. This was filtered under a stream of nitrogen 
to yield the product as a yellow brown solid (0.181 g, 53%). 
IR (KBr Disk): 3436, 3271, 2940, 1755, 1608, 1513, 1441, 1368, 1227, 1065, 1040, 907, 
834, 777, 598 cm-1. Mp: 141-142˚C. Anal. Calcd for C27H36N2Cl2O12Fe: C, 45.85; H, 
5.13; N, 3.96. Found: C, 45.99; H, 4.77; N, 4.05%. μeff: 5.16 B.M.  
 
 
2.16 (0.74 3g, 0.0012 mol) was dissolved in EtOH (12 mL) and a solution of CuCl2.2H2O 
(0.258 g, 0.0015 mol) in EtOH (10 mL) was added to immediately yield a dark green 
solution. This was stirred for 4 h at room temperature and after standing for an hour, 
the solution had undergone partial gelation to yield a blue viscous gel like substance. 
This was filtered and dried in vacuo using Abderhaldens Drying Pistol using refluxing 
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acetone as the heat source to yield a dark green solid which was dried further by 
lyophilisation for 24 h to produce a green powder (0.499 g, 57.7 %). IR (KBr Disk): 
3442, 3202, 2940, 2932, 2879, 1753, 1609, 1513, 1483, 1448, 1423, 1368, 1231, 1067, 
1040, 913, 834, 773, 600 cm-1. HRMS m/z (ESI+): 744.0897(C29H36Cl2CuN2NaO11: 
[M+Na]+ requires 744.0889). Mp: 117-118˚C. Anal. Calcd for C29H38Cl2CuN2O12: C, 
47.00; H, 5.17; N, 3.78 Found: C, 46.59; H, 5.11; N, 3.25 %. μeff: 1.98 B.M. 
 
 
 
2.17 (0.200 g, 0.00053 mol) was dissolved in EtOH (15 mL) with sonication, and added 
to a stirring solution of CuCl2.2H2O (0.109 g, 0.00063 mol) in EtOH (8 mL) at room 
temperature to immediately yield a pale green solid. The reaction was stirred for 3 h 
and the product was collected by vacuum filtration and dried under vacuum (0.117 
g, 43.2%). IR (KBr Disk): 3406, 2924, 2879, 1610, 1574, 1511, 1486, 1447, 1235, 1184, 
1074, 1045, 896, 830, 767, 658, 628, 575, 419 cm-1. HRMS m/z (ESI+): 532.0228 
(C19H24Cl2CuN2O6Na: [M+Na]+ requires 532.0200). Mp: 140 ˚C. Anal. Calcd for 
C19H24Cl2CuN2O6: C, 44.67; H, 4.74; N, 5.48. Found: C, 44.54; H, 5.17; N, 5.30%. μeff: 
1.84 BM. 
 
2.17 (0.300 g, 0.00079 mol) was dissolved in EtOH (15 mL) with sonication and added 
to a stirring solution of ZnCl2 (0.130 g, 0.00095 mol) in EtOH (8 mL) at room 
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temperature to immediately yield a beige solid. The reaction was stirred for 3 h and 
the product was collected by vacuum filtration and dried by lyophilisation for 72 h yo 
produce a pale yellow solid (0.092 g, 22.7%). 1H NMR (500 MHz, D2O) δ 8.21 (s, 1H, 
Pyr-H), 7.89 (s, 1H, Pyr-H), 7.51 – 7.43 (m, 1H, Pyr-H), 7.38 (d, J = 6.8 Hz, 1H, Ar-H), 
7.11-7.08 (m, 1H,  Pyr-H), 6.98(d, J = 6.8 Hz, 2H, Ar-H), 3.79 (s, 2H), 3.76 (bs,2H), 3.72 
(s, 2H), 3.69 (d, J = 9.8, 1H, H-6), 3.61 – 3.33(m, 6H). 13C NMR (126 MHz, D2O) δ  185.9 
(Pyr), 154.2 (Pyr), 148.8 (Pyr) 140.1 (Pyr), 133.3 (Ar) 130.8 (Pyr), 124.2 (Ar), 119.4 (Ar), 
117.7 (Ar), 99.5 (C-1), 77.8 (Glu-C), 76.6 (Glu-C), 73.5 (Gluc-C), 68.8 (Gluc-C), 59.1 
(Pyr-CH2), 51.6 (C-6) I, 50.7 (Ar-CH2). IR (KBr Disk): 3430, 2920, 2873, 1610, 1512, 
1446, 1236, 1074, 1043, 1015, 834, 767, 630, 565cm-1. HRMS m/z (ESI+): 548.9894 
(C19H24Cl2ZnN2O6K: [M+K]+ requires 548.9934). Mp: 127- 129 ˚C. Anal. Calcd for 
C19H24Cl2N2O6Zn: C, 44.51; H, 4.72; N, 5.47. Found: C, 44.98; H, 4.99; N, 5.01% 
 
 
 
2.17 (0.216 g, 0.00057 mol) was dissolved in EtOH (15 mL) with sonication and a 
solution of Zn(ClO4)2.6H2O (0.0854 g, 0.00028 mol) in EtOH (5 mL) was added to 
immediately produce a white precipitate. The reaction was stirred for 2 h at room 
temperature and reduced in vacuo to approximately 10 mL and the product was 
isolated by vacuum filtration and washed with cold ethanol to yield a sticky 
hygroscopic beige solid. This was lyophilized for 24 h to produce a beige solid. 
1H NMR (500 MHz, D2O) δ 8.28 (s, 1H, Pyr-H), 7.94 (s, 1H, Pyr-H), 7.48 – 7.41 (m, 1H, 
Pyr-H), 7.38 (d, J = 7.0 Hz, 1H, Arr-H), 7.13-7.15 (m, 1H, , Pyr-H), 7.00 (d, J = 7.0 Hz, 
2H, Ar-H), 3.89 (s, 2H), 3.84 (d, J = 12.2 Hz, 2H), 3.72 (s, 2H), 3.68 (dd, J = 12.5, 5.4 Hz, 
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1H, H-6), 3.59 – 3.46 (m, 5H), 3.45 – 3.35 (m, 1H). 13C NMR (126 MHz, D2O) δ  182.0 
(Pyr), 156.5 (Pyr), 148.9 (Pyr) 138.4 (Pyr), 132 (Ar) 130.6 (Pyr), 124.6 (Ar), 124.3 (Ar), 
116.9 (Ar), 100.2 (C-1), 76.2 (Glu-C), 75.6 (Glu-C), 72.9 (Gluc-C), 69.4 (Gluc-C), 60.6 
(Pyr-CH2), 51.6 (C-6) I, 50.1 (Ar-CH2). IR (KBr Disk): 3421, 3282, 2922, 2879, 1610, 
1575, 1512, 1487, 1446, 1397, 1303, 1237, 1183, 1121, 1078, 1015, 895, 833, 767, 
625, 565cm-1. Mp: 143-145˚C. Anal. Calcd for C38H56Cl2N4O24Zn: C, 41.90; H, 5.18; N, 
5.14. Found: C, 42.17; H, 4.97; N, 4.99% 
6.2.2   N2O Series 
 
 
 
2,4-dihydroxybenzaldehyde (2 g, 0.0144 mol) and 2-picolyamine (1.49 mL, 0.0144 
mol) were stirred at room temperature in EtOH (25 mL) for 4 h. The product 
precipitated out as a yellow solid which was collected by vacuum filtration and dried 
to give the product in a quantitative yield. 1H NMR (500 MHz, CDCl3) δ 8.60 (d, J = 4.9 
Hz, 1H, Pyr-H), 8.25 (s, 1H, C(=N)H), 7.77 (dd, J = 8.5, 6.9 Hz, 1H, Pyr-H), 7.42 (d, J = 
7.8 Hz, 1H, Pyr-H), 7.35 – 7.26 (m, 1H), 6.87 (d, J = 8.4 Hz, 1H, Ar-H), 6.29 (d, J = 2.2 
Hz, 1H, Ar-H), 6.20 (dd, J = 8.4, 2.2 Hz, 1H, Ar-H), 4.83 (s, 2H, CH2). 13C NMR (126 MHz, 
CDCl3) δ 166.2 (C=N), 164.0 (Pyr), 160.8 (Pyr), 157.9 (Ar), 149.1 (Pyr), 137.8 (Pyr), 
133.5 (Ar), 123.2 (Pyr), 123.05 (Ar), 112.5 (Ar), 107.3 (Ar), 103.4 (Ar), 64.3 (CH2). IR 
(KBr Disk): 3435, 3064, 2763, 2676, 2618, 1621, 1442, 1331, 1271, 1120cm-1. HRMS 
m/z (ESI+): 228.0905 (C13H12N2O2: [M+H]+ requires 228.0899). Mp: 159-160˚C. Anal. 
Calcd for C13H12N2O2: C, 68.41; H, 5.30; N, 12.27 Found: C, 68.63; H, 5.44; N, 12.28%.  
Crystals suitable for x-ray crystallography were grown by dissolving the sample in hot 
acetonitrile and letting the sample stand for several hours to yield pale orange 
trapezoid-like crystals. 
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Empirical formula  C13H12N2O2 
Formula weight  228.25 
Temperature  99.92 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 22.8835(13)            α= 90°. 
 b = 5.7669(3) Å             β= 112.5980(15)°. 
 c = 18.6703(10) Å         γ = 90°. 
Volume 2274.7(2) Å3 
Z 8 
Density (calculated) 1.333 Mg/m3 
Absorption coefficient 0.092 mm-1 
F(000) 960 
Crystal size 0.28 x 0.2 x 0.2 mm3 
Theta range for data collection 3.580 to 28.260°. 
Index ranges -30≤h≤28, -7≤k≤5, -18≤l≤24 
Reflections collected 8049 
Independent reflections 2810 [R(int) = 0.0258] 
Completeness to theta = 25.242° 99.6 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.7075 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2810 / 0 / 163 
Goodness-of-fit on F2 1.026 
Final R indices [I>2σ(I)] R1 = 0.0391, wR2 = 0.0949 
R indices (all data) R1 = 0.0529, wR2 = 0.1034 
Extinction coefficient 0.0049(6) 
Largest diff. peak and hole 0.359 and -0.213 e.Å-3 
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2.38 (0.954 g, 0.0052 mol) was dissolved in EtOH (20 mL, dried over 3 Å molecular 
sieves) at 35 ˚C and 2-picolylamine (0.54 mL, 0.0052 mol) was added. This was stirred 
overnight at room temperature under N2 and the solvent was reduced in vacuo to 
approximately 10 mL and cooled on ice to yield a yellow precipitate which was 
filtered and washed with cold EtOH to give the product as bright yellow solid (1.217 
g, 86%). 1H NMR (500 MHz, CDCl3) δ 13.83 (s, 1H, Ar-OH), 8.58 (d, J = 4.9 Hz, 1H, Pyr), 
8.41 (s, 1H, C(=N)H), 7.69 (td, J = 7.7, 1.8 Hz, 1H, Pyr), 7.35 (d, J = 7.7 Hz, 1H, Ar-H), 
7.22 – 7.20 (m, 1H, Ar-H), 7.18 (d, J = 8.9 Hz, 1H, Ar-H), 6.46 (m, 2H, Ar-H), 6.44 (d, J 
= 2.4 Hz, 1H, Ar-H), 4.89 (s, 2H, Pyr-CH2), 4.18 – 4.06 (t, J = 4.9, 2H, ArO-CH2), 4.01 – 
3.92 (t, J = 4.9,2H, CH2OH). 13C NMR (126 MHz, CDCl3) δ 166.1 (Ar-C), 164.2 (Ar-C), 
161.1 (C=N), 157.7 (Pyr-C), 148.9 (Pyr-CH), 137.8 (Pyr-CH), 133.4 (Ar-CH), 123.2 (Pyr-
CH), 123.0 (Pyr-CH), 112.3 (Ar-C), 107.3 (Ar-C), 103.3 (Ar-CH), 63.9 (CH2). IR (KBr Disk): 
3406, 3269, 2943, 2927, 2896.2, 1630, 1596, 1179.5, 1138, 1096, 1044, 844, 763, 614 
cm-1. HRMS m/z (ESI+): 273.1233 (C14H17N2O3: [M+H]+ requires 273.1239). Mp: 124 
˚C. Anal. Calcd for C15H14N2O3: C, 66.54; H, 5.92; N, 10.29 Found: C, 66.35; H, 6.05; N, 
10.26% 
Crystals suitable for x-ray crystallography were grown by dissolving the sample in hot 
acetonitrile and which yielded long needle shaped crystals upon cooling to room 
temperature. 
Empirical formula  C15H16N2O3 
Formula weight  272.30 
Temperature  99.99 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 5.3704(2) Å             α= 90°. 
 b = 20.0520(5)              β= 100.5131(15)°. 
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 c = 12.4990(4) Å             γ = 90°. 
Volume 1323.39(7) Å3 
Z 4 
Density (calculated) 1.367 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 576 
Crystal size 0.35 x 0.17 x 0.12 mm3 
Theta range for data collection 2.622 to 33.144°. 
Index ranges -8≤h≤8, -30≤k≤30, -17≤l≤19 
Reflections collected 32488 
Independent reflections 5038 [R(int) = 0.0495] 
Completeness to theta = 26.000° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7465 and 0.6856 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5038 / 0 / 189 
Goodness-of-fit on F2 1.037 
Final R indices [I>2σ(I)] R1 = 0.0487, wR2 = 0.1130 
R indices (all data) R1 = 0.0774, wR2 = 0.1271 
Largest diff. peak and hole 0.408 and -0.272 e.Å-3 
 
 
 
2.39 (1 g, 0.0021 mol) and 2-picolylamine (0.22 mL, 0.0021 mol) were refluxed in 
EtOH (20 mL, dried over 3Å molecular sieves) under N2 for 6 h. The solvent was 
removed in vacuo to yield the product as an orange solid in a quantitative yield. 1H 
NMR (500 MHz, CDCl3) δ 13.72 (s, 1H, OH), 8.58 (d, J = 4.9 Hz, 1H, Pyr-H), 8.45 (s, 1H, 
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C(H) =N), 7.69 (apptd, J = 7.8, 1.9 Hz, 1H, Pyr-H), 7.34 (d, J = 7.8 Hz, 1H, Pyr-H), 7.21 
(m, 2H, Pyr-H, Ar-H), 6.56 (d, J = 2.3 Hz, 1H, Ar-H), 6.50 (dd, J = 8.5, 2.3 Hz, 1H, Ar-H), 
5.36 – 5.20 (m, 2H, H-1, H-2), 5.14 (m, 2H, H-3, H-4), 4.91 (s, 2H, CH2-Pyr), 4.29 (dd, J 
= 12.3, 5.7 Hz, 1H, H-6), 4.18 (dd, J = 12.3, 2.3 Hz, 1H, H-6’), 3.89 (ddd, J = 10.1, 5.7, 
2.3 Hz, 1H, H-5), 2.10 (s, 3H, OAc), 2.05 (s, 6H, OAc), 2.04 (s, 3H, OAc). 13C NMR (126 
MHz, CDCl3) δ 170.8 (C=O), 170.3 (C=O), 169.5 (C=O), 169.4 (C=O), 165.9 (C=N), 163.8 
(Pyr), 160.2 (Ar), 157.9 (Ar), 149.6 (Pyr), 137.0 (Pyr), 132.9 (Pyr), 122.5 (Ar), 122.0 
(Pyr), 114.6 (Ar), 108.2 (Ar), 104.2 (Ar), 98.3 (H-1), 72.8 (H-2), 72.3 (H-3), 71.1 (C-5), 
68.3 (C-4), 64.6 (CH2-Pyr), 61.9 (C-6), 20.8 (OAc), 20.7 (OAc), 20.7 (OAc), 20.7 (OAc). 
IR (KBr Disk): 3472, 3053, 3017, 2965, 2870, 1749, 1635, 1589, 1572, 1532, 1505, 
1433, 1368, 1255, 1224, 1176, 1079, 1056, 749cm-1. HRMS m/z (ESI+): 559.1895 
(C27H31N2O11: [M+H+]+ requires 559.1895). Mp: 77-78 ˚C. [α]D
23
: -0.23˚ (c 2, CH2Cl2). 
Anal. Calcd for C27H30N2O11: C, 58.06; H, 5.41; N, 5.02 Found: C, 58.24; H, 5.42; N, 
5.25% 
 
 
2.40 (1.228 g, 0.00239 mol) and 2-picolylamine (0.247 mL, 0.00239 mol) were 
refluxed in EtOH (20 mL, dried over 3 Å molecular sieves) for 4 h under N2. The solvent 
was reduced in vacuo to approximately 15 mL and the reaction was cooled on ice to 
yield the product as a pale yellow precipitate which was isolated by vacuum filtration 
(1.126 g, 78%). 1H NMR (500 MHz, CDCl3) δ 13.80 (s, 1H, Ar-OH), 8.58 (d, J = 4.0 Hz, 
1H, Pyr-H), 8.41 (s, 1H, C(H)=N), 7.69 (td, J = 7.7, 1.8 Hz, 1H, Pyr-H), 7.35 (d, J = 7.8 
Hz, 1H, Pyr-H), 7.21 (dd, J = 7.0, 5.4 Hz, 1H, Pyr-H), 7.19 – 7.14 (m, 1H, Ar-H), 6.44 – 
6.39 (m, 2H, Ar-H), 5.22 (t, J = 9.6 Hz, 1H, H-3), 5.10 (t, J = 9.7 Hz, 1H, H-4), 5.02 (dd, J 
= 9.6, 8.0 Hz, 1H, H-2), 4.89 (s, 2H, CH2-Pyr), 4.66 (d, J = 8.0 Hz, 1H, H-1), 4.27 (dd, J = 
12.3, 4.7 Hz, 1H, H-6), 4.19 – 4.06 (m, 4H, H-6’, OCH2CH2OAr, OCHCH2OAr), 4.01 – 
3.86 (m, 1H, OCH’CH2OAr), 3.72 (ddd, J = 10.1, 4.7, 2.4 Hz, 1H, H-5), 2.08 (s, 3H, OAc), 
2.03 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.96 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 
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170.8 (C=O), 170.4 (C=O), 169.5 (C=O, 169.5 (C=O), 165.8 (C=N), 164.5 (Ar), 162.5 
(Ar), 158.2 (Pyr), 149.5 (Pyr), 136.9 (Pyr), 133.1 (Ar), 122.5 (Pyr), 121.9 (Pyr), 112.9 
(Ar), 106.8 (Ar), 101.8 (Ar), 101.2 (C-1), 72.8 (C-3), 72.0 (C-5), 71.2 (C-2), 68.4 (C-4), 
68.1 (OC H2CH2OAr), 67.2 (OCH2CH2OAr), 64.2 (CH2-Pyr), 61.9 (C-6), 20.8 (OAc), 20.7 
(OAc), 20.7 (OAc), 20.7 (OAc). IR (KBr Disk): 3467, 2964, 2935, 2885, 1744, 1630, 
1591, 1518, 1433, 1370, 1254, 1224, 1178, 1141, 1046, 981, 846, 606 cm-1. HRMS 
m/z (ESI+): 603.2177 (C29H35N2O12: [M+H]+ requires 603.2190). [α]D
23
: -0.16˚ (c 2, 
CH2Cl2). Mp: 118-119 ˚C. Anal. Calcd for C29H34N2O12: C, 57.80; H, 5.69; N, 4.65 Found: 
C, 58.04; H, 5.68; N, 4.65% 
 
 
2, 4-dihydroxybenzaldehyde (1 g, 0.0072 mol), 2-chloroethanol (0.97 mL, 0.0144 
mol), DBU (1.07 mL, 0.0072 mol) and NaI (0.539 g, 0.0036 mol) were dissolved in IPA 
(25 mL) and heated in a microwave to 150 ˚C for 4 h. The solvent was removed in 
vacuo and the residue was dissolved in EtOAc (50 mL) and washed with NaHCO3 
solution (50 mL), H2O (3 x 50 mL) and brine (50 mL) and the organic layer was then 
dried over Na2SO4. This yielded a brown oil was then purified by column 
chromatography (2:1 Pet Ether/EtOAc, Rf= 0.43) to give the product as a white solid 
(0.996 g, 76%). 1H NMR (500 MHz, CDCl3) δ 11.47 (s, 1H, Ar-OH), 9.72 (s, 1H, C(=O)H), 
7.44 (d, J = 8.7 Hz, 1H, Ar-H), 6.57 (dd, J = 8.7, 2.3 Hz, 1H, Ar-H), 6.44 (d, J = 2.3 Hz, 
1H), 4.15 – 4.12 (m, 2H, ArCH2), 3.99 (m, J = 3.8 Hz, 2H,CH2OH), 2.04 (s, 1H,CH2OH). 
13C NMR (126 MHz, CDCl3) δ 194.5 (C=O), 165.8 (Ar), 164.4 (Ar), 155.4 (Ar), 135.4 (Ar), 
115.4 (Ar), 108.6 (Ar), 69.7 (ArCH2), 61.1 (CH2OH). IR (KBr) Disk: 3462, 3446, 2959, 
2921, 2865, 1804, 1648, 1495, 1232, 1168, 1047cm-1. HRMS m/z (ESI+): 183.0661 
(C9H10O4: [M+H]+ requires 183.0657). Mp: 76-77 ˚C. Anal. Calcd for C9H10O4: C, 59.34; 
H, 5.53. Found: C, 58.98.04; H, 5.55% 
The NMR data is in agreement with that reported in the literature.224 
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2.7 (2 g, 0.0049 mol), 2, 4-dihydroxybenzaldehyde (1.344 g, 0.0097 mol) and Ag2CO3 
(1.344 g, 0.0097 mol) were dissolved in MeCN (50 mL, dried over 3 Å molecular 
sieves) under N2 in the dark and stirred overnight at room temperature. The solvent 
was removed in vacuo and the residue was dissolved in EtOAc (80 mL) with sonication 
and filtered through a Celite cake. The resulting solution was washed with 1M HCl 
(50 mL), saturated NaHCO3 solution (3 x 50 mL) and brine (50 mL) and dried over 
Na2SO4. The solvent was removed in vacuo to yield a dark brown oil which was 
purified by column chromatography (2:1 Pet. Ether/EtOAc, Rf: 0.13) to yield the 
product as a white solid (1.40 g, 61%). 1H NMR (300 MHz, CDCl3) δ 11.36 (s, 1H, OH), 
9.76 (s, 1H), 7.46 (d, J = 8.6 Hz, 1H, Ar-H), 6.59 (dd, J = 8.6, 2.3 Hz, 1H, Ar-H), 6.54 (d, 
J = 2.3 Hz, 1H, Ar-H), 5.36 – 5.26 (m, 2H, H-1, H-2), 5.15 (m, 2H, H-3, H-4), 4.26 (dd, J 
= 12.3, 5.9 Hz, 1H, H-6), 4.17 (dd, J = 12.3, 2.5 Hz, 1H, H-6’), 3.91 (ddd, J = 9.9, 5.9, 2.5 
Hz, 1H, H-5), 2.09 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.03 (s, 3H, OAc). 
13C NMR (75 MHz, CDCl3) δ 194.8 (HC=O)H, 170.6 (OAc), 170.1 (OAc), 169.4 (OAc), 
169.2(OAc), 164.0 (Ar), 163.2 (Ar), 135.4 (Ar), 116.7 (Ar), 109.6 (Ar), 103.6 (Ar), 97.7 
(C-1), 72.5 (C-2), 72.4 (C-5), 70.9 (C-3), 68.1 (C-6), 61.9 (C-4), 20.6 (OAc). IR (KBr Disk): 
3442, 2969, 2947, 2863, 1748, 1661, 1628. 1579, 1500, 1438, 1368, 1227, 1177, 1076, 
1035, 979, 908, 802, 761 cm-1. HRMS m/z (ESI+): 491.1167 (C21H24O12: [M+Na]+ 
requires 491.1166). Mp: 140-141 ˚C. [α]D
22
: -6˚ (c= 0.5, CH2Cl2). 
The NMR data is in agreement with reported data.225 
 
 
2.10 (1 g, 0.0024 mol) and NaI (0.359 g, 0.0024 mol) in anhydrous MeCN (15 mL) was 
added a solution of 2,4-dihydroxybenzaldehyde (0.660 g, 0.0048 mol) and DBU (0.359 
2.39 
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mL, 0.0024 mol) in anhydrous MeCN (10 mL) and the mixture was sealed in a 
microwave tube. This was heated in a microwave 125 ˚C for 4 h. The solvent was then 
removed in vacuo and the residue was dissolved in DCM (20 mL) and washed with 
H2O (2x 20 mL), sat. NaHCO3 solution (2x20 mL) and brine (20 mL) before being dried 
with Na2SO4 and the solvent was removed in vacuo to yield a heavy brown oil. This 
was purified by column chromatography (3:1 Pet. Ether/EtOAc, Rf: 0.17) to yield the 
product as dark yellow oil. 1H NMR (500 MHz, CDCl3) δ 11.39 (s, 1H, OH), 9.67 (s, 1H 
C(=O)H), 7.40 (d, J = 8.7 Hz, 1H, Ar-H), 6.49 (dd, J = 8.7, 2.3 Hz, 1H, Ar-H), 6.36 (d, J = 
2.3 Hz, 1H, Ar-H), 5.18 (appt, J = 9.6 Hz, 1H, H-3), 5.05 (appt, J = 9.7 Hz, 1H, H-4), 4.97 
(dd, J = 9.6, 8.0 Hz, 1H, H-2), 4.61 (d, J = 8.0 Hz, 1H, H-1), 4.22 (dd, J = 12.3, 4.7 Hz, 
1H, H-6), 4.16 – 4.05 (m, 4H, H-6’,OCH, CH2Cl), 3.91 (dt, J = 9.6, 3.5 Hz, 1H, OCH’), 3.69 
(ddd, J = 9.7, 4.7, 2.4 Hz, 1H, H-5), 2.03 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.95 (s, 3H, 
OAc), 1.91 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 194.4 (C(=O)H), 170.6 (OAc), 170.2 
(OAc), 169.4 (OAc), 169.3 (OAc), 165.7 (Ar), 164.3 (Ar), 148.7(Ar), 135.4 (Ar), 115.4(Ar), 108.4 
(Ar), 101.3(Ar), 101.0 (C-1), 72.7 (C-3), 71.9 (C-5), 71.1 (C-4), 68.3 (C-2), 67.7 (C-6), 67.4 
(OCH2)), 61.8 (CH2Cl), 20.7 (OAc), 20.6 (OAc), 20.5 (OAc), 20.5 (OAc). IR (KBr Disk): 3471, 2967, 
1745, 1633, 1581, 1430, 1379, 1230, 1123, 1044, 989 cm-1. HRMS m/z (ESI+): 513.1609 
(C23H29O13: [M+H]+ requires 513.1608). [α]D
20
: -2˚ (c= 0.25, CH2Cl2). 
 
 
 
2.33 (0.5 g, 0.002 mol) was dissolved in EtOH (15 mL) and heated to reflux. A solution 
of Cu(ClO4)2.6H2O (0.370 g, 0.001 mol) in EtOH (10 mL) was added upon which the 
reaction turned a dark green colour. This was refluxed for 5h after which it was 
reduced in vacuo to approximately 15 mL and cooled on ice to yield the product as a 
bluish green solid (0.158 g, 40 %). IR (KBr Disk): 3454, 3208, 3121, 2938, 2913, 2021, 
1636, 1615, 1541, 1490, 1334, 1231, 1170, 1057, 625 cm-1. Anal. Calcd for 
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C13H23N2ClO9Cu: C, 35.14; H, 3.86; N, 6.31. Found: C, 34.96; H, 3.75; N, 6.79 % μeff: 
1.91 B.M. 
 
 
Cu(ClO4)2.6H2O (0. 2g, 0.0005 mol) and 2-picolylamine (0.14 mL, 0.0010 mol) were 
stirred at room temperature in EtOH (10 mL) for 4h and cooled on ice for 30 min to 
yield a pale purple precipitate. This was collected by filtration and dried under 
vacuum (0.231 g, 89%). IR (KBr Disk): 3425, 3329, 3210, 3121, 2962, 2914, 1608, 1591, 
1570, 1486, 1434, 1375, 1332, 1291, 1146, 1087, 1029, 945, 779, 626cm-1. HRMS m/z 
(ESI+) 279.0661 (C12H16N4Cu: [M]+ requires 279.0671). Anal. Calcd for 
C12H16N4Cl2O8Cu: C, 30.11; H, 3.37; N, 11.70. Found: C, 30.16; H, 3.39; N, 11.74%. μeff: 
2.01 B.M. 
 
 
2.33 (0.750 g, 0.0032 mol) and Zn(ClO4)2.6H2O (1.223 g, 0.0032 mol) were refluxed in 
EtOH (30 mL) for 4 h. This was reduced to approximately 15 mL in vacuo and cooled 
on ice to yield a hygroscopic yellow solid (0.859 g, 65 %). 1H NMR (500 MHz, CD3CN) 
δ 8.52 (bs, 2H Pyr-H, HC(=N)), 8.11 (bs, 1H, Pyr-H), 7.61 (bs, 2H, Pyr-H), 7.44 (bs, 1H 
Ar-H), 6.60 (bs, 2H, Ar-H), 5.08 (bs, 2H, CH2), 3.81 (bs, H2O, OH). IR (KBr Disk): 3437, 
3335, 3278, 3090, 2954, 2011, 1611, 1589, 1489, 1439, 1381, 1293, 1089, 1027, 625 
cm-1. Anal. Calcd for C13H15N2ClO8Zn: C, 38.07; H, 3.20; N, 8.65. Found: C, 37.89; H, 
3.31; N, 8.40%  
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Zn(ClO4)2.6H2O (0. 723g, 0.0019 mol) and 2-picolylamine (0.4 mL, 0.0038 mol) were 
stirred at room temperature in EtOH (20 mL) for 4 h and cooled on ice for 30 min to 
yield a white precipitate which was collected by vacuum filtration and washed with 
cold EtOH and dried under vacuum (0.855 g, 94 %). 1H NMR (500 MHz, DMSO) δ 8.30 
(d, J = 2.9 Hz, 2H, Pyr-H), 8.05 (at, J = 7.2 Hz, 2H, Pyr-H), 7.59 (d, J = 7.9 Hz, 2H, Pyr-
H), 7.56 – 7.50 (m, 2H, Pyr-H), 4.08 (s, 4H, CH2), 3.91 (s, 4H, NH2).13C NMR (126 MHz, 
DMSO) δ 157.4 (Pyr-C), 146.8 (Pyr-CH), 139.7 (Pyr-C), 123.8 (Pyr-C), 123.5 (Pyr-C), 
42.6 (CH2). IR (KBr Disk): 3439, 3281, 3204, 3133, 2912, 1603, 1590, 1569, 1487, 1439, 
1383, 1334, 1294, 1141, 1114, 1090, 1032, 1017, 940, 772, 636, 626cm-1. Mp: 
Compound decomposes at 245 °C. Anal. Calcd C12H16N4Cl2O8Zn: C 29.99, H 3.36, N 
11.6. Found: C 29.51, H, 3.32, N 11.45%  
Grey rhombic crystals suitable for X-ray analysis were obtained from the NMR sample 
of 2.43 prepared in d8-THF. 
Empirical formula  C12H16Cl2N4O8Zn 
Formula weight  480.56 
Temperature  99.99 K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  I41/a 
Unit cell dimensions a = 14.9255(7) Å α= 90°. 
 b = 14.9255(7) Å β= 90°. 
 c = 15.3140(7) Å γ= 90°. 
Volume 3411.5(4) Å3 
Z 8 
Density (calculated) 1.871 Mg/m3 
Absorption coefficient 1.806 mm-1 
F(000) 1952 
Crystal size 0.18 x 0.12 x 0.1 mm3 
Theta range for data collection 1.905 to 28.289°. 
2.44 
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Index ranges -19≤h≤19, -17≤k≤19, -20≤l≤18 
Reflections collected 21050 
Independent reflections 2120 [R(int) = 0.0436] 
Completeness to theta = 26.000° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.6711 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2120 / 0 / 160 
Goodness-of-fit on F2 1.280 
Final R indices [I>2σ(I)] R1 = 0.0500, wR2 = 0.0984 
R indices (all data) R1 = 0.0606, wR2 = 0.1018 
Largest diff. peak and hole 0.381 and -0.528 e.Å-3 
 
 
 
The reaction was carried out on a Schlenk line under a positive pressure of nitrogen. 
Flame dried glassware was used and the methanol was dried over 3 Å molecular 
sieves and degassed using the freeze-pump-thaw method. 
To a solution of 2.33 (1 g, 0.00438 mol) in MeOH (40 mL) at 45 ˚ C was added a solution 
of Fe(ClO4)2.xH2O (0.279 g, 0.00109 mol) in MeOH (15 mL) via cannula. The reaction 
immediately turned to a deep purple/black colour and was allowed to stir overnight 
at room temperature and was then left to stand for several hours. Approximately 15 
mL of solvent was removed in vacuo and the resulting suspension was filtered under 
inert conditions to yield the product as air stable black solid (0.511 g). IR (KBr Disk): 
3430, 2989, 1607, 1569, 1475, 1442, 1308, 1288, 1262, 1222, 1122, 1109, 1096, 762, 
636 cm-1. HRMS m/z (ESI+): 510.0964 (C26H22FeN4O4: [M  ]̇+ requires 510.09795).Mp: 
>300˚C. Anal. Found: C 55.19, H, 3.95, N 8.77%  
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2.34 (0.230 g, 0.00084 mol) was heated to reflux in EtOH (10 mL, dried over 3Å 
molecular sieves) under N2 and a solution of Cu(ClO4)2.6H2O (0.155 g, 0.00042 mol) 
in EtOH (10 mL, dried over 3Å molecular sieves) was added and the reaction 
immediately turned a deep blue/green colour. This was refluxed for 4 h and the 
solvent was reduced by approximately half in vacuo and cooled on ice to yield the 
product as a dark green solid (0.154 g, 42%). IR (KBr Disk): 3431, 3074, 2936, 1641, 
1609, 1572, 1532, 1489, 1431, 1400, 1306, 1238, 1220, 1180, 1147, 1103, 1043, 988, 
848, 770, 622 cm-1. HRMS m/z (ESI+): 334.0380 (C15H15N2O3: [M-(ClO4-)]+ requires 
334.0378). Mp: 190-192 °C. Anal. Calcd for C15H15N2ClO7Cu: C, 41.48; H, 3.48; N, 6.45. 
Found: C, 41.99; H, 3.72; N, 6.51%. μeff: 1.83 B.M 
Crystals were obtained after storing the reaction filtrate in a freezer for one year to 
produce small rhombic green crystals. 
Empirical formula  C30H33ClCu2N4O12 
Formula weight  804.13 
Temperature  100.02 K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 11.4857(7) Å           α= 107.9394(19)°. 
 b = 11.5834(7) Å           β= 100.493(2)°. 
 c = 14.2410(9) Å            γ = 111.704(2)°. 
Volume 1578.06(17) Å3 
Z 2 
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Density (calculated) 1.692 Mg/m3 
Absorption coefficient 1.505 mm-1 
F(000) 824 
Crystal size 0.12 x 0.08 x 0.05 mm3 
Theta range for data collection 1.595 to 26.387°. 
Index ranges -14≤h≤14, -14≤k≤14, -17≤l≤17 
Reflections collected 32488 
Independent reflections 6354 [R(int) = 0.0634] 
Completeness to theta = 26.000° 98.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7454 and 0.6274 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6354 / 20 / 454 
Goodness-of-fit on F2 1.024 
Final R indices [I>2σ(I)] R1 = 0.0383, wR2 = 0.0854 
R indices (all data) R1 = 0.0648, wR2 = 0.0934 
Largest diff. peak and hole 1.152 and -0.698 e.Å-3 
 
 
 
2.35 (0.2 g, 0.00036 mol) was dissolved in EtOH (15 mL, dried over 3Å molecular 
sieves) and cooled to 0 °C. Cu(ClO4)2. 6H2O (0.146 g, 0.00039 mol) was added to 
immediately produce a deep green colour and the reaction was stirred at 0 °C for 1.5 
h. A green precipitate was collected by vacuum filtration and was washed with cold 
EtOH to yield the product as a green solid (0.125 g, 44 %).IR (KBr Disk): 3465, 2973, 
2941, 2900, 1750, 1628, 1611, 1602, 1572, 1540, 1402, 1379, 1260, 1228, 1188, 1121, 
1076, 1070, 1042, 990, 761, 636, 626 cm-1. HRMS m/z (ESI+): 620.1057 
(C27H29CuN2O11: [M-(4H2O, ClO4-)] + requires 620.1067). Mp: 157-160 °C. [α]D
22
: -0.1˚ (c 
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0.2, DMSO).  Anal. Calcd for C27H36N2ClO19Cu: C, 40.92; H, 4.73; N, 3.53. Found: C, 
41.06; H, 4.44; N, 3.59. μeff: 1.87 B.M 
 
 
2.35 (0.2 g, 0.00036 mol) was dissolved in EtOH (15 mL, dried over 3Å molecular 
sieves) and cooled to 0 °C. Zn(ClO4)2. 6H2O (0.146 g, 0.00039 mol) was added to 
immediately produce a beige colour and the reaction was stirred at 0 °C for 2 h. A 
beige precipitate was collected by vacuum filtration and was washed with cold EtOH 
to yield the product as a beige solid. IR (KBr Disk): 3463, 2969, 2946, 2901, 1750, 
1629, 1611, 1602, 1572, 1540, 1402, 1379, 1260, 1228, 1188, 1121, 1076, 1070, 1042, 
990, 761, 636, 626 cm-1. HRMS m/z (ESI+): 739.0994 (C27H31ClN2O16Zn: [M+H+)] + 
requires 739.0726). Mp: 141-142 °C. [α]D
20
: -0.21˚ (c 0.5, DMSO2).  Anal. Calcd for 
C27H31N2ClO16Zn: C, 43.80; H, 4.22; N, 3.78 Found: C, 44.29; H, 4.53; N, 4.04 % 
 
 
 
 
2.36 (0.200 g, 0.00033 mol) was heated to reflux in EtOH (10 mLl;, dried over 3 Å 
molecular sieves) under N2 to which a solution of Cu(ClO4)2.6H2O (0.0615 g, 0.000165 
mol) in EtOH (10 mL, dried over 3 Å molecular sieves) was added. The reaction was 
stirred at reflux for 4 h and reduced to approximately 15 mL in vacuo and cooled on 
2.48 
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ice to yield the product as a deep green solid (0.183 g,71 %). IR (KBr Disk): 3448, 2945, 
2890, 1745, 1627, 1611, 1572, 1529, 1489, 1431, 1368, 1226, 1172, 1122, 1099, 1068, 
1039, 910, 839, 768, 654, 623, 598 cm-1. HRMS m/z (ESI+): 664.1325 (C29H33N4O12Cu: 
[M-(ClO4-)]+ requires 664.1329). Mp: 132 °C. ). [α]D
23
: -0.2˚ (c 0.5, DMSO). Anal. Calcd for 
C29H35ClCuN2O17: C, 44.51; H, 4.51; N, 3.58. Found: C, 44.32 H, 4.78; N, 3.44%. μeff: 
1.81 B.M. 
 
 
 
 
2.36 (0.200 g, 0.00033 mol) was heated to reflux in EtOH (10 mL, dried over 3 Å 
molecular sieves) under N2 to which a solution of Zn(ClO4)2.6H2O (0.0614 g, 0.000165 
mol) in EtOH (10 mL, dried over 3 Å molecular sieves) was added. The reaction was 
stirred at reflux for 3 h and reduced to approximately 15 mL in vacuo and cooled on 
ice to yield the product as a hygroscopic white solid along with a sticky brown 
precipitate. The white solid was decanted from the reaction mixture as a suspension 
in cold EtOH and the remaining brown solid turned to an oil upon exposure to air 
overnight. The white solid darkened slightly upon exposure to air and was lyophilized 
for 24 h to yield a pale beige solid (0.082 g, 64 %). IR (KBr Disk): 3446, 2944, 2890, 
1756, 1636, 1607, 1574, 1541, 1487, 1432, 1376, 1368, 1229, 1172, 1122, 1093, 1062, 
1040, 909, 853, 766, 623, 599 cm-1. HRMS m/z (ESI+): S1246.3436 (C58H67N4O24Zn: 
[M+H]+ requires 1266.3431). Mp: 118-120 °C. ). [α]D
23
: -0.15˚ (c 0.25, DMSO).  Anal. Calcd 
for C29H35ClCuN2O17: C, 44.40; H, 4.50; N, 3.57. Found: C, 44.38 H, 4.89; N, 3.48%. 
 
6.3   Chapter 3 
G. mellonella Assay: 
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Sixth instar larvae of Galleria mellonella (the greater wax moth, which belongs to 
order Lepidoptera, family Pyralidae) were obtained from The Mealworm Company 
(Sheffield, England) and stored in wood shavings in the dark at 15 ˚C. Larvae chosen 
for experiments weighed between 0.17-0.23 g and displayed no discoloration on 
their cuticle. Five healthy larvae inoculated with each compound and were placed in 
sterile 9 cm Petri dishes containing a sheet of Whatman filter paper and a small 
amount of wood shavings. Compounds were tested at concentrations of 100, 10 and 
1 μM. These were administered as solutions in 10 % DMSO in PBS buffer by 
inoculation of the larvae through the last left pro-leg directly into the haemocoel 
using a 300 μL Thermo Myjector syringe (29G) with the sterile test solutions (20 μL). 
Larvae were incubated at 30 ˚C and survival was assessed at 24 h and 48 h by 
response to physical stimulus. 
Enzymatic Hydrolysis Susceptibility: 
Compounds were dissolved in 5% DMSO in 1M phosphate buffer at pH 7.4 at a 
concentration of 0.02 M. of β-Glucosidase (1.7 mg (≥10.2 Units), from almonds, 
obtained from Sigma Aldrich, ≥6U/ mg) was added to 1 mL of substrate solution in a 
1.5 mL Eppendorf tube. The solution was gently inverted several times and incubated 
at 37 °C for 24 h. Hydrolysis was monitored by HPLC and chromatogram changes were 
correlated with mass spectral analysis. Samples for HPLC and HRMS were filtered 
through a 0.45 μM syringe and diluted with H2O prior to analysis. 
HPLC studies were carried out using a SunFire C18 5 μm 4.6x 100mm column at room 
temperature with a flow rate of 1 mL/min. This was conducted using the following a 
gradient elution protocol: 
Time (min) % H2O % MeCN 
0 100 0 
20 95 5 
25 90 10 
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Following each run the system was flushed with 100% MeCN for 10 min and then 
100% H2O for 30 min to ensure no residue remained in the column. 
 
6.4   Chapter 4 
 
 
 
4.18 (0.100 g, 0.00024 mol) was dissolved in MeCN (40 mL) and added dropwise over 
2 h to a solution of CuSO4.5H2O (0.0065 g, 0.00002 mol) and sodium ascorbate 
(0.0080 g, 0.00004 mol) in MeCN (25 mL). This was stirred at room temperature for 
10 days and the solvent was removed in vacuo. The residue was suspended in DCM 
(15 mL) and was washed with water (3 x 5 mL) and the combined water layers were 
extracted with DCM (2 x 10 mL). The combined organic layers were washed with 
brined (20 mL) and dried over Na2SO4 and reduced in vacuo to yield a transparent 
yellow oil (0.081 g, 81 %, yield is based on the mass of recovered material).   
 
 
 
4.23 (0.100 g, 0.0021 mol) was dissolved in anhydrous DCM (50 mL) and was added 
dropwise over 3 h to a solution of BF3.OEt2 (0.77 mL, 0.0063 mol) in anhydrous DCM 
(30 mL) at 0 °C. This was allowed to warm to room temperature and stir for 48 h 
before it was transferred to a separating funnel and washed with NaHCO3 solution (2 
4.1b 
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x 20 mL), H2O (20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 
and the solvent was removed in vacuo to yield a yellow oil (0.071 g, 81%, yield is 
based on the mass of recovered material).  
 
 
 
4.25 (0.064 g, 0.00027 mol) was dissolved in anhydrous DCM (40 mL) with 3Å 
molecular sieves at -42 °C in an MeCN/liquid N2 bath. A 0.1M solution of promotor 
was prepared by adding trifluoromethanesulfonic anhydride (0.84 mL, 1 mmol) to a 
solution of dimethyl disulfide (0.10 mL, 1.1 mmol) in anhydrous DCM (7.5 mL) at 0 °C 
and stirring the mixture for 30 min to produce a yellow solution. 2 mL of this 
promotor solution (0.0004 mol) was added dropwise over 1 h and the reaction was 
allowed to stir overnight before it was quenched by the addition of 0.5 mL of 
triethylamine. The reaction mixture was transferred to a separating funnel and was 
washed with water (3x 10 mL). The combined aqueous layers were extracted with 
DCM (2 x 10 mL) and organic fractions were washed with brine (30 mL) and dried 
over Na2SO4. This was evaporated to yield a pale yellow oil (0.022 g, 34%, yield is 
based on the amount of recovered material).  
 
 
4.6 (3 g, 0.0137 mol) was dissolved in Ac2O (100 mL, 1.05 mol) with sodium acetate 
(1.123 g, 0.0137 mol) and heated to 80 °C for 20 h under N2. Toluene (100 mL) was 
added and the was concentrated in vacuo to yield a brown residue. This was diluted 
with DCM (80 mL), washed with NaHCO3 solution (4x 50ml), water (50 mL) and brine 
(100 mL) and then the organic layer was dried over Na2SO4. The solvent was removed 
4.1b 
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in vacuo to yield a brown oil which was purified by column chromatography (5:1 Pet. 
Ether/ EtOAc, Rf: 0.08) to yield a pale yellow oil (3.914 g, 74 %, compound obtained 
as a 16:84 α/β mixture of anomers as determined by NMR). 1H NMR (500 MHz, 
CDCl3): 6.29 (d, J = 3.2 Hz, 1H, Hα-1),  5.70 (d, J = 8.3 Hz, 1H, Hβ-1), 5.48 (dd, J = 3.4 Hz, 
J = 1.0 Hz, 1H, H-4), 5.35-5.29 (m, 1H, H-2), 5.08 (dd, J= 3.4 Hz, 10.5 Hz, 1H, H-3), 4.17-
4.09 (m, 2H, CH2C≡CH), 4.01 (m, 1H, H-5), 3.63 (dd, J = 4.4 Hz, 6.0 Hz, 1H, H-6), 3.57 
(dd , J = 6.0, 9.8 Hz, 1H, H-6’), 2.43 (s, 1H, CH2C≡CH), 2.17 (s, 3H, OAc), 2.16 (s, 3H, 
OAc), 2.01 (s, 3H, OAc), 1.99 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3): 170.3 (C=O), 
169.7 (C=O), 169.4 (C=O), 168.9 (C=O), 92.2 (C-1), 78.8 (CH2C≡CH), 75.1 (CH2C≡CH), 
72.8 (C-5) ,70.9 (C-3), 68.2 (C-6), 67.3 (C-4), 66.4 (C-2), 58.6 (CH2C≡CH), 20.8 (OAc), 
20.7 (OAc), 20.6 (OAc), 20.5 (OAc). IR (NaCl): 3276, 2937, 2362, 1748, 1373, 1220, 
982 cm-1. HRMS m/z (ESI+):  387.1287 (C17H23O10: [M + H]+  requires  387.1285). [α]D
22: 
13° (c= 0.5, CH2Cl2). 
The characterization data is in agreement that reported in the literature.151 
 
 
 
D-Galactose (5 g, 0.0277 mol) and FeCl3 (0.89 g, 0.0554 mol) were refluxed in acetone 
(200 mL) for 6 h. This was cooled to room temperature and aqueous 10% K2CO3 
solution (40 mL) was added and the acetone was removed in vacuo. The brown 
residue was suspended in brine and extracted with DCM (5 x 50 mL) and dried with 
Na2SO4. The solvent was removed to yield a brown oil which was filtered through a 
silica plug (4:1 Pet. Ether/ EtOAc) to yield a viscous yellow oil (5.323 g, 75 %). 1H NMR 
(300 MHz, CDCl3): δ 5.57 (d, J= 5.0 Hz, 1H, H-1), 4.62 (dd, J= 7.9, 2.2 Hz, 1H, H-3), 4.34 
(m, 1H, H-4), 4.29 (t, J= 6.3 Hz, 1H, H-2), 3.95–3.83 (m, 2H, H-6), 3.79–3.72 (m, 1H, H-
5), 2.10 (dd, J= 9.6, 3.0 Hz, 1H, OH), 1.54 (s, 3H, CH3), 1.46 (s, 3H, CH3), 1.34 (s, 6H, 
CH3).13C NMR (75 MHz, CDCl3): δ  109.2 (C-(O)2), 108.5 (C-(O)2), 96.1 (C-1), 71.2 (C-5), 
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70.5 (C-4), 70.4 (C-3), 68.2 (C-2), 61.8 (C-6) , 25.8 (CH3), 25.7 (CH3), 24.7 (CH3), 24.2 
(CH3). HRMS m/z (ESI+):  283.1153 (C12H20NaO6: [M + Na]+  requires  283.1158). 
 The characterization data is in agreement that reported in the literature.167 
 
 
4.4 (5.323 g, 0.0205 mol), propargyl bromide (5.51 mL, 0.0512 mol, 80 % solution in 
toluene) and TBAI (0.738 g, 0.002 mol) were dissolved in anhydrous THF (20 mL) 
under N2. This was added dropwise via cannula to a solution of NaH (2.46 g, 0.00615 
mol, stripped of oil) in anhydrous THF (30 mL) under N2 at 0 ˚C. The reaction was 
allowed to warm to room temperature and was stirred overnight before being 
quenched with ice (20 g) and the THF was removed in vacuo. The residue was then 
diluted with DCM (30 mL) and washed with brine (2 x 30 mL) and dried with Na2SO4 
and dried to a brown oil. This was filtered through a silica plug (4:1 Pet. Ether/ EtOAc) 
to yield a brown oil (5.443 g, 89 %). 1H NMR (500 MHz, CDCl3) δ 5.54 (d, J = 5.0 Hz, 
1H, H-1), 4.60 (dt, J = 6.2, 3.1 Hz, 1H, H-3), 4.31 (dd, J = 5.0, 2.4 Hz, 1H, H-4), 4.28 – 
4.24 (m, 1H, H-2), 4.23 (d, J = 2.4 Hz, 1H, CH2C≡CH), 4.21 (d, J = 2.4 Hz, 1H, CH2C≡CH), 
4.02 – 3.97 (m, 1H, H-5), 3.77 (dd, J = 10.1, 5.3 Hz, 1H, H-6), 3.67 (dd, J = 10.1, 7.1 Hz, 
1H, H-6’), 2.44 (t, J = 2.4 Hz, 1H,C≡CH), 1.54 (s, 3H, CH3), 1.44 (s, 3H, CH3), 1.34 (s, 3H, 
CH3), 1.33 (s, 3H, CH3). IR (KBr): 3273, 2925, 1382, 1211, 1070 cm-1. HRMS m/z (ESI+):  
299.1419 (C15H23O6: [M + H]+  requires  299.1417). 
The characterization data is in agreement with that reported in the literature.171 
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4.5 (5.443 g 0.0182 mol) was dissolved in TFA/ H2O (10 mL/5 mL) and stirred at room 
temperature for 4 h. The  TFA was  removed in vacuo  to yield a dark brown solution 
which was diluted with H2O and neutralised with basic Dowex Cl-. This was  filtered 
and the solution was washed with DCM (2 x 20 mL) and the water was removed in 
vacuo to yield the product as a brown oil (3.855 g, 97 %). 1H NMR (300 MHz, CD3OD): 
δ 5.14 (d, J= 3.8 Hz, 1H, Hα-1,), 4.46 (d, J= 7.5 Hz, 1H, Hβ -1), 4.22-4.18 (m, 3H, 
CH2C≡CH, H-5), 3.85-3.44 (m, 4H, H-2, H-3, H-4, H-6), 3.46-3.44 (m, 1H, H-6’), 2.85-
2.83 (m, 1H, CH2C≡CH). 13C NMR (75 MHz, CD3OD): δ 98.1 (Cβ -1), 94.1 (Cα -1), 76.0 
(CH2C≡CH), 74.9 (CH2C≡CH), 71.3 (C-5), 70.5 (C-3), 70.4 (C-2), 70.3 (C-4), 69.9 (C-6), 
59.8(CH2C≡CH). HRMS m/z (ESI+):  219.0852 (C9H15O6: [M + H]+  requires  219.0863). 
The characterization data is in agreement with that reported in the literature.151 
 
 
 
4.2 (0.512 g, 0.0013 mol) and thiophenol (0.4 mL, 0.0039 mol) were dissolved in DCM 
(15 mL) at 0 ˚C. A solution of BF3.OEt2 (0.48 mL, 0.0039 mol) in DCM (0.5 mL) was 
added dropwise via cannula over 12 min and the reaction was allowed to warm to 
room temperature and stirred for 18 h. This was then transferred to a separating 
funnel and washed with saturated NaHCO3 solution (2x 20 mL), H20 (20 mL) and the 
combined aqueous layers were extracted with DCM (20 mL). The combined organic 
layers were then washed with brine (50 mL) and dried with Na2SO4 before the solvent 
was removed in vacuo to yield a dark yellow oil. This was purified by column 
chromatography (92:8 DCM/ diethyl ether, Rf: 0.32) to yield a clear oil. (0.346 g, 61 
%). 1H NMR (500 MHz, CDCl3) δ 7.33-7.31 (m, 2H, Ar-H), 7.25- 7.22 (m, 2H, Ar-H), 7.13 
– 7.13- 7.04 (m, 1H, Ar-H), 5.77 (d, J = 7.4 Hz, 1H, H-1), 5.66 – 5.43 (m, 2H, H-4, H-3), 
4.92 – 4.74 (m, 1H, H-2), 4.44 (d, J = 2.8 Hz, 2H, CH2C≡CH), 4.18- 4.14 (m, 1H, H-5), 
3.67 (dd, J = 12.5, 4.7 Hz, 1H, H-6), 3.40 (dd, J = 12.3, 4.8 Hz, 1H, H-6’), 2.28-2.25 (bs, 
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1H, CH2≡CH), 2.08 (s, 3H, OAc), 1.98 (s, 3H, OAc), 1.95 (s, 3H, OAc). 13C NMR (126 MHz, 
CDCl3) δ 172.3 (C=O), 171.8 (C=O), 171.1 (C=O), 134.0 (Ar-C), 131.5 (Ar-C), 129.9 (Ar-
C), 128.7 (Ar-D), 89.3 (C-1), 79.9 (CH2C≡CH), 75.2 (CH2C≡CH), 74.1 (C-5), 71.5 (C-2), 
69.3 (C-3), 68.5 (C-6) 67.9 (C-4), 58.6 (CH2C≡CH), 21.3 (OAc), 21.3 (OAc), 22.9 (OAc). 
IR (NaCl): 2942, 2895, 2120, 1751, 1369, 1223, 1082, 1054cm-1. HRMS m/z (ESI+): 
437.1266 (C21H25O8S: [M+H]+ requires 437.1264). [α]D
24: 0.12 (c 0.5, CH2Cl2). 
 
 
 
Galactose pentaacetate (1 g, 0.0026 mol) and thiophenol (0.45 mL, 0.0038 mol) were 
dissolved in DCM (20 mL) at room temperature. SnCl4 (0.36 mL, 0.0031 mol) was 
added and the reaction was stirred for 5 h. This was then transferred to a separating 
funnel and washed with saturated NaHCO3 solution (2x 20 mL), H20 (20 mL) and the 
combined aqueous layers were extracted with DCM (20 mL). The combined organic 
layers were then washed with brine (50 mL) and dried with Na2SO4 before the solvent 
was removed in vacuo to yield an off white solid. This was purified by column 
chromatography (3:1 Pet. ether/ EtOAc, Rf: 0.31) to yield a white solid (1.075 g, 94%). 
1H NMR (500 MHz, CDCl3) δ 7.52-7.48 (m, 2H, Ar-H), 7.33-27 (m, 3H, Ar-H), 5.42 (dd, 
J = 3.4, 1.0 Hz, 1H, H-4), 5.24 (dd, J = 9.9, 9.9 Hz, 1H, H-2), 5.06 (dd, J = 3.3, 9.9 Hz, 1H, 
H-3), 4.72 (d, J = 9.9 Hz, 1H, H-1), 4.20 (dd, J = 7.0, 11.3 Hz, 1H, H-6), 4.12 (dd, J = 6.2, 
11.4 Hz, 1H, H-6’), 3.94 (ddd, J = 1.0, 6.1, 7.1 Hz, 1H, H-5), 2.12 (s, 3H, OAc), 2.10 (s, 
3H, OAc), 2.05 (s, 3H, OAc), 1.98 (s, 3H, OAc). 13CNMR (125 MHz, CDCl3) d 170.3 (C=O), 
170.2 (C=O), 170.0 (C=O), 169.6 (C=O), 132.7 (Ar), 132.8 (Ar), 129.1 (Ar), 128.3(Ar), 
86.8 (C-1), 74.5 (C-5), 72.2 (C-3), 67.3 (C-2), 67.2 (C-4), 61.8 (C-6), 20.8 (OAc), 20.7 
(OAc), 20.5 (OAc), 20.5 (OAc). 
The characterization data is in agreement with that reported in the literature.183 
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4.2 (1 g, 0.0026 mol) was dissolved in DCM (20 mL, anhydrous) with 3 Å molecular sieves 
under N2 at 0 ˚C. A solution of BF3.OEt2 (0.98 mL, 0.0078 mol) in DCM (1.5 mL) was 
prepared under N2 with 3 Å molecular sieves at 0 ˚C. This was added dropwise to the 
solution of (6-O-Propargyl)-1,2,3,4-tetra-O-acetyl-β-D-galactopyranoside over 10 min 
and this was allowed to stir for a further 15 min before EtSH (0.59 mL, 0.0078 mol) was 
added dropwise over 15 min. The reaction was then allowed to slowly warm to room 
temperature and stir overnight before being washed with NaHCO3 solution (2x 20 mL) 
and brine (50 mL). This was dried over Na2SO4 and reduced in vacuo to yield a dark brown 
oil which was purified by column chromatography (2:3:1 Toluene/Pet. Ether/EtOAc, Rf: 
0.28) to yield the product as a clear oil (0.336 g, 45 %). 1H NMR (500 MHz, CDCl3) δ 5.45 
(dd, J = 3.4, 0.8 Hz, 1H, H-4), 5.21 (at, J = 10.0 Hz, 1H, H-3), 5.03 (dd, J = 10.0, 3.4 Hz, 1H, 
H-2), 4.47 (d, J = 10.0 Hz, 1H, H-1), 4.11 (qd, J = 15.9, 2.4 Hz, 2H, OCH2C≡C), 3.86 (atd, J = 
6.2, 0.9 Hz, 1H, H-5), 3.58 (addd, J = 24.2, 9.8, 6.3 Hz, 2H, H-6), 2.81 – 2.63 (m, 2H, SCH2), 
2.41 (t, J = 2.4 Hz, 1H, C≡CH), 2.13 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.96 (s, 3H, OAc), 1.26 
(t, J = 7.5 Hz, 3H, SCH2CH3). 13C NMR (126 MHz, CDCl3) δ 170.2 (C=O), 170.0 (C=O), 169.6 
(C=O), 84.0 (C-1), 79.1 (CH2C≡C), 76.6 (C-5), 75.1 (C≡CH), 72.1 (C-3), 67.9 (C-4), 67.6 (C-
6), 67.5 (C-2), 58.6 (OCH2C≡CH), 24.4 (SCH2), 20.8 (OAc), 20.7 (OAc), 20.6 (OAc), 14.9 
(CH3). IR (NaCl Plate): 3275, 2970, 2933, 2875, 2116, 1750, 1432, 1370, 1245, 1224, 1100, 
1081, 1056, 944, 920 cm-1. HRMS m/z (ESI+): 411.1093 (C17H24O8SNa: [M+Na]+ requires 
411.1084). [α]D
24: 0.08 (c 0.3, CH2Cl2). 
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Galactose pentaacetate (1 g, 0.0026 mol) and ethanethiol (0.39 mL, 0.0052 mol) were 
dissolved in anhydrous DCM (20 mL) at room temperature. A solution of BF3.OEt2 (1 
mL, 0.0079 mol) in anhydrous DCM (1 mL) was added dropwise and the reaction was 
stirred overnight. This was then transferred to a separating funnel and washed with 
saturated NaHCO3 solution (2 x 20 mL), H20 (20 mL) and the combined aqueous layers 
were extracted with DCM (20 mL). The combined organic layers were then washed 
with brine (50 mL) and dried with Na2SO4 before the solvent was removed in vacuo 
to yield a yellow oil. This was purified by column chromatography (3:1 Pet. ether/ 
EtOAc, Rf: 0.21) to yield a white solid (0.938 g, 92 %). 1H NMR (500 MHz, CDCl3) δ 
5.44 (d, J = 3.7 Hz, 1H, H-1), 5.25 – 5.20 (m, 1H, H-4), 5.04 (dd, J = 10.1, 3.7 Hz, 1H, H-
2), 4.48 (d, J = 10.1 Hz, 1H, H-3), 4.18 – 4.10 (m, 2H, H-6), 3.94-3.88 (m, 1H , H-5), 2.78 
– 2.66 (m, 2H SCH2CH3), 2.18 (s, 3H, OAc), 2.05(s, 3H, OAc), 2.02 (s, 3H, OAc), 2.00 (s, 
3H, OAc), 1.27 (t, J = 7.2 Hz, 3H, SCH2CH3). 13C NMR (125 MHz, CDCl3) δ 170.3 (C=O), 
170.1 (C=O), 170.0 (C=O), 169.5 (C=O), 83.9 (C-1), 74.2 (C-5), 71.7 (C-2), 67.1 (C-3), 
67.0 (C-4), 61.3 (C-6), 24.3 (SCH2CH3), 20.7 (OAc), 20.6 (OAc), 20.6 (OAc), 20.5 (OAc), 
14.7 (SCH2CH3). 
The characterization data is in agreement with that reported in the literature.185 
 
 
 
4.2 (0.933 g, 0.0024 mol) and 2-chloroethanol (0.583 mL, 0.0072 mol) were dissolved 
in anhydrous DCM (20mL) and cooled to 0 °C. A solution of BF3. OEt2 (0.89 mL, 0.0072 
mol) in anhydrous DCM (1mL) was added dropwise by cannula over 5 min and the 
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solution was allowed to warm to room temperature and stir overnight. The solution 
was then transferred to a separating funnel and washed with saturated NaHCO3 
solution (2x 20 mL), H20 (20 mL) and the combined aqueous layers were extracted 
with DCM (20 mL). The combined organic layers were then washed with brine (50 
mL) and dried with Na2SO4 before the solvent was removed in vacuo to yield a yellow 
oil. This was purified by column chromatography (2:1 Pet. ether/ EtOAc, Rf: 0.3) to 
yield a clear oil. (0.478 g, 49 %). 1H NMR (500 MHz, CDCl3) δ 5.43 (ad, J = 2.8 Hz, 1H, 
H-4), 5.23 (dd, J = 10.5, 8.0 Hz, 1H, H-2), 5.03 (dd, J = 10.5, 3.4 Hz, 1H, H-3), 4.53 (d, J 
= 8.0 Hz, 1H, H-1), 4.19 – 4.08 (m, 3H, H-5, OCH2C≡CH), 3.87 (at, J = 6.4 Hz, 1H, 
OCH2CH2Cl), 3.81 – 3.70 (m, 1H, OCH’2CH2Cl), 3.67 – 3.56 (m, 4H, H-6, OCH2CH2Cl), 
2.44 (t, J = 2.3 Hz, 1H, C≡CH), 2.15 (s, 3H, OAc), 2.07 (s, 3H, OAc), 1.98 (s, 3H, OAc). 
13C NMR (126 MHz, CDCl3) δ 170.2 (C=O), 170.1 (C=O), 169.6 (C=O), 101.6 (C-1), 79.1 
(C≡CH), 75.0 (C≡CH), 72.2 (C-5), 70.9 (C-3), 69.9 (C-2), 68.8 (C-4), 67.6 (CH2C≡CH), 58.6 
(C-6), 42.6 (CH2CH2Cl), 30.9 (CH2CH2Cl), 20.8 (OAc), 20.7 (OAc), 20.6 (OAc). IR (KBr 
Disk): 3264, 2969, 2156, 1751, 1437, 1382, 1221, 1171 cm-1. HRMS m/z (ESI+): 
407.1104 (C17H24ClO9: [M+H+]+ requires 407.1103). [α]D
21: 0.1 (c 0.09, CH2Cl2). 
 
 
 
4.17 (0.498g, 0.001 mol) was dissolved in DMF (20 mL) with H2O (2 mL) and heated 
to 80 °C and NaN3 (0.159 g, 0.002 mol) was added. The reaction was stirred for 48 h 
and the solvent was removed in vacuo to yield a yellow oil. This was diluted with DCM 
(50 mL) and washed with brine (3x 30 mL) and the combined brine layers were 
extracted with a further 20 mL of DCM. The combined organic layers were dried with 
Na2SO4 and the solvent was dried to give a pale yellow oil. This was purified by 
column chromatography (3:1 Pet. Ether/EtOAc, Rf: 0.23) to yield the product as a 
transparent oil (83 %, 0.343 g). 1H NMR (500 MHz, CDCl3) δ 5.45 – 5.41 (m, 1H, H-4), 
5.24 (dd, J = 10.4, 8.0 Hz, 1H, H-3), 5.03 (dd, J = 10.4, 3.4 Hz, 1H, H-2), 4.56 (d, J = 8.0 
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Hz, 1H, H-1), 4.19-4.14 (m, 2H, OCH2C≡CH), 4.10 – 4.02 (m, 1H, OCH2CH2N3), 3.88 
(add, J = 6.1, 5.0 Hz, 1H, H-5), 3.77 – 3.66 (m, 1H, H-6), 3.62-3.66 (m, 2H, H-
6’,OCH2’CH2Cl), 3.55 – 3.46 (m, 1H, OCH2CH2Cl), 3.35 – 3.26 (m, 1H, OCH2CH2’N3), 
2.44 (t, J = 2.4 Hz, 1H, C≡CH), 2.16 (s, 3H, OAc), 2.06 (s, 3H, OAc), 1.98 (s, 3H, OAc). 
13C NMR (126 MHz, CDCl3) δ 170.2 (C=O), 170.1 (C=O), 169.5 (C=O), 101.2 (C-1), 79.1 
(C≡CH), 75.0 (C≡CH), 72.3 (C-5), 71.1 (C-3), 68.8 (C-2), 68.4 (C-4), 67.7(CH2C≡CH), 67.6 
(C-6), 58.7 (CH2CH2Cl), 50.6 (CH2CH2Cl), 20.8 (OAc), 20.7 (OAc), 20.6 (OAc). IR (KBr 
Disk): 2987, 2962, 2155, 2103, 2109, 1760, 1380, 1227, 1053 cm-1. HRMS m/z (ESI+): 
415.1508 (C17H24N3O9: [M+H+]+ requires 415.1507). [α]D
24: 0.13 (c 0.1, CH2Cl2). 
 
 
 
2-chloroethanol (3 mL, 0.0447 mol) and NaN3 (4 g, 0.0615 mol) were heated to 80 ˚C in 
H2O (30 mL) for 48 h. The reaction was allowed to cool and the product was extracted 
with Et2O (4 x 30 mL) and the combined organic layers were washed with brine (100 mL) 
and dried over Na2SO4 and the solvent removed in vacuo at room temperature to yield 
the product as a clear yellow oil (3.077 g, 85 %). 1H NMR (500 MHz, CDCl3) δ 3.76 – 3.63 
(m, 2H, CH2N3), 3.37 – 3.35 (m, 2H, CH2OH), 3.05 (bs, 1H, OH). 13C NMR (126 MHz, CDCl3) 
δ 61.3 (CH2N3), 53.4 (CH2OH). 
The characterization data is in agreement with that reported in the literature.189 
 
 
4.2 (0.100 g, 0.00026 mol) and 2-azidoethanol (0.05 mL, 0.00052 mol) were dissolved in 
MeCN (20 mL) along with CuSO4.5H2O (0.006 g,0.00002 mol) and sodium ascorbate 
(0.008 g, 0.04 mmol) and stirred at room temperature overnight. The solvent was 
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removed in vacuo and the residue was dissolved in H2O (20 mL) and DCM (20 mL). These 
were separated and the aqueous layer was extracted with a further 3 x 20 mL portions 
of DCM. The combined organic layers were washed with brine (50 mL), dried over Na2SO4 
and the solvent was removed in vacuo to yield a clear oil ( 0.112 g, 92 %).1H NMR (500 
MHz, CDCl3) δ 7.62 (s, 1H, Ar-H), 5.64 (d, J = 8.3 Hz, 1H, H-1), 5.34 (d, J = 3.2 Hz, 1H, H-4), 
5.25 (ad, J = 2.1 Hz, 1H, H-2), 5.00 (dd, J = 10.4, 3.2 Hz, 1H, H-3), 4.63 – 4.57(m, 2H, 
OCH2Ar), 4.50 – 4.42 (m, 2H, ArCH2CH2), 4.02 – 3.97 (m, 2H, ArCH2CH2), 3.92 (at, 1H, J = 
6.4 Hz, H-5) 3.63 (dd, J = 9.6, 5.6 Hz, 1H, H-6), 3.60 – 3.54 (m, 1H, H-6’), 3.48 (bs, 1H, OH), 
2.07 (s, 3H, OAc), 2.06 (s, 3H, OAc), 1.99 (s, 3H, OAc), 1.92 (s, 3H, OAc).13C NMR (126 
MHz, CDCl3) δ 170.6 (C=O), 169.9 (C=O), 169.4 (C=O), 169.1 (C=O), 144.4 (Ar-C), 124.2 
(Ar-H), 92.3 (C-1), 72.6 (C-5), 70.9 (C-3), 68.0 (C-2), 67.2 (C-4), 64.4 (OCH2Ar), 61.0 
(ArCH2CH2), 53.5 (C-6), 52.9 (CH2OH), 20.8 (OAc), 20.6 (OAc), 20.6 (OAc), 20.5 (OAc). IR 
(NaCl Plate): 3274, 2967, 2931, 2874, 2116, 1748, 1432, 1371, 1223, 1154, 1100, 1055, 
920 cm-1. HRMS m/z (ESI+): 474.1717 (C19H28N3O11: [M+H]+ requires 474.1718).  [α]D
22: 
0.21 (c 0.2, CH2Cl2). 
 
 
 
 
4.15 (0.100 g, 0.00025 mol) was dissolved in DMF/H2O (15:1 mL) with 2-azidoethanol 
(0.6 mL, 0.0005 mol). CuSO4.5H2O (0.01 g, 15 mol%) and sodium ascorbate (0.016 g, 30 
mol%) were added. The mixture was then sonicated for 5 min and stirred at room 
temperature for 2 h. The solvent was removed in vacuo and the residue was dissolved 
in H2O (10 mL) and DCM (10 mL). These were separated and the aqueous layer was 
extracted with a further 3 x 10 mL portions of DCM. The combined organic layers were 
washed with brine (20 mL), dried over Na2SO4 and the solvent was removed in vacuo to 
yield a clear oil. This was dissolved in MeOH (15 mL) and was stirred with approximately 
0.4 g of Chelex resin for 2 h before it was filtered and the solvent was evaporated to 
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produce a clear oil (0.117 g, 96 %). 1H NMR (500 MHz, CDCl3) δ 7.63 (s, 1H, Ar-H), 5.36 
(ad, J = 3.0 Hz, 1H, H-4), 5.18 (at, J = 10.0 Hz, 1H, H-2), 4.97 (dd, J = 10.0, 3.3 Hz, 1H, H-
3), 4.64 (d, J = 12.7 Hz, 1H, H-1), 4.53 – 4.37 (m, 4H, ArCH2CH2OH, OCH2Ar), 4.08 – 3.98 
(m, 2H, ArCH2CH2OH), 3.85 – 3.78 (m, 1H, H-5), 3.66 (dd, J = 9.4, 5.4 Hz, 1H, H-6), 3.60 
(dd, J = 9.4, 7.9 Hz, 1H, H-6’), 3.23 (bs, 1H, OH), 2.81 – 2.62 (2, 3H, SCH2), 2.08 (s, 3H, 
OAc), 2.04 (s, 3H, OAc), 1.93 (s, 3H, OAc), 1.26 (t, J = 7.4 Hz, 3H, SCH2CH3). 13C NMR (126 
MHz, CDCl3) δ 170.9 (C=O), 170.2 (C=O), 169.7 (C=O), 144.7 (Ar-C), 124.2 (Ar-H), 84.1 (C-
1), 67.8 (OCH2Ar), 67.6 (C-5),  67.6 (C-3), 67.5 (C-4), 64.5 (C-6), 61.3 (C-2), 53.5 
(ArCH2CH2), 53.0 (CH2OH), 24.3 (SCH2CH3), 20.9 (OAc), 20.8 (OAc), 20.7 (OAc), 14.9 
(SCH2CH3). IR (NaCl Plate): 3420, 3261, 2990, 2895, 1753, 1435, 1379, 1245, 1109, 1076, 
944, 920 cm-1. HRMS m/z (ESI+): 476.1693 (C19H29N3O9S: [M+H]+ requires 479.1697), 
[α]D
23: 0.04 (c 0.1, MeOH). 
 
6.5   Chapter 5 
6.5.1   Synthesis 
 
 
 
5.4 (1.125 g, 0.0024 mol) and 2-picolylamine (0.25 mL, 0.0024 mol) were refluxed 
overnight in EtOH (20 mL, dried over 3 Å molecular sieves) under N2. The solvent was 
removed in vacuo to yield the product as orange oil (1.339 g, >98 %). 1H NMR (500 
MHz, CDCl3) δ 13.64 (bs, 1H, OH), 8.57 (dd, J = 4.9, 0.8 Hz, 1H, Pyr-H), 8.45 (s, 1H, 
C=N), 7.68 (atd, J = 7.7, 1.8 Hz, 1H, Pyr-H), 7.34 (d, J = 7.8 Hz, 1H, Pyr-H), 7.23 – 7.18 
(m, 2H, Pyr-H, Ar-H), 6.70 (d, J = 2.4 Hz, 1H, Ar-H), 6.59 (dd, J = 8.5, 2.4 Hz, 1H, Ar-H), 
5.55-5.19 (m, 2H, H-1, H-2), 5.43 (dd, J = 3.5, 1.9 Hz, 1H, H-3), 5.35 (at, J = 10.0 Hz, 
1H, H-4), 4.90 (s, 2H, PyrCH2), 4.35 – 4.25 (m, 1H, H-5), 4.09 – 4.03 (m, 2H, H-6), 2.20 
(s, 3H, OAc), 2.04 (s, 6H, OAc), 2.03 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 170.9 
(C=O), 170.7 (C=O), 170.0 (C=O), 169.4 (C=O), 169.6 (C=N), 164.8 (Pyr), 160.8 (Ar), 
5.1 
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157.9 (Ar), 149.6 (Pyr), 137.0 (Pyr), 132.9 (Pyr), 122.5 (Ar), 122.2 (Pyr), 115.0 (Ar), 
109.2 (Ar), 104.2 (Ar), 98.3 (H-1), 72.6 (H-5), 71.3 (H-2), 71.0 (C-3), 68.8 (C-4), 64.7 
(CH2-Pyr), 62.0 (C-6), 20.8 (OAc), 20.8 (OAc), 20.7 (OAc), 20.7 (OAc). IR (NaCl Plate): 
3489, 3105, 2968, 2879, 1751, 1639, 1591, 1582, 1505, 1438, 1370, 1224, 1176, 1079, 
1056, 754cm-1. HRMS m/z (ESI+): 559.1897 (C27H31N2O11: [M+H+]+ requires 
559.1895). [α]D
22
: -2˚ (c= 0.25, CH2Cl2). 
 
5.2 
5.7 (1 g, 0.0021 mol) and 2-picolylamine (0.22 mL, 0.0021 mol) were refluxed in EtOH 
(20 mL, dried over 3Å molecular sieves) under N2 for 8 h. The solvent was removed 
in vacuo to yield the product as an orange solid in a quantitative yield. 1H NMR (500 
MHz, CDCl3) δ 13.76 (s, 1H, OH), 8.61 (d, J = 4.9 Hz, 1H, Pyr-H), 8.45 (s, 1H, C(H) =N), 
7.69 (atd, J = 7.8, 2 Hz, 1H, Pyr-H), 7.36 (d, J = 7.8 Hz, 1H, Pyr-H), 7.20 (m, 2H, Pyr-H, 
Ar-H), 6.57 (d, J = 2.2 Hz, 1H, Ar-H), 6.51 (dd, J = 8.5, 2.2 Hz, 1H, Ar-H), 5.34 – 5.28 (m, 
2H, H-1, H-2), 5.16-5.11 (m, 2H, H-3, H-4), 4.93 (s, 2H, CH2-Pyr), 4.30 (dd, J = 12.6, 5.7 
Hz, 1H, H-6), 4.18 (dd, J = 12.6, 2.2 Hz, 1H, H-6’), 3.88 (ddd, J = 10.1, 5.7, 2.2 Hz, 1H, 
H-5), 2.08 (s, 3H, OAc), 2.05 (s, 6H, OAc), 2.04 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3) 
δ 170.9 (C=O), 170.4 (C=O), 169.4 (C=O), 169.3 (C=O), 165.9 (C=N), 163.9 (Pyr), 160.8 
(Ar), 157.7(Ar), 149.5 (Pyr), 137.2 (Pyr), 133.0 (Pyr), 122.8 (Ar), 122.1 (Pyr), 114.6 (Ar), 
108.2 (Ar), 104.9 (Ar), 98.9 (H-1), 72.7 (H-5), 72.3 (H-3), 71.6 (C-2), 68.6 (C-4), 65.0 
(CH2-Pyr), 61.7 (C-6), 20.8 (OAc), 20.7 (OAc), 20.7 (OAc), 20.6 (OAc). IR (KBr Disk): 
3420, 3017, 2965, 2877, 1748, 1637, 1589, 1576, 1505, 1439, 1367, 1224, 1180, 1079 
cm-1. HRMS m/z (ESI+): 559.1895 (C27H31N2O11: [M+H+]+ requires 559.1895). Mp: 82-
83 ˚C. [α]D
23
: -0.2˚ (c 1, CH2Cl2).  
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5.9 (1 g, 0.0045 mol) and 2-picolylamine (0.46 mL, 0.0045 mol) were dissolved in 
anhydrous EtOH (20 mL). This was heated to 80 °C under N2 for 18 h before the solvent 
was removed in vacuo to produce a dark orange oil in quantitative yield. 
 
1H NMR (500 MHz, CDCl3) δ 8.56 (d, J = 4.8 Hz, 1H, Pyr-H), 8.42 (s, 1H, C=N), 7.68 (ddd, 
J = 7.8, 3.0, 1.5 Hz, 1H, Pyr-H), 7.35 (d, J = 7.8 Hz, 1H, Ar-H), 7.22 – 7.15 (m, Pyr-H, 
2H), 6.64 (d, J = 2.3 Hz, 1H, Ar-H), 6.56 (dd, J = 8.5, 2.3 Hz, 1H, Ar-H), 5.45 (t, J = 3.1 
Hz, 1H, t, J = 3 Hz, 1H, THP C(-O)2H ), 4.89 (s, 2H, PyrCH2), 3.95 – 3.82 (m, 1H, THP 
C(O)-H), 3.67 – 3.54 (m, 1H, THP C(O)-H’), 2.05 – 1.91 (m, 2H, CH2), 1.90 – 1.75 (m, 
2H, THP CH2), 1.75 – 1.43 (m, 2H, THP CH2). 13C NMR (126 MHz, CDCl3) δ 165.2 (C=N), 
164.8 (Ar-O), 163.4 (Ar-O), 162.1 (Pyr-C),148.3 (Pyr-H) 135.3 (Ar-H), 134.2 (Pyr-H), 
124.3 (Pyr-H), 121.6 (Pyr-H) 116.8 (Ar-C), 109.4 (Ar-H), 103.7 (Ar-H), 97.3 (CH), 61.9 
(CH2), 30.1 (CH2), 25.3 (CH2), 19.1 (CH2). IR (KBr Disk): 3289, 3075, 2867, 1621, 1442, 
1331, 1271, 1241, 1120, 985cm-1. HRMS m/z (ESI+): 313.3709 (C18H21N2O3: [M+H]+ 
requires 313.3703). [α]D
23
: -5˚ (c 0.5, CH2Cl2). 
 
 
5.14 (0.117 g, 0.00042 mol) and 2-picolylamine (0.044 mL, 0.00043 mol) were refluxed 
in EtOH (anhydrous, 10 mL) under N2 for 3 h. The solvent was removed in vacuo to give 
the product as a bright yellow oil in a quantitative yield. 1H NMR (500 MHz, CDCl3) δ 13.7 
(bs, 1H, OH), 8.48 (as, 1H, Pyr-H), 8.30 (s, 1H, HC=N)), 7.58 (ad, J = 7.0 Hz, 1H, Pyr-H), 
7.25 (ad, J = 7.5 Hz, 1H, Pyr-H), 7.17 – 7.00 (m, 2H Pyr-H, Ar-H), 6.37 (s, 1H, Ar-H), 6.33 
(d, J = 8.4 Hz, 1H, Ar-H), 4.79 (s, 2H PyrCH2), 4.58 (bs, 1H Cyclohexyl C(-O)H), 2.03 (ad, J 
= 13.5 Hz, 1H, CH), 1.70-1.63 (m, 2H), 1.61-1.52 (m, 2H), 1.47 (d, J = 12.7 Hz, 1H), 1.23 – 
5.3 
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1.06 (m, 1H), 1.05 – 0.90 (m, 2H, CH2) , 0.85 (d, J = 6.4 Hz, 3H, CH3), 0.74 (d, J = 6.5 Hz, 
6H, isopropyl CH3).13C NMR (126 MHz, CDCl3) δ 165.9 (C=N), 164.7 (Pyr), 162.6 (Ar), 158.4 
(Pyr), 149.4 (Pyr), 136.9 (Ar), 133.0 (Pyr), 122.3 (Ar), 121.9 (Pyr), 112.2 (Ar), 107.9 (Ar), 
102.5 (Ar), 73.6 (Cyclohexyl-C-O), 64.2 (PyrCH2), 47.7 (Cyclohexyl-C), 37.7 (Cyclohexyl-C), 
35.00 (Cyclohexyl-C), 29.39 (Cyclohexyl-C), 26, 24.9 (Cyclohexyl-C), 22.3 (Isopropyl-CH), 
21.1 (Cyclohexyl-CH3), 20.8 (Isopropyl-CH3). IR (NaCl Plate): 3062, 2944, 2875, 1641, 
1627, 1574, 1503, 1455, 1378, 1341, 1225, 1121, 990, 702cm-1. HRMS m/z (ESI+): 
367.2367 (C23H31N2O2: [M+H]+ requires 367.2380). . [α]D
21
: +2 (c 0.2, CH2Cl2). 
 
 
Mannose pentaacetate (1 g, 0.0026 mol) was dissolved in HBr/AcOH (7 mL) with 
acetic anhydride (1 mL) under N2 and stirred for 4 h at room temperature. This was 
diluted with DCM (20 mL) and washed with water (3 x 10 mL), saturated NaHCO3 
solution (20 mL) and brine (30 mL) before being dried with Na2SO4. The solvent was 
removed in vacuo to yield a pale yellow oil (1.068 g, >98 %). 1H NMR (300 MHz, CDCl3) 
δ 6.28 (d, J = 1.6 Hz, 1H, H-1), 5.70 (dd, J = 10.2, 3.4 Hz, 1H, H-3), 5.43 (dd, J = 3.4, 1.6 
Hz, 1H, H-2), 5.35 (at, J = 10.2 Hz, 1H, H-4), 4.31 (dd, J = 12.6, 5.0 Hz, 1H, H-6), 4.21 
(ddd, J = 10.2, 5.0, 2.3 Hz, 1H, H-5), 4.12 (dd, J = 12.6, 2.3 Hz, 1H, H-6’), 2.16 (s, 3H, 
OAc), 2.09 (s, 3H, OAc), 2.06 (s, 3H, OAc), 1.99 (s, 3H, OAc). 
The NMR data is in agreement with the data reported in the literature.211 
 
 
5.6 (2 g, 0.0049 mol), 2, 4-dihydroxybenzaldehyde (1.344 g, 0.0097 mol) and Ag2CO3 
(1.344 g, 0.0097 mol) were dissolved in MeCN (50 mL, dried over 3 Å molecular 
5.6 
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sieves) under N2 in the dark and stirred at room temperature for 48 h. The solvent 
was removed in vacuo and the residue was dissolved in EtOAc (80 mL) with sonication 
and filtered through a Celite cake. The resulting solution was washed with 1M HCl 
(50 mL), saturated NaHCO3 solution (3 x 50 mL) and brine (50 mL) and dried over 
Na2SO4. The solvent was removed in vacuo to yield a dark brown oil which was 
purified by column chromatography (2:1 Pet. Ether/EtOAc, Rf: 0.18) to yield the 
product as a white solid (1.40 g, 72 %). 1H NMR (500 MHz, CDCl3) δ 11.32 (s, 1H, OH), 
9.77 (s, 1H, HC=O), 7.49 (dd, J = 8.8, 2.3 Hz, 1H, Ar-H), 6.72 (d, J = 8.8, 1H, Ar-H), 6.70 
(d, J = 2.3 Hz, 1H, Ar-H), 5.58 (d, J = 1.7 Hz, 1H, H-1), 5.52 (dd, J = 10.0, 3.5 Hz, 1H, H-
3), 5.43 (dd, J = 3.5, 1.7 Hz, 1H, H-2), 5.35 (at, J = 10.1 Hz, 1H, H-4), 4.29 (dd, J = 12.3, 
5.7 Hz, 1H, H-6’), 4.06 (dd, J = 12.3, 2.4 Hz, 1H, H-6’), 4.01 (ddd, J = 10.1, 5.7, 2.3 Hz, 
1H, H-5), 2.20 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.04 (s, 3H, OAc). 13C 
NMR (126 MHz, CDCl3) δ 194.8 (HC=O), 170.5 (C=O), 169.9 (C=O), 169.9 (C=O), 169.6 
(C=O), 164.0 (Ar-O), 162.2 (Ar-O), 135.4 (Ar-H), 116.7 (Ar-C), 109.3 (Ar-H), 104.1 (Ar-
H), 95.5 (C-1), 69.6 (C-5), 69.0 (C-3), 68.6 (C-2), 65.8 (C-4), 62.0 (C-6), 20.8 (OAc), 20.6 
(OAc), 20.6 (OAc), 20.5 (OAc). IR (KBr Disk): 3431, 2969, 2869, 1750, 1663, 1627, 1579, 
1500, 1438, 1371, 1227, 1170, 1076, 1035, 979, 908 cm-1. HRMS m/z (ESI+): 491.1167 
(C21H24O12Na: [M+Na]+ requires 491.1166). [α]D
24
: -8˚ (c= 0.5, CH2Cl2). 
 
 
 
Galactose pentaacetate (1 g, 0.0026 mol) was dissolved in HBr/AcOH (7 mL) with 
acetic anhydride (1 mL) under N2 and stirred for 4 h at room temperature. This was 
diluted with DCM (20 mL) and washed with water (3 x 10 mL), saturated NaHCO3 
solution (20 mL) and brine (30 mL) before being dried with Na2SO4. The solvent was 
removed in vacuo to yield a clear oil which was diluted in Et2O (10 mL) and 
cyclohexane (50 mL) was added. The solution was cooled on ice to precipitate the 
product as a white solid (0.938 g, 89 %). 1H NMR (300 MHz, CDCl3) δ 6.64 (d, J =3.9 
Hz, 1H, H-1), 5.46 (dd, J = 3.3, 1.1 Hz, 1H, H-4), 5.35 (dd, J = 6.0, 3.3 Hz, 1H, H-3), 4.98 
5.9 
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(dd, J = 6.0, 3.9 Hz, 1H, H-2), 4.46-4.43 (m, 1H, H-5), 4.14 (dd, J = 11.5, 6.2 Hz, 1H, H-
6), 4.05 (dd, J = 11.5, 6.9 Hz, 1H, H-6’), 2.08 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.99 (s, 3H, 
OAc), 1.94 (s, 3H, OAc).13C NMR (75 MHz, CDCl3) δ 170.5 (C=O), 170.1 (C=O), 170.0 
(C=O), 169.8 (C=O), 87.9 (C-1), 70.97 (C-5), 67.9 (C-2), 67.7 (C-4), 67.0 (C-2), 60.8 (C-
6), 20.4 (OAc), 20.3 (OAc), 20.2 (OAc), 20.2 (OAc). 
The NMR data is in agreement with the data reported in the literature.212  
 
 
 
5.6 (0.900 g, 0.0022 mol), 2, 4-dihydroxybenzaldehyde (0.615 g, 0.0043 mol) and 
Ag2CO3 (0.605 g, 0.0043 mol) were dissolved in MeCN (25 mL, dried over 3 Å 
molecular sieves) under N2 in the dark and stirred overnight at room temperature. 
The solvent was removed in vacuo and the residue was dissolved in EtOAc (40 mL) 
with sonication and filtered through a Celite cake. The resulting solution was washed 
with 1M HCl (25 mL), saturated NaHCO3 solution (3 x 50 mL) and brine (50 mL) and 
dried over Na2SO4. The solvent was removed in vacuo to yield a dark brown oil which 
was purified by column chromatography (2:1 Pet. Ether/EtOAc, Rf: 0.16) to yield the 
product as a white solid (1.40 g, 61%).1H NMR (500 MHz, CDCl3) δ 11.35 (s, 1H, OH), 
9.76 (s, 1H, HC=O)), 7.46 (d, J = 8.6 Hz, 1H, Ar-H), 6.60 (dd, J = 8.6, 2.2 Hz, 1H, Ar-H), 
6.55 (d, J = 1.9 Hz, 1H, Ar-H), 5.53 – 5.43 (m, 2H, H-1, H-2), 5.20 – 5.06 (m, 2H, H-3, 
H-4), 4.29 – 4.08 (m, 3H, H-5, H-6), 2.17 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.05 (s, 3H, 
OAc), 2.01 (s, 3H, OAc). 13C NMR (126 MHz, CDCl3) δ 194.8 (HC=O), 170.4 (C=O), 170.1 
(C=O), 170.0 (C=O), 169.3 (C=O), 164.0 (Ar), 163.0 (Ar), 135.4 (Ar), 116.7 (Ar), 109.6 
(Ar), 103.7 (Ar), 98.3 (C-1), 71.5 (C-5), 70.7 (C-2), 68.3 (C-3), 66.8 (C-4), 61.4 (C-6), 
20.7 (OAc), 20.6 (OAc), 20.6 (OAc), 20.5 (OAc). IR (KBr Disk): 3459, 2971, 2863, 1755, 
1665, 1579, 1432, 1375, 1230, 1177, 1073, 979, 908cm-1. HRMS m/z (ESI+): 469.1341 
(C21H25O12: [M+H]+ requires 469.1340). Mp: 132-133 ˚C. [α]D
25
: -1˚ (c= 0.3, CH2Cl2). 
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2,4-Dihydroxybenzaldehyde (1.0 g, 0.0072 mol) and 2,4-dihydro-2H-pyran (0.96 g, 
0.0113 mol) were dissolved in anhydrous DCM (40 mL) with PPTS (0.175 g, 0.0007 mol). 
The reaction was stirred at ambient temperature for 4 h under N2 and then washed with 
saturated NaHCO3 solution (3 x 20 mL) and brine (50 mL). The organic fraction was dried 
over Na2SO4 and evaporated to yield a yellow oil. This was purified by column 
chromatography (5:1 Pet. Ether/EtOAc, Rf: 0.5) to produce the product as a pale yellow 
oil (1.439 g, 90 %). 1H NMR (500 MHz, CDCl3) δ 11.36 (s, 1H, OH), 9.72 (s, 1H, HC=O), 7.43 
(d, J = 8.6 Hz, 1H, Ar-H ), 6.65 (dd, J = 8.6, 1.9 Hz, 1H, Ar-H), 6.62 (s, 1H, Ar-H), 5.50 (t, J = 
3 Hz, 1H, THP C(-O)2H), 3.82 (td, J = 10.9, 3.0 Hz, 1H, THP C(O)-H), 3.66 – 3.56 (m, 1H, 
THP C(O)-H’), 1.86 (dt, J = 7.4, 3.5 Hz, 2H, THP CH2), 1.77 – 1.64 (m, 2H, THP CH2), 1.64 – 
1.45 (m, 2H, THP CH2). 13C NMR (126 MHz, CDCl3) δ 194.6 (C=O), 164.4 (Ar-O), 164.2 (Ar-
H), 135.3 (Ar-H), 109.4 (Ar-C), 103.7 (Ar-H), 96.3 (CH), 62.2 (CH2), 29.9 (CH2), 24.9 (CH2), 
18.4 (CH2). IR (KBr Disk): 3431, 2969, 2869, 1750, 1663, 1627, 1579, 1500, 1438, 1371, 
1227, 1170, 1076, 1035, 979, 908 cm-1. HRMS m/z (ESI+): 223.0900 (C12H14O4: [M+H]+ 
requires 223.0901). 
The characterization data is in agreement with that reported in the literature.213 
 
   
 
Menthol (0.5 g, 0.00319 mol) and PPh3 (3.147 g, 0.01276 mol) were dissolved in 
anhydrous THF (30 mL) under N2 in a two-neck flask fitted with a thermometer and 
cooled to -10 ˚C in an ice/acetone/NaCl bath. DIAD (2.44 mL, 0.01276 mol) was added 
dropwise, ensuring that the temperature of the reaction never exceeded 5 ˚C. This 
5.14 
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formed a bright yellow solution which was allowed to stir for 15 min to produce a cloudy 
white mixture to which was added a solution of 2, 4-dihydroxybenzaldehyde (1.657 g, 
0.01276 mol) in anhydrous THF (15 mL) by cannula transfer to immediately form a deep 
red solution. This was allowed to gradually warm to room temperature and was stirred 
overnight after which it was reduced in vacuo to a heavy brown oil. This was dissolved 
in EtOAc (25 mL) and washed with saturated NaHCO3 solution (3x 20 mL) and brine (50 
mL) and was then dried with Na2SO4 and the solvent was removed in vacuo to produce 
a heavy red oil.  
To remove TPPO and reduced DIAD by products,226 the oil was dissolved in toluene (30 
mL) and MgCl2 (3 g) was added and the mixture was heated to 60 ˚C for 2 h. A red 
precipitate was removed by vacuum filtration and the filtrate was concentrated in vacuo 
to yield a red oil which was purified by column chromatography (4:1 Cyclohexane/ Et2O, 
Rf: 0.65) to yield the product as an amber oil (0.143 g, 16 %). 1H NMR (500 MHz, CDCl3) 
δ 11.48 (s, 1H, OH), 9.69 (s, 1H, C(=O)H), 7.40 (d, J = 8.7 Hz, 1H, Ar-H), 6.52 (dd, J = 8.7, 
2.2 Hz, 1H, Ar-H), 6.42 (d, J = 2.1 Hz, 1H, Ar-H), 4.71 (ad, J = 1.4 Hz, 1H, OCH), 2.09 (add, 
J = 14.1, 2.1 Hz, 1H, CH), 1.83 – 1.72 (m, 2H, CH2), 1.72 – 1.57 (m, 2H, CH2), 1.53 (atd, J = 
12.7, 3.3 Hz, 1H, CH), 1.46 – 1.39 (m, 1H, CH), 1.12 – 1.01 (m, 2H, CH2), 0.92 (d, J = 6.7 
Hz, 3H, CH3), 0.83 (d, J = 6.7 Hz, 6H, isopropyl CH3). 13C NMR (126 MHz, CDCl3) δ 194.1 
(C=O), 165.9 (Ar), 164.8 (Ar), 135.4 (Ar), 114.9 (Ar), 109.4 (Ar), 101.7 (Ar), 74.4 
(Cyclohexyl-C-OAr), 47.6 (Cyclohexyl-C), 37.7 (Cyclohexyl-C), 34.8 (Cyclohexyl-C), 29.4 
(Cyclohexyl-C), 24.8 (Cyclohexyl-C), 22.2 (Isopropyl C-H), 21.1 (CH3), 20.7 (CH3). IR (NaCl 
Plate): 2949, 2925, 2869, 1752, 1641, 1627, 1574, 1503, 1455, 1374, 1335, 1288, 1220, 
1117, 980, 681cm-1. HRMS m/z (ESI+): 277.1808 (C13H16O7: [M+H]+ requires 277.1798). 
[α]D
24
: +3˚ (c 0.2, CH2Cl2). 
 
6.5.2   Fluorescence Studies 
 
Fluorescence spectra were obtained using a Jasco FP-6300 spectrofluorometer 
operating in emission mode using 1 cm quartz cuvette. Excitation and emission 
bandwidths were set at 2.5 nm. All experiments were carried out in triplicate using 
HPLC grade solvents at a concentration of 10μM. The λmax was determined by UV/vis 
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spectroscopy at a concentration of 10 μM using a Perkin Elmer Lambda 35 
spectrometer and Scan Lambda 35 software. 
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Chapter 7: Conclusions and Future Work 
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This thesis presents the results of a large body of research into the synthesis of 
functional glycosides and the investigation of their properties. From the work carried 
out on the synthesis of N2 and N2O ligands and an investigation of their coordination 
chemistry, it was identified that the N2 ligands proved to be more difficult synthetic 
targets than the N2O compounds. However, the N2 series displayed better metal 
chelating ability, producing stable metal complexes which could be, in several cases, 
analysed by X-ray crystallography. The metal complexes of the N2O series proved to 
be less stable and prone to hydrolysis in solution. Further work in this area should 
focus on diversifying the library of N2 ligands with different carbohydrate moieties, 
in addition to non-carbohydrate biomolecules such as peptides and nucleobases. 
Furthermore, a wider variety of metals should be investigated and their properties 
studied. Another avenue of investigation which holds promise is the reduction of the 
N2O imines to amines. Preliminary investigations into this reduction were carried out 
during this work, however, these studies were not exhaustive. Reduction of the imine 
bond would produce ligands which are not susceptible to hydrolysis, a problem which 
hampered work into the N2O metal complexes in this work. As this problem likely 
stems from the acidity of the phenol groups, work should focus on reducing 
compounds already functionalized at the para position as these would have fewer 
acidic protons to react with the reducing agent. 
The biological studies of these compounds identified very promising candidates for 
both Chagas disease and Leishmaniasis. The selectivity of the N2 core was shown to 
be modulated by both the choice of metal and the incorporation of the carbohydrate 
moiety. The metal provides a means to target the desired parasite and the glucose 
moiety serves to increase in the tolerance of the compounds by mammalian cells. 
The identification of these structure-activity relationships allows for the design of 
highly specific antiparasitic compounds. Further work should focus on the elucidation 
of the mode of action of these compounds with the aim to further identify 
possibilities for the optimization of the structure of the antiparasitic compounds. The 
influence of the halide ligands and counterions present in the compounds  on their 
antiparasitic activity should also be probed. The work presented here has focused on 
the use of chloride and perchlorate salts for the generation of the metal complexes. 
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Future work should investigate bromide ligands as metal complexes of these ligands 
are less prone to hydrolysis than the chlorides used in this work. Tetrafluoroborate 
counterions should also be tested as an alternative to perchlorate counterions as 
these are not explosive and are more amenable to a large scale synthesis which 
would be necessary if these compounds are to be synthesized on a scale necessary 
to carry out animal studies. 
The research into the synthesis of a carbohydrate derived macrocycle has yielded 
several useful synthetic intermediates and studied several modes for their activation 
in glycosylation reactions. In addition, this work has identified problems associated 
with the use of serine as a building block due to the difficulties encountered when 
trying to perform glycosylation reactions with this molecule. Instead, an alternative 
route using 2-chloroethanol was investigated and this proved to be more successful. 
Two macrocyclization routes were explored and the reaction products were analysed 
by MS. These reactions have indicated the presence of the target macrocycle along 
with oligomeric by products and from these studies it was shown that an 
intramolecular glycosylation route holds promise for the synthesis of the monomeric 
macrocycle. A reason for this selectivity is presented based on the examination and 
comparison of the reaction mechanisms.  
Future work on this should focus on exploring the ring closing glycosylation step with 
alternative glycosyl donors. Acetate based donors proved to generate less complex 
mixtures however the reaction was slow and it was difficult to achieve complete 
conversion of the starting material. Trichloroacetimidate donors should provide a 
higher reactivity which may overcome this while being activated using the same 
promotor which does not leave any products in the crude product, unlike the sulfur 
based promotors which were used for the thioglycoside glycosylations. The serine 
derived macrocycle may prove to be obtainable using an intramolecular glycosylation 
route following its so this strategy should be explored. In particular, InBr3 has been 
recently shown to be a useful glycosylation promotor of acetylated sugars and amino 
acids and this could generate the target macrocycle from the intermediates 
developed in this work. Another avenue of exploration worth pursuing is the use of 
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templating cations to control the selectivity of the reaction for different sized 
macrocycles. 
The studies on the photophysical properties revealed that the compounds containing 
a β-glycosidic linkage exhibited fluorescent behaviour while the α-glycosylated 
mannose derivative and the compounds containing non-carbohydrate moieties did 
not show fluorescence. A reason for this observation is proposed based on DFT 
studies of the glucosylated and non-glucosylated biaryl core which suggest that the 
pyran oxygen of the sugar moiety contributes electron density too the HOMO of the 
molecule. This electron donation appears to facilitate the fluorescent behaviour of 
the compounds with a β-glycoside moiety. While the fluorescent intensity of the 
compounds was quite low, this effect seems to be specific to sugars and therefore 
could have applications in fluorescent carbohydrate sensors. This avenue should be 
explored by exploring the use of these compounds to monitor glycosidase enzymes. 
In addition, modifications to the biaryl core should be explored in order to improve 
the water stability of the compounds and increase the fluorescent intensity of the 
compounds which would be necessary for their use as sensors with low detection 
limits.  
Overall, the work presented here has explored a wide range of the synthetic 
chemistry of carbohydrates and the use of glycosylated molecules. From this I have 
succeeded in identifying compounds with extremely promising antiparasitic 
properties, developing synthetic intermediates and protocols for the generation of 
conformationally constrained macrocycles and investigated the influence of 
carbohydrate residues on the fluorescent properties of a novel biaryl fluorophore.  
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Crystallographic Data 
2.18 
Empirical formula  C20H20N2O2 
Formula weight  320.38 
Temperature  99.99 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.4902(7) Å α= 90°. 
 b = 9.8711(6) Å β= 90.197(2)°. 
 c = 13.6216(8) Å γ = 90°. 
Volume 1679.42(17) Å3 
Z 4 
Density (calculated) 1.267 Mg/m3 
Absorption coefficient 0.083 mm-1 
F(000) 680 
Crystal size 0.31 x 0.19 x 0.17 mm3 
Theta range for data collection 2.991 to 29.557°. 
Index ranges -17≤h≤17, -13≤k≤13, -18≤l≤18 
Reflections collected 19589 
Independent reflections 4678 [R(int) = 0.0872] 
Completeness to theta = 26.000° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7459 and 0.6692 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4678 / 0 / 225 
Goodness-of-fit on F2 1.018 
Final R indices [I>2σ(I)] R1 = 0.0658, wR2 = 0.1067 
R indices (all data) R1 = 0.1316, wR2 = 0.1269 
Largest diff. peak and hole 0.252 and -0.286 e.Å-3 
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Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 
103) for 2.18.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
N(1) 6204(1) 362(2) 6252(1) 20(1) 
C(2) 5341(2) 20(2) 6790(1) 23(1) 
C(3) 4366(2) 636(2) 6691(1) 24(1) 
C(4) 4254(2) 1660(2) 6006(2) 26(1) 
C(5) 5132(2) 2031(2) 5456(2) 25(1) 
C(6) 6092(1) 1354(2) 5590(1) 19(1) 
C(7) 7030(2) 1672(2) 4938(2) 22(1) 
N(8) 7290(1) 3114(2) 4953(1) 19(1) 
C(9) 7801(2) 3516(2) 4030(1) 22(1) 
C(10) 6989(1) 3643(2) 3217(1) 18(1) 
C(11) 6957(1) 2764(2) 2422(1) 21(1) 
C(12) 6218(2) 2916(2) 1669(1) 23(1) 
C(13) 5482(2) 3967(2) 1709(1) 21(1) 
C(14) 5488(2) 4852(2) 2504(2) 22(1) 
C(15) 6235(2) 4673(2) 3246(1) 22(1) 
O(16) 4775(1) 4094(2) 950(1) 29(1) 
C(17) 7953(2) 3461(2) 5815(1) 22(1) 
C(18) 8005(1) 4968(2) 5968(1) 20(1) 
C(19) 7076(2) 5690(2) 6165(2) 25(1) 
C(20) 7097(2) 7074(2) 6321(2) 25(1) 
C(21) 8060(2) 7773(2) 6268(1) 21(1) 
C(22) 8992(2) 7077(2) 6069(1) 23(1) 
C(23) 8956(2) 5683(2) 5926(1) 21(1) 
O(24) 8124(1) 9137(1) 6422(1) 28(1) 
 
Bond lengths [Å] and angles [°] for 2.18  
 
N(1)-C(2)  1.349(2) 
N(1)-C(6)  1.339(2) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.368(3) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.382(3) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.380(3) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.384(3) 
C(6)-C(7)  1.505(2) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(7)-N(8)  1.461(2) 
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N(8)-C(9)  1.467(2) 
N(8)-C(17)  1.474(2) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(9)-C(10)  1.505(3) 
C(10)-C(11)  1.389(3) 
C(10)-C(15)  1.386(3) 
C(11)-H(11)  0.9500 
C(11)-C(12)  1.385(3) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.387(3) 
C(13)-C(14)  1.393(3) 
C(13)-O(16)  1.362(2) 
C(14)-H(14)  0.9500 
C(14)-C(15)  1.384(3) 
C(15)-H(15)  0.9500 
O(16)-H(16)  0.93(3) 
C(17)-H(17A)  0.9900 
C(17)-H(17B)  0.9900 
C(17)-C(18)  1.503(3) 
C(18)-C(19)  1.389(3) 
C(18)-C(23)  1.383(3) 
C(19)-H(19)  0.9500 
C(19)-C(20)  1.383(3) 
C(20)-H(20)  0.9500 
C(20)-C(21)  1.388(3) 
C(21)-C(22)  1.381(3) 
C(21)-O(24)  1.365(2) 
C(22)-H(22)  0.9500 
C(22)-C(23)  1.390(3) 
C(23)-H(23)  0.9500 
O(24)-H(24)  0.94(2) 
C(6)-N(1)-C(2) 117.90(16) 
N(1)-C(2)-H(2) 118.4 
N(1)-C(2)-C(3) 123.20(18) 
C(3)-C(2)-H(2) 118.4 
C(2)-C(3)-H(3) 120.6 
C(2)-C(3)-C(4) 118.70(17) 
C(4)-C(3)-H(3) 120.6 
C(3)-C(4)-H(4) 120.6 
C(5)-C(4)-C(3) 118.81(18) 
C(5)-C(4)-H(4) 120.6 
C(4)-C(5)-H(5) 120.3 
C(4)-C(5)-C(6) 119.36(18) 
C(6)-C(5)-H(5) 120.3 
N(1)-C(6)-C(5) 122.03(17) 
N(1)-C(6)-C(7) 118.02(16) 
C(5)-C(6)-C(7) 119.86(17) 
C(6)-C(7)-H(7A) 109.3 
C(6)-C(7)-H(7B) 109.3 
H(7A)-C(7)-H(7B) 108.0 
N(8)-C(7)-C(6) 111.60(15) 
N(8)-C(7)-H(7A) 109.3 
N(8)-C(7)-H(7B) 109.3 
C(7)-N(8)-C(9) 110.43(15) 
C(7)-N(8)-C(17) 111.25(15) 
C(9)-N(8)-C(17) 112.01(15) 
N(8)-C(9)-H(9A) 109.4 
N(8)-C(9)-H(9B) 109.4 
N(8)-C(9)-C(10) 111.06(15) 
H(9A)-C(9)-H(9B) 108.0 
C(10)-C(9)-H(9A) 109.4 
C(10)-C(9)-H(9B) 109.4 
C(11)-C(10)-C(9) 122.66(17) 
C(15)-C(10)-C(9) 119.77(18) 
C(15)-C(10)-C(11) 117.58(18) 
C(10)-C(11)-H(11) 119.1 
C(12)-C(11)-C(10) 121.78(18) 
C(12)-C(11)-H(11) 119.1 
C(11)-C(12)-H(12) 120.3 
C(11)-C(12)-C(13) 119.50(18) 
C(13)-C(12)-H(12) 120.3 
C(12)-C(13)-C(14) 119.84(18) 
O(16)-C(13)-C(12) 117.86(18) 
O(16)-C(13)-C(14) 122.30(18) 
C(13)-C(14)-H(14) 120.3 
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C(15)-C(14)-C(13) 119.32(18) 
C(15)-C(14)-H(14) 120.3 
C(10)-C(15)-H(15) 119.0 
C(14)-C(15)-C(10) 121.96(18) 
C(14)-C(15)-H(15) 119.0 
C(13)-O(16)-H(16) 109.0(17) 
N(8)-C(17)-H(17A) 109.4 
N(8)-C(17)-H(17B) 109.4 
N(8)-C(17)-C(18) 111.35(15) 
H(17A)-C(17)-H(17B) 108.0 
C(18)-C(17)-H(17A) 109.4 
C(18)-C(17)-H(17B) 109.4 
C(19)-C(18)-C(17) 119.95(17) 
C(23)-C(18)-C(17) 122.40(17) 
C(23)-C(18)-C(19) 117.65(18) 
C(18)-C(19)-H(19) 119.3 
C(20)-C(19)-C(18) 121.39(18) 
C(20)-C(19)-H(19) 119.3 
C(19)-C(20)-H(20) 120.0 
C(19)-C(20)-C(21) 120.00(18) 
C(21)-C(20)-H(20) 120.0 
C(22)-C(21)-C(20) 119.58(17) 
O(24)-C(21)-C(20) 122.23(17) 
O(24)-C(21)-C(22) 118.17(17) 
C(21)-C(22)-H(22) 120.2 
C(21)-C(22)-C(23) 119.55(17) 
C(23)-C(22)-H(22) 120.2 
C(18)-C(23)-C(22) 121.82(17) 
C(18)-C(23)-H(23) 119.1 
C(22)-C(23)-H(23) 119.1 
C(21)-O(24)-H(24) 111.3(14) 
 
Anisotropic displacement parameters (Å2x 103) for 2.18.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 
 U11 U22  U33 U23 U13 U12 
N(1) 22(1)  18(1) 20(1)  -2(1) 1(1)  0(1) 
C(2) 31(1)  19(1) 19(1)  -2(1) 4(1)  -2(1) 
C(3) 25(1)  24(1) 24(1)  -7(1) 7(1)  -6(1) 
C(4) 18(1)  24(1) 35(1)  -4(1) 1(1)  2(1) 
C(5) 25(1)  20(1) 30(1)  4(1) 0(1)  1(1) 
C(6) 21(1)  14(1) 21(1)  -4(1) -1(1)  -3(1) 
C(7) 21(1)  18(1) 26(1)  -1(1) 3(1)  0(1) 
N(8) 20(1)  18(1) 20(1)  2(1) 0(1)  -3(1) 
C(9) 16(1)  25(1) 26(1)  2(1) 2(1)  -1(1) 
C(10) 14(1)  20(1) 22(1)  3(1) 3(1)  -3(1) 
C(11) 16(1)  21(1) 26(1)  2(1) 5(1)  3(1) 
C(12) 22(1)  23(1) 23(1)  -2(1) 2(1)  -1(1) 
C(13) 18(1)  20(1) 25(1)  6(1) -1(1)  -6(1) 
C(14) 18(1)  18(1) 32(1)  3(1) 2(1)  3(1) 
C(15) 21(1)  20(1) 24(1)  -2(1) 3(1)  -2(1) 
O(16) 26(1)  28(1) 33(1)  2(1) -10(1)  1(1) 
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C(17) 23(1)  19(1) 25(1)  2(1) -3(1)  2(1) 
C(18) 20(1)  21(1) 18(1)  1(1) -3(1)  0(1) 
C(19) 18(1)  23(1) 34(1)  1(1) 1(1)  -4(1) 
C(20) 15(1)  23(1) 36(1)  -1(1) 1(1)  3(1) 
C(21) 21(1)  18(1) 22(1)  1(1) -3(1)  0(1) 
C(22) 15(1)  26(1) 27(1)  2(1) -2(1)  -3(1) 
C(23) 17(1)  24(1) 22(1)  -1(1) -1(1)  4(1) 
O(24) 20(1)  19(1) 43(1)  -4(1) -6(1)  1(1) 
 
Hydrogen coordinates (x104) and isotropic  displacement parameters (Å2x 103) for 
2.18 
 
 x  y  z  U(eq) 
H(2) 5415 -683 7262 28 
H(3) 3777 365 7084 29 
H(4) 3584 2100 5916 31 
H(5) 5078 2744 4991 30 
H(7A) 7660 1145 5160 26 
H(7B) 6860 1394 4256 26 
H(9A) 8345 2833 3847 27 
H(9B) 8170 4395 4122 27 
H(11) 7456 2039 2393 25 
H(12) 6215 2305 1130 27 
H(14) 4984 5572 2538 27 
H(15) 6231 5274 3790 26 
H(17A) 8686 3103 5721 27 
H(17B) 7649 3027 6407 27 
H(19) 6411 5223 6194 30 
H(20) 6454 7546 6464 30 
H(22) 9655 7546 6030 27 
H(23) 9602 5209 5796 25 
H(24) 7440(18) 9540(20) 6404(16) 37(6) 
H(16) 4270(20) 4760(30) 1110(20) 60(8) 
 
Torsion angles [°] for 2.18 
 
N(1)-C(2)-C(3)-C(4) 0.0(3) 
N(1)-C(6)-C(7)-N(8) -128.19(18) 
C(2)-N(1)-C(6)-C(5) 0.7(3) 
C(2)-N(1)-C(6)-C(7) -175.74(17) 
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C(2)-C(3)-C(4)-C(5) -0.6(3) 
C(3)-C(4)-C(5)-C(6) 1.2(3) 
C(4)-C(5)-C(6)-N(1) -1.3(3) 
C(4)-C(5)-C(6)-C(7) 175.04(18) 
C(5)-C(6)-C(7)-N(8) 55.3(2) 
C(6)-N(1)-C(2)-C(3) 0.0(3) 
C(6)-C(7)-N(8)-C(9) -152.83(16) 
C(6)-C(7)-N(8)-C(17) 82.14(19) 
C(7)-N(8)-C(9)-C(10) 76.47(19) 
C(7)-N(8)-C(17)-C(18) -166.47(15) 
N(8)-C(9)-C(10)-C(11) -111.99(19) 
N(8)-C(9)-C(10)-C(15) 68.1(2) 
N(8)-C(17)-C(18)-C(19) 62.2(2) 
N(8)-C(17)-C(18)-C(23) -118.10(19) 
C(9)-N(8)-C(17)-C(18) 69.4(2) 
C(9)-C(10)-C(11)-C(12) -178.54(17) 
C(9)-C(10)-C(15)-C(14) 178.45(17) 
C(10)-C(11)-C(12)-C(13) -0.5(3) 
C(11)-C(10)-C(15)-C(14) -1.4(3) 
C(11)-C(12)-C(13)-C(14) -0.4(3) 
C(11)-C(12)-C(13)-O(16) 179.24(17) 
C(12)-C(13)-C(14)-C(15) 0.3(3) 
C(13)-C(14)-C(15)-C(10) 0.7(3) 
C(15)-C(10)-C(11)-C(12) 1.3(3) 
O(16)-C(13)-C(14)-C(15) -179.32(17) 
C(17)-N(8)-C(9)-C(10) -158.94(16) 
C(17)-C(18)-C(19)-C(20) 179.27(19) 
C(17)-C(18)-C(23)-C(22) 179.95(18) 
C(18)-C(19)-C(20)-C(21) 0.9(3) 
C(19)-C(18)-C(23)-C(22) -0.4(3) 
C(19)-C(20)-C(21)-C(22) -0.7(3) 
C(19)-C(20)-C(21)-O(24) -179.53(19) 
C(20)-C(21)-C(22)-C(23) -0.1(3) 
C(21)-C(22)-C(23)-C(18) 0.6(3) 
C(23)-C(18)-C(19)-C(20) -0.4(3) 
O(24)-C(21)-C(22)-C(23) 178.81(18) 
 
Hydrogen bonds for 2.18 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 
C(17)-H(17A)...O(16)#1 0.99 2.58 3.402(2) 141 
O(24)-H(24)...N(1)#2 0.94(2) 1.75(2) 2.695(2) 174(2) 
O(16)-H(16)...O(24)#3 0.93(3) 1.85(3) 2.779(2) 171(2) 
 
 
2.19 
Empirical formula  C56H62Cl8Cu4N10O4 
Formula weight  1476.91 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  Pī 
Unit cell dimensions a = 11.9914(6)              α= 113.9980(10)°. 
 b = 12.6755(6) Å          β= 96.5800(10)°. 
 c = 12.6960(6) Å           γ= 115.3470(10)°. 
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Volume 1492.64(13) Å3 
Z 1 
Density (calculated) 1.643 Mg/m3 
Absorption coefficient 1.819 mm-1 
F(000) 752 
Crystal size 0.230 x 0.180 x 0.120 mm3 
Theta range for data collection 1.874 to 30.211°. 
Index ranges -16≤h≤16, -17≤k≤17, -17≤l≤17 
Reflections collected 58825 
Independent reflections 8816 [R(int) = 0.0282] 
Completeness to theta = 25.242° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7460 and 0.6898 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8816 / 0 / 381 
Goodness-of-fit on F2 1.030 
Final R indices [I>2σ(I)] R1 = 0.0223, wR2 = 0.0542 
R indices (all data) R1 = 0.0292, wR2 = 0.0572 
Largest diff. peak and hole 0.423 and -0.420 e.Å-3 
 
Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2x 
103) for 2.19.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
 x y z U(eq) 
 
C(2) 3174(1) 8490(1) 7358(1) 16(1) 
C(3) 3369(1) 8433(1) 8425(1) 18(1) 
C(4) 4474(1) 8416(1) 8872(1) 18(1) 
C(5) 5355(1) 8479(1) 8244(1) 16(1) 
C(6) 5095(1) 8537(1) 7178(1) 13(1) 
C(7) 6046(1) 8688(2) 6501(1) 16(1) 
C(9) 5098(1) 6872(1) 4318(1) 16(1) 
C(10) 6307(1) 6755(1) 4355(1) 14(1) 
C(11) 6195(1) 5517(1) 4074(1) 16(1) 
C(12) 7283(1) 5374(1) 4094(1) 17(1) 
C(13) 8514(1) 6484(1) 4417(1) 15(1) 
C(14) 8646(1) 7724(1) 4700(1) 16(1) 
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C(15) 7546(1) 7849(1) 4663(1) 16(1) 
C(17) 1253(1) 5171(1) 3654(1) 16(1) 
C(18) 11(1) 3888(1) 3113(1) 20(1) 
C(20) 3848(1) 3405(1) 10719(1) 18(1) 
C(21) 4925(1) 3808(2) 10352(2) 22(1) 
C(22) 4727(2) 3193(2) 9100(2) 24(1) 
C(23) 3465(2) 2226(2) 8263(1) 22(1) 
C(24) 2422(1) 1880(1) 8694(1) 16(1) 
C(25) 1023(1) 821(2) 7837(1) 18(1) 
C(27) -571(1) 1566(1) 8301(1) 16(1) 
C(28) 353(1) 3076(1) 8912(1) 15(1) 
C(29) 746(1) 3923(1) 10183(1) 16(1) 
C(30) 1565(1) 5317(1) 10747(1) 16(1) 
C(31) 1992(1) 5889(1) 10027(1) 15(1) 
C(32) 1622(1) 5067(1) 8764(1) 18(1) 
C(33) 803(1) 3670(1) 8218(1) 17(1) 
Cl(1) 4031(1) 8626(1) 3379(1) 17(1) 
Cl(2) 2208(1) 9050(1) 5165(1) 17(1) 
Cl(3) 2074(1) 2520(1) 12316(1) 17(1) 
Cl(4) -1041(1) 711(1) 10480(1) 16(1) 
Cu(1) 3788(1) 8460(1) 5097(1) 13(1) 
Cu(2) 1002(1) 1587(1) 10298(1) 13(1) 
N(1) 4014(1) 8530(1) 6734(1) 13(1) 
N(8) 5382(1) 8238(1) 5213(1) 13(1) 
N(16) 2216(1) 6184(1) 4076(1) 20(1) 
N(19) 2617(1) 2444(1) 9904(1) 15(1) 
N(26) 82(1) 849(1) 8491(1) 15(1) 
O(1) 9562(1) 6300(1) 4435(1) 19(1) 
O(2) 2762(1) 7263(1) 10519(1) 20(1) 
 
Bond lengths [Å] and angles [°] for 2.19. 
 
C(2)-N(1)  1.3484(16) 
C(2)-C(3)  1.3834(19) 
C(2)-H(2)  0.9500 
C(3)-C(4)  1.3930(19) 
C(3)-H(3)  0.9500 
C(4)-C(5)  1.3899(19) 
C(4)-H(4)  0.9500 
C(5)-C(6)  1.3922(18) 
C(5)-H(5)  0.9500 
C(6)-N(1)  1.3474(16) 
C(6)-C(7)  1.4988(18) 
C(7)-N(8)  1.4792(16) 
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C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(9)-N(8)  1.4866(17) 
C(9)-C(10)  1.5177(18) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(10)-C(15)  1.3946(19) 
C(10)-C(11)  1.3995(18) 
C(11)-C(12)  1.3912(18) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.3928(19) 
C(12)-H(12)  0.9500 
C(13)-O(1)  1.3723(15) 
C(13)-C(14)  1.3913(19) 
C(14)-C(15)  1.3932(18) 
C(14)-H(14)  0.9500 
C(15)-H(15)  0.9500 
C(17)-N(16)  1.1392(18) 
C(17)-C(18)  1.4549(19) 
C(18)-H(18A)  0.9800 
C(18)-H(18B)  0.9800 
C(18)-H(18C)  0.9800 
C(20)-N(19)  1.3484(18) 
C(20)-C(21)  1.383(2) 
C(20)-H(20)  0.9500 
C(21)-C(22)  1.392(2) 
C(21)-H(21)  0.9500 
C(22)-C(23)  1.380(2) 
C(22)-H(22)  0.9500 
C(23)-C(24)  1.3910(19) 
C(23)-H(23)  0.9500 
C(24)-N(19)  1.3449(17) 
C(24)-C(25)  1.505(2) 
C(25)-N(26)  1.4793(17) 
C(25)-H(25A)  0.9900 
C(25)-H(25B)  0.9900 
C(27)-N(26)  1.4974(17) 
C(27)-C(28)  1.5068(19) 
C(27)-H(27A)  0.9900 
C(27)-H(27B)  0.9900 
C(28)-C(33)  1.3911(19) 
C(28)-C(29)  1.4010(18) 
C(29)-C(30)  1.3869(19) 
C(29)-H(29)  0.9500 
C(30)-C(31)  1.3979(18) 
C(30)-H(30)  0.9500 
C(31)-O(2)  1.3712(17) 
C(31)-C(32)  1.3913(18) 
C(32)-C(33)  1.392(2) 
C(32)-H(32)  0.9500 
C(33)-H(33)  0.9500 
Cl(1)-Cu(1)  2.3130(4) 
Cl(2)-Cu(1)  2.3130(3) 
Cl(3)-Cu(2)  2.2571(4) 
Cl(4)-Cu(2)  2.3024(4) 
Cl(4)-Cu(2)#1  2.6922(4) 
Cu(1)-N(1)  2.0254(11) 
Cu(1)-N(8)  2.0463(11) 
Cu(1)-N(16)  2.3020(13) 
Cu(2)-N(19)  2.0101(12) 
Cu(2)-N(26)  2.0358(11) 
Cu(2)-Cl(4)#1  2.6922(4) 
N(8)-H(8)  0.863(18) 
N(26)-H(26)  0.854(19) 
O(1)-H(1)  0.8400 
O(2)-H(2A)  0.8400 
N(1)-C(2)-C(3) 122.53(12) 
N(1)-C(2)-H(2) 118.7 
C(3)-C(2)-H(2) 118.7 
C(2)-C(3)-C(4) 118.86(12) 
C(2)-C(3)-H(3) 120.6 
C(4)-C(3)-H(3) 120.6 
C(5)-C(4)-C(3) 118.93(12) 
C(5)-C(4)-H(4) 120.5 
C(3)-C(4)-H(4) 120.5 
C(4)-C(5)-C(6) 118.96(12) 
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C(4)-C(5)-H(5) 120.5 
C(6)-C(5)-H(5) 120.5 
N(1)-C(6)-C(5) 122.09(12) 
N(1)-C(6)-C(7) 116.38(11) 
C(5)-C(6)-C(7) 121.44(11) 
N(8)-C(7)-C(6) 111.04(10) 
N(8)-C(7)-H(7A) 109.4 
C(6)-C(7)-H(7A) 109.4 
N(8)-C(7)-H(7B) 109.4 
C(6)-C(7)-H(7B) 109.4 
H(7A)-C(7)-H(7B) 108.0 
N(8)-C(9)-C(10) 114.00(11) 
N(8)-C(9)-H(9A) 108.8 
C(10)-C(9)-H(9A) 108.8 
N(8)-C(9)-H(9B) 108.8 
C(10)-C(9)-H(9B) 108.8 
H(9A)-C(9)-H(9B) 107.6 
C(15)-C(10)-C(11) 118.17(12) 
C(15)-C(10)-C(9) 122.06(12) 
C(11)-C(10)-C(9) 119.77(12) 
C(12)-C(11)-C(10) 121.21(12) 
C(12)-C(11)-H(11) 119.4 
C(10)-C(11)-H(11) 119.4 
C(11)-C(12)-C(13) 119.68(12) 
C(11)-C(12)-H(12) 120.2 
C(13)-C(12)-H(12) 120.2 
O(1)-C(13)-C(14) 122.30(12) 
O(1)-C(13)-C(12) 117.72(12) 
C(14)-C(13)-C(12) 119.98(12) 
C(13)-C(14)-C(15) 119.77(12) 
C(13)-C(14)-H(14) 120.1 
C(15)-C(14)-H(14) 120.1 
C(14)-C(15)-C(10) 121.18(12) 
C(14)-C(15)-H(15) 119.4 
C(10)-C(15)-H(15) 119.4 
N(16)-C(17)-C(18) 179.01(15) 
C(17)-C(18)-H(18A) 109.5 
C(17)-C(18)-H(18B) 109.5 
H(18A)-C(18)-H(18B) 109.5 
C(17)-C(18)-H(18C) 109.5 
H(18A)-C(18)-H(18C) 109.5 
H(18B)-C(18)-H(18C) 109.5 
N(19)-C(20)-C(21) 122.16(13) 
N(19)-C(20)-H(20) 118.9 
C(21)-C(20)-H(20) 118.9 
C(20)-C(21)-C(22) 118.62(14) 
C(20)-C(21)-H(21) 120.7 
C(22)-C(21)-H(21) 120.7 
C(23)-C(22)-C(21) 119.30(14) 
C(23)-C(22)-H(22) 120.3 
C(21)-C(22)-H(22) 120.3 
C(22)-C(23)-C(24) 119.13(14) 
C(22)-C(23)-H(23) 120.4 
C(24)-C(23)-H(23) 120.4 
N(19)-C(24)-C(23) 121.64(13) 
N(19)-C(24)-C(25) 116.24(12) 
C(23)-C(24)-C(25) 122.08(13) 
N(26)-C(25)-C(24) 111.28(11) 
N(26)-C(25)-H(25A) 109.4 
C(24)-C(25)-H(25A) 109.4 
N(26)-C(25)-H(25B) 109.4 
C(24)-C(25)-H(25B) 109.4 
H(25A)-C(25)-H(25B) 108.0 
N(26)-C(27)-C(28) 113.40(11) 
N(26)-C(27)-H(27A) 108.9 
C(28)-C(27)-H(27A) 108.9 
N(26)-C(27)-H(27B) 108.9 
C(28)-C(27)-H(27B) 108.9 
H(27A)-C(27)-H(27B) 107.7 
C(33)-C(28)-C(29) 118.17(12) 
C(33)-C(28)-C(27) 120.65(12) 
C(29)-C(28)-C(27) 121.15(12) 
C(30)-C(29)-C(28) 121.53(12) 
C(30)-C(29)-H(29) 119.2 
C(28)-C(29)-H(29) 119.2 
C(29)-C(30)-C(31) 119.13(12) 
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C(29)-C(30)-H(30) 120.4 
C(31)-C(30)-H(30) 120.4 
O(2)-C(31)-C(32) 117.53(12) 
O(2)-C(31)-C(30) 122.11(12) 
C(32)-C(31)-C(30) 120.35(13) 
C(31)-C(32)-C(33) 119.50(12) 
C(31)-C(32)-H(32) 120.2 
C(33)-C(32)-H(32) 120.2 
C(28)-C(33)-C(32) 121.30(12) 
C(28)-C(33)-H(33) 119.3 
C(32)-C(33)-H(33) 119.3 
Cu(2)-Cl(4)-Cu(2)#1 84.542(11) 
N(1)-Cu(1)-N(8) 82.60(4) 
N(1)-Cu(1)-N(16) 90.95(5) 
N(8)-Cu(1)-N(16) 96.18(4) 
N(1)-Cu(1)-Cl(2) 95.76(3) 
N(8)-Cu(1)-Cl(2) 171.50(3) 
N(16)-Cu(1)-Cl(2) 92.18(3) 
N(1)-Cu(1)-Cl(1) 167.32(3) 
N(8)-Cu(1)-Cl(1) 86.94(3) 
N(16)-Cu(1)-Cl(1) 97.32(3) 
Cl(2)-Cu(1)-Cl(1) 93.526(13) 
N(19)-Cu(2)-N(26) 82.25(5) 
N(19)-Cu(2)-Cl(3) 95.98(3) 
N(26)-Cu(2)-Cl(3) 176.89(4) 
N(19)-Cu(2)-Cl(4) 167.96(3) 
N(26)-Cu(2)-Cl(4) 88.26(3) 
Cl(3)-Cu(2)-Cl(4) 93.148(13) 
N(19)-Cu(2)-Cl(4)#1 91.29(3) 
N(26)-Cu(2)-Cl(4)#1 86.06(3) 
Cl(3)-Cu(2)-Cl(4)#1 96.558(12) 
Cl(4)-Cu(2)-Cl(4)#1 95.459(11) 
C(6)-N(1)-C(2) 118.62(11) 
C(6)-N(1)-Cu(1) 114.24(8) 
C(2)-N(1)-Cu(1) 127.02(9) 
C(7)-N(8)-C(9) 113.03(10) 
C(7)-N(8)-Cu(1) 109.53(8) 
C(9)-N(8)-Cu(1) 114.73(8) 
C(7)-N(8)-H(8) 107.4(12) 
C(9)-N(8)-H(8) 110.4(11) 
Cu(1)-N(8)-H(8) 100.8(11) 
C(17)-N(16)-Cu(1) 163.95(11) 
C(24)-N(19)-C(20) 119.10(12) 
C(24)-N(19)-Cu(2) 114.06(9) 
C(20)-N(19)-Cu(2) 126.53(9) 
C(25)-N(26)-C(27) 114.14(11) 
C(25)-N(26)-Cu(2) 108.80(8) 
C(27)-N(26)-Cu(2) 113.25(8) 
C(25)-N(26)-H(26) 108.6(13) 
C(27)-N(26)-H(26) 107.4(12) 
Cu(2)-N(26)-H(26) 104.1(12) 
C(13)-O(1)-H(1) 109.5 
C(31)-O(2)-H(2A) 109.5 
 
Anisotropic displacement parameters (Å2x103) for 2.19. The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 
 U11 U22  U33 U23 U13 U12 
C(2) 12(1)  16(1) 20(1)  9(1) 7(1)  7(1) 
C(3) 16(1)  18(1) 20(1)  9(1) 10(1)  9(1) 
C(4) 20(1)  18(1) 15(1)  9(1) 6(1)  10(1) 
C(5) 15(1)  17(1) 16(1)  8(1) 4(1)  9(1) 
C(6) 11(1)  12(1) 15(1)  6(1) 4(1)  6(1) 
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C(7) 12(1)  22(1) 15(1)  10(1) 5(1)  10(1) 
C(9) 14(1)  14(1) 19(1)  6(1) 4(1)  8(1) 
C(10) 14(1)  16(1) 15(1)  7(1) 6(1)  9(1) 
C(11) 15(1)  14(1) 17(1)  8(1) 6(1)  7(1) 
C(12) 19(1)  15(1) 19(1)  9(1) 8(1)  11(1) 
C(13) 17(1)  20(1) 14(1)  9(1) 7(1)  12(1) 
C(14) 14(1)  16(1) 18(1)  8(1) 7(1)  8(1) 
C(15) 17(1)  15(1) 20(1)  9(1) 8(1)  10(1) 
C(17) 17(1)  17(1) 17(1)  8(1) 6(1)  11(1) 
C(18) 16(1)  14(1) 22(1)  6(1) 6(1)  5(1) 
C(20) 16(1)  17(1) 20(1)  10(1) 4(1)  8(1) 
C(21) 14(1)  23(1) 31(1)  16(1) 6(1)  8(1) 
C(22) 20(1)  31(1) 36(1)  23(1) 16(1)  16(1) 
C(23) 25(1)  28(1) 24(1)  16(1) 14(1)  17(1) 
C(24) 18(1)  16(1) 18(1)  10(1) 8(1)  11(1) 
C(25) 19(1)  19(1) 14(1)  7(1) 6(1)  10(1) 
C(27) 13(1)  15(1) 15(1)  7(1) 1(1)  6(1) 
C(28) 13(1)  16(1) 15(1)  8(1) 4(1)  8(1) 
C(29) 16(1)  18(1) 16(1)  10(1) 6(1)  10(1) 
C(30) 16(1)  17(1) 13(1)  7(1) 4(1)  9(1) 
C(31) 14(1)  15(1) 16(1)  8(1) 5(1)  7(1) 
C(32) 20(1)  19(1) 16(1)  11(1) 8(1)  10(1) 
C(33) 19(1)  19(1) 13(1)  8(1) 5(1)  10(1) 
Cl(1) 17(1)  15(1) 13(1)  7(1) 3(1)  6(1) 
Cl(2) 14(1)  17(1) 24(1)  10(1) 5(1)  9(1) 
Cl(3) 17(1)  21(1) 14(1)  8(1) 4(1)  11(1) 
Cl(4) 14(1)  14(1) 19(1)  8(1) 7(1)  8(1) 
Cu(1) 10(1)  14(1) 15(1)  8(1) 4(1)  7(1) 
Cu(2) 12(1)  13(1) 13(1)  6(1) 4(1)  7(1) 
N(1) 11(1)  13(1) 16(1)  7(1) 5(1)  6(1) 
N(8) 12(1)  14(1) 13(1)  8(1) 5(1)  7(1) 
N(16) 17(1)  18(1) 24(1)  9(1) 6(1)  9(1) 
N(19) 16(1)  14(1) 16(1)  8(1) 5(1)  8(1) 
N(26) 14(1)  12(1) 16(1)  6(1) 4(1)  6(1) 
O(1) 16(1)  21(1) 26(1)  13(1) 10(1)  13(1) 
O(2) 23(1)  15(1) 17(1)  7(1) 5(1)  6(1) 
 
Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x 10 3) for 
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2.19. 
 x  y  z  U(eq) 
 
H(2) 2420 8500 7055 19 
H(3) 2759 8406 8845 22 
H(4) 4622 8361 9595 21 
H(5) 6123 8484 8538 19 
H(7A) 6767 9649 6923 19 
H(7B) 6437 8143 6510 19 
H(9A) 4669 6642 3478 20 
H(9B) 4466 6199 4487 20 
H(11) 5360 4761 3865 19 
H(12) 7188 4524 3889 20 
H(14) 9484 8481 4918 19 
H(15) 7640 8696 4850 20 
H(18A) -431 3905 3717 30 
H(18B) 181 3148 2870 30 
H(18C) -552 3749 2386 30 
H(20) 3979 3819 11573 22 
H(21) 5783 4491 10943 27 
H(22) 5452 3437 8824 29 
H(23) 3310 1802 7405 27 
H(25A) 827 984 7158 22 
H(25B) 917 -86 7474 22 
H(27A) -1300 1388 8629 19 
H(27B) -957 1189 7407 19 
H(29) 444 3534 10669 19 
H(30) 1833 5876 11612 19 
H(32) 1926 5456 8277 21 
H(33) 546 3111 7354 21 
H(1) 10254 7040 4673 28 
H(2A) 3021 7650 11290 31 
H(8) 5886(17) 8834(18) 5049(16) 16(4) 
H(26) -524(19) 30(20) 8232(17) 23(5) 
 
Torsion angles [°] for 2.19 
 
N(1)-C(2)-C(3)-C(4) 0.0(2) C(2)-C(3)-C(4)-C(5) 1.1(2) 
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C(3)-C(4)-C(5)-C(6) -1.0(2) 
C(4)-C(5)-C(6)-N(1) -0.1(2) 
C(4)-C(5)-C(6)-C(7) 176.40(13) 
N(1)-C(6)-C(7)-N(8) -23.73(16) 
C(5)-C(6)-C(7)-N(8) 159.56(12) 
N(8)-C(9)-C(10)-C(15) -31.24(18) 
N(8)-C(9)-C(10)-C(11) 148.82(12) 
C(15)-C(10)-C(11)-C(12) -0.2(2) 
C(9)-C(10)-C(11)-C(12) 179.75(12) 
C(10)-C(11)-C(12)-C(13) 0.9(2) 
C(11)-C(12)-C(13)-O(1) 179.51(12) 
C(11)-C(12)-C(13)-C(14) -0.9(2) 
O(1)-C(13)-C(14)-C(15) 179.76(12) 
C(12)-C(13)-C(14)-C(15) 0.2(2) 
C(13)-C(14)-C(15)-C(10) 0.5(2) 
C(11)-C(10)-C(15)-C(14) -0.5(2) 
C(9)-C(10)-C(15)-C(14) 179.52(12) 
N(19)-C(20)-C(21)-C(22) -0.3(2) 
C(20)-C(21)-C(22)-C(23) 1.4(2) 
C(21)-C(22)-C(23)-C(24) -0.6(2) 
C(22)-C(23)-C(24)-N(19) -1.3(2) 
C(22)-C(23)-C(24)-C(25) -179.20(13) 
N(19)-C(24)-C(25)-N(26) 14.18(17) 
C(23)-C(24)-C(25)-N(26) -167.86(13) 
N(26)-C(27)-C(28)-C(33) 105.20(14) 
N(26)-C(27)-C(28)-C(29) -77.02(15) 
C(33)-C(28)-C(29)-C(30) -0.3(2) 
C(27)-C(28)-C(29)-C(30) -178.11(12) 
C(28)-C(29)-C(30)-C(31) 0.9(2) 
C(29)-C(30)-C(31)-O(2) 177.50(12) 
C(29)-C(30)-C(31)-C(32) -1.4(2) 
O(2)-C(31)-C(32)-C(33) -177.76(12) 
C(30)-C(31)-C(32)-C(33) 1.1(2) 
C(29)-C(28)-C(33)-C(32) 0.0(2) 
C(27)-C(28)-C(33)-C(32) 177.90(12) 
C(31)-C(32)-C(33)-C(28) -0.5(2) 
C(5)-C(6)-N(1)-C(2) 1.16(19) 
C(7)-C(6)-N(1)-C(2) -175.53(12) 
C(5)-C(6)-N(1)-Cu(1) -175.07(10) 
C(7)-C(6)-N(1)-Cu(1) 8.24(15) 
C(3)-C(2)-N(1)-C(6) -1.1(2) 
C(3)-C(2)-N(1)-Cu(1) 174.61(10) 
C(6)-C(7)-N(8)-C(9) -102.46(13) 
C(6)-C(7)-N(8)-Cu(1) 26.81(13) 
C(10)-C(9)-N(8)-C(7) -57.60(15) 
C(10)-C(9)-N(8)-Cu(1) 175.85(9) 
C(23)-C(24)-N(19)-C(20) 2.4(2) 
C(25)-C(24)-N(19)-C(20) -179.59(12) 
C(23)-C(24)-N(19)-Cu(2) -171.50(11) 
C(25)-C(24)-N(19)-Cu(2) 6.47(15) 
C(21)-C(20)-N(19)-C(24) -1.6(2) 
C(21)-C(20)-N(19)-Cu(2) 171.51(10) 
C(24)-C(25)-N(26)-C(27) 100.60(13) 
C(24)-C(25)-N(26)-Cu(2) -26.95(13) 
C(28)-C(27)-N(26)-C(25) -69.46(14) 
C(28)-C(27)-N(26)-Cu(2) 55.78(13) 
 
Hydrogen bonds for 2.19 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
C(2)-H(2)...Cl(2) 0.95 2.77 3.3431(14) 120 
 C(3)-H(3)...Cl(4)#2 0.95 2.80 3.6274(14) 146 
 C(7)-H(7B)...Cl(3)#3 0.99 2.79 3.7061(13) 153 
 C(18)-H(18B)...Cl(3)#4 0.98 2.78 3.6015(15) 142 
 C(20)-H(20)...Cl(3) 0.95 2.71 3.2697(15) 118 
 O(1)-H(1)...Cl(2)#5 0.84 2.37 3.2099(11) 175 
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 O(2)-H(2A)...Cl(1)#6 0.84 2.31 3.1412(11) 170 
 N(8)-H(8)...Cl(2)#7 0.863(18) 2.825(18) 3.6810(12) 172.1(15) 
 N(26)-H(26)...Cl(3)#1 0.854(19) 2.672(19) 3.5147(12) 169.1(16) 
 
2.21 
Empirical formula  C13H14Cl2N2OZn 
Formula weight  350.53 
Temperature  99.92 K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.7884(7) Å α= 90°. 
 b = 8.3147(5) Å β= 92.337(2)°. 
 c = 13.8733(7) Å γ = 90°. 
Volume 1473.94(14) Å3 
Z 4 
Density (calculated) 1.580 Mg/m3 
Absorption coefficient 2.021 mm-1 
F(000) 712 
Crystal size 0.2 x 0.2 x 0.13 mm3 
Theta range for data collection 2.857 to 28.420°. 
Index ranges -16≤h≤17, -11≤k≤7, -18≤l≤18 
Reflections collected 13564 
Independent reflections 3684 [R(int) = 0.0487] 
Completeness to theta = 26.000° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7457 and 0.6619 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3684 / 0 / 180 
Goodness-of-fit on F2 1.019 
Final R indices [I>2σ(I)] R1 = 0.0323, wR2 = 0.0596 
R indices (all data) R1 = 0.0548, wR2 = 0.0671 
Largest diff. peak and hole 0.389 and -0.435 e.Å-3 
 
Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2x 
103) for 2.21. U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
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Cl(1) 6317(1) 5323(1) 7553(1) 21(1) 
Zn(1) 5582(1) 3137(1) 8169(1) 13(1) 
N(1) 6178(2) 2476(2) 9509(1) 14(1) 
C(2) 6326(2) 3385(3) 10308(2) 17(1) 
Cl(2) 3854(1) 3103(1) 8151(1) 17(1) 
C(3) 6727(2) 2758(3) 11167(2) 19(1) 
C(4) 6988(2) 1147(3) 11204(2) 22(1) 
C(5) 6834(2) 209(3) 10389(2) 19(1) 
C(6) 6420(2) 902(3) 9550(2) 13(1) 
C(7) 6155(2) -86(3) 8661(2) 17(1) 
N(8) 6129(2) 913(2) 7776(1) 13(1) 
C(9) 5526(2) 102(3) 6969(2) 16(1) 
C(10) 5603(2) 1043(3) 6048(2) 14(1) 
C(11) 6458(2) 827(3) 5477(2) 15(1) 
C(12) 6549(2) 1659(3) 4618(2) 17(1) 
C(13) 5765(2) 2736(3) 4322(2) 16(1) 
C(14) 4911(2) 2970(3) 4884(2) 16(1) 
C(15) 4830(2) 2121(3) 5739(2) 16(1) 
O(16) 5903(2) 3525(2) 3472(1) 22(1) 
 
Bond lengths [Å] and angles [°] for 2.21. 
 
Cl(1)-Zn(1)  2.2318(6) 
Zn(1)-N(1)  2.0557(18) 
Zn(1)-Cl(2)  2.2093(6) 
Zn(1)-N(8)  2.0593(19) 
N(1)-C(2)  1.348(3) 
N(1)-C(6)  1.346(3) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.380(3) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.381(3) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.381(3) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.385(3) 
C(6)-C(7)  1.508(3) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(7)-N(8)  1.482(3) 
N(8)-C(9)  1.493(3) 
N(8)-H(8)  0.90(3) 
C(9)-H(9A)  0.9900 
C(9)-H(9B)  0.9900 
C(9)-C(10)  1.505(3) 
C(10)-C(11)  1.388(3) 
C(10)-C(15)  1.389(3) 
C(11)-H(11)  0.9500 
C(11)-C(12)  1.387(3) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.393(3) 
C(13)-C(14)  1.381(4) 
C(13)-O(16)  1.367(3) 
C(14)-H(14)  0.9500 
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C(14)-C(15)  1.388(3) 
C(15)-H(15)  0.9500 
O(16)-H(16)  0.76(3) 
 
N(1)-Zn(1)-Cl(1) 114.66(6) 
N(1)-Zn(1)-Cl(2) 109.95(6) 
N(1)-Zn(1)-N(8) 83.22(8) 
Cl(2)-Zn(1)-Cl(1) 116.28(2) 
N(8)-Zn(1)-Cl(1) 118.49(6) 
N(8)-Zn(1)-Cl(2) 109.65(6) 
C(2)-N(1)-Zn(1) 128.89(16) 
C(6)-N(1)-Zn(1) 111.94(15) 
C(6)-N(1)-C(2) 119.15(19) 
N(1)-C(2)-H(2) 118.9 
N(1)-C(2)-C(3) 122.2(2) 
C(3)-C(2)-H(2) 118.9 
C(2)-C(3)-H(3) 120.7 
C(2)-C(3)-C(4) 118.6(2) 
C(4)-C(3)-H(3) 120.7 
C(3)-C(4)-H(4) 120.3 
C(3)-C(4)-C(5) 119.4(2) 
C(5)-C(4)-H(4) 120.3 
C(4)-C(5)-H(5) 120.3 
C(4)-C(5)-C(6) 119.4(2) 
C(6)-C(5)-H(5) 120.3 
N(1)-C(6)-C(5) 121.2(2) 
N(1)-C(6)-C(7) 116.91(19) 
C(5)-C(6)-C(7) 121.7(2) 
C(6)-C(7)-H(7A) 109.3 
C(6)-C(7)-H(7B) 109.3 
H(7A)-C(7)-H(7B) 108.0 
N(8)-C(7)-C(6) 111.65(18) 
N(8)-C(7)-H(7A) 109.3 
N(8)-C(7)-H(7B) 109.3 
Zn(1)-N(8)-H(8) 111.5(18) 
C(7)-N(8)-Zn(1) 106.25(14) 
C(7)-N(8)-C(9) 111.20(17) 
C(7)-N(8)-H(8) 105.0(17) 
C(9)-N(8)-Zn(1) 115.65(14) 
C(9)-N(8)-H(8) 106.8(17) 
N(8)-C(9)-H(9A) 109.5 
N(8)-C(9)-H(9B) 109.5 
N(8)-C(9)-C(10) 110.60(18) 
H(9A)-C(9)-H(9B) 108.1 
C(10)-C(9)-H(9A) 109.5 
C(10)-C(9)-H(9B) 109.5 
C(11)-C(10)-C(9) 119.8(2) 
C(11)-C(10)-C(15) 118.4(2) 
C(15)-C(10)-C(9) 121.8(2) 
C(10)-C(11)-H(11) 119.3 
C(12)-C(11)-C(10) 121.4(2) 
C(12)-C(11)-H(11) 119.3 
C(11)-C(12)-H(12) 120.3 
C(11)-C(12)-C(13) 119.3(2) 
C(13)-C(12)-H(12) 120.3 
C(14)-C(13)-C(12) 120.0(2) 
O(16)-C(13)-C(12) 116.5(2) 
O(16)-C(13)-C(14) 123.5(2) 
C(13)-C(14)-H(14) 120.0 
C(13)-C(14)-C(15) 119.9(2) 
C(15)-C(14)-H(14) 120.0 
C(10)-C(15)-H(15) 119.5 
C(14)-C(15)-C(10) 121.0(2) 
C(14)-C(15)-H(15) 119.5 
C(13)-O(16)-H(16) 111(3 
 
 
 
 
Anisotropic displacement parameters (Å2x 103) for 2.21.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
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U12] 
 U11 U22  U33 U23 U13 U12 
Cl(1) 16(1)  20(1) 27(1)  9(1) -3(1)  -5(1) 
Zn(1) 14(1)  12(1) 11(1)  1(1) -1(1)  1(1) 
N(1) 17(1)  15(1) 11(1)  1(1) 0(1)  1(1) 
C(2) 18(1)  17(1) 17(1)  0(1) 0(1)  -1(1) 
Cl(2) 14(1)  21(1) 17(1)  1(1) 3(1)  2(1) 
C(3) 20(1)  25(1) 12(1)  -2(1) -2(1)  -5(1) 
C(4) 19(1)  29(1) 16(1)  5(1) -5(1)  0(1) 
C(5) 21(1)  17(1) 18(1)  4(1) -1(1)  2(1) 
C(6) 12(1)  15(1) 13(1)  1(1) 1(1)  -1(1) 
C(7) 24(1)  12(1) 14(1)  1(1) 1(1)  3(1) 
N(8) 15(1)  13(1) 10(1)  -1(1) -1(1)  1(1) 
C(9) 23(1)  15(1) 12(1)  -2(1) 0(1)  -4(1) 
C(10) 17(1)  14(1) 12(1)  -3(1) -2(1)  -2(1) 
C(11) 16(1)  14(1) 16(1)  -2(1) -2(1)  0(1) 
C(12) 14(1)  20(1) 17(1)  -1(1) 4(1)  -2(1) 
C(13) 19(1)  16(1) 14(1)  0(1) -1(1)  -5(1) 
C(14) 17(1)  13(1) 16(1)  -2(1) -2(1)  2(1) 
C(15) 16(1)  18(1) 15(1)  -5(1) 2(1)  -1(1) 
O(16) 22(1)  27(1) 18(1)  10(1) 1(1)  0(1) 
 
Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) 
for 2.21 
 x  y  z  U(eq) 
 
H(2) 6148 4494 10278 21 
H(3) 6821 3422 11721 23 
H(4) 7270 688 11785 26 
H(5) 7012 -900 10403 23 
H(7A) 6683 -949 8603 20 
H(7B) 5464 -601 8728 20 
H(9A) 4782 8 7134 20 
H(9B) 5805 -996 6878 20 
H(11) 6993 93 5679 18 
H(12) 7139 1496 4235 20 
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H(15) 4237 2280 6119 19 
H(8) 6800(20) 960(30) 7602(19) 20(7) 
H(16) 5390(30) 3910(40) 3290(20) 40(11) 
 
Torsion angles [°] for 2.21. 
 
Zn(1)-N(1)-C(2)-C(3) 179.17(19) 
Zn(1)-N(1)-C(6)-C(5) 179.93(19) 
Zn(1)-N(1)-C(6)-C(7) -3.8(3) 
Zn(1)-N(8)-C(9)-C(10) 64.8(2) 
N(1)-C(2)-C(3)-C(4) 0.3(4) 
N(1)-C(6)-C(7)-N(8) 26.2(3) 
C(2)-N(1)-C(6)-C(5) -1.3(4) 
C(2)-N(1)-C(6)-C(7) 175.0(2) 
C(2)-C(3)-C(4)-C(5) -0.5(4) 
C(3)-C(4)-C(5)-C(6) -0.2(4) 
C(4)-C(5)-C(6)-N(1) 1.1(4) 
C(4)-C(5)-C(6)-C(7) -175.1(2) 
C(5)-C(6)-C(7)-N(8) -157.5(2) 
C(6)-N(1)-C(2)-C(3) 0.6(4) 
C(6)-C(7)-N(8)-Zn(1) -33.8(2) 
C(6)-C(7)-N(8)-C(9) -160.4(2) 
C(7)-N(8)-C(9)-C(10) -173.9(2) 
N(8)-C(9)-C(10)-C(11) 84.0(3) 
N(8)-C(9)-C(10)-C(15) -96.8(3) 
C(9)-C(10)-C(11)-C(12) 179.2(2) 
C(9)-C(10)-C(15)-C(14) -179.5(2) 
C(10)-C(11)-C(12)-C(13) 0.1(3) 
C(11)-C(10)-C(15)-C(14) -0.3(3) 
C(11)-C(12)-C(13)-C(14) 0.2(3) 
C(11)-C(12)-C(13)-O(16) 179.6(2) 
C(12)-C(13)-C(14)-C(15) -0.5(3) 
C(13)-C(14)-C(15)-C(10) 0.6(3) 
C(15)-C(10)-C(11)-C(12) 0.0(3) 
O(16)-C(13)-C(14)-C(15) -179.9(2) 
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Hydrogen bonds for 2.21 [Å and °] 
 
 d(D-H) d(H...A) d(D...A) <(DHA) 
C(2)-H(2)...Cl(2)#1 0.95 2.96 3.632(2) 129 
C(5)-H(5)...Cl(2)#2 0.95 2.96 3.551(2) 121 
C(12)-H(12)...Cl(2)#3 0.95 2.73 3.655(3) 165 
N(8)-H(8)...Cl(1)#4 0.90(3) 2.49(3) 3.353(2) 162(2) 
O(16)-H(16)...Cl(1)#5 0.76(3) 2.52(3) 3.267(2) 168(3) 
 
2.33 
Atomic coordinates (x104) and equivalent isotropic displacement parameters (Å2x 
103) for 2.33.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
N(1) 5850(1) 7126(2) 9278(1) 20(1) 
O(1) 6255(1) 10023(2) 7190(1) 21(1) 
C(2) 5274(1) 7143(2) 9310(1) 26(1) 
O(2) 6725(1) 9517(2) 4918(1) 23(1) 
C(3) 4831(1) 5428(3) 8996(1) 28(1) 
C(4) 4985(1) 3594(3) 8624(1) 30(1) 
C(5) 5577(1) 3557(2) 8585(1) 27(1) 
C(6) 5996(1) 5351(2) 8916(1) 17(1) 
C(7) 6639(1) 5416(2) 8867(1) 20(1) 
N(8) 6596(1) 6618(2) 8156(1) 18(1) 
C(9) 6814(1) 5578(2) 7703(1) 16(1) 
C(10) 6795(1) 6657(2) 6992(1) 15(1) 
C(11) 6505(1) 8842(2) 6751(1) 16(1) 
C(12) 6471(1) 9804(2) 6051(1) 17(1) 
C(13) 6737(1) 8638(2) 5595(1) 17(1) 
C(14) 7040(1) 6495(2) 5837(1) 18(1) 
C(15) 7060(1) 5539(2) 6521(1) 16(1) 
 
Bond lengths [Å] and angles [°] for 2.33. 
 
N(1)-C(2)  1.3419(17) 
N(1)-C(6)  1.3375(16) 
O(1)-C(11)  1.3506(14) 
O(1)-H(1)  0.96(2) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.377(2) 
O(2)-C(13)  1.3527(14) 
O(2)-H(2A)  0.95(2) 
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C(3)-H(3)  0.9500 
C(3)-C(4)  1.383(2) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.386(2) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.3838(18) 
C(6)-C(7)  1.5093(17) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(7)-N(8)  1.4665(15) 
N(8)-C(9)  1.2851(15) 
C(9)-H(9)  0.9500 
C(9)-C(10)  1.4509(16) 
C(10)-C(11)  1.4146(16) 
C(10)-C(15)  1.4030(16) 
C(11)-C(12)  1.3942(16) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.3937(16) 
C(13)-C(14)  1.4047(17) 
C(14)-H(14)  0.9500 
C(14)-C(15)  1.3756(16) 
C(15)-H(15)  0.9500 
C(6)-N(1)-C(2) 117.94(11) 
C(11)-O(1)-H(1) 106.9(12) 
N(1)-C(2)-H(2) 118.2 
N(1)-C(2)-C(3) 123.50(13) 
C(3)-C(2)-H(2) 118.2 
C(13)-O(2)-H(2A) 110.8(11) 
C(2)-C(3)-H(3) 120.8 
C(2)-C(3)-C(4) 118.31(12) 
C(4)-C(3)-H(3) 120.8 
C(3)-C(4)-H(4) 120.6 
C(3)-C(4)-C(5) 118.82(13) 
C(5)-C(4)-H(4) 120.6 
C(4)-C(5)-H(5) 120.4 
C(6)-C(5)-C(4) 119.23(13) 
C(6)-C(5)-H(5) 120.4 
N(1)-C(6)-C(5) 122.20(12) 
N(1)-C(6)-C(7) 116.75(11) 
C(5)-C(6)-C(7) 121.03(12) 
C(6)-C(7)-H(7A) 109.7 
C(6)-C(7)-H(7B) 109.7 
H(7A)-C(7)-H(7B) 108.2 
N(8)-C(7)-C(6) 109.69(10) 
N(8)-C(7)-H(7A) 109.7 
N(8)-C(7)-H(7B) 109.7 
C(9)-N(8)-C(7) 117.87(11) 
N(8)-C(9)-H(9) 119.3 
N(8)-C(9)-C(10) 121.33(11) 
C(10)-C(9)-H(9) 119.3 
C(11)-C(10)-C(9) 121.25(10) 
C(15)-C(10)-C(9) 120.52(11) 
C(15)-C(10)-C(11) 118.22(10) 
O(1)-C(11)-C(10) 120.82(10) 
O(1)-C(11)-C(12) 118.99(11) 
C(12)-C(11)-C(10) 120.19(11) 
C(11)-C(12)-H(12) 120.0 
C(13)-C(12)-C(11) 120.06(11) 
C(13)-C(12)-H(12) 120.0 
O(2)-C(13)-C(12) 122.24(11) 
O(2)-C(13)-C(14) 117.41(11) 
C(12)-C(13)-C(14) 120.34(11) 
C(13)-C(14)-H(14) 120.4 
C(15)-C(14)-C(13) 119.18(11) 
C(15)-C(14)-H(14) 120.4 
C(10)-C(15)-H(15) 119.0 
C(14)-C(15)-C(10) 121.97(11) 
C(14)-C(15)-H(15) 119 
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Anisotropic displacement parameters (Å2x103) for 2.33. The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 U11 U22  U33 U23 U13 U12 
 
N(1) 21(1)  21(1) 20(1)  -1(1) 9(1)  -1(1) 
O(1) 26(1)  18(1) 23(1)  2(1) 13(1)  7(1) 
C(2) 24(1)  29(1) 28(1)  1(1) 14(1)  4(1) 
O(2) 26(1)  24(1) 20(1)  5(1) 11(1)  6(1) 
C(3) 15(1)  39(1) 28(1)  12(1) 6(1)  2(1) 
C(4) 24(1)  32(1) 29(1)  2(1) 4(1)  -11(1) 
C(5) 30(1)  23(1) 27(1)  -5(1) 10(1)  -4(1) 
C(6) 17(1)  20(1) 14(1)  4(1) 5(1)  0(1) 
C(7) 18(1)  24(1) 18(1)  4(1) 8(1)  2(1) 
N(8) 17(1)  19(1) 19(1)  2(1) 8(1)  0(1) 
C(9) 12(1)  14(1) 18(1)  1(1) 4(1)  0(1) 
C(10) 13(1)  14(1) 16(1)  -1(1) 4(1)  -2(1) 
C(11) 13(1)  15(1) 19(1)  -2(1) 6(1)  0(1) 
C(12) 16(1)  14(1) 20(1)  2(1) 5(1)  2(1) 
C(13) 15(1)  19(1) 16(1)  1(1) 4(1)  -3(1) 
C(14) 17(1)  19(1) 17(1)  -3(1) 6(1)  1(1) 
C(15) 14(1)  14(1) 19(1)  -1(1) 4(1)  1(1) 
 
Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) for 
2.33. 
 x  y  z  U(eq) 
H(2) 5167 8406 9562 31 
H(3) 4429 5502 9034 34 
H(4) 4690 2382 8400 36 
H(5) 5695 2315 8334 32 
H(7A) 6943 6233 9325 24 
H(7B) 6795 3815 8866 24 
H(9) 6991 4073 7835 19 
H(12) 6268 11255 5885 21 
H(14) 7229 5716 5532 22 
H(15) 7260 4077 6679 20 
H(2A) 6413(9) 10700(40) 4730(11) 50(5) 
H(1) 6318(10) 9090(40) 7639(12) 57(6) 
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Torsion angles [°] for 2.33. 
 
N(1)-C(2)-C(3)-C(4) -0.4(2) 
N(1)-C(6)-C(7)-N(8) -90.03(13) 
O(1)-C(11)-C(12)-C(13) 178.80(11) 
C(2)-N(1)-C(6)-C(5) -0.48(18) 
C(2)-N(1)-C(6)-C(7) 178.19(11) 
C(2)-C(3)-C(4)-C(5) 0.1(2) 
O(2)-C(13)-C(14)-C(15) -179.78(11) 
C(3)-C(4)-C(5)-C(6) -0.1(2) 
C(4)-C(5)-C(6)-N(1) 0.3(2) 
C(4)-C(5)-C(6)-C(7) -178.32(12) 
C(5)-C(6)-C(7)-N(8) 88.65(14) 
C(6)-N(1)-C(2)-C(3) 0.51(19) 
C(6)-C(7)-N(8)-C(9) -127.39(12) 
C(7)-N(8)-C(9)-C(10) -179.36(10) 
N(8)-C(9)-C(10)-C(11) -3.46(18) 
N(8)-C(9)-C(10)-C(15) 177.23(11) 
C(9)-C(10)-C(11)-O(1) 2.21(17) 
C(9)-C(10)-C(11)-C(12) -177.58(11) 
C(9)-C(10)-C(15)-C(14) 178.82(11) 
C(10)-C(11)-C(12)-C(13) -1.41(18) 
C(11)-C(10)-C(15)-C(14) -0.52(17) 
C(11)-C(12)-C(13)-O(2) -178.94(11) 
C(11)-C(12)-C(13)-C(14) -0.18(18) 
C(12)-C(13)-C(14)-C(15) 1.40(18) 
C(13)-C(14)-C(15)-C(10) -1.04(18) 
C(15)-C(10)-C(11)-O(1) -178.46(10) 
C(15)-C(10)-C(11)-C(12) 1.74(17) 
 
Hydrogen bonds for 2.33 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
O(2)-H(2A)...N(1)#1 0.95(2) 1.76(2) 2.7106(14) 173.1(17) 
O(1)-H(1)...N(8) 0.96(2) 1.70(2) 2.5772(13) 149.8(18) 
 
305 
 
 
2.34 
Atomic coordinates (x104) and equivalent isotropic displacement parameters 
(Å2x103) for 2.34.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
N(1) -2556(2) 4976(1) 2831(1) 16(1) 
C(2) -2518(2) 5624(1) 3108(1) 19(1) 
C(3) -434(2) 5933(1) 3722(1) 19(1) 
C(4) 1720(2) 5556(1) 4062(1) 20(1) 
C(5) 1718(2) 4889(1) 3782(1) 18(1) 
C(6) -460(2) 4614(1) 3167(1) 14(1) 
C(7) -632(2) 3896(1) 2812(1) 16(1) 
N(8) 1385(2) 3491(1) 3429(1) 15(1) 
C(9) 2551(2) 3074(1) 2916(1) 14(1) 
C(10) 4580(2) 2660(1) 3491(1) 12(1) 
C(11) 5409(2) 2727(1) 4628(1) 13(1) 
C(12) 7422(2) 2350(1) 5156(1) 15(1) 
C(13) 8613(2) 1893(1) 4577(1) 13(1) 
C(14) 7804(2) 1810(1) 3456(1) 14(1) 
C(15) 5808(2) 2197(1) 2932(1) 14(1) 
O(16) 4269(2) 3160(1) 5211(1) 18(1) 
O(17) 10546(2) 1549(1) 5185(1) 17(1) 
C(18) 11903(2) 1072(1) 4651(1) 17(1) 
C(19) 14058(2) 817(1) 5490(1) 18(1) 
O(20) 13097(2) 410(1) 6248(1) 22(1) 
 
Bond lengths [Å] and angles [°] for 2.34. 
 
N(1)-C(2)  1.3430(15) 
N(1)-C(6)  1.3414(14) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.3831(18) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.3824(18) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.3836(17) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.3909(16) 
C(6)-C(7)  1.5043(16) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(7)-N(8)  1.4567(14) 
N(8)-C(9)  1.2834(15) 
C(9)-H(9)  0.9500 
C(9)-C(10)  1.4517(15) 
C(10)-C(11)  1.4152(14) 
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C(10)-C(15)  1.3971(15) 
C(11)-C(12)  1.3844(15) 
C(11)-O(16)  1.3497(13) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.3934(15) 
C(13)-C(14)  1.3992(14) 
C(13)-O(17)  1.3576(13) 
C(14)-H(14)  0.9500 
C(14)-C(15)  1.3883(15) 
C(15)-H(15)  0.9500 
O(16)-H(16)  0.93(2) 
O(17)-C(18)  1.4386(14) 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(18)-C(19)  1.5024(16) 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(19)-O(20)  1.4172(15) 
O(20)-H(20)  0.89(2) 
C(6)-N(1)-C(2) 118.11(10) 
N(1)-C(2)-H(2) 118.3 
N(1)-C(2)-C(3) 123.31(11) 
C(3)-C(2)-H(2) 118.3 
C(2)-C(3)-H(3) 120.9 
C(4)-C(3)-C(2) 118.21(11) 
C(4)-C(3)-H(3) 120.9 
C(3)-C(4)-H(4) 120.4 
C(3)-C(4)-C(5) 119.25(11) 
C(5)-C(4)-H(4) 120.4 
C(4)-C(5)-H(5) 120.5 
C(4)-C(5)-C(6) 119.07(11) 
C(6)-C(5)-H(5) 120.5 
N(1)-C(6)-C(5) 122.05(10) 
N(1)-C(6)-C(7) 115.04(10) 
C(5)-C(6)-C(7) 122.90(10) 
C(6)-C(7)-H(7A) 109.2 
C(6)-C(7)-H(7B) 109.2 
H(7A)-C(7)-H(7B) 107.9 
N(8)-C(7)-C(6) 112.17(9) 
N(8)-C(7)-H(7A) 109.2 
N(8)-C(7)-H(7B) 109.2 
C(9)-N(8)-C(7) 118.82(10) 
N(8)-C(9)-H(9) 119.5 
N(8)-C(9)-C(10) 121.04(10) 
C(10)-C(9)-H(9) 119.5 
C(11)-C(10)-C(9) 120.84(10) 
C(15)-C(10)-C(9) 120.82(9) 
C(15)-C(10)-C(11) 118.32(10) 
C(12)-C(11)-C(10) 120.15(10) 
O(16)-C(11)-C(10) 120.86(10) 
O(16)-C(11)-C(12) 118.99(9) 
C(11)-C(12)-H(12) 119.9 
C(11)-C(12)-C(13) 120.26(10)  
C(13)-C(12)-H(12) 119.9 
C(12)-C(13)-C(14) 120.71(10) 
O(17)-C(13)-C(12) 114.86(9) 
O(17)-C(13)-C(14) 124.43(10) 
C(13)-C(14)-H(14) 120.7 
C(15)-C(14)-C(13) 118.51(10) 
C(15)-C(14)-H(14) 120.7 
C(10)-C(15)-H(15) 119.0 
C(14)-C(15)-C(10) 122.03(10) 
C(14)-C(15)-H(15) 119.0 
C(11)-O(16)-H(16) 105.1(13) 
C(13)-O(17)-C(18) 118.61(8) 
O(17)-C(18)-H(18A) 110.3 
O(17)-C(18)-H(18B) 110.3 
O(17)-C(18)-C(19) 107.04(9) 
H(18A)-C(18)-H(18B) 108.6 
C(19)-C(18)-H(18A) 110.3 
C(19)-C(18)-H(18B) 110.3 
C(18)-C(19)-H(19A) 109.8 
C(18)-C(19)-H(19B) 109.8 
H(19A)-C(19)-H(19B) 108.2 
O(20)-C(19)-C(18) 109.52(10) 
O(20)-C(19)-H(19A) 109.8 
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O(20)-C(19)-H(19B) 109.8 C(19)-O(20)-H(20) 106.0(13
Anisotropic displacement parameters (Å2x 103) for 2.34. The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 U11 U22  U33 U23 U13 U12 
N(1) 15(1)  16(1) 18(1)  1(1) 2(1)  2(1) 
C(2) 19(1)  16(1) 22(1)  2(1) 6(1)  4(1) 
C(3) 26(1)  14(1) 21(1)  -1(1) 10(1)  -1(1) 
C(4) 20(1)  20(1) 19(1)  -2(1) 3(1)  -5(1) 
C(5) 15(1)  17(1) 19(1)  0(1) 1(1)  0(1) 
C(6) 14(1)  14(1) 14(1)  2(1) 3(1)  0(1) 
C(7) 14(1)  13(1) 18(1)  1(1) -2(1)  1(1) 
N(8) 16(1)  12(1) 16(1)  2(1) 0(1)  1(1) 
C(9) 15(1)  13(1) 12(1)  2(1) 0(1)  -2(1) 
C(10) 14(1)  11(1) 10(1)  1(1) 1(1)  -1(1) 
C(11) 16(1)  12(1) 11(1)  0(1) 2(1)  1(1) 
C(12) 19(1)  15(1) 10(1)  -1(1) 0(1)  3(1) 
C(13) 14(1)  13(1) 12(1)  1(1) 1(1)  1(1) 
C(14) 17(1)  14(1) 12(1)  -2(1) 2(1)  1(1) 
C(15) 16(1)  14(1) 10(1)  -1(1) 2(1)  -1(1) 
O(16) 24(1)  18(1) 12(1)  -2(1) 1(1)  9(1) 
O(17) 19(1)  19(1) 12(1)  -1(1) 0(1)  8(1) 
C(18) 18(1)  16(1) 16(1)  -1(1) 3(1)  4(1) 
C(19) 15(1)  17(1) 22(1)  4(1) 3(1)  2(1) 
O(20) 18(1)  26(1) 23(1)  10(1) 1(1)  2(1) 
 
Hydrogen coordinates (x104) and isotropic displacement parameters (Å2x103) 
for 2.34. 
 x  y  z  U(eq) 
H(2) -3998 5882 2869 22 
H(3) -482 6392 3904 23 
H(4) 3185 5753 4485 24 
H(5) 3183 4623 4005 21 
H(7A) -2291 3712 2906 19 
H(7B) -540 3871 2029 19 
H(9) 2080 3036 2148 17 
H(12) 7994 2404 5916 18 
H(14) 8603 1494 3063 17 
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H(15) 5259 2147 2170 16 
H(16) 2930(40) 3341(11) 4714(18) 51(6) 
H(18A) 12555 1286 4044 20 
H(18B) 10772 700 4354 20 
H(19A) 15236 556 5131 22 
H(19B) 15004 1197 5874 22 
H(20) 14410(40) 311(10) 6763(17) 40(5)
Torsion angles [°] for 2.34. 
 
N(1)-C(2)-C(3)-C(4) 0.31(18) 
N(1)-C(6)-C(7)-N(8) -164.52(10) 
C(2)-N(1)-C(6)-C(5) -0.30(16) 
C(2)-N(1)-C(6)-C(7) -179.14(10) 
C(2)-C(3)-C(4)-C(5) -0.08(18) 
C(3)-C(4)-C(5)-C(6) -0.31(18) 
C(4)-C(5)-C(6)-N(1) 0.51(17) 
C(4)-C(5)-C(6)-C(7) 179.26(11) 
C(5)-C(6)-C(7)-N(8) 16.65(16) 
C(6)-N(1)-C(2)-C(3) -0.12(17) 
C(6)-C(7)-N(8)-C(9) -135.51(11) 
C(7)-N(8)-C(9)-C(10) 179.82(10) 
N(8)-C(9)-C(10)-C(11) -3.04(16) 
N(8)-C(9)-C(10)-C(15) 178.61(10) 
C(9)-C(10)-C(11)-C(12) -177.06(10) 
C(9)-C(10)-C(11)-O(16) 2.56(16) 
C(9)-C(10)-C(15)-C(14) 178.01(10) 
C(10)-C(11)-C(12)-C(13) -1.29(17) 
C(11)-C(10)-C(15)-C(14) -0.38(16) 
C(11)-C(12)-C(13)-C(14) 0.27(17) 
C(11)-C(12)-C(13)-O(17) -179.45(10) 
C(12)-C(13)-C(14)-C(15) 0.67(17) 
C(12)-C(13)-O(17)-C(18) -179.26(10) 
C(13)-C(14)-C(15)-C(10) -0.61(17) 
C(13)-O(17)-C(18)-C(19) 174.90(9) 
C(14)-C(13)-O(17)-C(18) 1.03(16) 
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C(15)-C(10)-C(11)-C(12) 1.34(16) 
C(15)-C(10)-C(11)-O(16) -179.04(10) 
O(16)-C(11)-C(12)-C(13) 179.08(10) 
O(17)-C(13)-C(14)-C(15) -179.63(10) 
O(17)-C(18)-C(19)-O(20) 70.49(12) 
 
Hydrogen bonds for 2.34 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
 
C(3)-H(3)...O(16)#1 0.95 2.64 3.2140(15) 119 
C(7)-H(7B)...O(17)#2 0.99 2.62 3.5685(15) 161 
C(9)-H(9)...O(17)#2 0.95 2.58 3.4699(13) 156 
O(16)-H(16)...N(8) 0.93(2) 1.70(2) 2.5578(12) 152(2) 
O(20)-H(20)...N(1)#3 0.89(2) 2.00(2) 2.8775(13) 174.6(19) 
 
2.44 
Atomic coordinates (x104) and equivalent  isotropic displacement parameters (Å2x 
103) for 2.44.  U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
 
Zn(1) 5000 7500 4060(1) 27(1) 
Cl(1) 2943(1) 8176(1) 5520(1) 21(1) 
N(4) 4028(2) 7106(2) 3196(2) 20(1) 
N(1) 4776(2) 6301(2) 4615(2) 26(1) 
C(3) 3658(2) 6322(2) 3430(2) 19(1) 
C(8) 3067(2) 5876(3) 2869(2) 24(1) 
C(2) 3895(2) 5962(3) 4315(2) 24(1) 
C(5) 3846(2) 7459(3) 2408(2) 24(1) 
C(6) 3286(3) 7041(3) 1822(2) 28(1) 
O(1) 3721(4) 7630(3) 5665(4) 41(1) 
C(7) 2884(3) 6243(3) 2065(3) 29(1) 
O(3) 2210(5) 7660(5) 5224(4) 47(2) 
O(2) 3180(3) 8861(3) 4876(3) 32(1) 
O(4) 2721(4) 8611(4) 6328(3) 38(1) 
O(2A) 3297(6) 8167(9) 4666(6) 38(4) 
O(1A) 3310(9) 7405(7) 6002(7) 33(3) 
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O(4A) 1957(8) 8036(9) 5447(9) 32(3) 
O(3A) 3085(8) 8969(6) 5974(9) 43(3) 
Bond lengths [Å] and angles [°] for 2.44. 
 
Zn(1)-N(4)#1  2.050(3) 
Zn(1)-N(4)  2.050(3) 
Zn(1)-N(1)#1  2.010(3) 
Zn(1)-N(1)  2.010(3) 
Cl(1)-O(1)  1.437(5) 
Cl(1)-O(3)  1.413(5) 
Cl(1)-O(2)  1.464(4) 
Cl(1)-O(4)  1.436(4) 
Cl(1)-O(2A)  1.410(8) 
Cl(1)-O(1A)  1.474(10) 
Cl(1)-O(4A)  1.491(13) 
Cl(1)-O(3A)  1.388(9) 
N(4)-C(3)  1.342(5) 
N(4)-C(5)  1.345(5) 
N(1)-H(1A)  0.9100 
N(1)-H(1B)  0.9100 
N(1)-C(2)  1.481(5) 
C(3)-C(8)  1.399(5) 
C(3)-C(2)  1.501(5) 
C(8)-H(8)  0.9500 
C(8)-C(7)  1.376(6) 
C(2)-H(2A)  0.9900 
C(2)-H(2B)  0.9900 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.376(5) 
C(6)-H(6)  0.9500 
C(6)-C(7)  1.385(6) 
C(7)-H(7)  0.9500 
N(4)-Zn(1)-N(4)#1 99.60(17) 
N(1)#1-Zn(1)-N(4)#1 84.22(12) 
N(1)-Zn(1)-N(4) 84.22(12) 
N(1)#1-Zn(1)-N(4) 130.27(13) 
N(1)-Zn(1)-N(4)#1 130.27(13) 
N(1)-Zn(1)-N(1)#1 129.99(19) 
O(1)-Cl(1)-O(2) 107.8(3) 
O(3)-Cl(1)-O(1) 111.4(4) 
O(3)-Cl(1)-O(2) 110.6(3) 
O(3)-Cl(1)-O(4) 110.2(4) 
O(4)-Cl(1)-O(1) 108.0(3) 
O(4)-Cl(1)-O(2) 108.7(3) 
O(2A)-Cl(1)-O(1A) 108.5(6) 
O(2A)-Cl(1)-O(4A) 107.4(7) 
O(1A)-Cl(1)-O(4A) 107.1(7) 
O(3A)-Cl(1)-O(2A) 114.6(7) 
O(3A)-Cl(1)-O(1A) 110.9(6) 
O(3A)-Cl(1)-O(4A) 108.0(7) 
C(3)-N(4)-Zn(1) 111.7(2) 
C(3)-N(4)-C(5) 119.8(3) 
C(5)-N(4)-Zn(1) 127.6(3) 
Zn(1)-N(1)-H(1A) 110.0 
Zn(1)-N(1)-H(1B) 110.0 
H(1A)-N(1)-H(1B) 108.3 
C(2)-N(1)-Zn(1) 108.7(2) 
C(2)-N(1)-H(1A) 110.0 
C(2)-N(1)-H(1B) 110.0 
N(4)-C(3)-C(8) 120.7(3) 
N(4)-C(3)-C(2) 117.1(3) 
C(8)-C(3)-C(2) 122.2(3) 
C(3)-C(8)-H(8) 120.5 
C(7)-C(8)-C(3) 119.0(4) 
C(7)-C(8)-H(8) 120.5 
N(1)-C(2)-C(3) 111.5(3) 
N(1)-C(2)-H(2A) 109.3 
N(1)-C(2)-H(2B) 109.3 
C(3)-C(2)-H(2A) 109.3 
C(3)-C(2)-H(2B) 109.3 
H(2A)-C(2)-H(2B) 108.0 
N(4)-C(5)-H(5) 119.0 
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N(4)-C(5)-C(6) 122.0(4) 
C(6)-C(5)-H(5) 119.0 
C(5)-C(6)-H(6) 120.7 
C(5)-C(6)-C(7) 118.6(4) 
C(7)-C(6)-H(6) 120.7 
C(8)-C(7)-C(6) 119.8(4) 
C(8)-C(7)-H(7) 120.1 
C(6)-C(7)-H(7) 12
  
Anisotropic displacement parameters (Å2x 103) for 2.44. The anisotropic 
displacement factor exponent takes the form:  -2 2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 
 U11 U22  U33 U23 U13 U12 
Zn(1) 29(1)  34(1) 18(1)  0 0  -16(1) 
Cl(1) 23(1)  23(1) 16(1)  1(1) -2(1)  -2(1) 
N(4) 17(1)  27(2) 16(1)  -2(1) 0(1)  -1(1) 
N(1) 24(2)  40(2) 14(2)  4(1) -1(1)  -7(1) 
C(3) 17(2)  23(2) 17(2)  -5(1) 2(1)  0(1) 
C(8) 21(2)  27(2) 26(2)  -9(2) 1(2)  -2(2) 
C(2) 24(2)  29(2) 18(2)  1(2) 0(1)  -6(2) 
C(5) 20(2)  31(2) 22(2)  3(2) 2(1)  3(2) 
C(6) 22(2)  47(2) 16(2)  -3(2) 1(1)  9(2) 
O(1) 42(3)  25(3) 55(4)  5(2) 1(3)  14(2) 
C(7) 22(2)  43(2) 23(2)  -14(2) -2(2)  4(2) 
O(3) 48(4)  64(5) 29(3)  14(3) -15(3)  -44(4) 
O(2) 33(2)  35(3) 28(2)  11(2) 0(2)  -7(2) 
O(4) 43(3)  50(3) 22(2)  -8(2) 5(2)  4(2) 
O(2A) 23(5)  77(10) 13(4)  4(5) 8(3)  8(5) 
O(1A) 48(7)  29(5) 22(5)  3(4) -16(5)  6(5) 
O(4A) 23(6)  35(7) 36(7)  -5(5) -4(5)  -6(5) 
O(3A) 53(7)  14(5) 61(8)  -10(5) -4(6)  -9(4)
 
Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x103) for 
2.44. 
 x  y  z  U(eq) 
 
H(1A) 5216 5910 4460 31 
H(1B) 4777 6355 5207 31 
H(8) 2797 5328 3041 29 
H(2A) 3427 6140 4739 28 
H(2B) 3911 5299 4292 28 
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H(5) 4112 8014 2251 29 
H(6) 3178 7294 1263 34 
H(7) 2483 5950 1677 35 
 
Torsion angles [°] for 2.44. 
 
Zn(1)-N(4)-C(3)-C(8) -171.4(3) 
Zn(1)-N(4)-C(3)-C(2) 9.6(4) 
Zn(1)-N(4)-C(5)-C(6) 168.2(3) 
Zn(1)-N(1)-C(2)-C(3) 27.8(4) 
N(4)-C(3)-C(8)-C(7) 1.4(5) 
N(4)-C(3)-C(2)-N(1) -25.6(5) 
N(4)-C(5)-C(6)-C(7) 1.6(6) 
C(3)-N(4)-C(5)-C(6) 0.0(5) 
C(3)-C(8)-C(7)-C(6) 0.2(5) 
C(8)-C(3)-C(2)-N(1) 155.5(3) 
C(2)-C(3)-C(8)-C(7) -179.7(3) 
C(5)-N(4)-C(3)-C(8) -1.5(5) 
C(5)-N(4)-C(3)-C(2) 179.5(3) 
C(5)-C(6)-C(7)-C(8) -1.6(6) 
 
Hydrogen bonds for 2.44 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
N(1)-H(1A)...O(2)#1 0.91 2.50 3.086(6) 123 
N(1)-H(1A)...O(4)#2 0.91 2.36 3.253(7) 167 
N(1)-H(1A)...O(4A)#2 0.91 2.43 3.014(14) 122 
N(1)-H(1B)...O(1)#3 0.91 2.50 3.404(7) 170 
N(1)-H(1B)...O(4)#3 0.91 2.61 3.168(6) 120 
N(1)-H(1B)...O(1A)#3 0.91 2.19 3.012(10) 150 
C(8)-H(8)...O(3A)#4 0.95 2.56 3.353(10) 141 
C(2)-H(2B)...O(1A)#2 0.99 2.53 3.290(15) 133 
C(2)-H(2B)...O(3A)#4 0.99 2.37 3.242(11) 146 
C(5)-H(5)...O(4A)#5 0.95 2.46 3.229(13) 138 
C(6)-H(6)...O(3)#6 0.95 2.35 3.251(7) 158 
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2.46 
Atomic coordinates  (x104) and equivalent isotropic displacement parameters 
(Å2x103) for 2.46  U(eq) is defined as one third of  the trace of the orthogonalized Uij 
tensor. 
 x y z U(eq) 
   
Cu(1) 6145(1) 2655(1) 1113(1) 17(1) 
N(1) 5889(3) 3407(3) 51(2) 19(1) 
C(2) 6832(3) 4452(3) -35(2) 22(1) 
Cu(2) 8572(1) 3346(1) 2959(1) 18(1) 
C(3) 6561(4) 4887(3) -808(3) 27(1) 
C(4) 5290(3) 4237(4) -1527(3) 28(1) 
C(5) 4322(3) 3150(4) -1449(3) 28(1) 
C(6) 4653(3) 2764(3) -653(2) 20(1) 
C(7) 3651(3) 1603(3) -518(2) 21(1) 
N(8) 4310(2) 1325(3) 305(2) 17(1) 
C(9) 3642(3) 255(3) 440(2) 18(1) 
C(10) 4094(3) -113(3) 1253(2) 17(1) 
C(11) 5425(3) 591(3) 1954(2) 16(1) 
O(12) 6387(2) 1567(2) 1855(2) 19(1) 
C(13) 5729(3) 217(3) 2786(2) 18(1) 
C(14) 4767(3) -806(3) 2916(2) 23(1) 
C(15) 3446(3) -1511(3) 2221(3) 23(1) 
C(16) 3138(3) -1164(3) 1416(2) 20(1) 
O(17) 4975(2) -1215(2) 3702(2) 32(1) 
C(18) 6246(4) -493(4) 4503(3) 36(1) 
C(19) 6224(4) -1284(4) 5171(3) 41(1) 
O(20) 6210(4) -2549(3) 4631(3) 75(1) 
N(21) 9555(2) 2572(3) 2138(2) 21(1) 
C(22) 9740(3) 2711(3) 1263(2) 22(1) 
C(23) 10405(3) 2125(3) 733(3) 27(1) 
C(24) 10916(3) 1386(3) 1117(3) 27(1) 
C(25) 10743(3) 1244(3) 2017(3) 26(1) 
C(26) 10056(3) 1861(3) 2518(3) 21(1) 
C(27) 9813(3) 1759(3) 3494(3) 26(1) 
N(28) 9199(2) 2630(3) 3896(2) 19(1) 
C(29) 9138(3) 2870(3) 4834(2) 20(1) 
C(30) 8515(3) 3629(3) 5317(2) 19(1) 
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C(31) 7923(3) 4291(3) 4851(2) 18(1) 
O(32) 7914(2) 4296(2) 3916(2) 19(1) 
C(33) 7319(3) 4994(3) 5406(2) 18(1) 
C(34) 7252(3) 4994(3) 6366(2) 17(1) 
C(35) 7822(3) 4331(3) 6828(2) 21(1) 
C(36) 8447(3) 3682(3) 6313(2) 20(1) 
O(37) 6653(2) 5616(2) 6934(2) 20(1) 
C(38) 6013(3) 6261(3) 6469(2) 21(1) 
C(39) 5462(3) 6938(3) 7216(2) 22(1) 
O(40) 4385(2) 6022(2) 7394(2) 23(1) 
O(41) 7979(2) 3915(2) 1900(2) 19(1) 
Cl(1) 389(1) 2293(1) -2132(1) 30(1) 
O(1) 1253(3) 3136(3) -2544(2) 36(1) 
O(2) -723(3) 1168(3) -2998(2) 45(1) 
O(3) -64(3) 3093(3) -1438(2) 42(1) 
O(4) 1119(2) 1803(3) -1568(2) 42(1) 
O(1S) 8421(17) -1890(20) 4322(11) 64(3) 
O(2S) 8874(19) -1150(20) 4433(10) 64(3) 
O(3S) 9410(40) -630(40) 4670(20) 64(3) 
 
Bond lengths [Å] and angles [°] for 2.46. 
 
Cu(1)-N(1)  1.994(3) 
Cu(1)-N(8)  1.939(2) 
Cu(1)-O(12)  1.937(2) 
Cu(1)-O(41)  1.919(2) 
N(1)-C(2)  1.350(4) 
N(1)-C(6)  1.347(4) 
C(2)-H(2)  0.9500 
C(2)-C(3)  1.377(4) 
Cu(2)-O(12)  2.400(2) 
Cu(2)-N(21)  2.007(3) 
Cu(2)-N(28)  1.939(3) 
Cu(2)-O(32)  1.926(2) 
Cu(2)-O(41)  1.934(2) 
C(3)-H(3)  0.9500 
C(3)-C(4)  1.383(5) 
C(4)-H(4)  0.9500 
C(4)-C(5)  1.389(5) 
C(5)-H(5)  0.9500 
C(5)-C(6)  1.382(4) 
C(6)-C(7)  1.505(4) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(7)-N(8)  1.463(4) 
N(8)-C(9)  1.288(4) 
C(9)-H(9)  0.9500 
C(9)-C(10)  1.428(4) 
C(10)-C(11)  1.422(4) 
C(10)-C(16)  1.422(4) 
C(11)-O(12)  1.323(4) 
C(11)-C(13)  1.411(4) 
C(13)-H(13)  0.9500 
C(13)-C(14)  1.378(4) 
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C(14)-C(15)  1.409(5) 
C(14)-O(17)  1.359(4) 
C(15)-H(15)  0.9500 
C(15)-C(16)  1.357(4) 
C(16)-H(16)  0.9500 
O(17)-C(18)  1.426(4) 
C(18)-H(18A)  0.9900 
C(18)-H(18B)  0.9900 
C(18)-C(19)  1.509(5) 
C(19)-H(19A)  0.9900 
C(19)-H(19B)  0.9900 
C(19)-O(20)  1.423(5) 
O(20)-H(20)  0.8400 
N(21)-C(22)  1.348(4) 
N(21)-C(26)  1.347(4) 
C(22)-H(22)  0.9500 
C(22)-C(23)  1.375(4) 
C(23)-H(23)  0.9500 
C(23)-C(24)  1.386(5) 
C(24)-H(24)  0.9500 
C(24)-C(25)  1.380(5) 
C(25)-H(25)  0.9500 
C(25)-C(26)  1.398(4) 
C(26)-C(27)  1.497(5) 
C(27)-H(27A)  0.9900 
C(27)-H(27B)  0.9900 
C(27)-N(28)  1.470(4) 
N(28)-C(29)  1.299(4) 
C(29)-H(29)  0.9500 
C(29)-C(30)  1.425(4) 
C(30)-C(31)  1.423(4) 
C(30)-C(36)  1.419(4) 
C(31)-O(32)  1.331(4) 
C(31)-C(33)  1.411(4) 
C(33)-H(33)  0.9500 
C(33)-C(34)  1.383(4) 
C(34)-C(35)  1.407(4) 
C(34)-O(37)  1.362(4) 
C(35)-H(35)  0.9500 
C(35)-C(36)  1.367(4) 
C(36)-H(36)  0.9500 
O(37)-C(38)  1.439(4) 
C(38)-H(38A)  0.9900 
C(38)-H(38B)  0.9900 
C(38)-C(39)  1.499(4) 
C(39)-H(39A)  0.9900 
C(39)-H(39B)  0.9900 
C(39)-O(40)  1.424(4) 
O(40)-H(40)  0.8400 
O(41)-H(41)  0.9834 
Cl(1)-O(1)  1.460(3) 
Cl(1)-O(2)  1.434(3) 
Cl(1)-O(3)  1.444(3) 
Cl(1)-O(4)  1.435(2) 
N(8)-Cu(1)-N(1) 82.86(10) 
O(12)-Cu(1)-N(1) 165.65(10) 
O(12)-Cu(1)-N(8) 92.54(10) 
O(41)-Cu(1)-N(1) 98.18(10) 
O(41)-Cu(1)-N(8) 177.80(10) 
O(41)-Cu(1)-O(12) 85.99(9) 
C(2)-N(1)-Cu(1) 126.3(2) 
C(6)-N(1)-Cu(1) 115.1(2) 
C(6)-N(1)-C(2) 118.6(3) 
N(1)-C(2)-H(2) 119.0 
N(1)-C(2)-C(3) 122.0(3) 
C(3)-C(2)-H(2) 119.0 
N(21)-Cu(2)-O(12) 96.02(9) 
N(28)-Cu(2)-O(12) 104.37(9) 
N(28)-Cu(2)-N(21) 82.17(11) 
O(32)-Cu(2)-O(12) 93.26(8) 
O(32)-Cu(2)-N(21) 170.58(10) 
O(32)-Cu(2)-N(28) 94.00(10) 
O(32)-Cu(2)-O(41) 92.43(9) 
O(41)-Cu(2)-O(12) 73.82(8) 
O(41)-Cu(2)-N(21) 91.68(10) 
O(41)-Cu(2)-N(28) 173.42(10) 
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C(2)-C(3)-H(3) 120.2 
C(2)-C(3)-C(4) 119.6(3) 
C(4)-C(3)-H(3) 120.2 
C(3)-C(4)-H(4) 120.7 
C(3)-C(4)-C(5) 118.6(3) 
C(5)-C(4)-H(4) 120.7 
C(4)-C(5)-H(5) 120.4 
C(6)-C(5)-C(4) 119.2(3) 
C(6)-C(5)-H(5) 120.4 
N(1)-C(6)-C(5) 122.1(3) 
N(1)-C(6)-C(7) 116.0(3) 
C(5)-C(6)-C(7) 122.0(3) 
C(6)-C(7)-H(7A) 109.7 
C(6)-C(7)-H(7B) 109.7 
H(7A)-C(7)-H(7B) 108.2 
N(8)-C(7)-C(6) 109.9(2) 
N(8)-C(7)-H(7A) 109.7 
N(8)-C(7)-H(7B) 109.7 
C(7)-N(8)-Cu(1) 115.42(19) 
C(9)-N(8)-Cu(1) 125.9(2) 
C(9)-N(8)-C(7) 118.6(3) 
N(8)-C(9)-H(9) 117.0 
N(8)-C(9)-C(10) 126.0(3) 
C(10)-C(9)-H(9) 117.0 
C(11)-C(10)-C(9) 123.2(3) 
C(11)-C(10)-C(16) 118.6(3) 
C(16)-C(10)-C(9) 118.0(3) 
O(12)-C(11)-C(10) 122.9(3) 
O(12)-C(11)-C(13) 118.9(3) 
C(13)-C(11)-C(10) 118.2(3) 
Cu(1)-O(12)-Cu(2) 91.19(8) 
C(11)-O(12)-Cu(1) 125.73(18) 
C(11)-O(12)-Cu(2) 135.86(18) 
C(11)-C(13)-H(13) 119.4 
C(14)-C(13)-C(11) 121.1(3) 
C(14)-C(13)-H(13) 119.4 
C(13)-C(14)-C(15) 121.0(3) 
O(17)-C(14)-C(13) 124.7(3) 
O(17)-C(14)-C(15) 114.3(3) 
C(14)-C(15)-H(15) 120.7 
C(16)-C(15)-C(14) 118.6(3) 
C(16)-C(15)-H(15) 120.7 
C(10)-C(16)-H(16) 118.8 
C(15)-C(16)-C(10) 122.5(3) 
C(15)-C(16)-H(16) 118.8 
C(14)-O(17)-C(18) 119.1(3) 
O(17)-C(18)-H(18A) 110.4 
O(17)-C(18)-H(18B) 110.4 
O(17)-C(18)-C(19) 106.6(3) 
H(18A)-C(18)-H(18B) 108.6 
C(19)-C(18)-H(18A) 110.4 
C(19)-C(18)-H(18B) 110.4 
C(18)-C(19)-H(19A) 109.2 
C(18)-C(19)-H(19B) 109.2 
H(19A)-C(19)-H(19B) 107.9 
O(20)-C(19)-C(18) 111.9(3) 
O(20)-C(19)-H(19A) 109.2 
O(20)-C(19)-H(19B) 109.2 
C(19)-O(20)-H(20) 109.5 
C(22)-N(21)-Cu(2) 125.5(2) 
C(26)-N(21)-Cu(2) 115.3(2) 
C(26)-N(21)-C(22) 119.2(3) 
N(21)-C(22)-H(22) 119.0 
N(21)-C(22)-C(23) 122.0(3) 
C(23)-C(22)-H(22) 119.0 
C(22)-C(23)-H(23) 120.5 
C(22)-C(23)-C(24) 119.0(3) 
C(24)-C(23)-H(23) 120.5 
C(23)-C(24)-H(24) 120.2 
C(25)-C(24)-C(23) 119.6(3) 
C(25)-C(24)-H(24) 120.2 
C(24)-C(25)-H(25) 120.7 
C(24)-C(25)-C(26) 118.6(3) 
C(26)-C(25)-H(25) 120.7 
N(21)-C(26)-C(25) 121.5(3) 
N(21)-C(26)-C(27) 116.0(3) 
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C(25)-C(26)-C(27) 122.4(3) 
C(26)-C(27)-H(27A) 109.7 
C(26)-C(27)-H(27B) 109.7 
H(27A)-C(27)-H(27B) 108.2 
N(28)-C(27)-C(26) 109.7(3) 
N(28)-C(27)-H(27A) 109.7 
N(28)-C(27)-H(27B) 109.7 
C(27)-N(28)-Cu(2) 115.7(2) 
C(29)-N(28)-Cu(2) 125.9(2) 
C(29)-N(28)-C(27) 118.4(3) 
N(28)-C(29)-H(29) 117.3 
N(28)-C(29)-C(30) 125.3(3) 
C(30)-C(29)-H(29) 117.3 
C(31)-C(30)-C(29) 124.4(3) 
C(36)-C(30)-C(29) 117.2(3) 
C(36)-C(30)-C(31) 118.4(3) 
O(32)-C(31)-C(30) 123.6(3) 
O(32)-C(31)-C(33) 117.6(3) 
C(33)-C(31)-C(30) 118.8(3) 
C(31)-O(32)-Cu(2) 126.56(19) 
C(31)-C(33)-H(33) 119.6 
C(34)-C(33)-C(31) 120.8(3) 
C(34)-C(33)-H(33) 119.6 
C(33)-C(34)-C(35) 120.8(3) 
O(37)-C(34)-C(33) 124.2(3) 
O(37)-C(34)-C(35) 114.9(3) 
C(34)-C(35)-H(35) 120.5 
C(36)-C(35)-C(34) 118.9(3)C(36)-C(35)-
H(35) 120.5 
C(30)-C(36)-H(36) 118.9 
C(35)-C(36)-C(30) 122.3(3) 
C(35)-C(36)-H(36) 118.9 
C(34)-O(37)-C(38) 116.6(2) 
O(37)-C(38)-H(38A) 109.8 
O(37)-C(38)-H(38B) 109.8 
O(37)-C(38)-C(39) 109.4(2) 
H(38A)-C(38)-H(38B) 108.2 
C(39)-C(38)-H(38A) 109.8 
C(39)-C(38)-H(38B) 109.8 
C(38)-C(39)-H(39A) 108.6 
C(38)-C(39)-H(39B) 108.6 
H(39A)-C(39)-H(39B) 107.6 
O(40)-C(39)-C(38) 114.5(3) 
O(40)-C(39)-H(39A) 108.6 
O(40)-C(39)-H(39B) 108.6 
C(39)-O(40)-H(40) 109.5 
Cu(1)-O(41)-Cu(2) 107.92(10) 
Cu(1)-O(41)-H(41) 114.5 
Cu(2)-O(41)-H(41) 110.5 
O(2)-Cl(1)-O(1) 108.21(16) 
O(2)-Cl(1)-O(3) 110.17(16) 
O(2)-Cl(1)-O(4) 110.00(16) 
O(3)-Cl(1)-O(1) 109.61(16) 
O(4)-Cl(1)-O(1) 109.14(15) 
O(4)-Cl(1)-O(3) 109.68(17)
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Anisotropic displacement parameters (Å2x103) for 2.46.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* 
U12] 
 U11 U22  U33 U23 U13 U12 
Cu(1) 16(1)  18(1) 19(1)  10(1) 9(1)  8(1) 
N(1) 22(1)  21(1) 20(1)  9(1) 12(1)  12(1) 
C(2) 26(2)  20(2) 23(2)  10(1) 12(1)  10(2) 
Cu(2) 18(1)  21(1) 20(1)  10(1) 10(1)  11(1) 
C(3) 37(2)  23(2) 34(2)  18(2) 21(2)  16(2) 
C(4) 36(2)  38(2) 32(2)  25(2) 19(2)  27(2) 
C(5) 26(2)  41(2) 34(2)  25(2) 17(2)  24(2) 
C(6) 21(2)  26(2) 25(2)  14(1) 14(1)  16(2) 
C(7) 17(2)  28(2) 23(2)  13(2) 8(1)  12(2) 
N(8) 16(1)  21(1) 17(1)  10(1) 8(1)  9(1) 
C(9) 16(2)  21(2) 18(2)  7(1) 9(1)  9(1) 
C(10) 18(2)  17(2) 18(2)  7(1) 9(1)  9(1) 
C(11) 18(2)  16(2) 21(2)  8(1) 11(1)  10(1) 
O(12) 18(1)  19(1) 22(1)  12(1) 9(1)  7(1) 
C(13) 18(2)  18(2) 18(2)  7(1) 7(1)  7(1) 
C(14) 28(2)  23(2) 21(2)  12(1) 10(1)  11(2) 
C(15) 22(2)  20(2) 29(2)  14(2) 14(1)  6(1) 
C(16) 16(2)  19(2) 22(2)  7(1) 8(1)  7(1) 
O(17) 30(1)  35(1) 27(1)  22(1) 7(1)  5(1) 
C(18) 32(2)  34(2) 32(2)  19(2) 2(2)  5(2) 
C(19) 46(2)  40(2) 31(2)  23(2) 7(2)  11(2) 
O(20) 136(4)  65(2) 51(2)  42(2) 36(2)  54(2) 
N(21) 16(1)  19(1) 23(1)  7(1) 8(1)  4(1) 
C(22) 15(2)  24(2) 21(2)  6(1) 7(1)  5(1) 
C(23) 19(2)  28(2) 24(2)  6(2) 10(1)  4(2) 
C(24) 20(2)  26(2) 29(2)  3(2) 13(2)  7(2) 
C(25) 20(2)  20(2) 36(2)  8(2) 12(2)  9(2) 
C(26) 16(2)  17(2) 29(2)  8(1) 11(1)  5(1) 
C(27) 30(2)  24(2) 35(2)  16(2) 19(2)  17(2) 
N(28) 16(1)  19(1) 27(2)  10(1) 11(1)  9(1) 
C(29) 20(2)  19(2) 24(2)  12(1) 8(1)  10(1) 
C(30) 18(2)  20(2) 21(2)  10(1) 5(1)  9(1) 
C(31) 15(2)  19(2) 18(2)  7(1) 6(1)  7(1) 
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O(32) 22(1)  25(1) 18(1)  12(1) 9(1)  16(1) 
C(33) 17(2)  21(2) 20(2)  10(1) 6(1)  11(1) 
C(34) 14(2)  16(2) 20(2)  6(1) 6(1)  6(1) 
C(35) 24(2)  21(2) 16(2)  9(1) 6(1)  9(1) 
C(36) 22(2)  21(2) 23(2)  12(1) 8(1)  11(1) 
O(37) 25(1)  25(1) 19(1)  11(1) 11(1)  17(1) 
C(38) 24(2)  27(2) 20(2)  12(1) 10(1)  16(2) 
C(39) 22(2)  28(2) 24(2)  13(2) 12(1)  15(2) 
O(40) 21(1)  34(1) 24(1)  16(1) 10(1)  17(1) 
O(41) 18(1)  20(1) 21(1)  10(1) 8(1)  8(1) 
Cl(1) 24(1)  28(1) 37(1)  18(1) 5(1)  11(1) 
O(1) 42(2)  35(2) 45(2)  26(1) 21(1)  19(1) 
O(2) 34(2)  35(2) 45(2)  8(1) -7(1)  11(1) 
O(3) 33(2)  43(2) 50(2)  14(1) 20(1)  18(1) 
O(4) 28(1)  46(2) 60(2)  38(2) 7(1)  16(1) 
O(1S) 73(7)  81(7) 53(4)  27(5) 27(4)  48(6) 
O(2S) 73(7)  81(7) 53(4)  27(5) 27(4)  48(6) 
O(3S) 73(7)  81(7) 53(4)  27(5) 27(4)  48(6) 
 
Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x103) for 
2.46. 
 
 x  y  z  U(eq) 
H(2) 7709 4900 453 27 
H(3) 7242 5628 -848 32 
H(4) 5083 4527 -2062 34 
H(5) 3443 2677 -1937 33 
H(7A) 2956 1839 -329 26 
H(7B) 3218 779 -1186 26 
H(9) 2769 -344 -45 22 
H(13) 6613 677 3265 22 
H(15) 2786 -2215 2313 27 
H(16) 2249 -1640 945 24 
H(18A) 6409 442 4929 43 
H(18B) 6958 -432 4190 43 
H(19A) 7018 -731 5813 49 
H(19B) 5426 -1456 5387 49 
H(20) 6915 -2404 4487 113 
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H(22) 9401 3229 1006 27 
H(23) 10511 2225 112 32 
H(24) 11384 980 764 33 
H(25) 11085 738 2289 32 
H(27A) 9219 801 3340 31 
H(27B) 10666 2050 4030 31 
H(29) 9542 2509 5231 24 
H(33) 6955 5474 5118 22 
H(35) 7773 4333 7487 25 
H(36) 8849 3252 6633 24 
H(38A) 5286 5571 5807 25 
H(38B) 6663 6947 6306 25 
H(39A) 6186 7558 7895 26 
H(39B) 5158 7502 6940 26 
H(40) 3663 5823 6960 35 
H(41) 8158 4873 2221 54(13) 
 
Torsion angles [°] for 2.46. 
Cu(1)-N(1)-C(2)-C(3) 179.0(2) 
Cu(1)-N(1)-C(6)-C(5) -178.9(2) 
Cu(1)-N(1)-C(6)-C(7) 1.3(3) 
Cu(1)-N(8)-C(9)-C(10) 4.3(4) 
N(1)-C(2)-C(3)-C(4) -0.4(5) 
N(1)-C(6)-C(7)-N(8) -6.8(4) 
C(2)-N(1)-C(6)-C(5) -0.6(4) 
C(2)-N(1)-C(6)-C(7) 179.6(3) 
C(2)-C(3)-C(4)-C(5) -0.5(5) 
Cu(2)-N(21)-C(22)-C(23) -178.7(2) 
Cu(2)-N(21)-C(26)-C(25) 178.9(2) 
Cu(2)-N(21)-C(26)-C(27) -0.3(3) 
Cu(2)-N(28)-C(29)-C(30) 4.6(5) 
C(3)-C(4)-C(5)-C(6) 0.8(5) 
C(4)-C(5)-C(6)-N(1) -0.2(5) 
C(4)-C(5)-C(6)-C(7) 179.5(3) 
C(5)-C(6)-C(7)-N(8) 173.4(3) 
C(6)-N(1)-C(2)-C(3) 0.9(4) 
C(6)-C(7)-N(8)-Cu(1) 9.4(3) 
C(6)-C(7)-N(8)-C(9) -171.4(3) 
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C(7)-N(8)-C(9)-C(10) -174.8(3) 
N(8)-C(9)-C(10)-C(11) -8.0(5) 
N(8)-C(9)-C(10)-C(16) 166.9(3) 
C(9)-C(10)-C(11)-O(12) -6.3(5) 
C(9)-C(10)-C(11)-C(13) 174.3(3) 
C(9)-C(10)-C(16)-C(15) -174.5(3) 
C(10)-C(11)-O(12)-Cu(1) 22.4(4) 
C(10)-C(11)-O(12)-Cu(2) 163.5(2) 
C(10)-C(11)-C(13)-C(14) 0.2(4) 
C(11)-C(10)-C(16)-C(15) 0.6(5) 
C(11)-C(13)-C(14)-C(15) 0.0(5) 
C(11)-C(13)-C(14)-O(17) -179.2(3) 
O(12)-C(11)-C(13)-C(14) -179.1(3) 
C(13)-C(11)-O(12)-Cu(1) -158.2(2) 
C(13)-C(11)-O(12)-Cu(2) -17.1(4) 
C(13)-C(14)-C(15)-C(16) 0.0(5) 
C(13)-C(14)-O(17)-C(18) 4.6(5) 
C(14)-C(15)-C(16)-C(10) -0.3(5) 
C(14)-O(17)-C(18)-C(19) -173.0(3) 
C(15)-C(14)-O(17)-C(18) -174.6(3) 
C(16)-C(10)-C(11)-O(12) 178.8(3) 
C(16)-C(10)-C(11)-C(13) -0.5(4) 
O(17)-C(14)-C(15)-C(16) 179.3(3) 
O(17)-C(18)-C(19)-O(20) 69.7(4) 
N(21)-C(22)-C(23)-C(24) -1.0(5) 
N(21)-C(26)-C(27)-N(28) -7.0(4) 
C(22)-N(21)-C(26)-C(25) -1.1(4) 
C(22)-N(21)-C(26)-C(27) 179.7(3) 
C(22)-C(23)-C(24)-C(25) 0.4(5) 
C(23)-C(24)-C(25)-C(26) -0.3(5) 
C(24)-C(25)-C(26)-N(21) 0.6(5) 
C(24)-C(25)-C(26)-C(27) 179.7(3) 
C(25)-C(26)-C(27)-N(28) 173.8(3) 
C(26)-N(21)-C(22)-C(23) 1.3(4) 
C(26)-C(27)-N(28)-Cu(2) 11.5(3) 
C(26)-C(27)-N(28)-C(29) -167.6(3) 
C(27)-N(28)-C(29)-C(30) -176.5(3) 
N(28)-C(29)-C(30)-C(31) -3.1(5) 
322 
 
N(28)-C(29)-C(30)-C(36) 174.6(3) 
C(29)-C(30)-C(31)-O(32) -1.6(5) 
C(29)-C(30)-C(31)-C(33) 179.0(3) 
C(29)-C(30)-C(36)-C(35) -177.1(3) 
C(30)-C(31)-O(32)-Cu(2) 4.2(4) 
C(30)-C(31)-C(33)-C(34) -2.8(4) 
C(31)-C(30)-C(36)-C(35) 0.7(5) 
C(31)-C(33)-C(34)-C(35) 2.1(5) 
C(31)-C(33)-C(34)-O(37) -178.0(3) 
O(32)-C(31)-C(33)-C(34) 177.8(3) 
C(33)-C(31)-O(32)-Cu(2) -176.4(2) 
C(33)-C(34)-C(35)-C(36) 0.0(5) 
C(33)-C(34)-O(37)-C(38) 2.5(4) 
C(34)-C(35)-C(36)-C(30) -1.4(5) 
C(34)-O(37)-C(38)-C(39) -177.6(3) 
C(35)-C(34)-O(37)-C(38) -177.7(3) 
C(36)-C(30)-C(31)-O(32) -179.3(3) 
C(36)-C(30)-C(31)-C(33) 1.4(4) 
O(37)-C(34)-C(35)-C(36) -179.8(3) 
O(37)-C(38)-C(39)-O(40) -67.6(3) 
 
 
Hydrogen bonds for 2.46 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
C(2)-H(2)...O(3)#1 0.95 2.58 3.457(4) 154 
C(7)-H(7A)...O(4) 0.99 2.47 3.142(4) 125 
C(19)-H(19A)...O(2)#2 0.99 2.51 3.450(5) 157 
O(20)-H(20)...O(1S) 0.84 1.70 2.531(17) 172 
O(20)-H(20)...O(2S) 0.84 2.21 3.00(2) 156 
C(22)-H(22)...O(41) 0.95 2.45 2.972(4) 114 
C(23)-H(23)...O(4)#3 0.95 2.57 3.464(4) 158 
C(27)-H(27B)...O(1S)#4 0.99 2.48 3.313(14) 142 
O(40)-H(40)...O(32)#5 0.84 1.94 2.766(3) 170 
O(41)-H(41)...O(1)#1 0.98 2.02 2.972(3) 163 
 
 
